
<html lang="en"     class="pb-page"  data-request-id="13bd6a05-913f-4f68-88d3-c921fd1671f6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.6b00157;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-18"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines" /></meta><meta name="dc.Creator" content="Eugene Guorong  Yang" /></meta><meta name="dc.Creator" content="Nurulhuda  Mustafa" /></meta><meta name="dc.Creator" content="Eng Chong  Tan" /></meta><meta name="dc.Creator" content="Anders  Poulsen" /></meta><meta name="dc.Creator" content="Pondy Murugappan  Ramanujulu" /></meta><meta name="dc.Creator" content="Wee Joo  Chng" /></meta><meta name="dc.Creator" content="Jeffrey J. Y.  Yen" /></meta><meta name="dc.Creator" content="Brian W.  Dymock" /></meta><meta name="dc.Description" content="Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmac..." /></meta><meta name="Description" content="Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmac..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 8, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00157" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00157" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00157" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00157" /></link>
        
    
    

<title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00157" /></meta><meta property="og:title" content="Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0024.jpeg" /></meta><meta property="og:description" content="Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is &lt;100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and &gt;50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is &lt;100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and &gt;50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0024.jpeg" /></meta><meta name="twitter:title" content="Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00157"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00157">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00157&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00157&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00157&amp;href=/doi/10.1021/acs.jmedchem.6b00157" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8233-8262</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00144" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00333" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eugene+Guorong++Yang">Eugene Guorong Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nurulhuda++Mustafa">Nurulhuda Mustafa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eng+Chong++Tan">Eng Chong Tan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Poulsen">Anders Poulsen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pondy+Murugappan++Ramanujulu">Pondy Murugappan Ramanujulu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wee+Joo++Chng">Wee Joo Chng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+J.+Y.++Yen">Jeffrey J. Y. Yen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+W.++Dymock">Brian W. Dymock</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Experimental Therapeutics Centre, 31 Biopolis Way, 03-01 Nanos, Singapore 138669</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Life Sciences Institute, National University of Singapore, Centre for Life Sciences, Level 5, 28 Medical Drive, Singapore 117456</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">∇</span> <span class="aff-text">Cancer Science Institute, Singapore, National University of Singapore, Singapore 117599</span></div><div class="aff-info" id="aff8"><span class="aff-symbol">○</span> <span class="aff-text">National University Cancer Institute of Singapore, National University Health SystemSingapore 119074</span></div><div class="corresp-info"><strong>*</strong>Phone: +6566012495. Fax: +6567791554. E-mail: <a href="/cdn-cgi/l/email-protection#a6d6cec7c2c4d1e6c8d3d588c3c2d388d5c1"><span class="__cf_email__" data-cfemail="8cfce4ede8eefbcce2f9ffa2e9e8f9a2ffeb">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00157&amp;href=/doi/10.1021%2Facs.jmedchem.6b00157" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8233–8262</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 19, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 February 2016</li><li><span class="item_label"><b>Published</b> online</span>8 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00157" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00157</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8233%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DEugene%2BGuorong%2BYang%252C%2BNurulhuda%2BMustafa%252C%2BEng%2BChong%2BTan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D18%26contentID%3Dacs.jmedchem.6b00157%26title%3DDesign%2Band%2BSynthesis%2Bof%2BJanus%2BKinase%2B2%2B%2528JAK2%2529%2Band%2BHistone%2BDeacetlyase%2B%2528HDAC%2529%2BBispecific%2BInhibitors%2BBased%2Bon%2BPacritinib%2Band%2BEvidence%2Bof%2BDual%2BPathway%2BInhibition%2Bin%2BHematological%2BCell%2BLines%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8262%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00157"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3257</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">52</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00157" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Eugene&quot;,&quot;last_name&quot;:&quot;Guorong Yang&quot;},{&quot;first_name&quot;:&quot;Nurulhuda&quot;,&quot;last_name&quot;:&quot;Mustafa&quot;},{&quot;first_name&quot;:&quot;Eng&quot;,&quot;last_name&quot;:&quot;Chong Tan&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Poulsen&quot;},{&quot;first_name&quot;:&quot;Pondy&quot;,&quot;last_name&quot;:&quot;Murugappan Ramanujulu&quot;},{&quot;first_name&quot;:&quot;Wee&quot;,&quot;last_name&quot;:&quot;Joo Chng&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;J. Y. Yen&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;W. Dymock&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8233-8262&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00157&quot;},&quot;abstract&quot;:&quot;Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is &lt;100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and &gt;50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00157&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00157" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00157&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00157" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00157&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00157" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00157&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00157&amp;href=/doi/10.1021/acs.jmedchem.6b00157" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00157" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00157" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26pmid%3D27541357%26genre%3Darticle%26aulast%3DYang%26date%3D2016%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BJanus%2BKinase%2B2%2B%2528JAK2%2529%2Band%2BHistone%2BDeacetlyase%2B%2528HDAC%2529%2BBispecific%2BInhibitors%2BBased%2Bon%2BPacritinib%2Band%2BEvidence%2Bof%2BDual%2BPathway%2BInhibition%2Bin%2BHematological%2BCell%2BLines%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D18%26spage%3D8233%26epage%3D8262%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/18" title="Go to Volume 59, Issue 18"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/jmcmar.2016.59.issue-18/20160922/jmcmar.2016.59.issue-18.largecover.jpg" alt="Go to Volume 59, Issue 18"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, <b>51</b>, inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and >50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is a multifaceted disease often requiring multiple therapeutic interventions for successful long-term outcomes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Traditional approaches to combating cancer, still in widespread use today, are nonselective, such as radiation or chemotherapy.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> At the other extreme, targeted treatment of cancer typically aims to target cancer cells via blockage of a single biological target. However, more intensive evaluation of typical “targeted” drugs often reveals multiple-target mechanisms.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Realization that simultaneous inhibition of multiple mechanisms can lead to additive effects, or even synergy, has led to a rise in combinations of targeted therapies with each other and with nonselective regimens.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In today’s therapeutic armory, an increasing array of complex combination strategies tailored to individual diseases, and increasingly, individual patients, is available.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Despite many significant improvements, it is clear that less complex approaches are required for multiple pathway intervention to tackle challenging or resistant tumors.</div><div class="NLM_p">There are generally three methods to achieve multitarget knockdown: use of a cocktail of separate drugs, a multicomponent drug, and the multiple ligand approach.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> Drug cocktails, specifically combinations of single agents each targeted to specific mechanisms, are associated with poor patient compliance, complex pharmacokinetics, and the challenge of drug–drug interactions.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Similarly, the multicomponent drug regimen, where two or more separate agents are formulated into a single tablet can suffer from drug–drug interactions and differing physicochemical properties between components that can affect the efficacy of the drugs administered. Polypharmacology is recognized as an approach where more than one therapeutic pathway can be modulated by a <i>single</i> molecule. Specific strategies to combine targeted mechanisms together are referred to as the multiple ligand, multicomponent ligand, or designed multiple ligand (DML) approaches. In these cases, a single drug molecule has multiple, but targeted, pharmacology.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> With this approach, once the potency ratio is determined it is fixed within the molecule, hence the variable pharmacokinetics usually seen with combinations of two single agents will not affect the potency ratio of a DML in the same way. However, it should be noted that DMLs are just as susceptible to metabolism as any other drug, reducing or eliminating the biological activity or pharmacodynamic profile of the compound. Being single molecules, DMLs will not suffer from drug–drug interactions, unless combined with another drug. There is also opportunity for structural novelty; design of a DML is not just a matter of joining two pharmacophores together, it is a creative process to balance multiple SARs while maintaining drug-like properties. Development costs for a DML are likely to be significantly lower than development of a multiple drug combination, but this must be balanced with other potential downsides such as molecular weight inflation, the challenge of balancing multiple SARs, and potentially more challenging synthesis are all present dangers. DMLs are not new, in fact, multi-GPCR modulators, as well as multikinase inhibitors, have been known for many years.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In this work, we focus on DMLs that target <i>two different classes</i> of enzyme rather than two enzymes performing the same type of transformation. Deliberate strategies to adopt such a DML approach at the outset for enzyme inhibitors in cancer are not commonly reported. Recent progress has been most successful combining the histone deacetylase (HDAC) pharmacophore with other enzyme inhibitor activities such as kinases. Examples of successful kinase–HDAC DMLs have now reached the clinic in oncology pioneered by Curis, although none are yet approved by the FDA. CUDC-101<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17">(13-17)</a> (HDAC/EGFR2 inhibitor) and CUDC-907<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (PI3K/HDAC inhibitor) have both entered phase I clinical trials (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Inspired by this progress we have been focused on designed combinations of JAK2 kinase/HDAC DMLs for study in cancer, using <b>1</b> (vorinostat/SAHA) and <b>2</b> (pacritinib/SB1518) as initial templates.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of dual inhibitors, HDAC inhibitor <b>1</b> and JAK2/FLT3 inhibitor <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Janus kinase (JAK) inhibitors<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> have been developed rapidly following the discovery of the JAK2-V617F<a onclick="showRef(event, 'ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24">(21-24)</a> mutation in patients with myeloproliferative neoplasms (MPNs). This has led to the approval of (3<i>R</i>)-3-cyclopentyl-3-[4-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile (ruxolitinib/INCB018424) and 3-[(3<i>R</i>,4<i>R</i>)-4-methyl-3-[methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile (tofacitinib/CP690550) as JAK inhibitors for the treatment of myelofibrosis (MF)<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> and rheumatoid arthritis,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> respectively. Compound <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) has been developed<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> as a dual JAK2 and fms-like tyrosine kinase-3 (FLT3) selective inhibitor and has successfully completed its first phase 3 trial, PERSIST-1, as an orphan drug<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> for myelofibrosis (MF) patients with thrombocytopenia (low platelet levels).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> On the basis of the phase 3 data, an NDA filing of <b>2</b> was recently initiated at the U.S. FDA.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Soon after this filing, compound <b>2</b> was put on full clinical hold by the FDA while investigations of patient deaths are carried out. At the time of writing, FDA reinstated use of <b>2</b> via an individual patient application protocol. Another clinical concern is the onset of resistance which has been shown in the case of ruxolitinib to be due to the reactivation of JAK-STAT signaling where heterodimerization between activated JAK2 and JAK1 or TYK2 occurs and not due to mutation or change in the active site of JAK2 itself.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> JAK2 inhibitor resensitization occurred upon withdrawal of treatment. More importantly JAK2 inhibitor resistant cells still remain dependent on JAK2 protein expression. Alternative therapies that degrade JAK2 indirectly are also effective and have been postulated to be good combinations with JAK2 inhibitors. Some of the possible targets for potentially synergistic JAK2 combination therapy include histone deacetylase (HDAC),<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34-36)</a> heat shock protein 90 (HSP90),<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34-36)</a> phosphoinositide 3-kinase (PI3K),<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> and B-cell lymphoma 2 (Bcl2).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> With this in mind, we postulated that a drug-like DML which could inhibit JAK2 and HDAC in a cell in a similar concentration range could be created and would be effective in JAK2-sensitive or resistant cells.</div><div class="NLM_p last">HDAC enzymes were initially discovered to deacetylate histones affecting how tightly the DNA is bound to the histone and subsequently regulation of gene expression.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> There are four classes of HDAC enzymes based on their function and DNA sequence similarity.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, HDACs have also been found to interact with nonhistone proteins,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> thus they are implicated in a wide range of biological functions. HDAC inhibitors have been shown to be clinically effective as single agents<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and entered the market earlier than the JAK inhibitors with the approval of <b>1</b> in 2007,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> romidepsin (FK228),<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and the recently approved belinostat (PXD101, FDA approval July 2014)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and panobinostat (LBH589, FDA approval February 2015).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> However, HDAC inhibitors have experienced slow and difficult clinical development as single agents due to limitations of toxicity.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Selective inhibition of individual HDAC isoforms, or smaller groups of isozymes, could prove beneficial in cancer therapy with some evidence of an improved therapeutic window in clinical studies such as with the class-I selective benzamides.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Obtaining selectivity between individual HDAC isoforms has generally been challenging, but there have been reports of HDAC3, 6, and 8 selective compounds.<a onclick="showRef(event, 'ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51 ref52 ref53">(49-53)</a> Selective HDAC6 inhibitors are achievable by optimization of the cap region of the inhibitor, taking advantage of the larger lip of the substrate binding pocket.<a onclick="showRef(event, 'ref54 ref55 ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56 ref57 ref58">(54-58)</a> Overexpression of HDAC6 correlates with oncogenesis and improved survival. Some effects of HDAC6 inhibition have been to prevent migration and invasion of cancer cells by acetylation of α-tubulin and cortactin, leading to a decrease in cell motility,<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59, 60)</a> sensitization of cancer cells to known DNA damaging agents,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and induction of apotosis in cancerous cells.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62, 63)</a> Increased HDAC activity has been observed in patients with MPN.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a> Specifically, HDAC inhibitors have been shown to be effective against MPN both as a single agent<a onclick="showRef(event, 'ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68">(66-68)</a> and in combination<a onclick="showRef(event, 'ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71">(69-71)</a> with JAK2 inhibitors. JAK2-selective TG101209 exerts synergistic toxic effects in MPN cell lines when combined with panobinostat.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Ruxolitinib and panobinostat in combination lead to improved efficacy in a mouse model of JAK2<sup>V617F</sup> driven disease.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> In preclinical mouse models of AML, a combination of <b>2</b> and pracinostat (SB939) were found to be synergistic.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Thus, we hypothesized that a single compound that selectively inhibits both JAK2 as well as HDAC enzymes could have utility, especially in resistant MPN and AML but perhaps also more broadly in solid tumors compared to a single inhibitor alone. A weaker inhibitor of either enzyme in a dual acting DML could also potentially lead to lower toxicity levels while maintaining therapeutic efficacy, leading to an overall safer profile.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In summary, our goal was to design and synthesize molecules, which inhibit <i>both</i> JAK2 and HDAC enzymes, seeking to explore selectivity between these two families of diverse enzymes.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Design of Dual Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67844" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67844" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Substrate competitive HDAC inhibitors consist of a zinc binding functional group, a long chain, or extended heterocycle and a cap group (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The zinc binding group can be a bidentate group (e.g., hydroxamic acid, benzamide, keto-thiol) which binds more strongly to the zinc cation or a monodentate group (e.g., carboxylic acid, thiols).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> With monodentate functional groups, the importance of the “cap” increases as the interaction with the inhibitor increases relative to the zinc binding group. It was envisioned that we could achieve some selectivity for HDAC6, which is slightly wider in the “cap” region relative to HDAC1.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Some selective HDAC6 inhibitors that have been reported include tubacin,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> tubastatin A,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and a small molecule hydroxamic acid without a cap group.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> A lead compound was reported by Auzzas et al., where the HDAC selectivity was reversed to achieve 10 times HDAC6 (IC<sub>50</sub> 0.4 nM) selectivity over HDAC1.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Even more potent compounds, with HDAC6 IC<sub>50</sub> down to 2 pM, have been reported based on a phenylisoxazole cap. These compounds were 10-fold more potent than <b>1</b> in pancreatic cells.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Several natural products (and analogues) containing macrocycles have been discovered as HDAC inhibitors, with most of them having moderate to high selectivity for HDAC1 over HDAC6. These are mainly macrocyclic tetrapeptides,<a onclick="showRef(event, 'ref64 ref77 ref78 ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref64 ref77 ref78 ref79 ref80">(64, 77-80)</a> depsipeptides,<a onclick="showRef(event, 'ref81 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref81 ref82 ref83">(81-83)</a> (e.g., romidepsin), azumamides,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and peptidomimetics.<a onclick="showRef(event, 'ref76 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref76 ref85 ref86">(76, 85, 86)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic showing plans for merged JAK–HDAC pharmacophore taking advantage of the solvent binding channel in JAK2 and the probable interactions to be gained by a merged inhibitor at the entrance to the HDAC substrate binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Aminopyrimidine <b>2</b>, which contains a macrocycle as its core JAK2-binding scaffold provides a suitable moiety to explore our hypothesis as it possesses key features required in both JAK2 and the cap of a potentially selective HDAC inhibitor. Furthermore, <b>2</b> is selective for JAK2 and FLT3, both enzymes which have been shown to be beneficial in MPN and AML, and it has been shown to be synergistic in both cellular and in vivo studies in combination with an HDAC inhibitor.<a onclick="showRef(event, 'ref28 ref29 ref70'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref70">(28, 29, 70)</a> A recent study has shown that JAK2/FLT3 kinase–HDAC dual inhibitors derived from the potent cyclin dependent kinase (CDK) inhibiting macrocycle TG02 can be prepared, however HDAC selectivity was not explored.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Rather than linking two known inhibitors together with a long chain, which will typically result in a compound with high molecular weight (addition of both compound’s molecular weight as well as the linker), a merged pharmacophore is more desirable.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> For <b>2</b>, it is known that the pyrolidine ring is located in a solvent exposed region when binding to the enzyme and its main purpose is to improve the aqueous solubility of the compound.<a onclick="showRef(event, 'ref28 ref88'); return false;" href="javascript:void(0);" class="ref ref28 ref88">(28, 88)</a> Thus, it was postulated that inserting the HDAC binding group here will retain JAK2 activity while giving rise to potentially selective HDAC inhibition activity. We then planned to study the resulting JAK–HDAC inhibitors in a range of both solid tumor and hematological cancer cell lines, seeking evidence of target modulation ideally within the same concentration range.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting from macrocycle chloride <b>3</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), substitution with Boc-protected anilines <b>4a</b>, <b>5a</b>, and <b>7a</b>, phenol <b>6a</b>, and piperidine-4-methyl ester <b>8a</b> gave esters <b>4</b>–<b>6</b> and <b>8</b> and nitro <b>7</b>, respectively. Boc protection was required to increase the acidity of the anilines, performing the reaction at 100 °C for 24 h or at 120 °C for 18 h in DMF. Higher temperature leads to degradation of the product (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Reaction with <b>8a</b> was slower, requiring heating for 3 days at 80 °C in acetonitrile. Nitro substituted aniline <b>7</b> provided a route to install a longer linker for the hydroxamic acid, similar to <b>1</b>. Reduction of nitro <b>7</b>, followed by coupling with monoester acids <b>10a</b>–<b>12a</b> bearing chain lengths of 4–6 methylenes, gave boc-protected esters <b>10</b>–<b>12</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). A more convergent approach attempted was to perform the substitution with 4-NHBoc substituted <b>10a</b>, but this gave a mixture of the desired product <b>12</b> and an amide alkylation product, thus it was abandoned in favor of the longer but more practical route using <b>7</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates <b>4</b>–<b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>4a</b>–<b>7a</b>, Cs<sub>2</sub>CO<sub>3</sub>, TBAI, DMF, 120 °C, 18 h, 45–82% yield; (b) <b>8a</b>, TBAI, MeCN, reflux, 72 h, 62% yield.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Intermediates <b>10</b>–<b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O (2:1), reflux, 3 h; (b) <b>10a</b>–<b>12a</b>, NMM, ClCO<sub>2</sub>Et, DCM, O °C to RT, 18 h, 59–79% (over 2 steps).</p></p></figure><div class="NLM_p">Following a merged pharmacophore strategy, compounds with long chain hydroxamic acids connected directly to the macrocycle ring were synthesized from commercially available <b>13</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The common intermediate phenol <b>14</b> was prepared using two strategies. The first was a three-step protocol, without purification or protecting groups, entailing the reduction of aldehyde <b>13</b> to the primary benzyl alcohol followed by chlorination using thionyl chloride. However, this chlorination reaction was capricious and does not go to completion. Furthermore, the benzylic chloride is susceptible to reaction with water and must be used quickly. Refluxing in neat allyl alcohol gives the desired allyl ether <b>14</b> in 35% yield over three steps. A cleaner method was to use methoxymethyl (MOM) as a temporary phenol protecting group, with concomitant reduction of the aldehyde, followed by alkylation of the benzyl alcohol with allyl bromide under phase transfer conditions. Finally, deprotection of the phenol is achieved by refluxing in aqueous 4 M hydrochloric acid in THF. This four-step protocol, while longer, gives a better overall yield of 72%. An alternative protecting group, 4-methoxybenzyl (PMB), gave only a 47% yield over four steps. Aside from the higher yield, the former was preferred due to the ease of purification of the product from the ether byproduct arising from cleavage of the protecting group. Alkylation of phenol <b>14</b> with the appropriate bromo esters <b>15a</b>–<b>19a</b> gave compounds <b>15</b>–<b>19</b>. As per the reported<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> synthesis of <b>3</b>, the nitro group was reduced using iron and ammonium chloride. The crude aniline was stirred with the pyrimidine at 95 °C in dioxane for 18 h to give the diallyl compounds <b>21</b>–<b>25</b>. Ring closing metathesis with the Grubbs II catalyst<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> in DCM with aqueous 4 M hydrochloric acid gave macrocycles <b>26</b>–<b>30</b> in good yields as approximately 85:15 mixtures of <i>trans</i> to <i>cis</i> isomers of the alkene.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Intermediates <b>26</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, RT, 2 h; (b) SOCl<sub>2</sub>, DCM, RT, 18 h; (c) allyl alcohol, reflux, 3 h, 35% (3 steps); (d) MOMCl, NaBH<sub>4</sub>, MeOH, RT, 2 h; (e) <i>c</i>·NaOH, NEt<sub>3</sub>BnCl, allyl bromide, RT, 72 h; (f) 4 M HCl, THF, reflux, 3 h, 72% yield (3 steps); (g) NaBH<sub>4</sub>, MeOH, RT, 2 h; (h) PPh<sub>3</sub>, CCl<sub>3</sub>CN, DCM, RT, 16 h; (i) allyl alcohol, reflux, 4 h, 35% (3 steps); (j) K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 18 h, 84–100%; (k) <b>20</b>, Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O (2:1), reflux, 3 h; (l) TsOH.H<sub>2</sub>O, dioxane, 95 °C, 18 h, 28–62% (2 steps); (m) Grubbs II, DCM, 4 M HCl, reflux, 3 h, 62–83% yield.</p></p></figure><div class="NLM_p last">Attempts to directly convert esters <b>26</b>–<b>30</b> to the hydroxamic acids using hydroxylamine hydrochloride and base such as sodium methoxide or sodium hydroxide at 0 °C or room temperature were not successful, with only the starting material being recovered. Attempted hydrolysis of the ester with lithium hydroxide was also not successful. Subsequently, it was found that by treating the ester with potassium trimethylsilanoate the acid could be successfully obtained. Attempts to couple the acids with <i>O</i>-THP protected hydroxylamine were ultimately successful using (1-[Bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxidhexafluorophosphate (HATU) but not 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDC). Deprotection of the THP using anhydrous hydrogen chloride in dioxane released the free hydroxamic acids in low to moderate yield (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Enzyme Inhibitory Activity</h3><div class="NLM_p">Carboxylic acids, such as valproic acid, are known to be weak HDAC inhibitors due to the weak chelating effect of the carboxylic acid to the zinc cation in the HDAC active site.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Thus, the carboxylic and hydroxamic acids were both tested in enzymatic and cellular assays. Reference compounds include <b>1</b> (pan-HDAC), <b>2</b> (JAK2 selective), and tubastatin A (HDAC6 selective). Data for acids is shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and hydroxamates in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. JAK2, HDAC1, and HDAC6 were selected for initial SAR studies, the latter due to the large macrocyclic cap group which we hypothesized would form additional interactions at the lip of the HDAC pocket potentially conferring HDAC isoform selectivity.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Unsurprisingly, given the common macrocyclic ring, significant inhibition of JAK2 enzymatic activity was observed with acids <b>31</b>–<b>34</b> (IC<sub>50</sub> < 39 nM). Of these compounds, only aminobenzoic acids <b>31</b> and <b>32</b> afforded weak HDAC6 inhibition and were completely inactive against HDAC1 at the highest concentration tested (10 μM). Likewise ether <b>33</b> and piperidine <b>34</b> were not HDAC active, probably due to the short distance between the acid and the bulky macrocycle. JAK2 potency was expected based on our design of the hybrid molecules whereby the zinc chelating functional group was in the solvent exposed region of the JAK2 enzyme while retaining the key binding features of <b>2</b> in the JAK2 enzyme binding pocket. Lengthening the distance between the Zn chelating group and macrocycle using an aniline linker yielded progressively more HDAC6 inhibition with a 5 methylene spacer (<b>35</b>, 20% inhibition at 10 μM) and with 6 methylenes (<b>36</b>, IC<sub>50</sub> = 2.6 μM). It is perhaps not entirely surprising that <b>36</b> would have HDAC activity, however, it is completely inactive against HDAC1 at 10 μM. Compound <b>36</b> was potent against JAK2 (IC<sub>50</sub> = 2.3 nM), similar to <b>2</b>, reassuring us that a wide range of HDAC-binding side chains were fully compatible with our targeted levels of JAK2 activity. We believed the observed high HDAC6/HDAC1 selectivity is due to the aforementioned differences in the cap binding region of the HDACs. Structure–activity relationships seen with <b>35</b>/<b>36</b> are mirrored in compounds <b>37</b>–<b>41</b>, with aliphatic linkers of increasing length directly attached to the macrocycle. Again, <b>40</b> (HDAC6 IC<sub>50</sub> = 2.8 μM) with 6 methylene groups proved to be the optimal length for HDAC6 activity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Following the trend observed with <b>35</b>/<b>36</b>, the inhibition of HDAC6 activity increases as the chain length increases to 6 methylenes before it decreases with an additional methylene. No HDAC inhibition could be detected with the shortest 3 and 4 carbon linkers in compounds <b>37</b> and <b>38</b>, whereas the 5 carbon linked <b>39</b> was weakly active (HDAC6 IC<sub>50</sub> = 45 μM). Increasing the chain length to 7 methylenes decreased the HDAC6 activity to 10 μM. Potency against JAK2 was maintained although with some variations. Shortening the linker as in <b>37</b> brings the negatively charged carboxylate closer to the JAK2 pocket decreasing JAK2 potency nearly 20-fold from 2.6 nM (<b>40</b>) to 47 nM (<b>37</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme Inhibition Data for Carboxylic Acids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0016.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0017.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds tested in the same assay format. IC<sub>50</sub> data are reported as the average of two independent determinations (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a> for IC<sub>50</sub> curves for <b>36</b> and <b>40</b>). Note that reported literature values vary depending on assay format.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Reported values.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Lowest concentration tested 39 nM.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzyme Inhibition Data for Hydroxamic Acids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0018.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0019.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> data are reported as the average of two independent determinations (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a> for IC<sub>50</sub> curves). Note that reported literature values vary depending on assay format.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Literature values range from 11 to 15 nM.<a onclick="showRef(event, 'ref54 ref93'); return false;" href="javascript:void(0);" class="ref ref54 ref93">(54, 93)</a></p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Reported values (<a href="http://www.reactionbiology.com" class="extLink">www.reactionbiology.com</a>).</p></div></div><div></div></div><div class="NLM_p">This HDAC6 selectivity and SAR profile is mirrored in the enzymatic activity of the hydroxamic acids but with significantly greater HDAC6 activity (>1000-fold in the most active cases). Thus, by changing the zinc binding group, it is possible to “tune” the HDAC activity to explore the effect of different levels of HDAC activity in these multiligand compounds in biological systems. Aminobenzhydroxamates <b>42</b> and <b>43</b> had much improved HDAC6 activity as did piperidine <b>45</b>, however, phenol ether <b>44</b> had the most surprising submicromolar potency against HDAC6 (IC<sub>50</sub> = 66 nM) and also had weak HDAC1 activity (56% at 10 μM), especially when compared with its acid derivative <b>33</b> (HDAC6 IC<sub>50</sub> > 100 μM), representing at least a 1500-fold improvement. With JAK2 IC<sub>50</sub> of 1.3 nM, this was the most promising compound to date. However, we were most interested in achieving compounds with potency in the same concentration range for both JAK2 and HDAC isoforms. We were heartened to discover that the longer <b>1</b>-like side chains in <b>46</b> and <b>47</b> conferred high HDAC6 potency, IC<sub>50</sub>s of 2.5 and 2.3 nM, respectively. HDAC1 potency was still not detectable at the highest concentration tested (10 μM). Furthermore, <b>46</b>, displayed a high level of JAK2 potency with an IC<sub>50</sub> of 6.9 nM, while <b>47</b> was approximately 4-fold lower at 30 nM. However, although <b>46</b> and <b>47</b> had reached our initial potency goals against these two different enzyme targets, they were not active in cells (with the exception of MDA-MB231 breast cancer cells for <b>47</b> (GI<sub>50</sub> = 3.43 μM) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>; further discussion below). Although <b>46</b> had a desirable LLE<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> [LLE = −Log IC<sub>50</sub> – cLogP] of 5.2, it had a high molecular weight of 666 and 5 hydrogen bond donors. Nevertheless, we were excited to find that the direct linking of the hydroxamate to the macrocycle, as in compounds <b>48</b>–<b>52</b>, addressed both issues while maintaining our target enzyme inhibition profile (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). With the long chain aliphatic hydroxamic acids <b>48</b>–<b>52</b>, JAK2 activity was similar (IC<sub>50</sub>s from 1 to 5 nM), but they had striking differences in their HDAC6 IC<sub>50</sub>s ranging from 2.1 to 510 nM. This data again illustrates the critical nature of the chain length, with 5-fold improvement in HDAC6 potency on going from 3 carbons (<b>48</b>) to 4 carbons (<b>49</b>), a further 4-fold with an additional methylene (<b>50</b>) then a further 10-fold with a sixth carbon in the linker giving <b>51</b>, which had the best HDAC6 activity of the series with an IC<sub>50</sub> of 2.1 nM. Approximately 8-fold HDAC6 potency is lost with a seventh carbon (<b>52</b>). HDAC1 potency roughly tracks that of HDAC6 with <b>51</b> having the highest (IC<sub>50</sub> = 222 nM) and, although not as high as the HDAC6/1 selectivity seen with other compounds, is still significant at 100-fold. Importantly, these compounds all maintain very strong JAK2 potency, with <b>51</b> being the most potent with an IC<sub>50</sub> of 1.4 nM. Compound <b>51</b> had a LLE of 5.2 (cLogP 3.5) matching that of <b>47</b> but with a lower mol wt of 518 and two fewer hydrogen bond donors. This is probably a contributing reason to the significant cellular activity seen with <b>51</b> and <b>52</b> compared with <b>46</b> and <b>47</b>. We were curious to understand the reasons for the very high HDAC6 potency and selectivity, hence we undertook molecular modeling studies against the three target enzymes focusing on the JAK2/HDAC6 equipotent <b>51</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Test Compounds <b>31</b>–<b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOTMS, THF, RT, 2 h; (b) <i>c.</i>HCl, RT, 18 h, 44 to 83% yield (2 steps); (c) HATU, NH<sub>2</sub>OTHP, NEt<sub>3</sub>, DMSO, RT, 3 d; (d) 4 M HCl in dioxane, RT, 18 h, 12–62% yield.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Modeling Studies</h3><div class="NLM_p">In an attempt to determine the reasons for the HDAC6 selectivity of the compounds, we docked compound <b>51</b> into a homology model of the HDAC6 protein. This model was derived from a crystal structure of the HDAC4 catalytic domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW">2VQW</a>) (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Both the N-terminal and C-terminal catalytic domains of HDAC6 modeled very similarly, not unexpected given they have 49% sequence similarity and 67% homology. As well as the expected zinc–hydroxamate interactions, the macrocycle of <b>51</b> was found to complement the surface of the cap region of HDAC6 very closely. In particular, a pocket unique to HDAC6 was formed by proline 748 and leucine 749 (proline 352 and lysine 353 in the N-terminal catalytic domain) into which the linker of <b>51</b> bound with many close contacts. A hydrogen bond appears to be formed between the aminopyrimidine NH of the macrocycle and the backbone carbonyl of Ser498. Given that this NH is critical for hinge binding to JAK2 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>), it is satisfying to find that it may also be serving a similar role in its interactions with HDAC6. From this point of view, <b>51</b> displays attributes of a truly merged bispecific pharmacophore. It must also be noted that the residues at the rim region of HDAC6 are quite flexible and the observed docking interactions cannot therefore be easily quantified and must be interpreted in this light.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking of <b>51</b> into HDAC6. (A) Electrostatic surface of HDAC6 shown with blue indicating positively charged areas and red indicating negatively charged areas. The hydroxamate is bound deep in the Zn pocket, while the large macrocyclic cap forms very good surface complementarity. A pocket unique to HDAC6 is formed by Pro748 and Leu749 into which the hydrophobic linker of the macrocyle is bound. (B) Detailed interactions between <b>51</b> and HDAC6 residues Tyr782, His610, and His611 of HDAC6 form hydrogen bonds with the hydroxamate that also coordinates the catalytic Zn in a bidentate manner. Tyr782 together with Pro501 also forms part of the surface for macrocycle binding. A possible hydrogen bond between the kinase hinge-binding pyrimidine NH can be seen with the backbone carbonyl of Ser498.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In HDAC1, there is a complete absence of the pocket formed by Pro352/Lys353 as seen in HDAC6 (see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Hence the macrocycle does not form good interactions with HDAC1 as it is binding to a solvent exposed surface with only the hydroxamate side chain buried inside HDAC1. This striking difference between the two proteins appears to account for the observed experimental selectivity. Work by Wiest et al. studying class II HDAC selectivity, specifically HDAC6, supports the notion that HDAC6 selectivity vs HDAC1 can be achieved by efficient nonconvalent interactions at the opening to the active site.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> However, <b>51</b> does still inhibit HDAC1 in the midnanomolar range (HDAC1/6 about 100-fold). It is possible that an apparent hydrogen bond formed between the pyrimidine NH and the backbone carbonyl of Gly27 contributes to its binding affinity. This is a similar interaction to the postulated hydrogen bond seen with the corresponding residue of HDAC6, Ser498.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docking of <b>51</b> into HDAC1. (A) Electrostatic surface of HDAC1 shown with blue indicating positively charged areas and red indicating negatively charged areas. The hydroxamate is bound in the Zn pocket, while the large macrocyclic cap is positioned on the highly solvent exposed surface. (B) Detailed interactions between <b>51</b> and HDAC1 residues Tyr303, His140, and His141 of HDAC1 form hydrogen bonds with the hydroxamate that also coordinates the catalytic Zn in a bidentate manner. There also appears to be a hydrogen bond formed between the pyrimidine NH and the backbone carbonyl of Gly27, possibly explaining the midnanomolar potency of <b>51</b> against HDAC1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In JAK2 the aminopyrimidine binds to the hinge region of the enzyme with hydrogen bonds to Leu932, while a number of important hydrophobic interactions are made between the aromatic rings and linker of the macrocycle as expected from the reported binding analysis of <b>2</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Furthermore, a bidentate interaction between one of the ether oxygens of <b>51</b> and Ser936 of JAK2 also matches that reported for <b>2</b>. Fewer interactions are seen between JAK2 and the hydroxamic acid linker as it is positioned in the solvent exposed channel. Taken together, the interactions assessed from the modeling of <b>51</b> bound to HDAC1/6 and JAK2 support the observed SAR between these 3 proteins.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking of <b>51</b> into JAK2. (A) Electrostatic surface of JAK2 shown with blue indicating positively charged areas and red indicating negatively charged areas. The macrocycle is binding in the ATP cavity with very good surface complementarity, very similar to the reported orientation of <b>2</b>.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> (B) Detailed interactions with the protein residues. The aminopyrimidine binds to the backbone of the hinge residue Leu932 with a donor–acceptor hydrogen bond arrangement. The oxygen of the macrocyclic linker of <b>51</b> makes close contacts, possibly hydrogen bonds, with both side chain hydroxyl and backbone NH of Ser936.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Isoform Selectivity</h3><div class="NLM_p">Potency in favor of one enzyme isoform is often sought where there is a strong possibility of toxicity via inhibition of too many isozymes. In the case of a multicomponent JAK–HDAC ligand, this challenge is significant because there are four JAK family members as well as over 500 other potential kinases and 11 HDAC isoforms. With a merged DML design, the interplay between the various pharmacophores and enzyme binding sites is complex, increasing the difficulty of carrying out structure-based design. We were intrigued to understand how selectivity would change when the pharmacophores of <b>1</b> and <b>2</b> are merged. Hence we tested compound <b>51</b> in a biochemical kinase assay, similar to the JAK2 assay, at a concentration of 100 nM (about 70- fold over JAK2 IC<sub>50</sub>) against the 4 JAK isoforms JAK1, JAK2, JAK3, and TYK2 as well as FLT3, an important kinase in AML and targeted by <b>2</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). We also tested <b>51</b> against 11 HDAC isoforms covering the four classes of zinc utilizing deacetylases, classes I, IIA, IIB, and IV (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). We did not test <b>51</b> against the distinctly different class III NAD-dependent sirtuins, which are not inhibited by <b>1</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Isoform Selectivity of <b>51</b> against the JAK and FLT3 Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isoform</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM) or % inhibition</th><th class="colsep0 rowsep0" align="center">JAK2 SI<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HDAC6 SI<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="center">8.7% @ 0.1 μM</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="center">0.0014</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="center">55% @ 0.1 μM</td><td class="colsep0 rowsep0" align="center">>50</td><td class="colsep0 rowsep0" align="center">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2</td><td class="colsep0 rowsep0" align="center">56% @ 0.1 μM</td><td class="colsep0 rowsep0" align="center">>50</td><td class="colsep0 rowsep0" align="center">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="center">67% @ 0.1 μM</td><td class="colsep0 rowsep0" align="center">>50</td><td class="colsep0 rowsep0" align="center">>25</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Kinases were tested in duplicate at 100 nM concentration.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">JAK2 SI = fold less potent compared to JAK2 IC<sub>50</sub> (1.4 nM).</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">HDAC6 SI = fold less potent compared to HDAC6 IC<sub>50</sub> (2.1 nM).</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Isoform Selectivity of <b>51</b> against the Class I, II, and IV HDAC Enzymes<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isoform</th><th class="colsep0 rowsep0" align="center">class</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM) or % inhibition</th><th class="colsep0 rowsep0" align="center">JAK2 SI<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HDAC6 SI<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC1</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="center">0.222</td><td class="colsep0 rowsep0" align="center">158</td><td class="colsep0 rowsep0" align="center">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC2</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="center">0.049</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC3</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="center">2.17</td><td class="colsep0 rowsep0" align="center">1550</td><td class="colsep0 rowsep0" align="center">1033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC4</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="center">8.6% @ 10 μM</td><td class="colsep0 rowsep0" align="center">>7000</td><td class="colsep0 rowsep0" align="center">>5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC5</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="center">16.1% @ 10 μM</td><td class="colsep0 rowsep0" align="center">>7000</td><td class="colsep0 rowsep0" align="center">>5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC6</td><td class="colsep0 rowsep0" align="left">IIB</td><td class="colsep0 rowsep0" align="center">0.0021</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC7</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="center">1.3% @ 10 μM</td><td class="colsep0 rowsep0" align="center">>7000</td><td class="colsep0 rowsep0" align="center">>5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC8</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="center">0.74</td><td class="colsep0 rowsep0" align="center">528</td><td class="colsep0 rowsep0" align="center">352</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC9</td><td class="colsep0 rowsep0" align="left">IIA</td><td class="colsep0 rowsep0" align="center">14% @ 10 μM</td><td class="colsep0 rowsep0" align="center">>7000</td><td class="colsep0 rowsep0" align="center">>5000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC10</td><td class="colsep0 rowsep0" align="left">IIB</td><td class="colsep0 rowsep0" align="center">0.080</td><td class="colsep0 rowsep0" align="center">57</td><td class="colsep0 rowsep0" align="center">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC11</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="center">0.93</td><td class="colsep0 rowsep0" align="center">664</td><td class="colsep0 rowsep0" align="center">443</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">HDAC enzymes were tested in a 10-dose IC<sub>50</sub>.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">JAK2 SI = fold less potent compared to JAK2 IC<sub>50</sub> (1.4 nM).</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">HDAC6 SI = fold less potent compared to HDAC6 IC<sub>50</sub> (2.1 nM).</p></div></div></div><div class="NLM_p">We were pleased to discover that <b>51</b> is selective for JAK2 against all the tested kinases. JAK1 was especially insensitive to <b>51</b>, with less than 10% inhibition at the test concentration of 100 nM, corresponding to a selectivity of much greater than 100-fold against both JAK2 and HDAC6. Inhibition of JAK3 and TYK2 is 55% and 56% at 100 nM, significantly greater than for JAK1. Selectivities for JAK3 and TYK2 over JAK2 are higher than <b>2</b> at over 50-fold, and over 25-fold over HDAC6. A surprisingly low potency against FLT3 of only 67% inhibition at 100 nM corresponded to over 50-fold selectivity and over 25-fold against HDAC6. Within the five tested kinases, compound <b>51</b> was over 50-fold selective in favor of JAK2.</div><div class="NLM_p">Having established selectivity within the JAK family of kinases, we also tested <b>51</b> in a kinase panel composed of 97 kinases from across the kinome. This data depicts binding to the ATP sites of the tested kinases, as opposed to biochemical inhibition of the phosphate transfer reaction in the well-known TREE<i>spot</i> interaction map<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and in tabular format for the kinases which <b>51</b> bound to most tightly (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Remarkably, <b>51</b> only fully binds JAK2 at the test concentration of 100 nM. There are no kinases inhibited in the 0.1–1.0% control range or 1–5% range, giving a low “S” score of <0.1 indicating a high degree of kinase selectivity for this compound. Eight other nonmutant kinases were bound by <b>51</b> at lower levels including TYK2 and JAK3, with 4.9 and 7.9% of control, respectively. These data correlate with biochemical IC<sub>50</sub>s in the 100 s of nanomolar, which is consistent with the data depicted in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Phosphoinositol-dependent kinase gamma (PI3K-γ) was also hit (5.7% of control). PI3K-γ is itself a relevant cancer target with no reports of selective compounds yet published in the literature.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96, 97)</a> The other 5 kinases hit by <b>51</b> were all significantly less active.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0025.jpeg" id="GRAPHIC-d88e1913-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Kinase panel screening data of compound <b>51</b> against 97 kinases (DiscoveRx) tested at a concentration of 100 nM. The TREE<i>spot</i> map indicates the very high selectivity of compound <b>51</b>. From 90 nonmutated kinases only nine were hit with <35% of control binding remaining (approximately equates to an IC<sub>50</sub> of around 10 μM). “S” scores are all less than 0.1, indicating a high degree of kinase selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Of 11 tested HDAC isoforms, compound <b>51</b> was very weakly active against the four class IIA HDACs 4, 5, 7, and 9 with less than 20% inhibition at 10 μM corresponding to >7000-fold selectivity over JAK2 and >5000-fold over HDAC6 (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Low micromolar potency against the class I isoform HDAC3 (IC<sub>50</sub> = 2.17 μM) still represented a high selectivity of >1000-fold for both JAK2 and HDAC6. The next most active isoforms were HDACs 11 and 8, with IC<sub>50</sub>s of 0.93 μM and 0.74 μM, respectively (SI of 352–664 for JAK2 and HDAC6). HDAC1 was next most potently inhibited followed by HDACs 2, 10, and 1, with IC<sub>50</sub>s of 49, 80, and 222 nM, respectively. It is perhaps not surprising that <b>51</b> is potent against HDAC10, a class IIB isoform like HDAC6. However, the selectivities within the class I isoforms HDACs 1, 2, 3, and 8 are more varied than expected with HDAC2, having the lowest IC<sub>50</sub> of 49 nM (23-fold selective versus HDAC6).</div><div class="NLM_p last">This enzyme inhibition data indicates that <b>51</b> is >50-fold selective for JAK2 over a broad panel of other kinases and >20-fold selective over HDAC6 compared to HDACs 2 and 10 and >100-fold selective over other HDAC isoforms. Compound <b>51</b> demonstrates that it is possible to achieve high potency with good selectivity for one member of each class from two distinctly different families of enzymes. Whether or not the observed selectivity transfers to cell lines was next explored with cancer cell proliferation and apoptosis assays, in both solid tumor and hematological cell lines, the latter characterized via specific pharmacodynamic biomarkers quantifying inhibitor modulation of the JAK2 and HDAC pathways.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Cellular Assays</h3><div class="NLM_p">Single agent JAK or HDAC inhibitors have been successfully launched in two indications: the JAK2-driven hematological malignancy myelofibrosis (ruxolitinib) and HDAC inhibitor sensitive T-cell lymphomas (including compound <b>1</b>, and belinostat). Recently panobinostat was approved as the first targeted HDAC agent to treat multiple myeloma.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Broadening of therapy into leukemias/lymphomas and solid tumors is highly desirable, and with this aim in mind much effort has been expended in the clinic to evaluate compounds inhibiting either the JAK or HDAC families with varying degrees of isoform selectivity. Notably, ruxolitinib has recently received wide coverage of its encouraging initial responses in combination with capecitabine (a prodrug of 5-FU) in patients with recurrent or treatment refractory metastatic pancreatic cancer, hinting at the potential value of JAK inhibitors in difficult to treat solid tumors.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Combination of ruxolitinib with panobinostat is being studied in the clinic for myelofibrosis, with the expectation that this combination could be extended to other indications if successful.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Solid Tumor Cell Lines</h4><div class="NLM_p">Given the emerging broader potential for a combination approach, we focused our initial efforts on the evaluation of our JAK–HDAC dual inhibitors in four solid tumor cell lines: breast cancer (MDA-MB-231, MCF-7), colorectal cancer (HCT-116), and prostate cancer (PC-3). Each compound was evaluated in a dose response study to establish their ability to inhibit cell proliferation (<a class="ref internalNav" href="#tbl5" aria-label="Tables 5">Tables 5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Compounds <b>1</b> and <b>2</b> were used as references with tubastatin as an HDAC6 selective inhibitor. IC<sub>50</sub> values obtained for these three reference compounds were generally in the low to submicromolar range and were within 3–5-fold of the reported values.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Solid Tumor Cell Proliferation Data for Carboxylic Acids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0020.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0021.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Values are the mean ± SD of at least 3 determinations unless noted.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Reported IC<sub>50</sub> values for <b>1</b>: MCF-7 (<i>c</i> 6 μM),<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> MDA-MB-231 (<i>c</i> 4.5 μM),<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> HCT-116 (2.85 μM), and PC-3 (1.21 μM).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Note that reported literature values vary depending on assay format.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">Reported IC<sub>50</sub> values for <b>2</b>: 1.69, 0.77, and 0.85 μM for HCT-116, PC-3, and MCF-7, respectively.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Compound <b>2</b> has not been reported for MDA-MB231.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">Ten-point dose response. NC = no dose response curve.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Solid Tumor Cell Proliferation Data for Hydroxamic Acids<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0022.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0023.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">See <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> footnotes. NC = no dose response curve.</p></div></div><div></div></div><div class="NLM_p">Because of the high polarity of the negatively charged carboxylic acids, we did not expected those compounds (<b>31</b>–<b>41</b>) to exhibit strong inhibition of cell proliferation. Despite this, even the poorly soluble JAK2-selective acids <b>31</b>–<b>33</b> had moderate IC<sub>50</sub>s in two cell lines. However, the zwitterionic piperidine acid <b>34</b> was more active, possibly due to improved solubility. Acid <b>36</b>, potent against JAK2 (IC<sub>50</sub> = 2.3 nM) and inhibiting HDAC6 in the low micromolar range (IC<sub>50</sub> = 2.6 μM), was more active against HCT-116 cells but in other cell lines the dose response was poor, with no sigmoidal curve fit possible. Short aliphatic chain acids <b>37</b>–<b>39</b> were tested in two cell lines and found to be weakly active. A longer six-carbon linker (<b>40</b>) conferred low micromolar HDAC6 inhibition and slightly improved cell activity while one carbon more (<b>41</b>) was less active against HDAC6 and slightly less active than <b>40</b> in all 4 cell lines. Clearly carboxylic acids are not potent in solid tumor cells.</div><div class="NLM_p last">We next studied the more HDAC potent hydroxamic acids in the same four cell lines. Aromatic hydroxamate <b>42</b> was more potent than expected, whereas its meta analogue, <b>43</b>, was only active against HCT-116 cells, perhaps due to poor physicochemical properties. Similarly, although phenolic ether <b>44</b> was potent against PC-3 cells, its poor solubility hampered studies in other cells. In general, a similar trend was seen as for the carboxylic acid analogues: the basic piperidine <b>45</b> was quite potent across all cell lines, most likely driven by its very potent JAK2 activity and higher solubility. This compound is a close analogue of <b>2</b>, with a tertiary amine two carbons distant from the oxygen in the side chain. This amine is well placed to form an electrostatic interaction with Asp939 in JAK2, similar to <b>2</b>, as demonstrated in extensive modeling studies<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> that will account for it having the best JAK2 potency of all the compounds. However, it had very weak HDAC6 inhibition (HDAC6 IC<sub>50</sub> is only 899 nM) compared to the other compounds with similar length, indicating the HDAC channel does not tolerate the tertiary amine so close to the hydroxamic acid. Despite being highly potent against both JAK2 and HDAC6, long chain analogues <b>46</b> and <b>47</b>, direct analogues of <b>1</b>, were only weakly active in these cells. The only exception was <b>47</b>, with an IC<sub>50</sub> of 3.43 μM in MB-MDA-231 cells. More positive results were obtained with directly attached aliphatic side chains of 3–7 carbons for compounds <b>48</b>–<b>52</b>, respectively. The best solid tumor cell potency of these analogues was obtained for six-carbon linked <b>51</b>, also the most potent inhibitor of JAK2 and HDAC6 with IC<sub>50</sub> values of 1.4 and 2.1 nM, respectively. Compound <b>51</b> had the lowest IC<sub>50</sub> values in all cell lines tested with the exception of HCT-116, where piperidine <b>45</b> and short chain <b>49</b> were more potent.</div></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Hematological Cell Lines</h4><div class="NLM_p">We studied the potency of selected compounds in a range of blood/bone marrow derived cancer cells. JAK and HDAC inhibitors have wide application to blood cancers as discussed previously and are expected to be sensitive to dual pathway inhibition. Dual inhibitors were selected on the basis of their IC<sub>50</sub> against <i>both</i> JAK2 and HDAC6 of less than 50 nM. Hence compounds <b>46</b>, <b>47</b>, <b>50</b>, <b>51</b>, and <b>52</b> were assessed in three hematological cells lines: the AML cell line HL-60, the erythroleukemia (EL) cell line HEL92.1.7 (expressing mutated JAK2<sup>V617F</sup>), and the acute T-cell leukemia cell line Jurkat (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). All compounds were more potent in these cell lines than in solid tumor cell lines. Compound <b>51</b>, having the strongest profile in vitro, was the most potent compound with around 1 μM IC<sub>50</sub> values in the HEL and Jurkat cell lines and about 4 μM in the FLT-3 sensitive HL-60 AML cell line. The JAK1/2 selective inhibitor ruxolitinib was not potent in these cells, indicating a lack of sensitivity to JAK pathway inhibition. However, they are sensitive to HDAC blockade indicated by the activity of <b>1</b>. Tubastatin is not potent, indicating lack of sensitivity to HDAC6. Compound <b>51</b> has similar potency to <b>1</b> and <b>2</b> in HEL and Jurkat cells probably driven by its HDAC/FLT-3 potency. This data suggests that the broad potency of <b>51</b> could be due to its ability to block multiple pathways but not necessarily eliciting synergy between those pathways in terms of inhibition of proliferation.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Cell Proliferation Inhibition Assay Data of Selected Compounds in Three Leukemia Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HL-60<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HEL92.1.7<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Jurkat<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tubastatin<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">≫4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">≫2<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">≫4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">2.28 ± 1.28</td><td class="colsep0 rowsep0" align="center">0.49 ± 0.10</td><td class="colsep0 rowsep0" align="center">0.59 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">1.78 ± 0.62</td><td class="colsep0 rowsep0" align="center">1.17 ± 0.03</td><td class="colsep0 rowsep0" align="center">1.09 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib<a class="ref internalNav" href="#t7fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">≫4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="center">≫4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">≫2<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">≫2<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>2<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">2.90 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="center">c.4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a>,<a class="ref internalNav" href="#t7fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="center">0.94 ± 0.22</td><td class="colsep0 rowsep0" align="center">1.19 ± 0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="center">>4<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">>2<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">2.48 ± 0.21</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Antiproliferative inhibitory activities are the average of at least 3 determinations.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Acute myeloid leumekia.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Erythroleukemia (JAK2<sup>V617F</sup>).</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Acute T-cell leukemia.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">HDAC6 selective inhibitor.</p></div><div class="footnote" id="t7fn6"><sup>f</sup><p class="last">Pan-HDAC inhibitor.</p></div><div class="footnote" id="t7fn7"><sup>g</sup><p class="last">JAK2/FLT3 selective inhibitor. Literature data:<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> HL-60, 0.52 μM; HEL92.1.7, 1.726 μM; Jurkat, 0.839 μM. Note that other JAK2 inhibitors are similar.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></p></div><div class="footnote" id="t7fn8"><sup>h</sup><p class="last">JAK1/JAK2 selective.</p></div><div class="footnote" id="t7fn9"><sup>i</sup><p class="last">Top concentration tested.</p></div><div class="footnote" id="t7fn10"><sup>j</sup><p class="last">47% inhibition at 4 μM.</p></div></div></div><div class="NLM_p">Given the clear superiority of <b>51</b>, we continued our studies in an expanded range of cell lines. Hence <b>51</b> was tested against the multiple myeloma (MM) cell lines KMS-12-BM and OPM-2, with different translocations in MM (t4:14 and t11:14), respectively, both being translocations which correspond to poor prognosis in MM<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104, 105)</a> (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). An additional two AML cell lines, KG-1 and MOLM-14, were selected, where MOLM-14 has a FLT3-ITD mutation while KG1 does not. MOLM-14 is a M5 stage (FAB) cancer, while KG-1 is a M6 stage (FAB) cancer.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106, 107)</a> Finally, two natural killer T-cell lymphoma (NKTCL) cell lines, NKYS and KHYG,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> with positive and negative EBV status,<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> respectively, were tested against <b>51</b>. NK cell neoplasms have been shown to be sensitive to compound <b>1</b> due to suppression of the JAK-STAT pathway, suggesting that a combination of both JAK and HDAC inhibition could be an effective strategy.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Antiproliferative potency of <b>51</b> in these six cell lines ranged from 1.08 to 2.11 μM, with the most sensitive cell lines being the NK T-cell lymphoma. Compound <b>51</b> was broadly potent at low micromolar concentrations, potentially supporting dual pathway blockage as an efficacious strategy. Most likely the very high potency of <b>2</b> in MOLM-14 cells is largely due to the very potent FLT-3 activity of this compound.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Cell Proliferation Inhibition Assay Data of <b>51</b> and Reference Standards in a Range of Hematological Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" char="±" /></col><col align="left" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">KMS-12-BM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">OPM-2<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">KG-1<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MOLM-14<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">NKYS<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">KHYG<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left" char="±">0.94 ± 0.24</td><td class="colsep0 rowsep0" align="left" char="±">2.91 ± 0.87</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t8fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left" char="±">0.75 ± 0.24</td><td class="colsep0 rowsep0" align="left" char="±">1.21 ± 0.65</td><td class="colsep0 rowsep0" align="left">1.48<a class="ref internalNav" href="#t8fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">0.079<a class="ref internalNav" href="#t8fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">1.60<a class="ref internalNav" href="#t8fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">1.24<a class="ref internalNav" href="#t8fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left" char="±">2.11 ± 0.91</td><td class="colsep0 rowsep0" align="left" char="±">2.05 ± 0.89</td><td class="colsep0 rowsep0" align="left">1.63 ± 0.53</td><td class="colsep0 rowsep0" align="left">1.14 ± 0.39</td><td class="colsep0 rowsep0" align="left">1.08 ± 0.22</td><td class="colsep0 rowsep0" align="left">1.09 ± 0.45</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Antiproliferative inhibitory activities are the average of at least three determinations unless noted.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Multiple myeloma.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Acute myeloid leumekia.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Natural killer T-cell lymphoma.</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last">Pan-HDAC inhibitor.</p></div><div class="footnote" id="t8fn6"><sup>f</sup><p class="last">JAK2/FLT3 inhibitor.</p></div><div class="footnote" id="t8fn7"><sup>g</sup><p class="last">Single determination of an 8-dose response in triplicate. Blank cells = not tested.</p></div></div></div><div class="NLM_p">A more physiologically relevant measure of a compound’s antiproliferative potential is to study its effects in blocking the formation of colonies of tumor cells growing in a 3D matrix. Compound <b>51</b> was tested against HEL92.1.7 cells grown over 14–16 days in methylcellulose and effectively blocked colony formation in a dose-dependent manner and at concentrations similar to its IC<sub>50</sub> against cells growing in 2D culture (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). Visually, photographs of selected colonies clearly indicate the potent antigrowth effects of compound <b>51</b>.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>51</b> effectively blocks colony formation in the erythroleukemia cell line HEL92.1.7 expressing endogenous JAK2<sup>V617F</sup>. HEL92.1.7 cells were grown in methylcellulose (ClonaCell-TCS medium) and treated with compound <b>51</b> at the respective concentrations. After 14–16 days, colonies were counted. (A) Bar graph indicating dose response based on total cell populations. Data is presented as mean ± SEM. (B) Photographs of selected colonies indicating controls (a1, a2), treatment with <b>51</b> at 0.2 μM (b1, b2), 1.0 μM (c1, c2), and 2.0 μM (d1, d2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having identified compound <b>51</b> as a preferred dual inhibitor, we wondered if it would be as toxic to a normal cell as is it is to the range of cancer cells tested. Hence we tested both <b>51</b> and <b>52</b> in transforming growth factor-α mouse hepatocytes (TAMH) (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>), comparing with 1 and 2 as controls. Compound <b>51</b> inhibited the proliferation of TAMH cells with an IC<sub>50</sub> of 9.57 μM, whereas <b>2</b> was nearly three times more potent (IC<sub>50</sub> of 3.68 μM). Compounds <b>1</b> and <b>52</b> were also slightly more potent than <b>51</b>. This data suggests that dual inhibitors are not simply toxic to every cell line.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Cell Proliferation Assay Data of Compounds in a Normal Cell Line</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">TAMH IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">therapeutic window (TAMH IC<sub>50</sub>/cancer cell IC<sub>50</sub>)<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">7.86 ± 2.2</td><td class="colsep0 rowsep0" align="char" char=".">13.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">3.68 ± 0.88</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char="±">9.57 ± 1.00</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="char" char="±">5.26 ± 0.24</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Average of 4 determinations.</p></div><div class="footnote" id="t9fn2"><sup>b</sup><p class="last">Pan-HDAC.</p></div><div class="footnote" id="t9fn3"><sup>c</sup><p class="last">JAK2/FLT3.</p></div><div class="footnote" id="t9fn4"><sup>d</sup><p class="last">Based on the most sensitive cell lines with average IC<sub>50</sub>s of 0.6 μM for <b>1</b>, 1.2 μM for <b>2</b> (excluding MOLM-14), 1.1 μM for <b>51</b>, and 2.9 μM for <b>52</b>.</p></div></div></div><div class="NLM_p last">Cell proliferation is a phenotypic readout that could result from off target effects, hence we next set out to prove that <b>51</b> blocked both the JAK-STAT pathway and HDAC mediated deacetylation in cells.</div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Intracellular Mechanism of Action</h3><div class="NLM_p">To investigate whether the dual enzyme inhibition profile of <b>51</b> translates into intracellular inhibition against both the JAK-STAT and HDAC pathways, we studied the effects of <b>51</b> in the MM cell line KMS-12-BM and the AML cell line MOLM-14. Compound <b>51</b> was tested at approximately 2 × IC<sub>50</sub>, where it showed increased histone-3 acetylation (Ac-H3 (Lys9/Lys14)), mediated by HDACs 1, 2, and 3,<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> and potent increase of acetylated tubulin (Ac-tubulin), mediated by HDAC6.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The HDAC6 selective inhibitor tubastatin (15 μM)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> was used as a positive control and indicated a significant increase in Ac-tubulin but no increase in Ac-H3 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A,B). Exposure of the cells to <b>51</b>, in a time course from 0 to 48 h, led to an increase of Ac-H3 indicating strong blockade of HDAC1/2/3 signaling. The in vitro selectivity profile of <b>51</b> is apparently sufficient to induce inhibition of histone deacetylation in cells. Increase of <b>51</b>-induced Ac-H3 peaked at 16 and 4 h in KMS-12-BM and MOLM-14 cells, respectively, and was still detectable at 48 h (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A,B). Similar effects were seen in both cell lines for Ac-tubulin, where <b>51</b> showed strong and constant induction of Ac-tubulin up to 48 h in KMS-12-BM cells and peaking at 16 h in MOLM-14 cells. Having shown that the HDAC enzyme inhibition profile led to the induction of Ac-H3 and Ac-tubulin by <b>51</b> in cells, we next studied the effects of <b>51</b> on the JAK-STAT pathway. Using <b>2</b> as a positive control at its IC<sub>50</sub> value in KMS-12-BM and MOLM-14 cells, STAT3 levels were significantly reduced (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C,D). Similarly, a dose response study with <b>51</b> revealed progressively increased suppression of STAT3 levels with increasing concentrations of the dual inhibitor. At concentrations around the proliferation IC<sub>50</sub> level, 1.5 μM, STAT3 was completely inhibited in both cell lines.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>51</b> effectively blocks dual signaling pathways in MM and AML cell lines. (A) KMS-12-BM and (B) MOLM-14 were treated with <b>51</b> at the respective concentrations and time points. Tubastatin was used as a positive control for HDAC6 inhibition (48 h treatment). After lysis, acetylated tubulin (Ac-Tubulin) and acetylated histone 3 (Ac-H3) were detected by immunoblotting. Subsequently, as a loading control, the same membranes were reprobed with tubulin and H3, respectively. (C) KMS-12-BM and (D) MOLM-14 were pretreated with <b>51</b> for 3 h and then were treated with 10 ng/mL of IL-6 for 15 min. Compound <b>2</b> was used as a positive control for the inhibition of the JAK2 pathway in each cell line at approximately its IC<sub>50</sub> concentration (2 μM for KMS-12-BM and 0.1 μM for MOLM-14). After lysis, p-STAT3(TY705) was detected by immunoblotting. The same membranes were reprobed with STAT3 to detect total protein levels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also studied the effects of <b>51</b> in V617F-expressing HEL92.1.7 cells (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A,B). Using <b>1</b> as a positive control, a strong increase in Ac-H3 was seen at 0.1, 0.5, and 1.0 μM. Compound <b>51</b> gave a dose response but with lower responses at the same concentrations, indicating effective HDAC1/2/3 pathway blockade but requiring higher concentrations compared to <b>1</b>. Approximately a 10-fold higher concentration of <b>51</b> was required to elicit the same Ac-H3 response as <b>1</b>. As expected from its potent HDAC6 inhibition, Ac-tubulin was more sensitive to the effects of <b>51</b>, with significant increases at the lowest concentration tested and a clear dose response. Even at 0.1 μM increase of Ac-tubulin could be seen with <b>51</b> but not with <b>1</b>. Hence <b>51</b> is 2 to 5-fold more sensitive than <b>1</b> for Ac-tubulin response. Comparing Ac-H3 to Ac-tubulin for compound <b>51</b> indicates that it is significantly more selective for HDAC6 in cells compared to SAHA. Considering that Ac-H3 is affected by HDAC1, 2, and 3 isoforms and Ac-tubulin is only affected by HDAC6, this data is consistent with the enzyme inhibitory profile of <b>51</b>. JAK-STAT pathway inhibition is clearly evident upon treatment of HEL92.1.7 cells with <b>51</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>C). Upregulation of phospho-JAK2 (p-JAK2) has been reported using the Y1007/8 p-JAK2 antibody described in studies with pacritnib in HEL92.1.7 cells.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Although phosphorylation of the specific Y1007/8 residue(s) increases, phosphorylation of the critical Y221 decreases as does total phosphorylation levels.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Compound <b>51</b> gives the same increase in p-JAK2 (Y1007/8) as <b>2</b> in this assay. Furthermore, upon treatment with <b>51</b>, STAT5 is decreased in this cell line at around its proliferation IC<sub>50</sub>, providing direct evidence for JAK pathway inhibition in HEL92.1.7 cells. Taken together, these data, in three hematological cell lines, provides strong evidence for dual JAK-STAT and HDAC pathway inhibition in cells induced by a single compound, <b>51</b>.</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>51</b> effectively blocks dual signaling pathways in the erythroleukemia cell line HEL92.1.7 expressing endogenous JAK2<sup>V617F</sup>. (A) HEL92.1.7 cells were treated with <b>1</b> and <b>51</b> at the respective concentrations for 1 h. After lysis, acetylated tubulin (Ac-tubulin) and acetylated histone 3 (Ac-H3) were detected by immunoblotting. Subsequently, as a loading control, the same membranes were reprobed with tubulin and H3, respectively. (B) Quantification of HDAC inhibitory responses by densitometry. (C) HEL92.1.7 cells were treated with <b>51</b> at the respective concentrations for 1 h. After lysis, p-JAK2 and p-STAT5 were detected by immunoblotting. The same membranes were reprobed with JAK2 and STAT5 to detect total protein levels. (D) Quantification of JAK inhibitory responses by densitometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Mechanism of Cell Death</h3><div class="NLM_p">We next wanted to confirm that the phenotypic observations of cell death induced by <b>51</b> were specifically due to apoptosis.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Early apoptosis involves translocation of membrane phosphatidylserine (PS) from the inner side of the plasma membrane to the surface. Annexin V, a Ca<sup>2+</sup>-dependent phospholipid-binding protein, has high affinity for PS, and fluorochrome-labeled annexin V can be used for the detection of exposed PS using flow cytometry.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> In the early stages of apoptosis, the cell membranes are still largely intact hence annexin V can enter and bind exposed PS, whereas propidium iodide (PI) cannot. In the later stages of apoptosis, the cell membrane is not intact and propidium iodide (PI) can also enter, giving a specific readout for dead cells. Conversely, viable cells with intact membranes exclude PI, therefore, cells that are considered viable are both annexin V and PI negative, while cells that are in early apoptosis are annexin V positive and PI negative, and cells that are in late apoptosis or already dead are both annexin V and PI positive. An effective strategy is to track the progress of cells over time through early to later phases of apoptosis, which further supports the assertion that the mechanism of cell death is indeed via apoptosis. Compound <b>51</b> was hence studied in a time course dose response experiment in the AML cell line MOLM-14 using doxorubicin as a positive control (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>B shows only 48 h data. For 4 and 24 h time points, see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a>. Both an increase in dose and time led to an increase in annexin V positive cells, indicating early apoptotic events. At 24 h, it became evident that cells were dying, shown by the increased levels of PI+ cells. At this time point, a dose response was achieved for both annexin V and PI, whereas at the earlier time point of 4 h no dose response was observed. At the later time point of 48 h, more cells were PI+, indicating late apoptosis (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>A,B).</div><figure id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound <b>51</b> triggers apoptosis in AML cell line, MOLM-14. (A) MOLM-14 cells were treated with compound <b>51</b> for 4, 24, and 48 h at the concentrations indicated and subsequently stained by annexin-V FITC and propidium iodide (PI). Fluorescence was measured via flow cytometry (LSRII), and at least 10000 events were analyzed. (B) Annexin V FITC vs propidium iodide plots from the gated cells show the populations corresponding to viable and nonapoptotic (annexin V–PI−), early (annexin V+PI−), and late (annexin V+PI+) apoptotic cells following 48 h treatment of compound <b>51</b> (for 4 and 24 h time points, see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a>) (C) MOLM-14 cells were treated with <b>51</b> at the respective concentrations and time points and then lysed. Doxorubicin (1 μM) was utilized as a positive control for induction of PARP cleavage. Cleaved PARP was detected by immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Poly(ADP-ribose) polymerase (PARP) has been implicated in cell death pathways via apoptosis.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115, 116)</a> During apoptosis, PARP is cleaved by caspases to give a N-terminal DNA binding domain. Increase in cleaved PARP upon drug treatment indicates cell death via apoptosis. Treatment of MOLM-14 cells with compound <b>51</b> led to dose related increases in cleaved PARP at both the 8 and 24 h time points (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>C). Taking all the data together, compound <b>51</b> has been shown to induce cell death via apoptosis.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Assessment of in Vitro Metabolism</h3><div class="NLM_p">Having identified compound <b>51</b> as a suitable dual-inhibitor template, we tested it and homologue <b>52</b> in male and female rat liver microsomes to assess the propensity of the template toward degradation by phase I metabolism. In female rat liver microsomes, <b>51</b> had a half-life of 26.3 min (apparent clearance of 10.7 L/h/kg) and was cleared more rapidly in male microsomes. Compound <b>52</b> showed no significant difference between male and female microsomes (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). Although <b>51</b> and <b>52</b> are rapidly cleared, this data compares favorably with <b>2</b>, which is reported to have a half-life in rat liver microsomes of 18 min.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Rat microsomal stability data for <b>51</b> and <b>52</b>. (A) Plot of parent remaining against time for male and female mirosomes. (B) The parameters of <i>T</i><sub>1/2</sub> and Cl<sub>int,app</sub> values (mean ± SD) for <b>51</b> and <b>52</b> (3 μM) upon incubation at 37 °C for 45 min in male (MRLM) and female (FRLM) rat liver microsomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec99" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, application of a pharmacophore merging strategy combining HDAC inhibitor <b>1</b> with JAK2/FLT3 inhibitor <b>2</b> resulted in the design and synthesis of a series of single-molecule dual-inhibitor macrocyclic carboxylic and hydroxamic acids. Following exploration of a range of aromatic and nonaromatic linkers, preferred compound <b>51</b>, applying a merged pharmacophore, was found to be optimal. Compound <b>51</b> has single-digit nanomolar potency against JAK2 and HDAC6, is selective within the JAK family and in a panel of 97 kinases, and has good potency (<100 nM) against HDACs 2 and 10 and submicromolar potency against HDACs 1, 8, and 11. Broad antiproliferative potency was observed for <b>51</b> across a range of solid and hematological cell lines. This activity translated into inhibition of tumor cell colony formation. In detailed studies in AML, MM, and EL cell lines <b>51</b> was shown to block both the JAK-STAT and HDAC pathways at concentrations around or below its IC<sub>50</sub>. Apoptosis was shown to be the mechanism of cell death via annexin V/PI studies and dose- and time-related increases in cleaved PARP. Compound <b>51</b> (EY3238) was also shown to be cleared in rat liver microsomes with a half-life of just over 25 min. This first detailed demonstration of isoform-selective JAK–HDAC bispecific inhibitors provides useful tool compounds for further studies of multiple pathway inhibition achieved with a single DML molecule.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Synthesis of Compounds</h3><div class="NLM_p">Unless stated otherwise, all nonaqueous reactions were performed in oven-dried round-bottom flasks under an inert nitrogen atmosphere. Commercially available AR grade solvents or anhydrous solvents packed in resealable bottles were used as received. All reaction temperatures stated in the procedures are external bath temperatures. Commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, TCI Chemicals, or Strem chemicals and used as received without further purification unless otherwise stated. Yields refer to chromatographically and spectroscopically homogeneous materials unless otherwise stated. Reaction progress was monitored by analytical thin layer chromatography (TLC) with 0.25 mm Merck precoated silica gel plates (60F-254) using UV light (254 nm) as visualizing agent and ceric ammonium molybdate or potassium permanganate solutions as developing stains. Flash chromatography was performed on silica gel 60 (0.040–0.063 mm) purchased from SiliCycle or Merck. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AMX400 (400 MHz) NMR spectrometer at ambient atmosphere. The deuterated solvent used was CDCl<sub>3</sub> unless otherwise stated. Chemical shifts are reported in parts per million (ppm), and residual undeuterated solvent peaks were used as internal reference: proton (7.26 ppm for CDCl<sub>3</sub>, 2.50 ppm for DMSO-<i>d</i><sub>6</sub>), carbon (77.0 ppm for CDCl<sub>3</sub>, 39.52 ppm for DMSO-<i>d</i><sub>6</sub>). <sup>1</sup>H NMR coupling constants (<i>J</i>) are reported in hertz (Hz), and multiplicities are presented as follows: s (singlet), d (doublet), t (triplet), m (multiplet), and br (broad). Low resolution mass spectra were obtained on an Agilent 6130B quadrupole LC/MS in ESI mode with an Agilent 1260 Infinity LC system using a ThermoScientific Hypersil 150 mm × 2.1 mm 5 μm column or a Shimadzu LCMS-2020 in ESI mode. Purity of the compounds were assessed by high pressure liquid chromatography by detection at 254 nm using an Agilent 1200 series HPLC system with a Zorbax SB-C18 5 μm 4.6 mm × 250 mm column using a gradient elution starting from a 5% solution of acetonitrile and 1% trifluoroacetic acid (TFA) and a 95% solution of water and 1% TFA to a 100% solution of acetonitrile and 1% TFA at 0.5 mL per minute over 15 min. HPLC purity is above 99% unless stated. For macrocycles which are isolated as <i>trans:cis</i> isomers, only data for the major <i>trans</i> isomer is reported below. Compounds <b>2</b> and <b>3</b> were a gift from S*BIO Pte Ltd. Ruxolitinb and Tubastatin were purchased from Selleckchem (<a href="http://www.selleckchem.com" class="extLink">www.selleckchem.com</a>).</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 11-(2-Chloroethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>3</b>)</h4><div class="NLM_p last">Following the literature procedure,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> 29.4 mg (0.0631 mmol) of the diallyl compound <b>S4</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a>) and 6.7 mg (0.00789 mmol, 0.13 equiv) of the second-generation Grubbs catalyst were dissolved in 14 mL of degassed DCM (5 mM concentration) to obtain an orange solution. One mL of 4 M hydrochloric acid was added, changing the solution to yellow color. The reaction mixture was refluxed for 3 h. After cooling to rt, the reaction was quenched with saturated sodium bicarbonate solution and extracted with DCM three times. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate. The organic layer was concentrated and purified by column chromatography using 3:2 Hex/EtOAc to obtain 17.1 mg (62%) in a 87:13 <i>E</i>/<i>Z</i> ratio of macrocycle <b>3</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 438.0 (M + H<sup>+</sup>). <i>E</i> isomer only: <sup>1</sup>H NMR δ 8.70 (s, 1 H), 8.47–8.40 (m, 1 H), 8.30 (s, 1 H), 7.81 (d, <i>J</i> = 7.8 Hz, 1 H), 7.60 (d, <i>J</i> = 7.7 Hz, 1 H), 7.49 (t, <i>J</i> = 7.7 Hz, 1 H), 7.39 (br s, 1 H), 7.17 (d, <i>J</i> = 5.3 Hz, 1 H), 6.85 (s, 2 H), 5.92–5.77 (m, 2 H), 4.66 (d, <i>J</i> = 2.6 Hz, 4 H), 4.26 (t, <i>J</i> = 5.8 Hz, 3 H), 4.17 (d, <i>J</i> = 4.9 Hz, 2 H), 4.07 (d, <i>J</i> = 4.4 Hz, 2 H), 3.87–3.80 (m, 2 H). <sup>13</sup>C NMR δ 164.3, 160.2, 158.7, 151.5, 138.6, 137.1, 134.1, 132.0, 130.9, 129.9, 128.9, 127.9, 127.7, 126.3, 121.4, 119.2, 113.7, 107.9, 70.2, 69.5, 69.3, 67.6, 65.6, 42.2, 29.7.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 11-(2-<i>N</i>-(<i>tert</i>-Butyl 4-(Methoxycarbonyl)phenylcarbamate)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>4</b>)</h4><div class="NLM_p last">Macrocycle chloride (0.147 g, 0.335 mmol) (<b>3</b>), 0.183 g (0.562 mmol, 1.7 equiv) of cesium carbonate, 0.122 g (0.330 mmol, 1.0 equiv) of tetrabutylammonium iodide, and 0.129 g (0.514 mmol, 1.5 equiv) of <b>4a</b> was mixed, and 3 mL of DMF was added. The mixture was stirred at 120 °C for 16 h. The mixture was cooled to rt and diluted with water. It was extracted with ethyl acetate three times. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate. The organic layer was concentrated and purified by column chromatography using 2:1 to 1:1 to 2:3 Hex/EtOAc solution to obtain 117 mg (53%) of <b>4</b> as a yellow solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.31. LRMS (ESI) <i>m</i>/<i>z</i> 653.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.60 (d, <i>J</i> = 2.6 Hz, 1 H), 8.38 (d, <i>J</i> = 5.1 Hz, 1 H), 8.25 (s, 1 H), 8.06–8.01 (m, 2 H), 7.82–7.76 (m, 2 H), 7.58 (d, <i>J</i> = 7.7 Hz, 1 H), 7.47 (t, <i>J</i> = 7.7 Hz, 1 H), 7.42–7.37 (m, <i>J</i> = 8.7 Hz, 2 H), 7.13 (d, <i>J</i> = 5.3 Hz, 1 H), 6.83 (dd, <i>J</i> = 2.6, 8.7 Hz, 1 H), 6.77 (d, <i>J</i> = 8.7 Hz, 1 H), 5.81–5.76 (m, 2 H), 4.62 (s, 2 H), 4.33 (s, 2 H), 4.19–4.14 (m, 2 H), 4.04 (d, <i>J</i> = 4.0 Hz, 2 H), 4.01 (d, <i>J</i> = 4.5 Hz, 2 H), 3.91 (s, 3 H), 1.45 (s, 9 H). <sup>13</sup>C NMR δ 166.5, 164.3, 160.0, 158.4, 154.0, 151.6, 147.3, 138.5, 137.0, 133.4, 132.0, 130.9, 130.1, 129.8, 128.8, 127.6, 127.1, 126.9, 126.3, 126.2, 121.4, 119.2, 111.9, 107.6, 81.1, 70.1, 69.2, 67.4, 66.8, 65.3, 52.0, 49.6, 28.2.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 11-(2-(<i>tert</i>-Butyl 3-(Methoxycarbonyl)phenylcarbamate)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>5</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>4</b> using 190 mg (0.434 mmol) of <b>3</b>, 447 mg (1.37 mmol, 3.2 equiv) of cesium carbonate, 201 mg (0.544 mmol, 1.3 equiv) of tetrabutylammonium iodide, and 171 mg (0.678 mmol, 1.6 equiv) of <b>5a</b>. The compound was purified by column chromatography using 2:1 to 1:1 Hex/EtOAc solution to obtain 127 mg (45%) of <b>5</b> as a yellow solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.24. LRMS (ESI) <i>m</i>/<i>z</i> 653.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.44 (d, <i>J</i> = 2.64 Hz, 1H), 8.25 (d, <i>J</i> = 5.15 Hz, 1H), 8.13 (s, 1H), 7.83 (s, 1H), 7.75–7.80 (m, 1H), 7.68 (d, <i>J</i> = 7.91 Hz, 1H), 7.48 (d, <i>J</i> = 9.29 Hz, 2H), 7.32–7.40 (m, 2H), 7.30 (d, <i>J</i> = 7.78 Hz, 1H), 7.13 (s, 1H), 7.03 (d, <i>J</i> = 5.27 Hz, 1H), 6.72 (dd, <i>J</i> = 2.70, 8.72 Hz, 1H), 6.66 (d, <i>J</i> = 8.66 Hz, 1H), 5.66 (q, <i>J</i> = 5.14 Hz, 2H), 4.50 (s, 2H), 4.23 (s, 2H), 4.01–4.06 (m, 2H), 3.95–4.01 (m, 3H), 3.92 (d, <i>J</i> = 4.52 Hz, 2H), 3.88 (d, <i>J</i> = 4.77 Hz, 2H), 3.79 (s, 3H), 1.28–1.36 (m, 9H). <sup>13</sup>C NMR δ 166.5, 164.7, 159.7, 157.8, 154.3, 151.8, 143.2, 138.6, 136.9, 133.1, 132.1, 131.8, 131.1, 130.9, 129.8, 129.0, 128.7, 127.9, 127.7, 127.1, 127.1, 126.3, 121.4, 119.4, 112.0, 107.6, 81.0, 70.1, 69.2, 67.5, 66.7, 65.3, 52.2, 49.6, 28.3.</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 11-(2-(Methyl 4-Hydroxybenzoate))-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>6</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>4</b> using 201 mg (0.459 mmol) of <b>3</b>, 307 mg (0.943 mmol, 2.0 equiv) of cesium carbonate, 169 mg (0.457 mmol, 1.0 equiv) of tetrabutylammonium iodide, and 142 mg (0.932 mmol, 2.0 equiv) of <b>6a</b>. The crude product was purified by column chromatography using 2:1 to 2:3 to 1:2 Hex/EtOAc solution to obtain 206 mg (82%) of <b>6</b> as a yellow solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.22. LRMS (ESI) <i>m</i>/<i>z</i> 554.2 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.65 (d, <i>J</i> = 2.3 Hz, 1 H), 8.40 (br s, 1 H), 8.28 (s, 1 H), 8.05–7.99 (m, 2 H), 7.81 (d, <i>J</i> = 7.7 Hz, 1 H), 7.60 (d, <i>J</i> = 7.3 Hz, 2 H), 7.52–7.45 (m, 1 H), 7.17 (d, <i>J</i> = 5.3 Hz, 1 H), 7.02–6.96 (m, 2 H), 6.95–6.84 (m, 2 H), 5.87–5.78 (m, 2 H), 4.66–4.60 (m, 2 H), 4.59 (s, 2 H), 4.43–4.33 (m, 4 H), 4.09 (d, <i>J</i> = 4.5 Hz, 2 H), 4.05 (d, <i>J</i> = 4.0 Hz, 2 H), 3.93–3.84 (m, 3 H). <sup>13</sup>C NMR δ 166.8, 164.7, 162.5, 159.7, 157.9, 151.9, 138.7, 136.9, 133.7, 131.9, 131.6, 131.1, 129.9, 129.0, 127.9, 127.7, 126.4, 122.9, 121.4, 119.5, 114.3, 113.6, 107.8, 70.1, 69.3, 68.0, 67.6, 66.7, 65.6.</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 11-(2-<i>N</i>-(<i>tert</i>-Butyl 4-Nitrophenylcarbamate)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>7</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>4</b> using 432 mg (0.988 mmol) of <b>3</b>, 387 mg (1.19 mmol, 1.2 equiv) of cesium carbonate, 185 mg (0.502 mmol, 0.51 equiv) of tetrabutylammonium iodide, and 275 mg (1.15 mmol, 1.2 equiv) of <b>7a</b> in 4 mL of DMF. The crude product was purified by column chromatography using 1:1 Hex/EtOAc solution to obtain 395 mg (62%) of <b>7</b> as a light-yellow solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.18. LRMS (ESI) <i>m</i>/<i>z</i> 640.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.64 (d, <i>J</i> = 2.4 Hz, 1 H), 8.40 (d, <i>J</i> = 5.3 Hz, 1 H), 8.26 (s, 1 H), 8.25–8.19 (m, 2 H), 7.80 (d, <i>J</i> = 7.8 Hz, 1 H), 7.62–7.52 (m, 4 H), 7.51–7.45 (m, 1 H), 7.15 (d, <i>J</i> = 5.3 Hz, 1 H), 6.86–6.77 (m, 2 H), 5.82–5.77 (m, 2 H), 4.63 (s, 2 H), 4.34 (s, 2 H), 4.24–4.19 (m, 2 H), 4.17–4.11 (m, 2 H), 4.06 (d, <i>J</i> = 3.9 Hz, 2 H), 4.01 (d, <i>J</i> = 4.3 Hz, 2 H), 1.52–1.45 (m, 9 H). <sup>13</sup>C NMR δ 164.4, 160.1, 158.5, 153.5, 151.6, 149.1, 144.7, 138.6, 137.1, 133.7, 131.6, 131.0, 130.1, 128.9, 127.6, 126.9, 126.6, 126.3, 124.1, 121.5, 119.2, 112.2, 107.8, 82.0, 70.1, 69.4, 67.6, 67.0, 65.4, 49.9, 28.2.</div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 11-(2-(Methyl Isonipecotate)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>8</b>)</h4><div class="NLM_p last"><b>3</b> (1.00 g, 2.29 mmol) was dissolved in 20 mL of acetonitrile. Then 0.90 mL (6.66 mmol, 2.9 equiv) of <b>8a</b> was added to the solution and it was refluxed for 64 h. The solution was cooled to rt and concentrated. The crude product was purified by column chromatography using 45:55 to 3:7 Hex/EtOAc to EtOAc to 9:1 EtOAc/MeOH to give 255 mg (25%) of recovered <b>1</b> and 771 mg (62%) of <b>8</b> as a yellow solid. TLC (10:1 EtOAc/MeOH) <i>R</i><sub>f</sub> = 0.16. LRMS (ESI) <i>m</i>/<i>z</i> 544.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.68 (s, 1 H), 8.40 (d, <i>J</i> = 5.1 Hz, 1 H), 8.29 (s, 1 H), 7.79 (d, <i>J</i> = 7.8 Hz, 1 H), 7.61–7.55 (m, 2 H), 7.51–7.44 (m, 1 H), 7.14 (d, <i>J</i> = 5.3 Hz, 1 H), 6.86–6.82 (m, 2 H), 5.91–5.77 (m, 2 H), 4.64 (s, 2 H), 4.60 (s, 2 H), 4.20–4.10 (m, 4 H), 4.06 (d, <i>J</i> = 4.5 Hz, 2 H), 3.70–3.65 (m, 3 H), 3.09–3.00 (m, 2 H), 2.89 (t, <i>J</i> = 5.6 Hz, 2 H), 2.41–2.30 (m, 3 H), 2.02–1.93 (m, 2 H), 1.92–1.80 (m, 2 H). <sup>13</sup>C NMR δ 175.1, 164.2, 160.2, 158.7, 151.9, 138.6, 137.1, 133.5, 131.9, 130.9, 129.9, 128.9, 127.6, 127.0, 126.2, 121.4, 119.2, 112.7, 107.7, 77.2, 70.0, 69.3, 67.6, 66.7, 65.8, 57.2, 53.1, 51.6, 40.3, 27.8.</div></div><div id="sec3_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 11-(2-<i>N</i>-(<i>tert</i>-Butyl 4-Aminophenylcarbamate)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>9</b>)</h4><div class="NLM_p last"><b>7</b> (395 mg, 0.617 mmol), 140 mg (2.51 mmol, 4.0 equiv) of iron, and 219 mg (4.10 mmol, 6.6 equiv) of ammonium chloride were dissolved in 10 mL of ethanol, 5 mL of ethyl acetate, and 3 mL of water. Compound <b>9</b> was used without further purification. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.09. LRMS (ESI) <i>m</i>/<i>z</i> 610.3 (M + H<sup>+</sup>).</div></div><div id="sec3_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 11-(2-(<i>tert</i>-Butyl 4-(Methyl 7-Carbamoylpentanoyl)phenylcarbamate))-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21, 23-decaene (<b>10</b>)</h4><div class="NLM_p last">Aniline <b>9</b> (100.3 mg, 0.1645 mmol), 30 μL (0.2025 mmol, 1.2 equiv) of monomethyl adipate (<b>10a</b>), 85.1 mg (0.224 mmol, 1.4 equiv) of HATU, and 43 μL (0.307 mmol, 1.9 equiv) of triethylamine were dissolved in 2 mL of DMF and stirred at 60 °C for 18 h. The reaction was cooled to rt, diluted with water, and extracted with ethyl acetate three times. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate.. The crude product was purified by column chromatography using 2:3 to 1:4 Hex/EtOAc to EtOAc solution to obtain 97.5 mg (79%) of <b>10</b> as a yellow amorphous solid (contains 1:1 DMF). TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.51. LRMS (ESI) <i>m</i>/<i>z</i> 752.4 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.48 (d, <i>J</i> = 2.51 Hz, 1H), 8.35 (d, <i>J</i> = 5.65 Hz, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 7.78–7.87 (m, 2H), 7.62 (d, <i>J</i> = 7.78 Hz, 1H), 7.47–7.57 (m, 3H), 7.16–7.23 (m, 3H), 6.87 (dd, <i>J</i> = 2.70, 8.72 Hz, 1H), 6.78 (d, <i>J</i> = 8.78 Hz, 1H), 5.73–5.87 (m, 2H), 4.62 (s, 2H), 4.48 (s, 2H), 4.08–4.15 (m, 4H), 3.99–4.06 (m, 4H), 3.67 (s, 3H), 2.32–2.43 (m, 4H), 1.63–1.80 (m, 4H). <sup>13</sup>C NMR δ 174.0, 171.0, 162.7, 158.1, 155.5, 154.8, 152.3, 138.8, 136.2, 131.8, 129.7, 129.1, 127.9, 127.7, 127.3, 126.7, 121.8, 120.0, 112.0, 107.5, 80.6, 70.2, 69.2, 67.6, 66.3, 65.4, 51.6, 49.5, 38.6, 37.0, 36.5, 33.6, 28.3, 24.9, 24.4, 24.2.</div></div><div id="sec3_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 11-(2-(<i>tert</i>-Butyl 4-(Methyl 7-Carbamoylhexanoyl)phenylcarbamate))-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>11</b>)</h4><div class="NLM_p last">Synthesized using the method for <b>10</b> with 83.3 mg (0.137 mmol) of <b>9</b>, 36 μL (0.203 mmol, 1.5 equiv) of ethyl hydrogen pimelate (<b>11a</b>), 63.3 mg (0.166 mmol, 1.2 equiv) of HATU, and 40 μL (0.285 mmol, 2.1 equiv) of triethylamine. The crude product was purified by column chromatography using 3:7 to 1:3 Hex/EtOAc solution to obtain 78.0 mg (73%) of <b>11</b> as a pale-yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.36. LRMS (ESI) <i>m</i>/<i>z</i> 780.4 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.58 (d, <i>J</i> = 2.51 Hz, 1H), 8.33–8.42 (m, 1H), 8.27 (s, 1H), 7.75–7.85 (m, 2H), 7.55–7.67 (m, 2H), 7.43–7.55 (m, 3H), 7.11–7.23 (m, 3H), 6.85 (dd, <i>J</i> = 2.76, 8.66 Hz, 1H), 6.78 (d, <i>J</i> = 8.78 Hz, 1H), 5.72–5.89 (m, 2H), 4.63 (s, 2H), 4.48 (s, 2H), 3.97–4.20 (m, 12H), 3.25–3.42 (m, 1H), 2.24–2.42 (m, 7H), 1.56–1.78 (m, 7H), 1.32–1.56 (m, 13H), 1.19–1.31 (m, 5H). <sup>13</sup>C NMR δ 173.7, 171.2, 164.8, 159.7, 157.7, 154.8, 151.9, 138.6, 136.9, 136.2, 132.1, 131.1, 129.7, 128.9, 127.7, 127.7, 127.1, 126.3, 121.4, 119.9, 119.5, 112.1, 107.6, 70.1, 69.2, 67.5, 66.4, 65.5, 60.2, 60.1, 49.6, 37.2, 34.1, 34.0, 32.8, 28.9, 28.5, 28.3, 25.1, 25.0, 24.7, 24.6, 24.4, 14.2.</div></div><div id="sec3_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 11-(2-(<i>tert</i>-Butyl 4-(Methyl 7-Carbamoylheptanoyl)phenylcarbamate))-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>12</b>)</h4><div class="NLM_p last">Monomethyl suberate, (73.5 mg, 0.391 mmol, 1.7 equiv), 140 mg (0.229 mmol) of aniline <b>9</b>, 158 mg (0.414 mmol, 1.8 equiv), and 90 μL (0.642 mmol, 2.8 equiv) of triethylamine. The crude product was purified by column chromatography using 2:3 (<b>12a</b>) to 1:4 Hex/EtOAc solution to obtain 105 mg (59%) of <b>12</b> as a pale-yellow solid. TLC (3:7 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.33. LRMS (ESI) <i>m</i>/<i>z</i> 780.4 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.60 (d, <i>J</i> = 2.4 Hz, 1 H), 8.38 (d, <i>J</i> = 4.5 Hz, 1 H), 8.27 (s, 1 H), 7.80 (d, <i>J</i> = 7.8 Hz, 1 H), 7.63 (s, 1 H), 7.59 (d, <i>J</i> = 7.7 Hz, 1 H), 7.53–7.45 (m, 4 H), 7.19 (d, <i>J</i> = 7.7 Hz, 2 H), 7.14 (d, <i>J</i> = 5.3 Hz, 1 H), 6.83 (dd, <i>J</i> = 2.6, 8.7 Hz, 1 H), 6.78 (d, <i>J</i> = 8.7 Hz, 1 H), 5.80 (q, <i>J</i> = 4.8 Hz, 2 H), 4.63 (s, 2 H), 4.48 (s, 2 H), 4.15–4.07 (m, 4 H), 4.07–3.98 (m, 4 H), 3.65 (s, 3 H), 2.35–2.27 (m, 4 H), 1.76–1.66 (m, 2 H), 1.62 (td, <i>J</i> = 7.3, 14.3 Hz, 2 H), 1.49–1.40 (m, 9 H), 1.40–1.32 (m, 6 H). <sup>13</sup>C NMR δ 174.2, 171.2, 164.5, 160.0, 158.2, 154.8, 151.8, 138.6, 137.0, 133.2, 132.1, 131.0, 129.8, 128.9, 127.7, 127.1, 126.3, 121.4, 119.9, 119.4, 112.1, 107.6, 80.5, 70.2, 69.2, 67.5, 66.4, 65.5, 51.5, 49.6, 37.4, 33.9, 29.6, 28.7, 28.7, 28.3, 25.3, 24.6.</div></div><div id="sec3_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-((Allyloxy)methyl)-4-nitrophenol (<b>14</b>)</h4><div class="NLM_p last">2-Hydroxy-5-nitrobenzaldehyde (2.00 g, 12.0 mmol) (<b>13</b>) was dissolved in 30 mL of DCM and cooled to 0 °C. Then 2.5 mL (17.8 mmol, 1.5 equiv) of triethylamine and 1.1 mL (14.5 mmol, 1.2 equiv) of chloromethyl methyl ether was added, and the solution was allowed to warm to rt and stirred for 18 h at rt. The solution was concentrated, and the crude product used directly in the next step. TLC (4:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.13. The crude mixture was redissolved in 30 mL of methanol and cooled to 0 °C, then 0.461 g (12.2 mmol, 1.0 equiv) of sodium borohydride was added portionwise and the mixture was stirred at rt for 1 h. The reaction was quenched with saturated ammonium chloride solution. This was extracted four times with dichloromethane. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate. The solution was concentrated and the crude product used directly in the next step. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.54. The crude product was redissolved in 10 mL of DCM. Then 0.845 g (3.71 mmol, 0.3 equiv) of triethylbenzylammonium chloride, 3.1 mL (35.8 mmol, 3.0 equiv) of allyl bromide, and 19 mL (363 mmol, 30 equiv) of concentrated sodium hydroxide solution were added sequentially at rt. The biphasic mixture was stirred at rt for 66 h. This was extracted three times with dichloromethane. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate. The solution was concentrated and the crude product used directly in the next step. TLC (3:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.59. The crude product was redissolved in 20 mL of THF, and 10 mL of 4 M HCl was added to the solution. The solution was refluxed for 3 h, after which it was cooled to rt. This was extracted three times with dichloromethane. The combined organic layer was washed with saturated sodium bicarbonate solution and dried with anhydrous sodium sulfate. The solution was concentrated, and the product was purified using column chromatography starting from 9:1 to 85:15 to 3:1 to 2:1 Hex/EtOAc solutions to obtain 1.81 g (72% over 4 steps) of the product as a yellow oil. TLC (2:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.30. LRMS (ESI) <i>m</i>/<i>z</i> 152.0 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.09 (dd, <i>J</i> = 2.7, 9.0 Hz, 1 H), 7.98 (d, <i>J</i> = 2.6 Hz, 1 H), 6.92 (d, <i>J</i> = 9.0 Hz, 1 H), 6.00–5.86 (m, 1 H), 5.38–5.25 (m, 2 H), 4.75 (s, 2 H), 4.12 (d, <i>J</i> = 5.8 Hz, 2 H). <sup>13</sup>C NMR δ 161.9, 140.7, 132.7, 125.4, 124.1, 122.7, 119.0, 116.8, 71.9, 70.3.</div></div><div id="sec3_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Methyl 4-(2-((Allyloxy)methyl)-4-nitrophenoxy)butanoate (<b>15</b>)</h4><div class="NLM_p last">Phenol <b>14</b> (0.126 g, 0.602 mmol) was dissolved in 6 mL of acetonitrile. Then 0.172 g (1.24 mmol, 2.1 equiv) of potassium carbonate and 0.11 mL (0.888 mmol, 1.5 equiv) of methyl 4-bromobutyrate (<b>15a</b>) was added to the solution. The mixture was refluxed for 18 h with stirring. The solution was cooled to rt, diluted with water, and extracted three times with DCM. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate. The organic layer was concentrated and purified by column chromatography using 3:1 to 2:1 Hex/EtOAc to obtain 0.151 g (100%) of <b>15</b> as a light-yellow oil. TLC (2:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.28. LRMS (ESI) <i>m</i>/<i>z</i> 310.1 (M + H<sup>+</sup>), 332.1 (M + Na<sup>+</sup>). <sup>1</sup>H NMR δ 8.29 (d, <i>J</i> = 2.9 Hz, 1 H), 8.12 (dd, <i>J</i> = 2.8, 9.0 Hz, 1 H), 6.87 (d, <i>J</i> = 9.0 Hz, 1 H), 6.02–5.90 (m, 1 H), 5.33 (qd, <i>J</i> = 1.6, 17.2 Hz, 1 H), 5.22 (qd, <i>J</i> = 1.3, 10.4 Hz, 1 H), 4.52 (s, 2 H), 4.15–4.08 (m, 4 H), 3.67 (s, 3 H), 2.52 (t, <i>J</i> = 7.2 Hz, 2 H), 2.20–2.10 (m, 2 H). <sup>13</sup>C NMR δ 173.1, 160.6, 141.3, 134.3, 128.3, 124.7, 123.9, 117.3, 110.3, 71.9, 67.6, 65.9, 51.6, 30.1, 24.2.</div></div><div id="sec3_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Methyl 5-(2-((Allyloxy)methyl)-4-nitrophenoxy)pentanoate (<b>16</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>15</b> using 145 mg (0.691 mmol) of <b>14</b>, 0.15 mL (1.05 mmol, 1.5 equiv) of methyl 5-bromopentanoate (<b>16a</b>), and 209 mg (1.51 mmol, 2.2 equiv) of potassium carbonate in 6 mL of acetonitrile. The compound was purified by flash column chromatography using 4:1 to 2:1 Hex/EtOAc solution to obtain 165 mg (90%) of <b>16</b> as a light-yellow oil. TLC (7:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.32. LRMS (ESI) <i>m</i>/<i>z</i> 346.1 (M + Na<sup>+</sup>). <sup>1</sup>H NMR δ 8.27 (d, <i>J</i> = 2.8 Hz, 1 H), 8.10 (dd, <i>J</i> = 2.8, 9.0 Hz, 1 H), 6.85 (d, <i>J</i> = 9.2 Hz, 1 H), 6.01–5.89 (m, 1 H), 5.32 (qd, <i>J</i> = 1.6, 17.2 Hz, 1 H), 5.20 (qd, <i>J</i> = 1.4, 10.4 Hz, 1 H), 4.51 (s, 2 H), 4.12–4.03 (m, 4 H), 3.64 (s, 3 H), 2.38 (t, <i>J</i> = 7.0 Hz, 2 H), 1.91–1.76 (m, 4 H). <sup>13</sup>C NMR δ 173.5, 160.8, 141.2, 134.3, 128.3, 124.6, 123.8, 117.2, 110.2, 71.8, 68.3, 65.9, 51.4, 33.3, 28.2, 21.3.</div></div><div id="sec3_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Ethyl 6-(2-((Allyloxy)methyl)-4-nitrophenoxy)hexanoate (<b>17</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>15</b> using 429 mg (2.05 mmol) of <b>14</b>, 0.45 mL (2.53 mmol, 1.2 equiv) of ethyl 6-bromohexanoate (<b>17a</b>), and 730 mg (5.28 mmol, 2.6 equiv) of potassium carbonate in 10 mL of acetonitrile. The compound was purified by flash column chromatography using 9:1 to 85:15 Hex/EtOAc solution to obtain 631 mg (88%) of <b>17</b> as a yellow solid. TLC (7:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.34. LRMS (ESI) <i>m</i>/<i>z</i> 374.1 (M + Na<sup>+</sup>). <sup>1</sup>H NMR δ 8.31–8.25 (m, 1 H), 8.10 (td, <i>J</i> = 3.2, 9.0 Hz, 1 H), 6.85 (dd, <i>J</i> = 1.6, 9.0 Hz, 1 H), 6.01–5.89 (m, 1 H), 5.37–5.28 (m, 1 H), 5.24–5.17 (m, 1 H), 4.51 (d, <i>J</i> = 2.1 Hz, 2 H), 4.14–4.01 (m, 6 H), 2.31 (dt, <i>J</i> = 1.9, 7.4 Hz, 2 H), 1.88–1.77 (m, 2 H), 1.74–1.63 (m, 2 H), 1.54–1.44 (m, 2 H), 1.22 (dt, <i>J</i> = 2.3, 7.2 Hz, 3 H). <sup>13</sup>C NMR δ 173.3, 160.9, 141.2, 134.3, 128.3, 124.6, 123.8, 117.2, 110.2, 71.8, 68.5, 65.9, 60.1, 34.0, 28.5, 25.4, 24.5, 14.1.</div></div><div id="sec3_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Methyl 7-(2-((Allyloxy)methyl)-4-nitrophenoxy)heptanoate (<b>18</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>15</b> using 409 mg (1.96 mmol) of <b>14</b>, 0.42 mL (2.37 mmol, 1.2 equiv) of methyl 7-bromoheptanoate (<b>18a</b>), and 579 mg (4.19 mmol, 2.1 equiv) of potassium carbonate in 15 mL of acetonitrile. The crude product was purified using flash column chromatography using 9:1 to 4:1 Hex/EtOAc solution to obtain 576 mg (84%) of <b>18</b> as a light-yellow oil. TLC (2:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.42. LRMS (ESI) <i>m</i>/<i>z</i> 374.1 (M + Na<sup>+</sup>). <sup>1</sup>H NMR δ 8.33–8.28 (m, 1 H), 8.16–8.10 (m, 1 H), 6.86 (d, <i>J</i> = 9.0 Hz, 1 H), 6.03–5.91 (m, 1 H), 5.34 (qd, <i>J</i> = 1.6, 17.3 Hz, 1 H), 5.26–5.20 (m, 1 H), 4.53 (s, 2 H), 4.15–4.09 (m, 2 H), 4.06 (t, <i>J</i> = 6.3 Hz, 2 H), 3.68–3.63 (m, 3 H), 2.35–2.28 (m, 2 H), 1.87–1.78 (m, 2 H), 1.70–1.59 (m, 2 H), 1.53–1.44 (m, 2 H), 1.44–1.35 (m, 3 H). <sup>13</sup>C NMR δ 174.0, 161.0, 141.2, 134.4, 128.3, 124.7, 123.9, 117.3, 110.2, 71.9, 68.7, 66.0, 51.4, 33.8, 28.7, 25.6, 24.7.</div></div><div id="sec3_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Methyl 8-(2-((Allyloxy)methyl)-4-nitrophenoxy)octanoate (<b>19</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>15</b> using 188 mg (0.901 mmol) of <b>14</b>, 254 mg (1.07 mmol, 1.2 equiv) of methyl 8-bromooctanoate (<b>19a</b>), and 284 mg (2.06 mmol, 2.3 equiv) of potassium carbonate in 5 mL of acetonitrile. The crude product was purified by flash column chromatography using 5:1 to 4:1 Hex/EtOAc solution to obtain 286 mg (87%) of <b>19</b> as a yellow oil. TLC (2:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.54. LRMS (ESI) <i>m</i>/<i>z</i> 366.1 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.30–8.24 (m, 1 H), 8.13–8.06 (m, 1 H), 6.84 (d, <i>J</i> = 9.2 Hz, 1 H), 6.01–5.87 (m, 1 H), 5.36–5.27 (m, 1 H), 5.23–5.15 (m, 1 H), 4.51 (s, 2 H), 4.09 (dd, <i>J</i> = 1.3, 5.6 Hz, 2 H), 4.07–4.00 (m, 2 H), 3.63 (s, 3 H), 2.28 (t, <i>J</i> = 7.5 Hz, 2 H), 1.85–1.76 (m, 2 H), 1.61 (quin, <i>J</i> = 7.2 Hz, 2 H), 1.50–1.41 (m, 2 H), 1.41–1.28 (m, 4 H). <sup>13</sup>C NMR δ 174.0, 160.9, 141.1, 134.3, 128.3, 124.6, 123.7, 117.1, 110.2, 71.8, 68.7, 65.9, 51.3, 33.8, 28.8, 28.8, 28.7, 25.6, 24.7.</div></div><div id="sec3_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Methyl 4-(4-(4-(3-((Allyloxy)methyl)phenyl)pyrimidin-2-ylamino)-2-((allyloxy)methyl) phenoxy)butanoate (<b>21</b>)</h4><div class="NLM_p last"><b>15</b> (196 mg, 0.634 mmol) was dissolved in 10 mL of methanol and 5 mL of water (on bigger scale, a small volume of ethyl acetate was added to aid the dissolution of the compound). Then 108 mg (1.94 mmol, 3.1 equiv) of iron and 216 mg (4.04 mmol, 6.4 equiv) of ammonium chloride was added and the reaction mixture was refluxed for 4 h. The reaction mixture was cooled to rt and filtered through a pad of Celite, washing with DCM. Saturated sodium bicarbonate was added to the filtrate, and it was extracted three times with DCM. The combined organic layers were washed with brine solution and dried over anhydrous sodium sulfate. The combined organic layer was concentrated and dissolved in 10 mL of dioxane. Then 459 mg (1.76 mmol, 2.8 equiv) of pyrimidine <b>20</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a> and ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>) and 97.4 mg (0.512 mmol, 0.81 equiv) of PTSA was added to the solution. The reaction mixture was stirred at 95 °C for 16 h. The reaction was cooled to rt and quenched with saturated sodium bicarbonate solution and extracted three times with DCM. The combined organic layers were washed with brine solution and dried over anhydrous sodium sulfate. The crude product was purified using flash column chromatography using 3:1 to 7:3 to 3:2 Hex/EtOAc solution to obtain 186 mg (58%) of <b>21</b> as a brown amorphous solid and 107 mg of pyrimidine starting material. TLC (2:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.23. LRMS (ESI) <i>m</i>/<i>z</i> 504.2 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.41 (d, <i>J</i> = 5.3 Hz, 1 H), 8.05–7.98 (m, 2 H), 7.63 (s, 2 H), 7.61–7.59 (m, 1 H), 7.50–7.43 (m, 3 H), 7.12 (d, <i>J</i> = 5.3 Hz, 1 H), 6.85 (d, <i>J</i> = 8.8 Hz, 1 H), 6.04–5.91 (m, 2 H), 5.35 (q, <i>J</i> = 1.6 Hz, 1 H), 5.30 (q, <i>J</i> = 1.6 Hz, 1 H), 5.20 (dddd, <i>J</i> = 1.3, 3.0, 10.6, 14.0 Hz, 2 H), 4.60 (s, 2 H), 4.58 (s, 2 H), 4.50–4.46 (m, 1 H), 4.36 (s, 1 H), 4.08 (tdd, <i>J</i> = 1.4, 5.6, 12.4 Hz, 4 H), 4.02 (t, <i>J</i> = 6.0 Hz, 2 H), 3.88–3.83 (m, 1 H), 3.69 (s, 3 H), 2.54 (t, <i>J</i> = 7.3 Hz, 2 H), 2.17–2.08 (m, 2 H). <sup>13</sup>C NMR δ 173.6, 164.9, 160.3, 158.1, 152.0, 139.0, 137.2, 134.9, 134.6, 132.6, 130.0, 128.9, 127.5, 126.4, 126.3, 121.2, 120.1, 117.2, 116.8, 111.7, 107.9, 71.8, 71.5, 71.3, 68.5, 67.2, 66.8, 66.2, 62.6, 51.6, 30.5, 24.7.</div></div><div id="sec3_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Methyl 5-(4-(4-(3-((Allyloxy)methyl)phenyl)pyrimidin-2-ylamino)-2-((allyloxy)methyl)phenoxy) pentanoate (<b>22</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>21</b> using 209 mg (0.646 mmol) of <b>16</b>, 110 mg (1.97 mmol, 3.0 equiv ) of iron, and 315 mg (5.89 mmol, 9.1 equiv) of ammonium chloride in 6 mL of methanol and 3 mL of water; for the second step, 264 mg (1.01 mmol, 1.5 equiv) of <b>20</b> and 110 mg (0.577 mmol, 0.89 equiv) of PTSA in 5 mL of dioxane was used. The crude product was purified by flash column chromatography using 3:1 to 3:2 Hex/EtOAc solution to obtain 93.7 mg (28%) of <b>22</b> as a yellow oil. TLC (aniline <b>16</b>) (7:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.11; TLC (<b>22</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.43. LRMS (ESI) <i>m</i>/<i>z</i> 518.2 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.42 (d, <i>J</i> = 5.3 Hz, 1 H), 8.05–7.97 (m, 2 H), 7.66–7.60 (m, 2 H), 7.50–7.44 (m, 3 H), 7.10 (d, <i>J</i> = 5.1 Hz, 1 H), 6.87–6.80 (m, 1 H), 5.97 (tdd, <i>J</i> = 5.4, 10.6, 17.3 Hz, 2 H), 5.37–5.28 (m, 2 H), 5.25–5.15 (m, 2 H), 4.59 (d, <i>J</i> = 3.6 Hz, 4 H), 4.49–4.43 (m, 1 H), 4.36 (s, 1 H), 4.08 (tdd, <i>J</i> = 1.3, 5.6, 14.4 Hz, 4 H), 3.98 (br s, 2 H), 3.84 (dd, <i>J</i> = 4.2, 5.2 Hz, 1 H), 3.67 (s, 3 H), 2.40 (t, <i>J</i> = 6.8 Hz, 2 H), 1.87–1.79 (m, 4 H). <sup>13</sup>C NMR δ 173.8, 164.6, 160.5, 158.5, 152.0, 138.9, 137.3, 134.9, 134.6, 132.6, 129.8, 128.8, 127.4, 126.3, 126.2, 121.0, 120.0, 117.1, 116.7, 111.6, 107.8, 71.8, 71.4, 71.2, 68.4, 67.8, 66.8, 66.2, 62.5, 51.4, 33.6, 28.7, 21.6.</div></div><div id="sec3_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Methyl 5-(4-(4-(3-((Allyloxy)methyl)phenyl)pyrimidin-2-ylamino)-2-((allyloxy)methyl)phenoxy)hexanoate (<b>23</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>21</b> using 193 mg (0.549 mmol) of <b>17</b>, 115 mg (2.05 mmol, 3.7 equiv) of iron, and 162 mg (3.02 mmol, 5.5 equiv) of ammonium chloride in 6 mL of methanol and 3 mL of water; for the second step, 244 mg (0.934 mmol, 1.7 equiv) of <b>20</b> and 81.2 mg (0.427 mmol, 0.78 equiv) of PTSA in 5 mL of dioxane was used. The crude product was purified by flash column chromatography using 7:3 to 3:2 Hex/EtOAc solution to obtain 122 mg (41%) of <b>23</b> as a yellow oil. TLC (aniline <b>17</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.33. TLC (<b>23</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.33. LRMS (ESI) <i>m</i>/<i>z</i> 545.4 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.43 (d, <i>J</i> = 5.1 Hz, 1 H), 8.06–7.97 (m, 2 H), 7.66–7.60 (m, 2 H), 7.51–7.42 (m, 3 H), 7.11 (d, <i>J</i> = 5.1 Hz, 1 H), 6.87–6.81 (m, 1 H), 6.04–5.92 (m, 2 H), 5.35 (d, <i>J</i> = 1.4 Hz, 1 H), 5.31 (d, <i>J</i> = 1.3 Hz, 1 H), 5.25–5.15 (m, 2 H), 4.60 (d, <i>J</i> = 4.1 Hz, 4 H), 4.18–4.04 (m, 6 H), 3.97 (t, <i>J</i> = 6.3 Hz, 2 H), 2.34 (t, <i>J</i> = 7.5 Hz, 2 H), 1.86–1.76 (m, 2 H), 1.76–1.66 (m, 2 H), 1.57–1.49 (m, 2 H), 1.30–1.21 (m, 2 H). <sup>13</sup>C NMR δ 173.5, 164.7, 160.6, 158.5, 152.2, 138.9, 137.3, 135.0, 134.6, 132.6, 129.8, 128.8, 127.4, 126.3, 126.2, 121.0, 120.0, 117.1, 116.7, 111.7, 107.8, 71.8, 71.4, 71.2, 68.1, 66.8, 60.1, 34.2, 29.0, 25.7, 24.7, 14.2.</div></div><div id="sec3_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Methyl 5-(4-(4-(3-((Allyloxy)methyl)phenyl)pyrimidin-2-ylamino)-2-((allyloxy)methyl)phenoxy)heptanoate (<b>24</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>21</b> using 440 mg (1.25 mmol) of <b>18</b>, 212 mg (3.79 mmol, 3.0 equiv) of iron, and 407 mg (7.61 mmol, 6.1 equiv) of ammonium chloride in 6 mL of methanol and 6 mL of water; for the second step, 496 mg (1.90 mmol, 1.5 equiv) of <b>20</b> and 195 mg (1.02 mmol, 0.82 equiv) of PTSA in 6 mL of dioxane was used. The crude product was purified by flash column chromatography using 3:1 to 7:3 to 3:2 to 1:1 Hex/EtOAc solution to obtain 390 mg (57%) of <b>24</b> as a dark-yellow oil and 97.9 mg (24%) of the aniline <b>18</b> as a yellow oil. TLC (aniline <b>18</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.27. TLC (<b>23</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.46. LRMS (ESI) <i>m</i>/<i>z</i> 546.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.41 (d, <i>J</i> = 5.1 Hz, 1 H), 8.02 (s, 1 H), 7.99 (td, <i>J</i> = 2.0, 6.4 Hz, 1 H), 7.76 (br s, 1 H), 7.66–7.57 (m, 2 H), 7.47–7.41 (m, 2 H), 7.08 (d, <i>J</i> = 5.3 Hz, 1 H), 6.82 (d, <i>J</i> = 8.5 Hz, 1 H), 6.02–5.89 (m, 2 H), 5.31 (tdd, <i>J</i> = 1.7, 3.7, 17.2 Hz, 2 H), 5.22–5.13 (m, 2 H), 4.61–4.55 (m, 4 H), 4.13–4.07 (m, 2 H), 4.07–4.02 (m, 2 H), 3.93 (t, <i>J</i> = 6.3 Hz, 2 H), 3.64 (s, 3 H), 2.35–2.27 (m, 2 H), 1.81–1.72 (m, 2 H), 1.65 (td, <i>J</i> = 7.5, 15.0 Hz, 2 H), 1.52–1.42 (m, 2 H), 1.42–1.33 (m, 2 H). <sup>13</sup>C NMR δ 173.9, 170.8, 164.5, 160.5, 158.4, 152.0, 138.8, 137.2, 134.9, 134.5, 132.6, 129.7, 128.7, 127.3, 126.2, 126.1, 120.9, 119.9, 117.0, 116.5, 111.5, 107.6, 71.7, 71.3, 71.2, 71.1, 68.1, 66.7, 60.1, 51.2, 33.8, 29.0, 28.7, 25.6, 24.7, 20.8, 14.0.</div></div><div id="sec3_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Methyl 5-(4-(4-(3-((Allyloxy)methyl)phenyl)pyrimidin-2-ylamino)-2-((allyloxy)methyl)phenoxy)octanoate (<b>25</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>21</b> using 328 mg (0.896 mmol) of <b>19</b>, 188 mg (3.37 mmol, 3.8 equiv) of iron, and 407 mg (5.60 mmol, 6.3 equiv) of ammonium chloride in 5 mL of methanol and 5 mL of water; for the second step, 351 mg (1.35 mmol, 1.5 equiv) of <b>20</b> and 136 mg (0.715 mmol, 0.80 equiv) of PTSA in 5 mL of dioxane was used. The crude product was purified by flash column chromatography using 3:1 to 7:3 to 65:35 Hex/EtOAc solution to obtain 311 mg (62%) of <b>25</b> as a yellow solid. TLC (aniline <b>19</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = X.XX. TLC (<b>25</b>) (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.45. LRMS (ESI) <i>m</i>/<i>z</i> 560.3 (M + H<sup>+</sup>). <sup>1</sup>H NMR δ 8.43 (d, <i>J</i> = 5.3 Hz, 1 H), 8.04 (s, 1 H), 8.03–7.98 (m, 1 H), 7.72 (br s, 1 H), 7.66–7.60 (m, 2 H), 7.49–7.41 (m, 2 H), 7.09 (d, <i>J</i> = 5.1 Hz, 1 H), 6.84 (d, <i>J</i> = 8.8 Hz, 1 H), 5.97 (dtdd, <i>J</i> = 2.6, 5.5, 10.6, 17.2 Hz, 2 H), 5.33 (td, <i>J</i> = 1.6, 17.3 Hz, 2 H), 5.20 (ddd, <i>J</i> = 1.6, 10.5, 13.6 Hz, 2 H), 4.59 (d, <i>J</i> = 2.0 Hz, 4 H), 4.11 (td, <i>J</i> = 1.3, 5.5 Hz, 2 H), 4.06 (td, <i>J</i> = 1.3, 5.6 Hz, 2 H), 3.95 (t, <i>J</i> = 6.4 Hz, 2 H), 3.66 (s, 3 H), 2.32 (t, <i>J</i> = 7.5 Hz, 2 H), 1.82–1.73 (m, 2 H), 1.69–1.61 (m, 2 H), 1.52–1.43 (m, 2 H), 1.43–1.31 (m, 4 H). <sup>13</sup>C NMR δ 174.0, 164.5, 160.5, 158.4, 152.1, 138.8, 137.3, 134.9, 134.5, 132.5, 129.7, 128.7, 127.3, 126.3, 126.2, 120.9, 119.9, 117.0, 116.6, 111.6, 107.7, 71.8, 71.3, 71.1, 68.3, 66.7, 51.3, 33.9, 29.2, 28.9, 28.9, 25.8, 24.7.</div></div><div id="sec3_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 11-(4-(Butanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Methyl Ester (<b>26</b>)</h4><div class="NLM_p last">Following the literature procedure,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> 29.4 mg (0.0631 mmol) of <b>21</b> and 6.7 mg (0.00789 mmol, 0.13 equiv) of the second-generation Grubbs catalyst (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a> for structure) were dissolved in 14 mL of degassed DCM (5 mM concentration) to obtain an orange solution. Then 1 mL of 4 M hydrochloric acid was added, changing it to a yellow solution. The reaction mixture was refluxed for 3 h. After cooling to rt, the reaction was quenched with saturated sodium bicarbonate solution and extracted with DCM three times. The combined organic layer was washed with brine solution and dried with anhydrous sodium sulfate. The organic layer was concentrated and purified by column chromatography using 3:2 Hex/EtOAc to obtain 17.1 mg (62%) of <b>26</b> in an 87:13 <i><i>E</i>/<i>Z</i></i> ratio as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 476.2 (M + H<sup>+</sup>). <i>E</i> isomer only: <sup>1</sup>H NMR δ 8.64 (d, <i>J</i> = 2.4 Hz, 1 H), 8.43–8.37 (m, 1 H), 8.29 (s, 1 H), 7.80 (d, <i>J</i> = 7.8 Hz, 1 H), 7.71–7.67 (m, 1 H), 7.59 (d, <i>J</i> = 7.7 Hz, 1 H), 7.48 (t, <i>J</i> = 7.7 Hz, 1 H), 7.14 (d, <i>J</i> = 5.1 Hz, 1 H), 6.88–6.79 (m, 2 H), 5.88–5.82 (m, 2 H), 4.64 (s, 2 H), 4.62 (s, 2 H), 4.16 (d, <i>J</i> = 4.8 Hz, 2 H), 4.08–4.00 (m, 4 H), 3.70 (s, 3 H), 2.57 (t, <i>J</i> = 7.3 Hz, 2 H), 2.18–2.10 (m, 2 H). <sup>13</sup>C NMR δ 173.7, 164.4, 160.1, 158.3, 152.0, 138.6, 137.1, 133.2, 132.0, 131.0, 129.8, 128.9, 127.7, 127.1, 126.3, 121.4, 119.3, 112.4, 107.6, 70.1, 69.3, 67.6, 67.5, 65.7, 51.6, 30.6, 24.7.</div></div><div id="sec3_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 11-(5-(Pentanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Methyl Ester (<b>27</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>26</b> using 156.5 mg (0.302 mmol) of <b>22</b> and 25.9 mg (0.0305 mmol, 0.10 equiv) of Grubbs II catalyst in 30 mL of DCM and 3 mL of 4 M HCl. The crude product was purified by flash column chromatography using 1:1 to 2:3 Hex/EtOAc solution to obtain 104 mg (70%) (5:1 <i><i>E</i>/<i>Z</i></i> isomers) of <b>27</b> as a yellowish-green solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.23. LRMS (ESI) <i>m</i>/<i>z</i> 490.2 (M + H<sup>+</sup>). <i>E</i> isomer only: <sup>1</sup>H NMR δ 8.65 (d, <i>J</i> = 2.4 Hz, 1 H), 8.39 (d, <i>J</i> = 5.3 Hz, 1 H), 8.29 (s, 1 H), 7.95 (s, 1 H), 7.78 (d, <i>J</i> = 7.8 Hz, 1 H), 7.58 (d, <i>J</i> = 7.7 Hz, 1 H), 7.49–7.45 (m, 1 H), 7.12 (d, <i>J</i> = 5.3 Hz, 1 H), 6.87–6.77 (m, 2 H), 5.87–5.82 (m, 2 H), 4.63 (s, 4 H), 4.16 (d, <i>J</i> = 4.4 Hz, 2 H), 4.05 (d, <i>J</i> = 4.1 Hz, 2 H), 3.98 (m., 2 H), 3.69–3.65 (s, 3 H), 2.42 (t, <i>J</i> = 7.0 Hz, 2 H), 1.88–1.81 (m, 4 H). <sup>13</sup>C NMR δ 173.8, 164.1, 160.2, 158.5, 152.0, 138.5, 137.1, 133.2, 132.0, 130.8, 129.7, 128.8, 127.6, 126.9, 126.1, 121.5, 119.2, 112.2, 107.5, 70.0, 69.2, 68.1, 67.5, 65.6, 51.4, 33.6, 28.6, 21.6.</div></div><div id="sec3_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 11-(6-(Hexanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Methyl Ester (<b>28</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>26</b> using 151 mg (0.277 mmol) of <b>23</b> and 26.4 mg (0.0311 mmol, 0.11 equiv) of Grubbs II catalyst in 30 mL of DCM and 3 mL of 4 M HCl. The crude product was purified by flash column chromatography using 1:1 to 2:3 Hex/EtOAc solution to obtain 113 mg (79%) (5:1 <i><i>E</i>/<i>Z</i></i> isomers) of <b>28</b> as a green amorphous solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.20. LRMS (ESI) <i>m</i>/<i>z</i> 518.3 (M + H<sup>+</sup>). <i>E</i> isomer only: <sup>1</sup>H NMR δ 8.64 (d, <i>J</i> = 2.0 Hz, 1 H), 8.40 (d, <i>J</i> = 5.1 Hz, 1 H), 8.29 (s, 1 H), 7.80 (d, <i>J</i> = 7.7 Hz, 1 H), 7.67 (s, 1 H), 7.58 (d, <i>J</i> = 7.7 Hz, 1 H), 7.51–7.41 (m, 1 H), 7.13 (d, <i>J</i> = 5.1 Hz, 1 H), 6.88–6.78 (m, 2 H), 5.88–5.81 (m, 2 H), 4.68–4.60 (m, 4 H), 4.19–4.09 (m, 4 H), 4.06 (d, <i>J</i> = 4.0 Hz, 2 H), 3.98 (t, <i>J</i> = 6.3 Hz, 2 H), 2.35 (t, <i>J</i> = 7.5 Hz, 3 H), 1.88–1.78 (m, 2 H), 1.72 (quin, <i>J</i> = 7.6 Hz, 2 H), 1.59–1.47 (m, 2 H), 1.31–1.21 (m, 3 H). <sup>13</sup>C NMR δ 173.6, 164.2, 160.2, 158.6, 152.2, 138.5, 137.1, 133.1, 132.1, 130.8, 129.7, 128.8, 127.7, 127.0, 126.2, 121.4, 119.3, 112.4, 107.6, 70.1, 69.2, 68.5, 67.5, 65.7, 60.2, 34.2, 29.0, 25.7, 24.7, 14.2.</div></div><div id="sec3_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 11-(7-(Heptanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Methyl Ester (<b>29</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>26</b> using 390 mg (0.715 mmol) of <b>24</b> and 31.3 mg (0.0369 mmol, 0.05 equiv) of Grubbs II catalyst in 40 mL of DCM and 4 mL of 4 M HCl. The crude product was purified by flash column chromatography using 65:35 to 3:2 to 1:1 Hex/EtOAc solution to obtain 266 mg (72%) (10:3 <i><i>E</i>/<i>Z</i></i> isomers) of <b>29</b> as a green amorphous solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.24. LRMS (ESI) <i>m</i>/<i>z</i> 518.2 (M + H<sup>+</sup>). <i>E</i> isomer only: <sup>1</sup>H NMR δ 8.63 (d, <i>J</i> = 2.3 Hz, 1 H), 8.42–8.37 (m, 1 H), 8.29 (s, 1 H), 7.79 (d, <i>J</i> = 7.8 Hz, 1 H), 7.73 (s, 1 H), 7.58 (d, <i>J</i> = 7.7 Hz, 1 H), 7.47 (t, <i>J</i> = 7.7 Hz, 1 H), 7.13 (d, <i>J</i> = 5.1 Hz, 1 H), 6.89–6.78 (m, 2 H), 5.84 (q, <i>J</i> = 4.7 Hz, 2 H), 4.66–4.60 (m, 4 H), 4.16 (d, <i>J</i> = 4.8 Hz, 2 H), 4.05 (d, <i>J</i> = 4.1 Hz, 2 H), 3.97 (t, <i>J</i> = 6.4 Hz, 2 H), 3.66 (s, 3 H), 2.36–2.29 (m, 2 H), 1.85–1.76 (m, 2 H), 1.72–1.63 (m, 2 H), 1.54–1.45 (m, 2 H), 1.45–1.36 (m, 2 H). <sup>13</sup>C NMR δ 174.1, 164.1, 160.3, 158.6, 152.2, 138.5, 137.1, 133.0, 132.1, 130.8, 129.7, 128.8, 127.6, 127.0, 126.2, 121.4, 119.3, 112.4, 107.5, 70.1, 69.2, 68.6, 67.5, 65.6, 60.3, 51.4, 33.9, 29.1, 28.8, 25.7, 24.8, 14.1.</div></div><div id="sec3_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 11-(8-(Octanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Methyl Ester (<b>30</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>26</b> using 311 mg (0.555 mmol) of <b>25</b> and 48.3 mg (0.0569 mmol, 0.10 equiv) of Grubbs II catalyst in 55 mL of DCM and 5.5 mL of 4 M HCl. The crude product was purified using flash column chromatography using 1:1 to 45:55 Hex/EtOAc solution to obtain 246 mg (83%) (4:1 <i><i>E</i>/<i>Z</i></i> isomers) of <b>30</b> as a brown amorphous solid. TLC (1:1 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.29. LRMS (ESI) <i>m</i>/<i>z</i> 532.3 (M + H<sup>+</sup>). <i>E</i> isomer only: <sup>1</sup>H NMR δ 8.66–8.62 (m, 1 H), 8.40 (d, <i>J</i> = 5.1 Hz, 1 H), 8.29 (s, 1 H), 7.83–7.71 (m, 2 H), 7.58 (d, <i>J</i> = 7.5 Hz, 1 H), 7.47 (t, <i>J</i> = 7.7 Hz, 1 H), 7.13 (d, <i>J</i> = 5.1 Hz, 1 H), 6.88–6.78 (m, 2 H), 5.91–5.81 (m, 2 H), 4.66–4.60 (m, 3 H), 4.16 (d, <i>J</i> = 4.5 Hz, 2 H), 4.05 (d, <i>J</i> = 4.0 Hz, 2 H), 3.96 (t, <i>J</i> = 6.4 Hz, 2 H), 3.66 (s, 3 H), 2.32 (t, <i>J</i> = 7.5 Hz, 2 H), 1.85–1.75 (m, 2 H), 1.69–1.60 (m, 2 H), 1.54–1.44 (m, 2 H), 1.44–1.31 (m, 4 H). <sup>13</sup>C NMR δ 174.1, 164.1, 160.2, 158.6, 152.3, 138.5, 137.1, 133.0, 132.1, 130.8, 129.7, 128.8, 127.6, 127.0, 126.2, 121.4, 119.2, 112.3, 107.5, 70.0, 69.2, 68.7, 67.5, 65.6, 51.3, 34.0, 29.2, 29.0, 28.9, 25.8, 24.8.</div></div><div id="sec3_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 11-(4-(4-Aminobenzoic Acid)ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>31</b>)</h4><div class="NLM_p last"><b>4</b> (117 mg, 0.179 mmol) was dissolved in 4 mL of THF, and 0.811 g (5.69 mmol, 32 equiv) of 90% potassium trimethylsilanoate was added. The resultant orange suspension was stirred at rt for 2 h, after which 1.5 mL of concentrated hydrochloric acid was added to the reaction and a yellow precipitate was formed. The reaction was stirred for a further 24 h at rt. Then 5 mL of water was added to the mixture and stirred at rt for 1 h. The solid was filtered and washed successively three times each with water, ethyl acetate, and acetone. The resulting solid was dried under vacuum overnight to obtain 69.9 mg (56%) of <b>31</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 539.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1 H), 8.51 (d, <i>J</i> = 5.0 Hz, 1 H), 8.47 (br s, 1 H), 8.15 (s, 1 H), 8.01 (d, <i>J</i> = 4.0 Hz, 1 H), 7.70 (d, <i>J</i> = 8.4 Hz, 2 H), 7.55 (br s, 2 H), 7.39 (d, <i>J</i> = 5.0 Hz, 1 H), 7.10 (d, <i>J</i> = 6.3 Hz, 1 H), 7.00–6.95 (m, 1 H), 6.68 (d, <i>J</i> = 8.5 Hz, 2 H), 5.79 (d, <i>J</i> = 14.9 Hz, 1 H), 5.66 (d, <i>J</i> = 15.2 Hz, 1 H), 4.53 (s, 2 H), 4.43 (s, 3 H), 4.11 (br s, 3 H), 3.99 (br s, 4 H), 3.52 (br s, 2 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 167.4, 163.0, 160.0, 159.2, 152.6, 151.1, 138.5, 136.7, 133.9, 131.1, 130.8, 129.8, 129.1, 126.6, 126.5, 120.6, 119.6, 117.1, 113.1, 111.0, 107.4, 69.1, 68.9, 67.9, 67.0, 65.0, 41.8.</div></div><div id="sec3_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 11-(4-(3-Aminobenzoic acid)ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>32</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 58.2 mg (0.0892 mmol) of ester <b>5</b>, 416 mg of potassium trimethylsilanoate (2.92 mmol, 33 equiv), and 37.7 mg (72%) of <b>32</b> was isolated as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 539.2 (M + H<sup>+</sup>). HPLC purity 95.6%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.55 (s, 1 H), 8.51 (d, <i>J</i> = 5.1 Hz, 1 H), 8.46 (d, <i>J</i> = 2.5 Hz, 1 H), 8.15 (s, 1 H), 8.02 (dd, <i>J</i> = 1.8, 5.9 Hz, 1 H), 7.58–7.53 (m, 2 H), 7.39 (d, <i>J</i> = 5.3 Hz, 1 H), 7.27 (s, 1 H), 7.21 (t, <i>J</i> = 7.7 Hz, 1 H), 7.16 (d, <i>J</i> = 7.5 Hz, 1 H), 7.10 (dd, <i>J</i> = 2.6, 8.8 Hz, 1 H), 6.98 (d, <i>J</i> = 8.8 Hz, 1 H), 6.93–6.88 (m, 1 H), 5.83–5.75 (m, 1 H), 5.71–5.61 (m, 1 H), 4.53 (s, 2 H), 4.44 (s, 2 H), 4.11 (t, <i>J</i> = 5.3 Hz, 2 H), 3.99 (d, <i>J</i> = 5.0 Hz, 4 H), 3.48 (t, <i>J</i> = 5.3 Hz, 2 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 167.9, 163.0, 160.0, 159.1, 151.1, 148.8, 138.6, 136.7, 133.8, 131.4, 130.8, 129.8, 129.1, 129.0, 126.6, 126.5, 126.5, 120.6, 119.6, 116.9, 116.4, 113.1, 112.8, 107.4, 69.1, 68.9, 67.9, 67.0, 64.9, 54.9, 42.3.</div></div><div id="sec3_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 11-(2-(4-Hydroxybenzoate))-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>33</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 133 mg (0.241 mmol) of <b>6</b> and 1.06 g of potassium trimethylsilanoate (7.43 mmol, 31 equiv) in 5 mL of THF and 1.5 mL of conc HCl, and 66.8 mg (47%) of <b>33</b> was isolated as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 540.2 (M + H<sup>+</sup>). HPLC purity 95.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.67 (s, 1 H), 8.53 (d, <i>J</i> = 5.3 Hz, 1 H), 8.45 (d, <i>J</i> = 2.6 Hz, 1 H), 8.14 (s, 1 H), 8.03 (d, <i>J</i> = 5.8 Hz, 1 H), 7.91 (d, <i>J</i> = 8.8 Hz, 2 H), 7.59–7.54 (m, 2 H), 7.43 (d, <i>J</i> = 5.4 Hz, 1 H), 7.15–7.08 (m, 3 H), 7.07–7.02 (m, 1 H), 5.83–5.74 (m, 1 H), 5.69–5.60 (m, 1 H), 4.52 (s, 2 H), 4.44–4.39 (m, 4 H), 4.36–4.31 (m, 2 H), 3.98 (d, <i>J</i> = 4.9 Hz, 4 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 166.9, 163.4, 162.1, 159.5, 158.5, 151.0, 138.6, 136.5, 133.8, 131.3, 131.0, 130.7, 129.8, 129.1, 126.9, 126.6, 126.6, 123.1, 120.7, 119.8, 114.4, 113.7, 107.4, 69.2, 68.9, 67.8, 67.0, 66.7, 64.8.</div></div><div id="sec3_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 11-(2-(Isonipecotate)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>34</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 182 mg (0.335 mmol) of <b>8</b> and 1.30 g of potassium trimethylsilanoate (9.12 mmol, 27 equiv), and 157 mg (83%) of <b>31</b> was isolated as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 531.2 (M + H<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 11.21 (br s, 1 H), 9.89 (s, 1 H), 8.56–8.49 (m, 2 H), 8.14 (s, 1 H), 8.01 (d, <i>J</i> = 6.9 Hz, 1 H), 7.60–7.49 (m, 2 H), 7.43 (d, <i>J</i> = 5.5 Hz, 1 H), 7.16 (dd, <i>J</i> = 2.3, 8.7 Hz, 1 H), 7.00 (dd, <i>J</i> = 3.9, 8.7 Hz, 1 H), 5.88–5.75 (m, 1 H), 5.71–5.63 (m, 1 H), 4.52 (s, 2 H), 4.47 (s, 2 H), 4.40 (br s, 3 H), 4.03 (d, <i>J</i> = 5.1 Hz, 4 H), 3.97 (d, <i>J</i> = 5.0 Hz, 2 H), 3.65–3.52 (m, 2 H), 3.47–3.38 (m, 2 H), 3.16–3.01 (m, 2 H), 2.07–1.92 (m, 4 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.6, 164.2, 158.8, 157.6, 150.7, 138.7, 136.4, 133.8, 131.2, 130.9, 129.9, 129.2, 126.9, 126.8, 126.3, 120.9, 119.8, 112.9, 107.5, 69.0, 68.9, 67.2, 67.0, 65.6, 63.2, 55.0, 54.9, 51.6, 37.8, 25.2, 25.1.</div></div><div id="sec3_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 11-(2-(7-(4-Aminophenylcarbamoyl)hexanoic acid))-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>35</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 82.0 mg (0.105 mmol) of <b>11</b> and 461 mg (3.23 mmol, 31 equiv) of potassium trimethylsilanoate in 5 mL of THF and 1.5 mL of concentrated HCl, and 52.2 mg (76%) of <b>35</b> was obtained as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 652.3 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.98 (br s, 1H), 9.62 (s, 1H), 8.52 (d, <i>J</i> = 5.14 Hz, 1H), 8.46 (d, <i>J</i> = 2.76 Hz, 1H), 8.14 (s, 1H), 7.99–8.05 (m, 1H), 7.62 (d, <i>J</i> = 8.66 Hz, 2H), 7.52–7.59 (m, 2H), 7.41 (d, <i>J</i> = 5.40 Hz, 1H), 7.25 (d, <i>J</i> = 6.65 Hz, 2H), 7.10 (dd, <i>J</i> = 2.64, 8.78 Hz, 1H), 6.96 (d, <i>J</i> = 8.91 Hz, 1H), 5.81 (td, <i>J</i> = 5.47, 15.65 Hz, 1H), 5.67 (td, <i>J</i> = 6.04, 15.65 Hz, 1H), 4.54 (s, 2H), 4.43 (s, 2H), 4.18 (t, <i>J</i> = 4.89 Hz, 2H), 4.01 (dd, <i>J</i> = 5.58, 15.62 Hz, 4H), 2.28 (t, <i>J</i> = 7.40 Hz, 2H), 2.19 (t, <i>J</i> = 7.34 Hz, 2H), 1.46–1.61 (m, 4H), 1.26–1.34 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.4, 163.3, 159.7, 158.8, 150.6, 138.6, 136.6, 134.1, 131.0, 129.8, 129.2, 126.7, 126.6, 126.6, 120.7, 120.1, 119.7, 113.1, 107.5, 69.2, 68.8, 67.0, 64.8, 36.2, 33.5, 28.2, 24.8, 24.3.</div></div><div id="sec3_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 11-(2-(7-(4-Aminophenylcarbamoyl)heptanoic Acid))-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>36</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 41.6 mg (0.0533 mmol) of <b>12</b> and 231 mg (1.62 mmol, 30 equiv) of potassium trimethylsilanoate in 3 mL of THF and 1 mL of concentrated HCl, and 26.7 mg (75%) of <b>36</b> was obtained as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 666.3 (M + H<sup>+</sup>). HPLC purity 91%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 12.25 (br s, 2 H), 9.53 (s, 1 H), 9.47 (s, 1 H), 8.54–8.47 (m, 2 H), 8.16 (s, 1 H), 8.04–7.98 (m, 1 H), 7.59–7.52 (m, 2 H), 7.41–7.35 (m, 1 H), 7.32 (d, <i>J</i> = 8.8 Hz, 1 H), 7.16–7.07 (m, 1 H), 6.96 (d, <i>J</i> = 8.9 Hz, 1 H), 6.60 (d, <i>J</i> = 8.7 Hz, 2 H), 5.91–5.78 (m, 1 H), 5.73–5.63 (m, 1 H), 4.54 (s, 2 H), 4.50–4.43 (m, 2 H), 4.12–3.94 (m, 6 H), 3.46–3.38 (m, 2 H), 2.76 (d, <i>J</i> = 15.4 Hz, 2 H), 2.66 (d, <i>J</i> = 15.4 Hz, 2 H), 2.20 (q, <i>J</i> = 7.6 Hz, 2 H), 1.62–1.43 (m, 4 H), 1.28 (br s, 4 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.5, 174.4, 171.2, 170.2, 162.9, 160.2, 159.4, 151.2, 138.6, 136.8, 133.9, 131.0, 130.8, 129.8, 129.1, 126.6, 126.5, 126.5, 120.8, 120.5, 119.6, 113.2, 112.2, 107.4, 72.4, 69.1, 68.9, 68.0, 67.0, 65.1, 42.7, 42.6, 36.2, 33.6, 28.4, 28.3, 25.1, 24.4.</div></div><div id="sec3_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 11-(4-(Butanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>37</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 58.5 mg (0.123 mmol) of <b>26</b> and 527 mg (3.70 mmol, 30 equiv) of potassium trimethylsilanoate in 5 mL of THF and 1.5 mL of concentrated HCl, and 50.1 mg (80%) of <b>37</b> was obtained as an orange solid. LRMS (ESI) <i>m</i>/<i>z</i> 462.3 (M+H<sup>+</sup>). HPLC purity >99% (ratio of 77.9%. acid to 22.1% ester). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.01 (br s, 1 H), 8.56 (d, <i>J</i> = 5.3 Hz, 1 H), 8.41–8.36 (m, 1 H), 8.18–8.10 (m, 1 H), 8.05 (d, <i>J</i> = 6.7 Hz, 1 H), 7.60–7.54 (m, 2 H), 7.53–7.44 (m, 1 H), 7.11 (dd, <i>J</i> = 2.3, 8.7 Hz, 1 H), 6.95 (d, <i>J</i> = 8.8 Hz, 1 H), 5.87–5.75 (m, 1 H), 5.67 (td, <i>J</i> = 5.8, 15.8 Hz, 1 H), 4.52 (s, 2 H), 4.51–4.44 (m, 2 H), 4.11–4.03 (m, 2 H), 4.02–3.93 (m, 4 H), 1.97 (quin, <i>J</i> = 6.4 Hz, 2 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 173.1, 164.9, 158.0, 156.3, 151.6, 138.7, 136.1, 132.5, 131.5, 130.8, 129.8, 129.2, 127.0, 126.8, 126.5, 121.1, 120.1, 112.6, 107.3, 69.1, 68.8, 67.2, 67.1, 64.9, 51.3, 29.9, 24.3.</div></div><div id="sec3_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 11-(5-(Pentanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>38</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 330 mg (0.674 mmol) of <b>27</b> and 2.90 g (20.3 mmol, 30 equiv) of potassium trimethylsilanoate in 10 mL of THF and 2 mL of concentrated HCl, and 288 mg (83%) of <b>38</b> was obtained as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 476.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.60 (s, 1 H), 8.52 (d, <i>J</i> = 5.3 Hz, 1 H), 8.48 (d, <i>J</i> = 2.6 Hz, 1 H), 8.17 (s, 1 H), 8.03 (td, <i>J</i> = 2.2, 6.2 Hz, 1 H), 7.58–7.54 (m, 2 H), 7.41 (d, <i>J</i> = 5.4 Hz, 1 H), 7.11 (dd, <i>J</i> = 2.7, 8.7 Hz, 1 H), 6.98–6.93 (m, 1 H), 5.88–5.80 (m, 1 H), 5.74–5.65 (m, 1 H), 4.55 (s, 2 H), 4.51–4.47 (m, 2 H), 4.06 (d, <i>J</i> = 6.0 Hz, 3 H), 3.98 (dd, <i>J</i> = 5.7, 13.7 Hz, 7 H), 2.31 (t, <i>J</i> = 7.1 Hz, 2 H), 1.80–1.65 (m, 5 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.4, 163.3, 159.7, 158.7, 151.5, 138.6, 136.6, 133.4, 131.0, 130.9, 129.8, 129.1, 126.6, 126.3, 120.7, 119.7, 112.7, 107.3, 69.1, 68.9, 68.0, 67.1, 65.1, 33.3, 28.2, 21.3.</div></div><div id="sec3_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 11-(6-(Hexanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>39</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 113 mg (0.218 mmol) of <b>28</b> and 951 mg (6.67 mmol, 31 equiv) of potassium trimethylsilanoate in 5 mL of THF and 1.5 mL of concentrated HCl, and 51.4 mg (44%) of <b>39</b> was obtained as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 490.2 (M + H<sup>+</sup>). HPLC purity 91.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1 H), 8.57–8.53 (m, 1 H), 8.43 (d, <i>J</i> = 2.6 Hz, 1 H), 8.16 (s, 1 H), 8.04 (td, <i>J</i> = 1.9, 6.8 Hz, 1 H), 7.61–7.54 (m, 2 H), 7.45 (d, <i>J</i> = 5.5 Hz, 1 H), 7.11 (dd, <i>J</i> = 2.8, 8.8 Hz, 1 H), 6.99–6.92 (m, 1 H), 5.88–5.79 (m, 1 H), 5.74–5.64 (m, 1 H), 4.54 (s, 2 H), 4.52–4.47 (m, 2 H), 4.06 (d, <i>J</i> = 5.8 Hz, 2 H), 4.02–3.93 (m, 4 H), 2.25 (t, <i>J</i> = 7.3 Hz, 2 H), 1.72 (quin, <i>J</i> = 6.9 Hz, 2 H), 1.58 (td, <i>J</i> = 7.3, 15.0 Hz, 2 H), 1.51–1.40 (m, 2 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.4, 164.1, 158.9, 157.5, 151.7, 138.7, 136.4, 132.9, 131.2, 130.9, 129.8, 129.2, 126.8, 126.7, 126.4, 120.9, 119.9, 112.7, 107.3, 69.1, 68.8, 68.2, 67.1, 65.1, 33.7, 28.5, 25.2, 24.2.</div></div><div id="sec3_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 11-(7-(Heptanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>40</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 266 mg (0.514 mmol) of <b>29</b> and 2.24 g (15.7 mmol, 30 equiv) of potassium trimethylsilanoate in 10 mL of THF and 2 mL of concentrated HCl, and 203 mg (72%) of <b>40</b> was obtained as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 504.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.85 (br s, 1 H), 8.55 (d, <i>J</i> = 5.4 Hz, 1 H), 8.41 (d, <i>J</i> = 2.4 Hz, 1 H), 8.23–8.12 (m, 2 H), 8.05 (d, <i>J</i> = 6.8 Hz, 1 H), 7.62–7.55 (m, 2 H), 7.55–7.50 (m, 1 H), 7.49–7.42 (m, 1 H), 7.16–7.05 (m, 1 H), 6.96 (d, <i>J</i> = 8.8 Hz, 1 H), 5.89–5.78 (m, 1 H), 5.74–5.63 (m, 1 H), 4.58–4.44 (m, 4 H), 4.12–4.02 (m, 2 H), 4.02–3.91 (m, 4 H), 2.22 (t, <i>J</i> = 7.3 Hz, 2 H), 1.78–1.65 (m, 2 H), 1.53 (quin, <i>J</i> = 7.3 Hz, 2 H), 1.44 (td, <i>J</i> = 7.2, 14.4 Hz, 2 H), 1.38–1.28 (m, 2 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.4, 164.4, 158.5, 157.1, 151.8, 138.7, 136.3, 132.7, 131.3, 130.8, 130.0, 129.8, 129.2, 128.7, 126.9, 126.8, 126.4, 121.0, 120.1, 112.6, 107.3, 69.2, 68.8, 68.2, 67.1, 65.0, 33.6, 28.6, 28.2, 25.3, 24.4.</div></div><div id="sec3_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 11-(8-(Octanoate)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>41</b>)</h4><div class="NLM_p last">Synthesized using the procedure for <b>31</b> using 246 mg (0.463 mmol) of <b>30</b> and 2.00 g (14.0 mmol, 30 equiv) of potassium trimethylsilanoate in 10 mL of THF and 2 mL of concentrated HCl, and 136 mg (51%) of <b>41</b> was obtained as a light-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 518.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.93 (br s, 1 H), 8.56 (d, <i>J</i> = 5.4 Hz, 1 H), 8.39 (d, <i>J</i> = 2.5 Hz, 1 H), 8.14 (s, 1 H), 8.06 (d, <i>J</i> = 6.9 Hz, 1 H), 7.62–7.53 (m, 2 H), 7.53–7.44 (m, 1 H), 7.11 (dd, <i>J</i> = 2.6, 8.8 Hz, 1 H), 6.96 (d, <i>J</i> = 8.8 Hz, 1 H), 5.88–5.77 (m, 1 H), 5.74–5.62 (m, 1 H), 4.53 (s, 2 H), 4.51–4.45 (m, 2 H), 4.06 (d, <i>J</i> = 5.9 Hz, 2 H), 4.01–3.91 (m, 4 H), 2.21 (t, <i>J</i> = 7.3 Hz, 2 H), 1.78–1.64 (m, 2 H), 1.57–1.48 (m, 2 H), 1.48–1.39 (m, 2 H), 1.39–1.26 (m, 4 H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.4, 164.7, 158.2, 156.7, 151.9, 138.7, 136.2, 132.5, 131.5, 130.8, 129.8, 129.2, 127.0, 126.8, 126.5, 121.1, 120.2, 112.6, 107.3, 69.2, 68.8, 68.2, 67.1, 65.0, 33.7, 28.7, 28.5, 28.4, 25.4, 24.4.</div></div><div id="sec3_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 11-(2-(4-Aminophenylhydroxamate)ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>42</b>)</h4><div class="NLM_p last"><b>31</b> (39.4 mg, 0.0732 mmol), 12.0 mg (0.102 mmol, 1.4 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 33.8 mg (0.0889 mmol, 1.2 equiv) of HATU, and 21 μL (0.150 mmol, 2.0 equiv) of triethylamine were dissolved in 2 mL of DMF. The solution was stirred at rt for 24 h, after which it was diluted with water to precipitate out a yellow solid. There were two methods to obtain the crude product. The solid obtained could be filtered under vacuum to obtain the product. However, if the precipitate cannot be filtered easily, extraction of the mixture with 10% methanol in ethyl acetate three times was performed. The combined organic layer was washed with brine and dried with anhydrous sodium sulfate. The crude product was purified by flash column chromatography using 2:3 Hex/EtOAC to EtOAc to 40:1 to 20:1 DCM/MeOH to obtain 11.8 mg of the THP protected hydroxamate as a pale-yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.17. LRMS (ESI) <i>m</i>/<i>z</i> 638.4 (M + H<sup>+</sup>). This product was dissolved in 5 mL of dioxane, and 1 mL of 4 M HCl in dioxane was added. An orange precipitate formed immediately upon addition of the acid solution. The mixture was stirred for 18 h at rt. The reaction was quenched with saturated sodium bicarbonate solution to precipitate out a yellow solid. The mixture was concentrated to remove the volatile organic solvent. The precipitate was then filtered and dried under vacuum to obtain 6.7 mg (23%) of <b>42</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 554.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.53 (br s, 1H), 8.42–8.59 (m, 2H), 8.16 (s, 1H), 8.01 (d, <i>J</i> = 6.15 Hz, 1H), 7.49–7.61 (m, 4H), 7.39 (d, <i>J</i> = 4.52 Hz, 1H), 7.07–7.14 (m, 1H), 6.97 (d, <i>J</i> = 8.78 Hz, 1H), 6.60–6.73 (m, 2H), 6.29 (br s, 1H), 5.79 (br s, 1H), 5.69 (s, 1H), 4.50–4.61 (m, 2H), 4.40–4.50 (m, 2H), 4.10 (t, <i>J</i> = 5.08 Hz, 2H), 4.00 (d, <i>J</i> = 4.27 Hz, 4H), 3.49 (d, <i>J</i> = 5.27 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 162.8, 160.2, 159.4, 151.2, 151.1, 138.6, 136.8, 134.0, 130.9, 130.9, 130.8, 129.8, 129.1, 128.2, 126.6, 126.5, 126.4, 120.5, 119.6, 119.3, 115.4, 114.0, 113.2, 111.0, 107.4, 69.1, 68.9, 67.9, 67.0, 65.0, 41.9.</div></div><div id="sec3_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 11-(2-(3-Aminophenylhydroxamate)ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>43</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 163 mg (0.302 mmol) of <b>32</b>, 36.3 mg (0.310 mmol, 1.0 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 128 mg (0.336 mmol, 1.1 equiv) of HATU, and 130 μL (0.928 mmol, 3.1 equiv) of triethylamine were dissolved in 3 mL of DMF. The crude product was purified by flash column chromatography using 1:4 Hex/EtOAC to 25:1 to 25:1.5 to 25:2 DCM/MeOH to obtain 17.6 mg of the THP protected hydroxamate as a yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.16. LRMS (ESI) <i>m</i>/<i>z</i> 638.4 (M + H<sup>+</sup>). This product was dissolved in 4 mL of dioxane, and 0.5 mL of 4 M HCl in dioxane was added to give 12.4 mg (7%) of <b>43</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 554.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.52 (s, 1H), 8.46–8.54 (m, 2H), 8.16 (s, 1H), 8.01 (d, <i>J</i> = 3.89 Hz, 1H), 7.52–7.60 (m, 2H), 7.39 (d, <i>J</i> = 5.14 Hz, 1H), 7.08–7.17 (m, 2H), 7.04 (s, 1H), 6.98 (d, <i>J</i> = 8.78 Hz, 1H), 6.93 (d, <i>J</i> = 7.53 Hz, 1H), 6.77 (dd, <i>J</i> = 1.69, 7.97 Hz, 1H), 5.92 (t, <i>J</i> = 5.40 Hz, 1H), 5.73–5.88 (m, 1H), 5.61–5.73 (m, 1H), 4.54 (s, 2H), 4.47 (s, 2H), 4.12 (t, <i>J</i> = 5.27 Hz, 2H), 3.96–4.04 (m, 4H), 3.43–3.50 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.9, 160.2, 159.4, 151.1, 148.7, 138.6, 136.8, 133.9, 130.9, 130.8, 129.8, 129.1, 128.8, 126.6, 126.5, 126.4, 120.5, 119.6, 114.9, 114.2, 113.2, 110.3, 107.4, 69.1, 68.9, 67.8, 67.0, 66.3, 65.0, 42.0.</div></div><div id="sec3_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 11-(2-(4-Hydroxyphenyl hydroxamate))-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>44</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 33.9 mg (0.0628 mmol) of <b>33</b>, 11.0 mg (0.0.0939 mmol, 1.5 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 47.7 mg (0.125 mmol, 2.0 equiv) of HATU, and 26 μL (0.186 mmol, 3.0 equiv) of triethylamine were dissolved in 2 mL of DMF. The crude product was purified by flash column chromatography using DCM to 30:1 to 20:1 DCM/MeOH to obtain 31.0 mg of the THP protected hydroxamate as a yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.19. LRMS (ESI) <i>m</i>/<i>z</i> 639.4 (M + H<sup>+</sup>). This product was dissolved in 5 mL of dioxane, and 0.5 mL of 4 M HCl in dioxane was added to give 6.5 mg (18%) of <b>44</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 555.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.55 (s, 1H), 8.47–8.56 (m, 2H), 8.17 (s, 1H), 8.02 (d, <i>J</i> = 3.39 Hz, 1H), 7.77 (t, <i>J</i> = 9.35 Hz, 2H), 7.53–7.61 (m, 2H), 7.40 (d, <i>J</i> = 5.15 Hz, 1H), 7.00–7.18 (m, 4H), 5.75–5.86 (m, 1H), 5.61–5.72 (m, 1H), 4.54 (s, 2H), 4.45 (d, <i>J</i> = 3.14 Hz, 2H), 4.39 (br s, 2H), 4.34 (br s, 2H), 3.99 (d, <i>J</i> = 5.14 Hz, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 162.9, 161.1, 160.2, 159.4, 150.9, 138.6, 136.7, 134.2, 130.8, 130.8, 129.9, 129.1, 129.0, 128.6, 126.8, 126.5, 126.5, 120.5, 119.7, 114.3, 114.3, 113.8, 107.4, 101.0, 69.1, 68.9, 67.9, 67.0, 66.7, 66.3, 64.9, 61.4.</div></div><div id="sec3_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 11-(2-(<i>N</i>-Hydroxy-1-piperidine-4-carboxamide)-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene Hydrochloride (<b>45</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 70.9 mg (0.134 mmol) of <b>34</b>, 24.6 mg (0.210 mmol, 1.6 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 78.1 mg (0.205 mmol, 1.5 equiv) of HATU, and 100 μL (0.714 mmol, 5.3 equiv) of triethylamine were dissolved in 5 mL of DMF. The crude product was purified by flash column chromatography using EtOAC to 25:1 to 22:3 DCM/MeOH to obtain 68.8 mg of the THP protected hydroxamate as a yellow solid. TLC (9:1 DCM/MeOH) <i>R</i><sub>f</sub> = 0.18; LRMS (ESI) <i>m</i>/<i>z</i> 630.5 (M + H<sup>+</sup>). This product was dissolved in 5 mL of dioxane, and 0.5 mL of 4 M HCl in dioxane was added to give 16.4 mg (23%) of <b>45</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 546.3 (M + H<sup>+</sup>). HPLC purity 81% (19% carboxylic acid). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 10.38 (br s, 1H), 9.53 (s, 1H), 8.48–8.55 (m, 2H), 8.18 (s, 1H), 7.96–8.04 (m, 1H), 7.51–7.59 (m, 2H), 7.39 (d, <i>J</i> = 5.14 Hz, 1H), 7.08–7.15 (m, 1H), 6.97 (d, <i>J</i> = 8.78 Hz, 1H), 5.79–5.88 (m, 1H), 5.63–5.74 (m, 1H), 4.55 (s, 2H), 4.48 (s, 2H), 4.02–4.10 (m, 4H), 4.00 (d, <i>J</i> = 5.14 Hz, 2H), 2.98 (d, <i>J</i> = 11.54 Hz, 1H), 2.68 (t, <i>J</i> = 5.58 Hz, 2H), 1.91–2.20 (m, 3H), 1.56–1.69 (m, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 162.9, 160.2, 159.3, 151.2, 138.6, 136.8, 133.8, 131.0, 130.7, 129.8, 129.1, 126.5, 126.5, 126.3, 120.6, 119.6, 113.1, 107.3, 69.1, 68.9, 67.1, 65.3, 56.9, 53.1, 28.5.</div></div><div id="sec3_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 11-(2-(<i>N</i>1-(4-Aminophenyl)-<i>N</i>7-hydroxyheptanediamide)ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>46</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 25.9 mg (0.0397 mmol) of <b>35</b>, 7.0 mg (0.0600 mmol, 1.5 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 27.2 mg (0.0715 mmol, 1.8 equiv) of HATU, and 20 μL (0.143 mmol, 3.6 equiv) of triethylamine were dissolved in 1 mL of DMF. The crude product was purified by flash column chromatography using 1:4 Hex/EtOAC to 25:1 to 25:1.5 DCM/MeOH to obtain 10.5 mg of the THP protected hydroxamate as an off-white solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.05; LRMS (ESI) <i>m</i>/<i>z</i> 751.6 (M+H<sup>+</sup>). This product was dissolved in 5 mL of dioxane, and 0.3 mL of 4 M HCl in dioxane was added to give 3.2 mg (12%) of <b>46</b> as a pale-brown solid. LRMS (ESI) <i>m</i>/<i>z</i> 666.4 (M + H<sup>+</sup>). HPLC purity 93.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.52 (br s, 1H), 9.47 (br s, 1H), 8.45–8.55 (m, 2H), 8.17 (br s, 1H), 8.01 (br s, 1H), 7.56 (br s, 2H), 7.39 (d, <i>J</i> = 4.39 Hz, 1H), 7.25–7.35 (m, <i>J</i> = 8.28 Hz, 2H), 7.10 (d, <i>J</i> = 8.91 Hz, 1H), 6.97 (d, <i>J</i> = 8.66 Hz, 1H), 6.48–6.68 (m, <i>J</i> = 8.28 Hz, 2H), 5.83 (d, <i>J</i> = 15.81 Hz, 1H), 5.68 (d, <i>J</i> = 15.94 Hz, 1H), 4.55 (br s, 2H), 4.47 (s, 2H), 4.10 (br s, 2H), 3.90–4.07 (m, 5H), 2.21 (t, <i>J</i> = 6.90 Hz, 2H), 1.94 (t, <i>J</i> = 7.34 Hz, 2H), 1.40–1.69 (m, 4H), 1.24 (d, <i>J</i> = 6.90 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 162.8, 162.4, 160.2, 159.3, 151.2, 138.6, 131.0, 129.8, 129.1, 126.5, 120.8, 120.5, 119.6, 115.7, 113.2, 112.1, 107.3, 68.9, 67.0, 65.1, 42.7, 28.7, 28.3.</div></div><div id="sec3_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 11-(2-(<i>N</i>1-(4-Aminophenyl)-<i>N</i>8-hydroxyoctanediamide)ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>47</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 26.7 mg (0.0496 mmol) of <b>36</b>, 11.6 mg (0.0990 mmol, 2.0 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 31.1 mg (0.818 mmol, 1.6 equiv) of HATU, and 30 μL (0.214 mmol, 4.3 equiv) of triethylamine were dissolved in 2 mL of DMF. The crude product was purified by flash column chromatography using 2:3 Hex/EtOAC to 50:1 to 25:1 DCM/MeOH to obtain 29.8 mg of the THP protected hydroxamate as a yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.18. LRMS (ESI) <i>m</i>/<i>z</i> 765.4 (M + H<sup>+</sup>). This product was dissolved in 4 mL of dioxane, and 0.5 mL of 4 M HCl in dioxane was added to give 21.0 mg (62%) of <b>47</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 681.6 (M + H<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.44–9.54 (m, 2H), 8.46–8.55 (m, 2H), 8.16 (s, 1H), 8.01 (d, <i>J</i> = 5.27 Hz, 1H), 7.50–7.59 (m, 2H), 7.35–7.42 (m, 1H), 7.31 (d, <i>J</i> = 8.78 Hz, 2H), 7.10 (dd, <i>J</i> = 2.38, 8.78 Hz, 1H), 6.96 (d, <i>J</i> = 8.78 Hz, 1H), 6.54–6.64 (m, 2H), 5.75–5.89 (m, 1H), 5.61–5.75 (m, 1H), 4.54 (s, 2H), 4.47 (s, 2H), 4.06–4.12 (m, 2H), 4.01 (dd, <i>J</i> = 5.14, 14.68 Hz, 4H), 2.13–2.25 (m, 2H), 1.79–1.98 (m, 2H), 1.37–1.61 (m, 4H), 1.16–1.33 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 162.9, 160.2, 159.4, 151.2, 144.8, 138.6, 136.8, 133.9, 131.0, 130.8, 129.8, 129.1, 128.9, 126.6, 126.5, 126.5, 120.8, 120.5, 119.6, 113.2, 112.1, 107.4, 69.1, 68.9, 68.0, 67.1, 65.1, 48.6, 42.7, 36.2, 32.2, 29.0, 28.4, 25.2, 25.0.</div></div><div id="sec3_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 11-(4-(<i>N</i>-Hydroxybutanamide)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>48</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 170 mg (0.368 mmol) of <b>37</b>, 123 mg (1.05 mmol, 2.9 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 228 mg (0.600 mmol, 1.6 equiv) of HATU, and 0.24 mL (1.71 mmol, 4.7 equiv) of triethylamine were dissolved in 5 mL of DMF. The crude product was purified by flash column chromatography using 2:3 Hex/EtOAC to 25:1 EOAc/MeOH to obtain 100 mg of the THP protected hydroxamate as a yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.11. LRMS (ESI) <i>m</i>/<i>z</i> 561.2 (M + H<sup>+</sup>). This product was dissolved in 5 mL of dioxane, and 1.2 mL of 4 M HCl in dioxane was added to give 78.2 mg (45%) of <b>48</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 477.2 (M + H<sup>+</sup>). HPLC purity >99%. Major <i>E</i> isomer only: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.42 (br s, 1H), 9.52 (s, 1H), 8.45–8.58 (m, 2H), 8.13–8.23 (m, 1H), 8.01 (d, <i>J</i> = 5.90 Hz, 1H), 7.52–7.62 (m, 2H), 7.45–7.52 (m, 1H), 7.38 (d, <i>J</i> = 5.27 Hz, 1H), 7.06–7.15 (m, 1H), 6.89–6.98 (m, 1H), 5.76–5.90 (m, 1H), 5.62–5.76 (m, 1H), 4.55 (s, 2H), 4.47–4.53 (m, 2H), 4.07 (d, <i>J</i> = 5.77 Hz, 2H), 3.92–4.03 (m, 5H), 2.17 (t, <i>J</i> = 7.22 Hz, 1H), 1.94 (quin, <i>J</i> = 6.68 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.7, 163.0, 160.1, 159.2, 151.2, 138.6, 136.8, 133.7, 131.0, 130.8, 129.7, 129.1, 126.5, 126.5, 126.3, 120.5, 119.6, 112.8, 107.3, 69.1, 68.8, 67.7, 67.0, 65.1, 28.8, 24.9.</div></div><div id="sec3_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 11-(4-(<i>N</i>-Hydroxypentanamide)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>49</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 103 mg (0.217 mmol) of acid <b>38</b>, 38.0 mg (0.324 mmol, 1.5 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 128 mg (0.336 mmol, 1.6 equiv) of HATU, and 91 μL (0.649 mmol, 3.0 equiv) of triethylamine were dissolved in 3 mL of DMF. The crude product was purified by flash column chromatography using 2:3 Hex/EtOAC to 25:0.5 to 25:1 DCM/MeOH to obtain 131 mg of the THP protected hydroxamate as a yellow oil. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.18. LRMS (ESI) <i>m</i>/<i>z</i> 575.4 (M + H<sup>+</sup>). This product was dissolved in 8 mL of dioxane, and 1 mL of 4 M HCl in dioxane was added to give 81.9 mg (77%) of <b>49</b> as a pale-yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 491.3 (M+H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.52 (br s, 1H), 8.44–8.60 (m, 2H), 8.12–8.21 (m, 1H), 7.99 (d, <i>J</i> = 5.77 Hz, 1H), 7.50–7.61 (m, 2H), 7.37 (d, <i>J</i> = 5.02 Hz, 1H), 7.04–7.20 (m, 2H), 6.88–6.99 (m, 1H), 5.75–5.89 (m, 1H), 5.61–5.74 (m, 1H), 4.54 (s, 2H), 4.48 (s, 2H), 4.05 (d, <i>J</i> = 5.52 Hz, 2H), 3.90–4.01 (m, 4H), 2.02 (t, <i>J</i> = 6.15 Hz, 2H), 1.60–1.78 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 173.3, 168.7, 162.9, 160.2, 159.3, 151.3, 138.6, 136.8, 133.6, 131.0, 130.7, 130.1, 129.8, 129.1, 128.9, 128.6, 128.2, 126.6, 126.4, 126.2, 126.2, 125.3, 120.6, 119.6, 112.8, 107.3, 69.1, 68.9, 68.0, 67.9, 67.1, 65.8, 65.2, 51.2, 32.9, 32.1, 28.4, 28.2, 21.9, 21.3, 21.0.</div></div><div id="sec3_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 11-(4-(<i>N</i>-Hydroxyhexanamide)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>50</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 292 mg (0.597 mmol) of <b>39</b>, 106 mg (0.905 mmol, 1.5 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 342 mg (0.901 mmol, 1.5 equiv) of HATU, and 250 μL (1.78 mmol, 3.0 equiv) of triethylamine were dissolved in 3 mL of DMF. The crude product was purified by flash column chromatography using 1:4 Hex/EtOAC to 50:1 to 25:1 DCM/MeOH to obtain 686 mg of the THP protected hydroxamate as a yellow oil with DMF. TLC (1:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.38. LRMS (ESI) <i>m</i>/<i>z</i> 589.4 (M + H<sup>+</sup>). This product was dissolved in 10 mL of dioxane, and 2 mL of 4 M HCl in dioxane was added to give 111 mg (37%) of <b>50</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 505.2 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.52 (br s, 1H), 8.44–8.55 (m, 2H), 8.12–8.20 (m, 1H), 7.88–8.05 (m, 1H), 7.43–7.61 (m, 2H), 7.28–7.42 (m, 1H), 7.11 (dd, <i>J</i> = 2.57, 8.72 Hz, 1H), 6.85–6.98 (m, 1H), 5.74–5.89 (m, 1H), 5.68 (td, <i>J</i> = 5.93, 15.62 Hz, 1H), 4.53 (s, 2H), 4.48 (s, 2H), 4.01–4.09 (m, 2H), 3.79–4.01 (m, 4H), 1.84–2.02 (m, 2H), 1.62–1.78 (m, 2H), 1.48–1.62 (m, 2H), 1.32–1.48 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 168.7, 162.9, 162.3, 160.2, 159.3, 151.4, 138.6, 136.8, 133.7, 131.1, 130.8, 129.8, 129.1, 126.6, 126.5, 126.3, 120.6, 119.6, 112.8, 107.3, 69.1, 68.9, 68.3, 67.1, 65.2, 40.4, 38.2, 35.8, 32.4, 28.6, 25.3, 25.1.</div></div><div id="sec3_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 11-(4-(<i>N</i>-Hydroxyheptanamide)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>51</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 46.6 mg (0.0925 mmol) of <b>40</b>, 11.2 mg (0.0956 mmol, 1.0 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 49.4 mg (0.130 mmol, 1.4 equiv) of HATU, and 20 μL (0.143 mmol, 1.5 equiv) of triethylamine were dissolved in 1.5 mL of DMF. The crude product was purified by flash column chromatography using 2:3 Hex/EtOAC to 50:1 EOAc/MeOH to obtain 30.5 mg of the THP protected hydroxamate as a yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.18. LRMS (ESI) <i>m</i>/<i>z</i> 603.3 (M + H<sup>+</sup>). This product was dissolved in 2 mL of dioxane, and 0.5 mL of 4 M HCl in dioxane was added to give 13.4 mg (36%) of <b>51</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 519.3 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, 1H), 8.46–8.54 (m, 2H), 8.13–8.23 (m, 1H), 8.01 (d, <i>J</i> = 6.15 Hz, 1H), 7.50–7.60 (m, 2H), 7.38 (d, <i>J</i> = 5.14 Hz, 1H), 7.10 (dd, <i>J</i> = 2.57, 8.72 Hz, 1H), 6.94 (d, <i>J</i> = 8.78 Hz, 1H), 5.78–5.89 (m, 1H), 5.61–5.75 (m, 1H), 4.55 (s, 2H), 4.43–4.53 (m, 3H), 4.06 (d, <i>J</i> = 5.77 Hz, 2H), 3.90–4.03 (m, 4H), 1.96 (t, <i>J</i> = 7.34 Hz, 2H), 1.64–1.79 (m, 2H), 1.52 (td, <i>J</i> = 7.26, 14.71 Hz, 2H), 1.43 (td, <i>J</i> = 7.39, 14.46 Hz, 2H), 1.26–1.37 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 169.1, 162.9, 160.2, 159.3, 151.4, 138.6, 136.8, 133.6, 131.0, 130.7, 129.8, 129.1, 126.5, 126.5, 126.2, 120.6, 119.6, 112.8, 107.3, 69.1, 68.8, 68.2, 67.0, 66.3, 65.2, 40.1, 39.9, 39.7, 39.3, 39.1, 38.9, 32.2, 28.7, 28.3, 25.3, 25.1. HRMS (ESI) <i>m/</i>z 541.2425, calcd 541.2421 (diff 0.7 ppm).</div></div><div id="sec3_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 11-(4-(<i>N</i>-Hydroxyoctanamide)oxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (<b>52</b>)</h4><div class="NLM_p last">Synthesized following the procedure for <b>42</b>; 58.9 mg (0.114 mmol) of <b>41</b>, 16.6 mg (0.142 mmol, 1.2 equiv) of <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine, 56.3 mg (0.148 mmol, 1.3 equiv) of HATU, and 30 μL (0.214 mmol, 1.9 equiv) of triethylamine were dissolved in 1 mL of DMF. The crude product was purified by flash column chromatography using 2:3 Hex/EtOAC to 50:1 EOAc/MeOH to obtain 41.6 mg of the THP protected hydroxamate as a yellow solid. TLC (2:3 Hex/EtOAc) <i>R</i><sub>f</sub> = 0.18; LRMS (ESI) <i>m</i>/<i>z</i> 617.4 (M + H<sup>+</sup>). This product was dissolved in 2 mL of dioxane, and 0.5 mL of 4 M HCl in dioxane was added to give 24.7 mg (41%) of <b>52</b> as a yellow solid. LRMS (ESI) <i>m</i>/<i>z</i> 533.3 (M + H<sup>+</sup>). HPLC purity >99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (br s, 1H), 9.51 (s, 1H), 8.66 (br s, 1H), 8.44–8.57 (m, 2H), 8.11–8.22 (m, 1H), 8.01 (d, <i>J</i> = 5.77 Hz, 1H), 7.48–7.59 (m, 2H), 7.38 (d, <i>J</i> = 5.02 Hz, 1H), 7.06–7.14 (m, 1H), 6.94 (d, <i>J</i> = 8.78 Hz, 1H), 5.85 (td, <i>J</i> = 5.43, 15.75 Hz, 1H), 5.69 (td, <i>J</i> = 5.93, 15.62 Hz, 1H), 4.55 (s, 2H), 4.41–4.53 (m, 2H), 4.06 (d, <i>J</i> = 5.77 Hz, 2H), 3.88–4.02 (m, 4H), 1.95 (t, <i>J</i> = 7.34 Hz, 2H), 1.64–1.77 (m, 2H), 1.38–1.58 (m, 4H), 1.22–1.38 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.0, 162.9, 160.2, 159.3, 151.4, 138.6, 136.8, 133.6, 131.0, 130.7, 129.8, 129.1, 126.5, 126.4, 126.2, 120.6, 119.6, 112.8, 107.3, 69.1, 68.8, 68.3, 67.0, 66.3, 65.2, 32.2, 28.8, 28.5, 28.4, 25.4, 25.0.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Molecular Modeling</h3><div class="NLM_p">JAK2 modeling is described in ref <a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">88</a>. The HDAC1 X-ray structure (ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>), HDAC2 structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a>), and HDAC4 structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW">2VQW</a>) were downloaded from the Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>) and prepared using the protein preparation wizard in Maestro version 10110 using standard settings. This included the addition of hydrogen atoms, bond assignments, removal of water molecules further than 5 Å from the ligand, protonation state assignment, optimization of the hydrogen bond network, and restrained minimization using the OPLS2005 force field.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The proteins were superimposed using structural alignment, and the HDAC2 structure ligand SAHA was duplicated into HDAC1 and HDAC4. The HDAC6 protein sequence (ID: Q9UBN7) was downloaded from Uniprot (<a href="http://www.uniprot.org" class="extLink">http://www.uniprot.org</a>). A homology model was built for each of the catalytic domains of HDAC6 using the HDAC4–SAHA complex as template and Prime version 3.8110 with default settings. The two HDAC6 homology models are very similar to 49% sequence identity and 67% homology. Both the C-terminal catalytic domain model (HDAC6 residues 482–800) and the N-terminal catalytic domain model (HDAC6 residues 87–404) were used for modeling. The inhibitors were found to model into both HDAC6 models in a similar conformation and orientation. Following Wiest  et al.,<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> the C-terminal catalytic domain model is discussed unless otherwise stated.</div><div class="NLM_p">A conformational analysis of each inhibitor was done to obtain a conformational ensemble for docking.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Grids for docking were prepared for HDAC1 and HDAC6 using Glide version 6.5<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> with standard settings. Constraints for the zinc atom and the residues that hydrogen bond with the hydroxamate were included. Docking procedures were carried out as previously described.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Docking of the hybrid inhibitors with constraints did not produce low energy poses. Docking of <b>2</b> without constraints resulted in reasonable poses of low energy conformations binding to the cap region of HDAC1 and HDAC6. Poses of <b>2</b> were then merged with the linker and hydroxamate part of <b>1</b>.</div><div class="NLM_p last">The HDAC1 and HDAC6 inhibitor–protein complexes were finally minimized using Macromodel10.6.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Distance constraints between the hydroxamate and Zinc (2.3 Å) as well as the three residues that hydrogen bond with the hydroxamate (2.8 Å) were included. All residues more than 9 Å from the ligand were constrained before the complex was subjected to 500 steps of Polak–Ribiere Conjugate Gradient<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> (Polak and Ribiere, 1969) minimization using the OPLS2005 force field and GB/SA continuum solvation model (Hasel et al., 1988).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Enzyme Assays</h3><div class="NLM_p">Enzyme inhibition assays were carried out by Reaction Biology Corporation (RBC).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> For HDAC assays: Add 2× of HDAC enzyme into reaction plate except control wells (no enzyme), where buffer (50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, and 1 mM MgCl<sub>2</sub>) was added instead. Add inhibitors in 100% DMSO into the enzyme mixture via acoustic technology (Echo550; nanoliter range). Spin down and preincubate. Add 2× substrate mixture: Fluorogenic HDAC General Substrate: 50 μM, Arg-His-Lys-Lys(Ac). HDAC8 only substrate: 50 μM, Arg-His-Lys(Ac)-Lys(Ac). Class2A substrate: acetyl-Lys(trifluoroacetyl)-AMC) in all reaction wells to initiate the reaction. Spin and shake. Incubate for 2 h at 30 °C with seal. Add developer with trichostatin A to stop the reaction and to generate fluorescent color. Carry out kinetic measurements for 1.5 h with Envision with 15 min interval (Ex/Em = 360/460 nm). Take end point reading for analysis after the development reaches plateau. Kinase assays were carried out according to the published procedures.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Kinase profiling was performed using the “HotSpot” assay platform. Briefly, specific kinase/substrate pairs along with required cofactors were prepared in reaction buffer: 20 mM Hepes pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM DTT, and 1% DMSO. Compounds were delivered into the reaction, followed ∼20 min later by addition of a mixture of ATP (Sigma) and <sup>33</sup>P ATP (PerkinElmer) to a final concentration of 10 μM. Reactions were carried out at 25 °C for 120 min, followed by spotting of the reactions onto P81 ion exchange filter paper (Whatman). Unbound phosphate was removed by extensive washing of filters in 0.75% phosphoric acid. After subtraction of background derived from control reactions containing inactive enzyme, kinase activity data were expressed as the percent remaining kinase activity in test samples compared to vehicle (dimethyl sulfoxide) reactions. IC<sub>50</sub> values and curve fits were obtained using Prism (GraphPad Software).</div><div class="NLM_p last">Kinase profiling was carried out by DiscoveRx according to published protocols.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Cellular Assays</h3><div id="sec3_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Cell Proliferation Inhibition Assays</h4><div class="NLM_p">Human breast cancer MCF-7 cells, human breast cancer MDA-MB231 cells, prostate cancer cell line PC-3, and colon cell line HCT-116 cells were purchased from ATCC (Rockville, MD). The first three cell lines were grown in DMEM Media (Invitrogen, Singapore) and the last in McCoy’s Media. They were supplemented with 10% fetal bovine serum, 50 μg/mL penicillin, and 50 μg/mL streptomycin at 37 °C with 5% CO<sub>2</sub>. The cells were subcultured to 80–90% confluency and used within 15–20 passages for the assay. Cell viability was assessed with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) as follows: cells were seeded at 2500 cells per well in a 96-well plate for 24 h. The media was removed and aliquots of test compounds (initially prepared as 10 mM stock solutions in DMSO) were added to each well and the plates were incubated for 72 h. The final amount of DMSO per well was maintained at 0.5% v/v. At the end of the incubation period, the media was removed and replaced with FBS free media (150 μL) and MTT (50 μL of 2 mg/mL solution in phosphate buffer saline, pH 7.4). After incubation for 3 h at 37 °C with 5% CO<sub>2</sub>, the supernatant was removed and a solution of 100 μL of DMSO was added to dissolve the formazan crystals. Absorbance was measured at 570 nm on a micro plate reader (Tecan Infinite 200). Cell viability was determined from readings of treated wells compared to control wells (absence of test compound) with correction of background absorbance. The IC<sub>50</sub> (concentration required to reduce cell viability to 50% of control/untreated cells) was determined in triplicates on separate occasions, using two different stock solutions. Percent viability readings for each test compound were plotted against log concentration on GraphPad Prism (version 5.0, GraphPad Software, San Diego, CA), with constraints set at ≥0 and ≤100%. A sigmoidal curve was generated from which the IC<sub>50</sub> was obtained.</div><div class="NLM_p">Multiple myeloma cell Lines, KMS-12-BM, OPM2, AML cell lines KG1 and MOLM14, and NKT-cell lymphoma cell lines, NKYS and KHYG were cultured in RPMI 1640 (Biowest) supplemented with 10% fetal bovine serum (Biowest), 100 units/mL penicillin, and 100 μg/mL streptomycin. An additional supplementation of IL-2 was required for NKYS (100 units/mL of IL-2) and (200 units/mL of IL-2) for KHYG. All cells were grown in a humidified atmosphere at 37 °C with 5% CO<sub>2.</sub> KMS-12-BM, OPM2, KG1, MOLM14, NKYS, and KHYG cells were treated in 96-well plates at a density of 25000 cells per well in triplicates for 48 h in a 37 °C incubator with 5% CO<sub>2.</sub> Cell viability was assessed using the CellTiter-Glo luminescent cell proliferation assay (CTG assay, Promega, Madison, WI). The luminescence was measured with a Tecan spectrophotometer. Dose response curves were plotted as above.</div><div class="NLM_p last">HEL cells were cultured in RPMI 1640 medium containing 10% FBS (Life Technology) and 55 μM β-mercaptoethanol (Sigma-Aldrich). HEL cells (2.5 × 10<sup>4</sup>/ 90 μL) were seeded in 96-well plates, and inhibitors of various concentrations were added accordingly. As negative control, cells were treated with vehicle (DMSO) only. After 36 h of incubation, 10 μL of PrestoBlue dye were added into each well and further incubated for 2.5 h. Measurement was done according to PrestoBlue dye protocol at 570 nm against 600 nm. This experiment was performed in triplicates and repeated twice. Mean values ± SD for each concentration were determined. Calculation of cell viability was done according to the protocol (Life Technology).</div></div><div id="sec3_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Immunoblotting</h4><div id="sec3_4_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> HEL92.1.7 Cells</h5><div class="NLM_p last">SDS-PAGE and Western blot analyses were performed as previously described.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> HEL cells (5 × 10<sup>5</sup>/ mL) were seeded into 6-well plates and treated with inhibitor (0, 0.1, 0.5, and 1 μM) for 1 h. Cells were collected and washed with PBS. Pellet was lysed in RIPA buffer supplemented with phosphatase inhibitor cocktail (Roche Life Science) and protease inhibitor cocktail (Sigma-Aldrich). The lysate was loaded into 10% (HEL cells) or 8% (HeLa stable clone) polyacrylamide gel. Proteins were then transferred to PVDF membrane (Milipore) and detected through specific antibodies: anti-acetylated tubulin (6–11B-1) (Biolegend), anti-STAT5 (Santa Cruz Biotechnology), anti-H3 (9715S), anti-acetylated H3 (Lys9/Lys14) (9677S), anti-pJAK2 (Y1007/1008), anti-JAK2 (D2E12), anti-pSTAT5 (Tyr694), and anti-tubulin (Cell Signaling Technology).</div></div><div id="sec3_4_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> KMS-12-BM and MOLM-14</h5><div class="NLM_p last">For immunoblotting analysis, at least 3 × 10<sup>6</sup> cells were seeded for each condition. Cells were treated with <b>51</b> at stated concentrations and harvested at indicated time points. Equal amounts of protein were separated on an SDS polyacrylamide gel and transferred onto a PVDF membrane. Membrane was then probed with following antibodies: antiphosho-STAT3 (no. 9138 Cell Signaling Technology), anti-STAT3 (no. SC-482 Santa Cruz), anti-acetylated alpha tubulin (no. SC-23590, Santa Cruz), anti-alpha tubulin (no. SC-5286), anti-acetylated histone 3 (Lys9/Lys14) (no. 9677 Cell Signaling Technology), anti-histone (no. 9715, Novus Biological).</div></div></div><div id="sec3_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Colony Forming Unit Assay</h4><div class="NLM_p last">HEL cells (200 cells/mL) were mixed vigorously with methylcellulose semisolid medium according to ClonaCell-TCS medium (StemCell Technologies). Inhibitors of various concentrations were added accordingly. The mixture was vortexed and aliquoted into 6-well plates for 14–16 days incubation after which colonies were counted.</div></div><div id="sec3_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Determination of Toxicity in Transforming Growth Factor-Alpha Mouse Hepatocyte (TAMH) Cells</h4><div class="NLM_p last">TAMH cells were seeded at a cell density of 12000 cells/well (60000 cells/mL) in a 96-well plate (NUNC) a day before drug treatment. Cells were then treated with test compounds starting from a concentration of 100 μM (0.5% DMSO concentration: 1.0 μL of <b>51</b> and <b>52</b> of a 10 mM stock solution in 99 μL of media in each well; drug stock concentration is 10 mM). Drug-treated cells were then incubated at 37 °C for 24 h, after which time cell viability was determined with CellTiter-Glo cell viability assay (Promega Corporation) as per manufacturer’s instructions. The cell-reagent mixture was then transferred to a solid white flat-bottom 96-well plate (Greiner). Luminescence was then recorded with an integration time of 0.25 s (Tecan Infinite M200 Microplate reader). Either percentage inhibition at the top concentration or an IC<sub>50</sub> was calculated as for the cell assays above.</div></div><div id="sec3_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Determination of in Vitro Metabolic Stability in Male (MRLM) and Female Rat Liver Microsomes (FRLM)</h4><div class="NLM_p">Liver microsomal incubations were conducted in triplicate. Incubation mixtures consisted of 7.5 μL of 20 mg/mL FRLM and MRLM (final: 0.3 mg microsome protein/mL), 2.5 μL of 600 μM <b>51</b>/<b>52</b> in acetonitrile (final: 3 μM), 440 μL of 0.1 M phosphate buffer (pH 7.4). The mixture was first shaken for 5 min for preincubation in a shaking water bath at 37 °C. Reaction was initiated by adding 50 μL of 10 mM NADPH to obtain a final concentration of 1 mM NADPH in the mixture. The total volume of the reaction mixture was 500 μL. For metabolic stability studies, aliquots of 50 μL of the incubation sample mixture were collected at 0, 5, 10, 15, 30, and 45 min. After collection of samples, the reaction was terminated with 100 μL of chilled acetonitrile containing the internal standard (1.5 μM compound <b>1</b>). The mixture was then centrifuged at 10000<i>g</i> to remove the protein and the supernatant was subsequently applied to LC-MS/MS analysis.</div><div class="NLM_p last">Positive control (PC) samples were prepared as described above, except the test compound was replaced with the known P450 substrate (Midazolam, 3 μM). The samples were assayed for the degradation of midazolam to evaluate the adequacy of the experimental conditions for drug metabolism study. Negative control samples were also prepared as described above but without NADPH.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00157">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00157" class="ext-link">10.1021/acs.jmedchem.6b00157</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional synthesis of compounds, NMR and HPLC spectra for all final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf">jm6b00157_si_001.pdf (21.77 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_002.csv">jm6b00157_si_002.csv (3.33 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00157" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian W. Dymock</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#32425a53565045725c47411c5756471c4155"><span class="__cf_email__" data-cfemail="0f7f676e6b6d784f617a7c216a6b7a217c68">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eugene Guorong Yang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nurulhuda Mustafa</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eng Chong Tan</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Poulsen</span> - <span class="hlFld-Affiliation affiliation">Experimental
Therapeutics Centre, 31 Biopolis Way, 03-01 Nanos, Singapore 138669</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pondy Murugappan Ramanujulu</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543</span>; 
    <span class="hlFld-Affiliation affiliation">Life Sciences
Institute, National University of Singapore, Centre for Life Sciences, Level
5, 28 Medical Drive, Singapore 117456</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wee Joo Chng</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228</span>; 
    <span class="hlFld-Affiliation affiliation">Cancer
Science Institute, Singapore, National University
of Singapore, Singapore 117599</span>; 
    <span class="hlFld-Affiliation affiliation">National
University Cancer Institute of Singapore, National University Health SystemSingapore 119074</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey J. Y. Yen</span> - <span class="hlFld-Affiliation affiliation">Institute
of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. N.M. and E.C.T. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d88e6978-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge Sheela David Packiaraj and Associate Professor Ho Han Kiat for providing TAMH data and Dr. Yang Shilli and Professor Paul Ho for RLM data. This research was funded by generous grants from the National University of Singapore (Drug Development Unit grant (M.R.) and Faculty of Science start-up grant to B.D.). W.J.C. is supported by NMRC Clinician Scientist Investigator award and partly supported by a Singapore Cancer Syndicate Grant, the National Research Foundation Singapore, and the Singapore Ministry of Education under the Research Centers of Excellence initiative. J.J.Y.Y. is supported by research grant NSC 102-2320-B-001-007-MY3 from the Ministry of Science and Technology, Taiwan.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i91" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i91"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i92" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i92"> Abbreviations Used</h2><tr><td class="NLM_term">DML</td><td class="NLM_def"><p class="first last">designed multiple ligand</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 123 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Stewart, B. W.; Wild, C. P.</span> <span class="citation_source-book">World Cancer Report 2014</span>; <span class="NLM_publisher-name">World Health Organization: International Agency for Research on Cancer</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+W.+Stewart&author=C.+P.+Wild&title=World+Cancer+Report+2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DB.%2BW.%26btitle%3DWorld%2520Cancer%2520Report%25202014%26pub%3DWorld%2520Health%2520Organization%253A%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Combinatorial drug therapy for cancer in the post-genomic era</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span><span class="refDoi"> DOI: 10.1038/nbt.2284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt.2284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22781697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=679-692&author=B.+Al-Lazikaniauthor=U.+Banerjiauthor=P.+Workman&title=Combinatorial+drug+therapy+for+cancer+in+the+post-genomic+era&doi=10.1038%2Fnbt.2284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug therapy for cancer in the post-genomic era</span></div><div class="casAuthors">Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted.  Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups.  This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach.  However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.  One soln. to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5IOOPfsgR7Vg90H21EOLACvtfcHk0liHX2tgwD_PQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D&md5=a61b1b222a7146a92366f57cb0e708ca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2284%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DCombinatorial%2520drug%2520therapy%2520for%2520cancer%2520in%2520the%2520post-genomic%2520era%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnbt.2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0liHX2tgwD_PQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C. T.</span><span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leharauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eZ0AtlkgRFpYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Schwartz, G. K.</span> <span class="citation_source-book">Combination Cancer Therapy: Modulators and Potentiators</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1385%2F1592598641" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=G.+K.+Schwartz&title=Combination+Cancer+Therapy%3A+Modulators+and+Potentiators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1385%2F1592598641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1385%252F1592598641%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26btitle%3DCombination%2520Cancer%2520Therapy%253A%2520Modulators%2520and%2520Potentiators%26pub%3DHumana%2520Press%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span><span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lgaSc8P74S-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Designed multiple ligands for cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4722</span><span class="NLM_x">–</span> <span class="NLM_lpage">4737</span><span class="refDoi"> DOI: 10.2174/092986711797535344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.2174%2F092986711797535344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21919848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyhsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4722-4737&author=N.+M.+O%E2%80%99Boyleauthor=M.+J.+Meegan&title=Designed+multiple+ligands+for+cancer+therapy&doi=10.2174%2F092986711797535344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands for cancer therapy</span></div><div class="casAuthors">O'Boyle, N. M.; Meegan, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">4722-4737</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of a single chem. entity with desirable activity at more than one biol. target is an attractive one.  Increasingly, multiple complex biochem. pathways are implicated in a variety of diseases including cancer.  Successful treatment of these conditions often depends on pharmaceutical intervention at multiple pathways, with a combination of different drugs.  Designed multiple ligands (DMLs) are drugs which act at multiple biomol. targets.  Numerous terms have been used to describe such ligands, including multiple-target directed ligands, heterodimers, promiscuous drugs and pan-agonists.  However, although there are many reported examples of multiple-targeting anti-cancer agents, no review of these has been presented to date.  A huge variety of biol. signalling-pathways, proteins and enzymes are currently targeted and implicated in the pathogenesis of cancer.  This review will provide an overview of reported designed multiple ligands for cancer and an exploration of the advantages and drawbacks of such compds.  The review also provides brief commentaries on the biol. processes and proteins that are currently targeted in cancer therapy and the potential for dual or triple targeting of these with designed multiple ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS2P_3Ows00bVg90H21EOLACvtfcHk0lgaSc8P74S-CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyhsLnF&md5=6d9f613ed668a18663fc2369a1041341</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986711797535344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797535344%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DDesigned%2520multiple%2520ligands%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4722%26epage%3D4737%26doi%3D10.2174%2F092986711797535344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhj9ZMJ_zAclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Rodrigues, D. A.</span> <span class="citation_source-book">Drug-Drug Interactions</span>, <span class="NLM_edition">2nd</span> ed.; <span class="NLM_publisher-name">CRC Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+A.+Rodrigues&title=Drug-Drug+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26btitle%3DDrug-Drug%2520Interactions%26pub%3DCRC%2520Press%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Costantino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlocco, D.</span><span> </span><span class="NLM_article-title">Designed multiple ligands: basic research vs clinical outcomes</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3353</span><span class="NLM_x">–</span> <span class="NLM_lpage">3387</span><span class="refDoi"> DOI: 10.2174/092986712801215883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.2174%2F092986712801215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22680630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3353-3387&author=L.+Costantinoauthor=D.+Barlocco&title=Designed+multiple+ligands%3A+basic+research+vs+clinical+outcomes&doi=10.2174%2F092986712801215883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands: basic research vs clinical outcomes</span></div><div class="casAuthors">Costantino, L.; Barlocco, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3353-3387</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. treatment of multifactorial pathologies (e.g. cancer, Alzheimer's disease, psychiatric disorders), is still a major challenge.  Many researches have been published dealing with the design of multiple ligands, able to act at the same time towards several targets relevant for a given pathol.  In the present review, the clin. results about these compds. have been reported, together with the design strategy adopted, in order to allow a crit. evaluation of the outcomes of these efforts.  What is emerging is that several effective design strategies of multitarget compds. are available, and the choice among these appears to be dependent on the therapeutic area considered.  However, at present, besides multitarget drugs discovered during optimization efforts by means of phenotypic assays, drug coadministrations or fixed dose formulations appear to be more useful therapeutic options than designed multiple ligands; this scenario will change when systems biol. will be able to select crit. targets, i.e. nodal proteins that should be inhibited in order to obtain a therapeutic action; at this point, the design of multiple ligands will allow a renaissance of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobv_P2UM6L_7Vg90H21EOLACvtfcHk0lhj9ZMJ_zAclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN&md5=82123bbafc10a19c65a0bc0c5be72546</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F092986712801215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801215883%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DDesigned%2520multiple%2520ligands%253A%2520basic%2520research%2520vs%2520clinical%2520outcomes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3353%26epage%3D3387%26doi%3D10.2174%2F092986712801215883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Peters, J.-U.</span> <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2F9781118098141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F9781118098141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26pub%3DWiley%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Peters, J. U.</span><span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span><span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lhj9ZMJ_zAclw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0lhK8k5PfjvG1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasco, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5032</span><span class="NLM_x">–</span> <span class="NLM_lpage">5040</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-14-0570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25107918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5032-5040&author=T.+Shimizuauthor=P.+M.+LoRussoauthor=K.+P.+Papadopoulosauthor=A.+Patnaikauthor=M.+Beeramauthor=L.+S.+Smithauthor=D.+W.+Rascoauthor=T.+A.+Maysauthor=G.+Chambersauthor=A.+Maauthor=J.+Wangauthor=R.+Laliberteauthor=M.+Voiauthor=A.+W.+Tolcher&title=Phase+I+first-in-human+study+of+CUDC-101%2C+a+multitargeted+inhibitor+of+HDACs%2C+EGFR%2C+and+HER2+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shimizu, Toshio; LoRusso, Patricia M.; Papadopoulos, Kyri P.; Patnaik, Amita; Beeram, Muralidhar; Smith, Lon S.; Rasco, Drew W.; Mays, Theresa A.; Chambers, Glenda; Ma, Anna; Wang, Jing; Laliberte, Robert; Voi, Maurizio; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-h i.v. (i.v.) infusion for 5 consecutive days every 2 wk.  Exptl. Design: Twenty-five patients with advanced solid tumors received escalating doses of CUDC-101 (range, 75-300 mg/m2/day) following a std. 3 + 3 dose escalation design.  Results: The MTD was detd. to be 275 mg/m2.  Common grade 1/2 adverse events included nausea, fatigue, vomiting, dyspnea, pyrexia, and dry skin.  DLTs occurred in 1 patient in the 275-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 1) and 3 patients in the 300-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 2; pericarditis, n = 1), all of which were transient and reversible.  CUDC-101 exposure increased linearly with the mean max. concn. (Cmax), clearance (CL), vol. of distribution at steady-state (Vdss), area under curve (AUC), and terminal elimination half-life (t1/2) at the MTD dose of 9.3 mg/L, 51.2 L/h, 39.6 L, 9.95 h·ng/mL and 4.4 h, resp.  Acetylated histone H3 induction was obsd. in posttreatment skin samples from 3 patients in the 275-mg/m2 dose cohort, suggesting adequate systemic exposure and target inhibition.  One patient with gastric cancer had a partial response and 6 patients had stable disease.  Conclusion: CUDC-101 administered by 1-h i.v. infusion for 5 consecutive days every 2 wk was generally well tolerated with preliminary evidence of antitumor activity.  A dose of 275 mg/m2 is recommended for further clin. testing.  Clin Cancer Res; 20(19); 5032-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUrKXLHOzT6LVg90H21EOLACvtfcHk0lhK8k5PfjvG1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP&md5=62860afa08733980f47047880e11a5ba</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0570%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DL.%2BS.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DMays%26aufirst%3DT.%2BA.%26aulast%3DChambers%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPhase%2520I%2520first-in-human%2520study%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5032%26epage%3D5040%26doi%3D10.1158%2F1078-0432.CCR-14-0570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pursell, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selmi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savagner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span> </span><span class="NLM_article-title">Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1535-7163.MCT-12-1045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23536719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=925-936&author=J.+Wangauthor=N.+W.+Pursellauthor=M.+E.+Samsonauthor=R.+Atoyanauthor=A.+W.+Maauthor=A.+Selmiauthor=W.+Xuauthor=X.+Caiauthor=M.+Voiauthor=P.+Savagnerauthor=C.+J.+Lai&title=Potential+advantages+of+CUDC-101%2C+a+multitargeted+HDAC%2C+EGFR%2C+and+HER2+inhibitor%2C+in+treating+drug+resistance+and+preventing+cancer+cell+migration+and+invasion&doi=10.1158%2F1535-7163.MCT-12-1045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion</span></div><div class="casAuthors">Wang, Jing; Pursell, Natalie W.; Samson, Maria Elena S.; Atoyan, Ruzanna; Ma, Anna W.; Selmi, Abdelkader; Xu, Wanlu; Cai, Xiong; Voi, Maurizio; Savagner, Pierre; Lai, Cheng-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">925-936</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a novel, small-mol., anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2.  It is currently in phase I clin. development in patients with solid tumors.  Previously, we reported that CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models.  We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.  CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non-small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells.  Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration.  Mol Cancer Ther; 12(6); 925-36. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgzk8IJVCcT7Vg90H21EOLACvtfcHk0lgxumjd05cjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D&md5=3d2d647e92c06c6f4c5293c6d0e1285d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPursell%26aufirst%3DN.%2BW.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DSelmi%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DSavagner%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26atitle%3DPotential%2520advantages%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%252C%2520in%2520treating%2520drug%2520resistance%2520and%2520preventing%2520cancer%2520cell%2520migration%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D925%26epage%3D936%26doi%3D10.1158%2F1535-7163.MCT-12-1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Seo, S. Y.</span><span> </span><span class="NLM_article-title">Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery</span> <span class="citation_source-journal">Arch. Pharmacal Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span><span class="refDoi"> DOI: 10.1007/s12272-012-0221-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs12272-012-0221-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22370774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=197-200&author=S.+Y.+Seo&title=Multi-targeted+hybrids+based+on+HDAC+inhibitors+for+anti-cancer+drug+discovery&doi=10.1007%2Fs12272-012-0221-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery</span></div><div class="casAuthors">Seo, Seung-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-200</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">Multi-targeted hybrids combine two drugs in a single mol. to have greater medicinal effects than its individual components.  Recently, a no. of anti-cancer drug candidates such as CUDC-101 (Curis) have been designed based on linking properly two selected pharmacophores endowed with activity against different therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSulm2ApOOprVg90H21EOLACvtfcHk0lgxumjd05cjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyns7o%253D&md5=3285f75262c7a19e05822ad48624fc05</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs12272-012-0221-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-012-0221-9%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DS.%2BY.%26atitle%3DMulti-targeted%2520hybrids%2520based%2520on%2520HDAC%2520inhibitors%2520for%2520anti-cancer%2520drug%2520discovery%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2012%26volume%3D35%26spage%3D197%26epage%3D200%26doi%3D10.1007%2Fs12272-012-0221-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2000</span><span class="NLM_x">–</span> <span class="NLM_lpage">2009</span><span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDC-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lgxumjd05cjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDC-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4104</span><span class="NLM_x">–</span> <span class="NLM_lpage">4113</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.+J.+Laiauthor=R.+Baoauthor=D.+G.+Wangauthor=J.+Wangauthor=G.+X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.+X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lgxumjd05cjvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu-Farseeva, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span> </span><span class="NLM_article-title">Selective JAK inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1471</span><span class="refDoi"> DOI: 10.4155/fmc.14.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.4155%2Ffmc.14.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25329199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1439-1471&author=B.+W.+Dymockauthor=E.+G.+Yangauthor=Y.+Chu-Farseevaauthor=L.+Yao&title=Selective+JAK+inhibitors&doi=10.4155%2Ffmc.14.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK inhibitors</span></div><div class="casAuthors">Dymock, Brian W.; Yang, Eugene Guorong; Chu-Farseeva, Yuyi; Yao, Lianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1471</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders.  Recent progress in the discovery of selective inhibitors has been significant, with selective compds. now reported for each isoform.  This article summarizes the current state-of-the-art with a discussion of the most recently described selective compds.  X-ray co-crystal structures reveal the mol. reasons for the obsd. biochem. selectivity.  A concluding anal. of JAK inhibitors in the clinic highlights increased clin. trial activity and diversity of indications.  Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncol., immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6G9eFT7Ww27Vg90H21EOLACvtfcHk0lhD6de78Vhq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI&md5=343aa75228918e6e4e063adb1fed96f1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.92%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DChu-Farseeva%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26atitle%3DSelective%2520JAK%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1439%26epage%3D1471%26doi%3D10.4155%2Ffmc.14.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">See, C. S.</span><span> </span><span class="NLM_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1517/13543776.2013.765862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1517%2F13543776.2013.765862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23367873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=449-501&author=B.+W.+Dymockauthor=C.+S.+See&title=Inhibitors+of+JAK2+and+JAK3%3A+an+update+on+the+patent+literature+2010+-+2012&doi=10.1517%2F13543776.2013.765862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012</span></div><div class="casAuthors">Dymock, Brian W.; See, Cheng Shang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-501</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Janus kinases (JAKs) comprise a family of four enzymes, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), centrally implicated in cell signaling processes important in cancer and immune-inflammatory diseases.  Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.  There are many new JAK family enzyme inhibitors in the clinic now with a range of selectivity profiles.  More selective JAK2 or JAK3 compds. are now coming through in considerable nos. and this review attempts to provide an update of the recent patent literature of those new compds.  An overview is given on the diversity of core structures employed for inhibitor design showing that the vast majority of compds. are based on classic ATP-competitive kinase inhibitor heterocycles.Areas covered: This review updates new patents claiming JAK2 and/or JAK3 inhibitors published from 2010 to 2012.  Pre-2010 patents have been extensively covered in previous reviews.  Comments on the context of each chem. series are given where applicable to orient the readers on the bewildering array of mol. designs now available.  This review does not cover JAK1 or TYK2 inhibitors but mention is made of these where they occur within series of JAK2/3 inhibitors.  Given the overlap between many pharmacophores, it was not possible to completely sep. inhibitors of JAK2 from JAK3, hence the material is organized by JAK2, JAK3 and JAK2/3 and within each section by alphabetical order of the patent assignee, some companies having published five or more patents, such as Ambit (10), Incyte (9), Galapagos (7), Almirall (6) and Biocryst (5).  A total of 98 patents are reviewed herein.Expert opinion: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.  Selectivity against the four individual JAK family enzymes, JAK1, 2, 3 and TYK2, is now a key goal since they each play subtly different roles in cytokine-induced cell signaling.  The future looks bright for patients as many new drugs are being developed and now combinations of JAK inhibitors with other targeted agents are being studied in the clinic.  These advances are expected to lead to further significant progress improving patient outcomes and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbpx3w37MTHrVg90H21EOLACvtfcHk0lhD6de78Vhq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D&md5=a958c185f6c6d500ce19c04eb5665247</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DSee%26aufirst%3DC.%2BS.%26atitle%3DInhibitors%2520of%2520JAK2%2520and%2520JAK3%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202010%2520-%25202012%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D449%26epage%3D501%26doi%3D10.1517%2F13543776.2013.765862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Couedic, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raslova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennaceur-Griscelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span><span class="refDoi"> DOI: 10.1038/nature03546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Couedicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Garconauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signalling+causes+polycythaemia+vera&doi=10.1038%2Fnature03546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0lhD6de78Vhq-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCouedic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGarcon%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signalling%2520causes%2520polycythaemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148%26doi%3D10.1038%2Fnature03546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kralovics, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passamonti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passweg, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tichelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazzola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoda, R. C.</span><span> </span><span class="NLM_article-title">A gain-of-function mutation of JAK2 in myeloproliferative disorders</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">1779</span><span class="NLM_x">–</span> <span class="NLM_lpage">1790</span><span class="refDoi"> DOI: 10.1056/NEJMoa051113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1056%2FNEJMoa051113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15858187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1779-1790&author=R.+Kralovicsauthor=F.+Passamontiauthor=A.+S.+Buserauthor=S.+S.+Teoauthor=R.+Tiedtauthor=J.+R.+Passwegauthor=A.+Tichelliauthor=M.+Cazzolaauthor=R.+C.+Skoda&title=A+gain-of-function+mutation+of+JAK2+in+myeloproliferative+disorders&doi=10.1056%2FNEJMoa051113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A gain-of-function mutation of JAK2 in myeloproliferative disorders</span></div><div class="casAuthors">Kralovics, Robert; Passamonti, Francesco; Buser, Andreas S.; Teo, Soon-Siong; Tiedt, Ralph; Passweg, Jakob R.; Tichelli, Andre; Cazzola, Mario; Skoda, Radek C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1779-1790</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal myeloproliferative disorders arising from a multi-potent progenitor.  The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases.  METHODS We performed microsatellite mapping of the 9pLOH region and DNA sequencing in 244 patients with myeloproliferative disorders (128 with polycythemia vera, 93 with essential thrombocythemia, and 23 with idiopathic myelofibrosis).  RESULTS Microsatellite mapping identified a 9pLOH region that included the Janus kinase 2 (JAK2) gene.  In patients with 9pLOH, JAK2 had a homozygous G→T transversion, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F).  All 51 patients with 9pLOH had the V617F mutation.  Of 193 patients without 9pLOH, 66 were heterozygous for V617F and 127 did not have the mutation.  The frequency of V617F was 65 % among patients with polycythemia vera (83 of 128), 57 % among patients with idiopathic myelofibrosis (13 of 23), and 23 % among patients with essential thrombocythemia (21 of 93).  V617F is a somatic mutation present in hematopoietic cells.  Mitotic recombination probably causes both 9pLOH and the transition from heterozygosity to homozygosity for V617F.  Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages.  Patients with the V617F mutation had a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage, and thrombosis) and treatment with cytoreductive therapy than patients with wild-type JAK2.  CONCLUSIONS A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqTe7EsB_527Vg90H21EOLACvtfcHk0lgLsLAKbUu-4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D&md5=5dd4bc090ded1c812b61923cad36e77e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051113%26sid%3Dliteratum%253Aachs%26aulast%3DKralovics%26aufirst%3DR.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DBuser%26aufirst%3DA.%2BS.%26aulast%3DTeo%26aufirst%3DS.%2BS.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DPassweg%26aufirst%3DJ.%2BR.%26aulast%3DTichelli%26aufirst%3DA.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DA%2520gain-of-function%2520mutation%2520of%2520JAK2%2520in%2520myeloproliferative%2520disorders%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1779%26epage%3D1790%26doi%3D10.1056%2FNEJMoa051113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourouclas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassiliou, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bench, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, A. R.</span><span> </span><span class="NLM_article-title">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1016/S0140-6736(05)74230-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0140-6736%2805%2974230-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erberauthor=A.+R.+Green&title=Acquired+mutation+of+the+tyrosine+kinase+JAK2+in+human+myeloproliferative+disorders&doi=10.1016%2FS0140-6736%2805%2974230-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974230-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974230-6%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DAcquired%2520mutation%2520of%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520human%2520myeloproliferative%2520disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061%26doi%3D10.1016%2FS0140-6736%2805%2974230-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krantz, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z. J.</span><span> </span><span class="NLM_article-title">Identification of an acquired JAK2 mutation in polycythemia vera</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">22788</span><span class="NLM_x">–</span> <span class="NLM_lpage">22792</span><span class="refDoi"> DOI: 10.1074/jbc.C500138200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1074%2Fjbc.C500138200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=22788-22792&author=R.+Zhaoauthor=S.+Xingauthor=Z.+Liauthor=X.+Fuauthor=Q.+Liauthor=S.+B.+Krantzauthor=Z.+J.+Zhao&title=Identification+of+an+acquired+JAK2+mutation+in+polycythemia+vera&doi=10.1074%2Fjbc.C500138200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C500138200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C500138200%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DXing%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DKrantz%26aufirst%3DS.%2BB.%26aulast%3DZhao%26aufirst%3DZ.%2BJ.%26atitle%3DIdentification%2520of%2520an%2520acquired%2520JAK2%2520mutation%2520in%2520polycythemia%2520vera%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D22788%26epage%3D22792%26doi%3D10.1074%2Fjbc.C500138200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiladjian, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ali, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisslinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalbovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuitty, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoops, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barosi, G.</span><span> </span><span class="NLM_article-title">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1056/NEJMoa1110556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1056%2FNEJMoa1110556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22375970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=787-798&author=C.+Harrisonauthor=J.+J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=R.+Waltzmanauthor=V.+Stalbovskayaauthor=M.+McQuittyauthor=D.+S.+Hunterauthor=R.+Levyauthor=L.+Knoopsauthor=F.+Cervantesauthor=A.+M.+Vannucchiauthor=T.+Barbuiauthor=G.+Barosi&title=JAK+inhibition+with+ruxolitinib+versus+best+available+therapy+for+myelofibrosis&doi=10.1056%2FNEJMoa1110556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Treatment options for myelofibrosis are limited.  We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.  METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy.  The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% redn. in spleen vol. at week 48 and at week 24, resp., as assessed with the use of magnetic resonance imaging or computed tomog.  RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% redn. in spleen vol. at week 48, as compared with 0% in the group receiving the best available therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% (P<0.001).  At 48 wk, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy.  The median duration of response with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 mo.  Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a redn. in symptoms assocd. with myelofibrosis.  The most common hematol. abnormalities of grade 3 or higher in either group were thrombocytopenia and anemia, which were managed with a dose redn., interruption of treatment, or transfusion.  One patient in each group discontinued treatment owing to thrombocytopenia, and none discontinued owing to anemia.  Nonhematol. adverse events were rare and mostly grade 1 or 2.  Two cases of acute myeloid leukemia were reported with the best available therapy.  CONCLUSIONS: Continuous ruxolitinib therapy, as compared with the best available therapy, was assocd. with marked and durable redns. in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.  An influence on overall survival has not yet been shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7WEm5MUTc7Vg90H21EOLACvtfcHk0liPsemxp2vq5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D&md5=80494b8923fa49536383523066b22b19</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1110556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1110556%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DWaltzman%26aufirst%3DR.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DBarosi%26aufirst%3DG.%26atitle%3DJAK%2520inhibition%2520with%2520ruxolitinib%2520versus%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D787%26epage%3D798%26doi%3D10.1056%2FNEJMoa1110556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Ruxolitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0liPsemxp2vq5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0liPsemxp2vq5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span><span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0liI6KwUNI5sRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. W.</span><span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1751</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span><span class="refDoi"> DOI: 10.1038/leu.2011.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fleu.2011.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21691275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies&doi=10.1038%2Fleu.2011.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span></div><div class="casAuthors">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 n for JAK2WT and JAK2V617F, resp.) within the JAK family (IC50=1280, 520 and 50 n for JAK1, JK3 and TYK2, resp.) and fms-like tyrosine kinase-3 (FLT3; IC50=22 n).  SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs.  As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.  SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model.  SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a s.c. model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia.  Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease.  In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models.  These favorable properties are now being confirmed in clin. studies in patients with myelofibrosis and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOG8Fk52CR87Vg90H21EOLACvtfcHk0liI6KwUNI5sRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL&md5=ae5a5ae0efaaa8f51909e8c82c84610d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.148%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26spage%3D1751%26epage%3D1759%26doi%3D10.1038%2Fleu.2011.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Padrnos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis</span> <span class="citation_source-journal">Expert Opin. Orphan Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span><span class="refDoi"> DOI: 10.1517/21678707.2014.927761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1517%2F21678707.2014.927761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKhs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=725-733&author=L.+Padrnosauthor=R.+A.+Mesa&title=A+closer+look+at+pacritinib%3A+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+myelofibrosis&doi=10.1517%2F21678707.2014.927761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A closer look at : a JAK2/FLT3 inhibitor for the treatment of myelofibrosis</span></div><div class="casAuthors">Padrnos, Leslie; Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Orphan Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">725-733</span>CODEN:
                <span class="NLM_cas:coden">EOODAJ</span>;
        ISSN:<span class="NLM_cas:issn">2167-8707</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Myelofibrosis (MF) is a chronic myeloid neoplasm that bears a significant symptom burden, impacts on quality of life and carries a risk of transformation to acute leukemia.  Advances in MF therapy by inhibition of Janus kinase type 2 (JAK2) receptor have shown clin. improvements in spleen size and symptom burden, but are often limited by hematol. side effects.  Areas covered: Treatment for patients with MF who are not suitable candidates for allogeneic stem cell transplant is limited and, historically, palliative in intent.  The approval of ruxolitinib, a JAK2 inhibitor, has enabled clin. improvement in these individuals.  In this paper, treatments for MF are briefly reviewed, including historically palliative therapies and the clin. data leading to ruxolitinib approval.  This JAK2 therapy is limited by cytopenias, either due to the disease process or a medication side effect.  Finally, the preclin. and clin. data of use in MF and other hematol. conditions are evaluated.  Expert opinion: Ruxolitinib use in patients with MF who are deemed to be inappropriate transplant candidates can be limited by cytopenias, particularly thrombocytopenia.  This demonstrates an unmet therapeutic need in patients with MF.  Pacritinib, SB1518, a dual JAK2 and FMS-like tyrosine kinase 3 inhibitor has been suggested to provide clin. benefit to patients with MF without producing adverse hematol. events that restrict ruxolitinib utility.  If ongoing phase 3 trials of pacritinib are pos., based on efficacy to improve splenomegaly and constitutional symptoms with a tolerable adverse event profile, pacritinib may provide a much needed oral therapeutic option for patients with MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvl1lEpppHo7Vg90H21EOLACvtfcHk0liI6KwUNI5sRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKhs77N&md5=95456c875deb0a52b36823877e2bcac5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F21678707.2014.927761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F21678707.2014.927761%26sid%3Dliteratum%253Aachs%26aulast%3DPadrnos%26aufirst%3DL.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DA%2520closer%2520look%2520at%2520pacritinib%253A%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2014%26volume%3D2%26spage%3D725%26epage%3D733%26doi%3D10.1517%2F21678707.2014.927761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span> </span><span class="NLM_article-title">Oral pacritinib versus best available therapy to treat myelofibrosis with thrombocytopenia (PAC326)</span>. ClinicalTrials.gov; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/ct2/show/NCT02055781?term=pacritinib&amp;rank=2" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02055781?term=pacritinib&rank=2</a> (accessed April10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+pacritinib+versus+best+available+therapy+to+treat+myelofibrosis+with+thrombocytopenia+%28PAC326%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2014%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02055781%3Fterm%3Dpacritinib%26rank%3D2+%28accessed+April10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DOral%2520pacritinib%2520versus%2520best%2520available%2520therapy%2520to%2520treat%2520myelofibrosis%2520with%2520thrombocytopenia%2520%2528PAC326%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><div class="note"><p class="first last">CTI BioPharma initiates rolling submission of U.S. new drug application for pacritinib for the treatment of patients with myelofibrosis.</p></div><a href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&amp;p=RssLanding&amp;cat=news&amp;id=2114525" class="extLink">http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2114525</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CTI+BioPharma+initiates+rolling+submission+of+U.S.+new+drug+application+for+pacritinib+for+the+treatment+of+patients+with+myelofibrosis.http%3A%2F%2Finvestors.ctibiopharma.com%2Fphoenix.zhtml%3Fc%3D92775%26p%3DRssLanding%26cat%3Dnews%26id%3D2114525+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Koppikar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilpivaara, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hricik, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullally, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Wahab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marubayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">489</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+Gonenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+activation+as+a+mechanism+of+persistence+to+JAK2+inhibitor+therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0lgNUPG1f8TPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520activation%2520as%2520a%2520mechanism%2520of%2520persistence%2520to%2520JAK2%2520inhibitor%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">LaFave, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">JAK2 the future: therapeutic strategies for JAK-dependent malignancies</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">582</span><span class="refDoi"> DOI: 10.1016/j.tips.2012.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.tips.2012.08.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=574-582&author=L.+M.+LaFaveauthor=R.+L.+Levine&title=JAK2+the+future%3A+therapeutic+strategies+for+JAK-dependent+malignancies&doi=10.1016%2Fj.tips.2012.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DLaFave%26aufirst%3DL.%2BM.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DJAK2%2520the%2520future%253A%2520therapeutic%2520strategies%2520for%2520JAK-dependent%2520malignancies%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D574%26epage%3D582%26doi%3D10.1016%2Fj.tips.2012.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Santos, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1097/MOH.0b013e32835d8e10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1097%2FMOH.0b013e32835d8e10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=123-129&author=F.+P.+Santosauthor=S.+Verstovsek&title=What+is+next+beyond+janus+kinase+2+inhibitors+for+primary+myelofibrosis%3F&doi=10.1097%2FMOH.0b013e32835d8e10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymic inhibition is timely.  Recent findings: There are several compds. with different mechanisms of action undergoing preclin. and clin. testing in myelofibrosis.  Heat shock protein inhibitors and histone deacetylase inhibitors induce JAK2 degrdn. and downregulation of intracellular oncogenic signalling, and may overcome resistance to JAK2 inhibitors.  Reversal of bone marrow fibrosis is still a therapeutic challenge in this disease, and mAbs targeting transforming growth factor-β and lysyl oxidase like-2 may prove efficacious.  Promising compds. inhibiting signal transducer and activator of transcription 5 activity and inducing megakaryocyte polyploidization are in preclin. testing.  Summary: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clin. trials, alone or in combination with JAK2 inhibitors.  Patients with myelofibrosis should be encouraged to participate in clin. trials testing novel compds. for this disorder, particularly if they have failed a trial of JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gqDFCRlvYrVg90H21EOLACvtfcHk0lgNUPG1f8TPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D&md5=49159c335e02a416c0541d8b92069f4e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32835d8e10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32835d8e10%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DWhat%2520is%2520next%2520beyond%2520janus%2520kinase%25202%2520inhibitors%2520for%2520primary%2520myelofibrosis%253F%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2013%26volume%3D20%26spage%3D123%26epage%3D129%26doi%3D10.1097%2FMOH.0b013e32835d8e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Meyer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2059</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lil0hXbIz_C3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Bartalucci, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotunno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. M.</span><span> </span><span class="NLM_article-title">Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms</span> <span class="citation_source-journal">J. Cell Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1385</span><span class="NLM_x">–</span> <span class="NLM_lpage">1396</span><span class="refDoi"> DOI: 10.1111/jcmm.12162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1111%2Fjcmm.12162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24237791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFel" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1385-1396&author=N.+Bartalucciauthor=L.+Tozziauthor=C.+Boganiauthor=S.+Martinelliauthor=G.+Rotunnoauthor=J.+L.+Villevalauthor=A.+M.+Vannucchi&title=Co-targeting+the+PI3K%2FmTOR+and+JAK2+signalling+pathways+produces+synergistic+activity+against+myeloproliferative+neoplasms&doi=10.1111%2Fjcmm.12162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms</span></div><div class="casAuthors">Bartalucci, Niccolo; Tozzi, Lorenzo; Bogani, Costanza; Martinelli, Serena; Rotunno, Giada; Villeval, Jean-Luc; Vannucchi, Alessandro M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1385-1396</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aberrant JAK2 signalling plays a central role in myeloproliferative neoplasms (MPN).  JAK2 inhibitors have proven to be clin. efficacious, however, they are not mutation-specific and competent enough to suppress neoplastic clonal hematopoiesis.  We hypothesized that, by simultaneously targeting multiple activated signalling pathways, MPN could be more effectively treated.  To this end we investigated the efficacy of BEZ235, a dual PI3K/mTOR inhibitor, alone and in combination with the JAK1/JAK2 inhibitor ruxolitinib, in different preclin. models of MPN.  Single-agent BEZ235 inhibited the proliferation and induced cell cycle arrest and apoptosis of mouse and human JAK2V617F mutated cell lines at concns. significantly lower than those required to inhibit the wild-type counterpart, and preferentially prevented colony formation from JAK2V617F knock-in mice and patients' progenitor cells compared with normal ones.  Co-treatment of BEZ235 and ruxolitinib produced significant synergism in all these in-vitro models.  Co-treatment was also more effective than single drugs in reducing the extent of disease and prolonging survival of immunodeficient mice injected with JAK2V617F-mutated Ba/F3-EPOR cells and in reducing spleen size, decreasing reticulocyte count and improving spleen histopathol. in conditional JAK2V617F knock-in mice.  In conclusion, combined inhibition of PI3K/mTOR and JAK2 signalling may represent a novel therapeutic strategy in MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMZ0bIwRV_fbVg90H21EOLACvtfcHk0lil0hXbIz_C3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFel&md5=9c57f8ab9657273f6492bea4d3e82847</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12162%26sid%3Dliteratum%253Aachs%26aulast%3DBartalucci%26aufirst%3DN.%26aulast%3DTozzi%26aufirst%3DL.%26aulast%3DBogani%26aufirst%3DC.%26aulast%3DMartinelli%26aufirst%3DS.%26aulast%3DRotunno%26aufirst%3DG.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26atitle%3DCo-targeting%2520the%2520PI3K%252FmTOR%2520and%2520JAK2%2520signalling%2520pathways%2520produces%2520synergistic%2520activity%2520against%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1385%26epage%3D1396%26doi%3D10.1111%2Fjcmm.12162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Choong, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecquet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendharkar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaconu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defour, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. A.</span><span> </span><span class="NLM_article-title">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span> <span class="citation_source-journal">J. Cell Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1397</span><span class="NLM_x">–</span> <span class="NLM_lpage">1409</span><span class="refDoi"> DOI: 10.1111/jcmm.12156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1111%2Fjcmm.12156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24251790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFan" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1397-1409&author=M.+L.+Choongauthor=C.+Pecquetauthor=V.+Pendharkarauthor=C.+C.+Diaconuauthor=J.+W.+Yongauthor=S.+J.+Taiauthor=S.+F.+Wangauthor=J.+P.+Defourauthor=K.+Sangthongpitagauthor=J.+L.+Villevalauthor=W.+Vainchenkerauthor=S.+N.+Constantinescuauthor=M.+A.+Lee&title=Combination+treatment+for+myeloproliferative+neoplasms+using+JAK+and+pan-class+I+PI3K+inhibitors&doi=10.1111%2Fjcmm.12156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span></div><div class="casAuthors">Choong, Meng Ling; Pecquet, Christian; Pendharkar, Vishal; Diaconu, Carmen C.; Yong, Jacklyn Wei Yan; Tai, Shi Jing; Wang, Si Fang; Defour, Jean-Philippe; Sangthongpitag, Kanda; Villeval, Jean-Luc; Vainchenker, William; Constantinescu, Stefan N.; Lee, May Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1397-1409</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiol. JAK2 signalling.  We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clin. trials, synergized in inhibiting growth of haematopoietic cells expressing mutant and wild-type forms of JAK2 (V617F) or thrombopoietin receptor (W515L).  Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol-3'-kinase (PI3K) inhibitor mol. showed strong synergic inhibition by Chou and Talalay anal. with JAK2 and JAK2/JAK1 inhibitors.  Other pan-class I, but not gamma or delta specific PI3K inhibitors, also synergized with JAK2 inhibitors.  Synergy was not obsd. in Bcr-Abl transformed cells.  The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen wt. in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.  It also exerted strong inhibitory effects on erythropoietin-independent erythroid colonies from MPN patients and JAK2 V617F knock-in mice, where at certain doses, a preferential inhibition of JAK2 V617F mutated progenitors was detected.  Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwYG9JAajg0rVg90H21EOLACvtfcHk0lil0hXbIz_C3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFan&md5=f2fdba575d0402f6d971b1db53d41981</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12156%26sid%3Dliteratum%253Aachs%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DPecquet%26aufirst%3DC.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DDiaconu%26aufirst%3DC.%2BC.%26aulast%3DYong%26aufirst%3DJ.%2BW.%26aulast%3DTai%26aufirst%3DS.%2BJ.%26aulast%3DWang%26aufirst%3DS.%2BF.%26aulast%3DDefour%26aufirst%3DJ.%2BP.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DLee%26aufirst%3DM.%2BA.%26atitle%3DCombination%2520treatment%2520for%2520myeloproliferative%2520neoplasms%2520using%2520JAK%2520and%2520pan-class%2520I%2520PI3K%2520inhibitors%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1397%26epage%3D1409%26doi%3D10.1111%2Fjcmm.12156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Waibel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralli, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidacs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virely, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sia, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracken, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins-Underwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takiguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghysdael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullighan, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1047</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span><span class="refDoi"> DOI: 10.1016/j.celrep.2013.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.celrep.2013.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24268771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1047-1059&author=M.+Waibelauthor=V.+S.+Solomonauthor=D.+A.+Knightauthor=R.+A.+Ralliauthor=S.+K.+Kimauthor=K.+M.+Banksauthor=E.+Vidacsauthor=C.+Virelyauthor=K.+C.+Siaauthor=L.+S.+Brackenauthor=R.+Collins-Underwoodauthor=C.+Drenbergauthor=L.+B.+Ramseyauthor=S.+C.+Meyerauthor=M.+Takiguchiauthor=R.+A.+Dickinsauthor=R.+Levineauthor=J.+Ghysdaelauthor=M.+A.+Dawsonauthor=R.+B.+Lockauthor=C.+G.+Mullighanauthor=R.+W.+Johnstone&title=Combined+targeting+of+JAK2+and+Bcl-2%2FBcl-xL+to+cure+mutant+JAK2-driven+malignancies+and+overcome+acquired+resistance+to+JAK2+inhibitors&doi=10.1016%2Fj.celrep.2013.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors</span></div><div class="casAuthors">Waibel, Michaela; Solomon, Vanessa S.; Knight, Deborah A.; Ralli, Rachael A.; Kim, Sang-Kyu; Banks, Kellie-Marie; Vidacs, Eva; Virely, Clemence; Sia, Keith C. S.; Bracken, Lauryn S.; Collins-Underwood, Racquel; Drenberg, Christina; Ramsey, Laura B.; Meyer, Sara C.; Takiguchi, Megumi; Dickins, Ross A.; Levine, Ross; Ghysdael, Jacques; Dawson, Mark A.; Lock, Richard B.; Mullighan, Charles G.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1047-1059</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To design rational therapies for JAK2-driven hematol. malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2.  In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathways were constitutively active, and gene expression profiling of TEL-JAK2 T-ALL cells revealed the upregulation of prosurvival Bcl-2 family genes.  Combining the Bcl-2/Bcl-xL inhibitor ABT-737 with JAK2 inhibitors mediated prolonged disease regressions and cures in mice bearing primary human and mouse JAK2 mutant tumors.  Moreover, combined targeting of JAK2 and Bcl-2/Bcl-xL was able to circumvent and overcome acquired resistance to single-agent JAK2 inhibitor treatment.  Thus, inhibiting the oncogenic JAK2 signaling network at two nodal points, at the initiating stage (JAK2) and the effector stage (Bcl-2/Bcl-xL), is highly effective and provides a clearly superior therapeutic benefit than targeting just one node.  Therefore, we have defined a potentially curative treatment for hematol. malignancies expressing constitutively active JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiJQ8J0GL_7Vg90H21EOLACvtfcHk0lirZsO1S8vfrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN&md5=cd6ec40bd071fa0f811dee36bb882588</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DWaibel%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DV.%2BS.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DRalli%26aufirst%3DR.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DBanks%26aufirst%3DK.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DVirely%26aufirst%3DC.%26aulast%3DSia%26aufirst%3DK.%2BC.%26aulast%3DBracken%26aufirst%3DL.%2BS.%26aulast%3DCollins-Underwood%26aufirst%3DR.%26aulast%3DDrenberg%26aufirst%3DC.%26aulast%3DRamsey%26aufirst%3DL.%2BB.%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DTakiguchi%26aufirst%3DM.%26aulast%3DDickins%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DGhysdael%26aufirst%3DJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DCombined%2520targeting%2520of%2520JAK2%2520and%2520Bcl-2%252FBcl-xL%2520to%2520cure%2520mutant%2520JAK2-driven%2520malignancies%2520and%2520overcome%2520acquired%2520resistance%2520to%2520JAK2%2520inhibitors%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D5%26spage%3D1047%26epage%3D1059%26doi%3D10.1016%2Fj.celrep.2013.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Grunstein, M.</span><span> </span><span class="NLM_article-title">Histone acetylation in chromatin structure and transcription</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">389</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1038/38664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2F38664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=9311776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=349-352&author=M.+Grunstein&title=Histone+acetylation+in+chromatin+structure+and+transcription&doi=10.1038%2F38664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Histone acetylation in chromatin structure and transcription</span></div><div class="casAuthors">Grunstein, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6649</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review with 75 refs.  The amino termini of histones extend from the nucleosomal core and are modified by acetyltransferase and deacetylases during the cell cycle.  These acetylation patterns may direct histone assembly and help regulate the unfolding and activity of genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodv2Ds8rzh-rVg90H21EOLACvtfcHk0lirZsO1S8vfrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D&md5=cdd287ff2d87e9c89944366b71aaf6d9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2F38664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F38664%26sid%3Dliteratum%253Aachs%26aulast%3DGrunstein%26aufirst%3DM.%26atitle%3DHistone%2520acetylation%2520in%2520chromatin%2520structure%2520and%2520transcription%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D349%26epage%3D352%26doi%3D10.1038%2F38664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">de Ruijter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gennip, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kuilenburg, A. B.</span><span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span><span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=12429021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+de+Ruijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases (HDACs): characterization of the classical HDAC family</span></div><div class="casAuthors">de Ruijter, Annemieke J. M.; van Gennip, Albert H.; Caron, Huib N.; Kemp, Stephan; van Kuilenburg, Andre B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation.  Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect.  Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones.  The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.  SAGE (serial anal. of gene expression) data show that HDACs are generally expressed in almost all tissues investigated.  Surprisingly, no major differences were obsd. between the expression pattern in normal and malignant tissues.  However, significant variation in HDAC expression was obsd. within tissue types.  HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis.  This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN1-6ct5EQtrVg90H21EOLACvtfcHk0lirZsO1S8vfrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D&md5=8a521cd3ddcf046b4b806ebf9f1476b4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Witt, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deubzer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehme, I.</span><span> </span><span class="NLM_article-title">HDAC family: What are the cancer relevant targets?</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=HDAC+family%3A+What+are+the+cancer+relevant+targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0liO3AOwWU5NMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520family%253A%2520What%2520are%2520the%2520cancer%2520relevant%2520targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wagner, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackanson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</span> <span class="citation_source-journal">Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1007/s13148-010-0012-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs13148-010-0012-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21258646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=117-136&author=J.+M.+Wagnerauthor=B.+Hackansonauthor=M.+Lubbertauthor=M.+Jung&title=Histone+deacetylase+%28HDAC%29+inhibitors+in+recent+clinical+trials+for+cancer+therapy&doi=10.1007%2Fs13148-010-0012-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</span></div><div class="casAuthors">Wagner, Julia M.; Hackanson, Bjoern; Luebbert, Michael; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">117-136</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7075</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heritable changes in gene expression that are not based upon alterations in the DNA sequence are defined as epigenetics.  The most common mechanisms of epigenetic regulation are the methylation of CpG islands within the DNA and the modification of amino acids in the N-terminal histone tails.  In the last years, it became evident that the onset of cancer and its progression may not occur only due to genetic mutations but also because of changes in the patterns of epigenetic modifications.  In contrast to genetic mutations, which are almost impossible to reverse, epigenetic changes are potentially reversible.  This implies that they are amenable to pharmacol. interventions.  Therefore, a lot of work in recent years has focussed on the development of small mol. enzyme inhibitors like DNA-methyltransferase inhibitors or inhibitors of histone-modifying enzymes.  These may reverse misregulated epigenetic states and be implemented in the treatment of cancer or other diseases, e.g., neurol. disorders.  Today, several epigenetic drugs are already approved by the FDA and the EMEA for cancer treatment and around ten histone deacetylase (HDAC) inhibitors are in clin. development.  This review will give an update on recent clin. trials of the HDAC inhibitors used systemically that were reported in 2009 and 2010 and will present an overview of different biomarkers to monitor the biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62EyFQbmSEbVg90H21EOLACvtfcHk0liO3AOwWU5NMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF&md5=c2b02cc37f94c85c4496822b9bf13af9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs13148-010-0012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13148-010-0012-4%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BM.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%2520in%2520recent%2520clinical%2520trials%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Epigenet.%26date%3D2010%26volume%3D1%26spage%3D117%26epage%3D136%26doi%3D10.1007%2Fs13148-010-0012-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0liO3AOwWU5NMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Pazdur, R.</span> <span class="citation_source-book">FDA Approval for Romidepsin</span>; <span class="NLM_publisher-name">National Cancer Institute</span>: <span class="NLM_publisher-name">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.cancer.gov/about-cancer/treatment/drugs/fda-romidepsin" class="extLink">http://www.cancer.gov/about-cancer/treatment/drugs/fda-romidepsin</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Pazdur&title=FDA+Approval+for+Romidepsin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPazdur%26aufirst%3DR.%26btitle%3DFDA%2520Approval%2520for%2520Romidepsin%26pub%3DNational%2520Cancer%2520Institute%26pub%3DBethesda%252C%2520MD%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span>Belinostat; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm" class="extLink">http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Belinostat%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm403960.htm+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DBelinostat%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Panobinostat: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span><span class="refDoi"> DOI: 10.1007/s40265-015-0388-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs40265-015-0388-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=695-704&author=K.+P.+Garnock-Jones&title=Panobinostat%3A+first+global+approval&doi=10.1007%2Fs40265-015-0388-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0388-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0388-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DPanobinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D695%26epage%3D704%26doi%3D10.1007%2Fs40265-015-0388-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">HDAC inhibitors still need a home run, despite recent approval</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1038/nrd4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnrd4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25829268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=225-226&author=M.+Guha&title=HDAC+inhibitors+still+need+a+home+run%2C+despite+recent+approval&doi=10.1038%2Fnrd4583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors still need a home run, despite recent approval</span></div><div class="casAuthors">Guha, Malini</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-226</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A beleaguered class of epigenetic modulators continues to struggle for oncol. success, but new insights into their mechanisms in cancer may yet offer hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdd1X74wEP7Vg90H21EOLACvtfcHk0lhxd5hvD83OFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D&md5=011db36451b31bc7d19e8ffab8281af8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4583%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHDAC%2520inhibitors%2520still%2520need%2520a%2520home%2520run%252C%2520despite%2520recent%2520approval%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D225%26epage%3D226%26doi%3D10.1038%2Fnrd4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Yao, T. P.; Seto, E.</span> <span class="citation_source-book">Histone Deacetylases: The Biology and Clinical Implications</span>; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2F978-3-642-21631-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+P.+Yao&author=E.+Seto&title=Histone+Deacetylases%3A+The+Biology+and+Clinical+Implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-21631-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-21631-2%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DT.%2BP.%26btitle%3DHistone%2520Deacetylases%253A%2520The%2520Biology%2520and%2520Clinical%2520Implications%26pub%3DSpringer-Verlag%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Malvaez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuown, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogge, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astarabadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusche, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. A.</span><span> </span><span class="NLM_article-title">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2647</span><span class="NLM_x">–</span> <span class="NLM_lpage">2652</span><span class="refDoi"> DOI: 10.1073/pnas.1213364110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1073%2Fpnas.1213364110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23297220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2647-2652&author=M.+Malvaezauthor=S.+C.+McQuownauthor=G.+A.+Roggeauthor=M.+Astarabadiauthor=V.+Jacquesauthor=S.+Carreiroauthor=J.+R.+Ruscheauthor=M.+A.+Wood&title=HDAC3-selective+inhibitor+enhances+extinction+of+cocaine-seeking+behavior+in+a+persistent+manner&doi=10.1073%2Fpnas.1213364110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span></div><div class="casAuthors">Malvaez, Melissa; McQuown, Susan C.; Rogge, George A.; Astarabadi, Mariam; Jacques, Vincent; Carreiro, Samantha; Rusche, James R.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2647-2652, S2647/1-S2647/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement.  A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior.  Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement.  We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to neg. effects on performance or reconsolidation.  These are key distinctions with regard to any compd. being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction.  Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects.  During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens.  Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance.  These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzdD0_EQYfrVg90H21EOLACvtfcHk0lhxd5hvD83OFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D&md5=37fd432cbf96bd2c30b7d5ac9eefcf45</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213364110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213364110%26sid%3Dliteratum%253Aachs%26aulast%3DMalvaez%26aufirst%3DM.%26aulast%3DMcQuown%26aufirst%3DS.%2BC.%26aulast%3DRogge%26aufirst%3DG.%2BA.%26aulast%3DAstarabadi%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DCarreiro%26aufirst%3DS.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHDAC3-selective%2520inhibitor%2520enhances%2520extinction%2520of%2520cocaine-seeking%2520behavior%2520in%2520a%2520persistent%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D2647%26epage%3D2652%26doi%3D10.1073%2Fpnas.1213364110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Decroos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christianson, D. W.</span><span> </span><span class="NLM_article-title">Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2135</span><span class="refDoi"> DOI: 10.1021/acs.biochem.5b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFWhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=2126-2135&author=C.+Decroosauthor=D.+J.+Clausenauthor=B.+E.+Hainesauthor=O.+Wiestauthor=R.+M.+Williamsauthor=D.+W.+Christianson&title=Variable+active+site+loop+conformations+accommodate+the+binding+of+macrocyclic+largazole+analogues+to+HDAC8&doi=10.1021%2Facs.biochem.5b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Variable Active Site Loop Conformations Accommodate the Binding of Macrocyclic Largazole Analogues to HDAC8</span></div><div class="casAuthors">Decroos, Christophe; Clausen, Dane J.; Haines, Brandon E.; Wiest, Olaf; Williams, Robert M.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2126-2135</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The macrocyclic depsipeptide Largazole is a potent inhibitor of metal-dependent histone deacetylases (HDACs), some of which are drug targets for cancer chemotherapy.  Indeed, Largazole partially resembles Romidepsin (FK228), a macrocyclic depsipeptide already approved for clin. use.  Each inhibitor contains a pendant side chain thiol that coordinates to the active site Zn2+ ion, as obsd. in the x-ray crystal structure of the HDAC8-Largazole complex [Cole, K. E., Dowling, D. P., Boone, M. A., Phillips, A. J., and Christianson, D. W. (2011) J. Am. Chem. Soc.133, 12474].  Here, the authors report the x-ray crystal structures of HDAC8 complexed with three synthetic analogs of Largazole in which the depsipeptide ester is replaced with a rigid amide linkage.  In two of these analogs, a six-membered pyridine ring is also substituted (with two different orientations) for the five-membered thiazole ring in the macrocycle skeleton.  The side chain thiol group of each analog coordinates to the active site Zn2+ ion with nearly ideal geometry, thereby preserving the hallmark structural feature of inhibition by Largazole.  Surprisingly, in comparison with the binding of Largazole, these analogs trigger alternative conformational changes in loops L1 and L2 flanking the active site.  However, despite these structural differences, inhibitory potency is generally comparable to, or just moderately less than, the inhibitory potency of Largazole.  Thus, this study reveals important new structure-affinity relationships for the binding of macrocyclic inhibitors to HDAC8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVqkyTC6gxrVg90H21EOLACvtfcHk0lhQ9Du7EgRGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFWhsrw%253D&md5=10dc284a6e017f9881be14de4bff2c03</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00010%26sid%3Dliteratum%253Aachs%26aulast%3DDecroos%26aufirst%3DC.%26aulast%3DClausen%26aufirst%3DD.%2BJ.%26aulast%3DHaines%26aufirst%3DB.%2BE.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DWilliams%26aufirst%3DR.%2BM.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DVariable%2520active%2520site%2520loop%2520conformations%2520accommodate%2520the%2520binding%2520of%2520macrocyclic%2520largazole%2520analogues%2520to%2520HDAC8%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D2126%26epage%3D2135%26doi%3D10.1021%2Facs.biochem.5b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Huang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. I.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1815</span><span class="NLM_x">–</span> <span class="NLM_lpage">1824</span><span class="refDoi"> DOI: 10.1002/cmdc.201200300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fcmdc.201200300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22907916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1815-1824&author=W.+J.+Huangauthor=Y.+C.+Wangauthor=S.+W.+Chaoauthor=C.+Y.+Yangauthor=L.+C.+Chenauthor=M.+H.+Linauthor=W.+C.+Houauthor=M.+Y.+Chenauthor=T.+L.+Leeauthor=P.+Yangauthor=C.+I.+Chang&title=Synthesis+and+biological+evaluation+of+ortho-aryl+N-hydroxycinnamides+as+potent+histone+deacetylase+%28HDAC%29+8+isoform-selective+inhibitors&doi=10.1002%2Fcmdc.201200300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of ortho-Aryl N-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors</span></div><div class="casAuthors">Huang, Wei-Jan; Wang, Yi-Ching; Chao, Shi-Wei; Yang, Chen-Yui; Chen, Liang-Chieh; Lin, Mei-Hsiang; Hou, Wen-Chi; Chen, Mei-Yu; Lee, Tai-Lin; Yang, Ping; Chang, Chung-I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1815-1824, S1815/1-S1815/41</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes that play a crucial role in biol. process and diseases.  In contrast to other isoenzymes, HDAC8 is uniquely incapable of histone acetylation.  To delineate its physiol. function, we developed HDAC8-selective inhibitors using knowledge-based design combined with structural modeling techniques.  Enzyme inhibitory anal. demonstrated that some of the resulting compds. exhibited anti-HDAC8 activity superior to PCI34051, a known HDAC8-specific inhibitor, with IC50 values in the range of 5-50 nM.  Among them, compd. (I) showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5); it exhibited cytotoxicity against human lung CL1-5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR-90 cells.  Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1-5 is higher than that in H1299 and CL1-1 cells, a result consistent with the differential cytotoxicity of compd. I.  These results suggest the effectiveness of our design concept, which may lead to a tool compd. for studying the specific role of HDAC8 in cellular biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop4xm7qu7wc7Vg90H21EOLACvtfcHk0lhQ9Du7EgRGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL&md5=05279fdc5e9bc353f12fa3b1b0f3e365</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200300%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DChao%26aufirst%3DS.%2BW.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DHou%26aufirst%3DW.%2BC.%26aulast%3DChen%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%2BI.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520ortho-aryl%2520N-hydroxycinnamides%2520as%2520potent%2520histone%2520deacetylase%2520%2528HDAC%2529%25208%2520isoform-selective%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1815%26epage%3D1824%26doi%3D10.1002%2Fcmdc.201200300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahige, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, N.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1002/cmdc.201300414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fcmdc.201300414" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=657-664&author=T.+Suzukiauthor=N.+Mutoauthor=M.+Bandoauthor=Y.+Itohauthor=A.+Masakiauthor=M.+Riauthor=Y.+Otaauthor=H.+Nakagawaauthor=S.+Iidaauthor=K.+Shirahigeauthor=N.+Miyata&title=Design%2C+synthesis%2C+and+biological+activity+of+NCC149+derivatives+as+histone+deacetylase+8-selective+inhibitors&doi=10.1002%2Fcmdc.201300414"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300414%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMuto%26aufirst%3DN.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DMasaki%26aufirst%3DA.%26aulast%3DRi%26aufirst%3DM.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DShirahige%26aufirst%3DK.%26aulast%3DMiyata%26aufirst%3DN.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activity%2520of%2520NCC149%2520derivatives%2520as%2520histone%2520deacetylase%25208-selective%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D657%26epage%3D664%26doi%3D10.1002%2Fcmdc.201300414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="NLM_x">–</span> <span class="NLM_lpage">10846</span><span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0liFXmu1Upu79g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Aldana-Masangkay, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, K. M.</span><span> </span><span class="NLM_article-title">The role of HDAC6 in cancer</span> <span class="citation_source-journal">J. Biomed. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">875824</span><span class="refDoi"> DOI: 10.1155/2011/875824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1155%2F2011%2F875824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21076528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=875824&author=G.+I.+Aldana-Masangkayauthor=K.+M.+Sakamoto&title=The+role+of+HDAC6+in+cancer&doi=10.1155%2F2011%2F875824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The role of HDAC6 in cancer</span></div><div class="casAuthors">Aldana-Masangkay Grace I; Sakamoto Kathleen M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">875824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a member of the HDAC family whose major substrate is α-tubulin, has become a target for drug development to treat cancer due to its major contribution in oncogenic cell transformation.  Overexpression of HDAC6 correlates with tumorigenesis and improved survival; therefore, HDAC6 may be used as a marker for prognosis.  Previous work demonstrated that in multiple myeloma cells, inhibition of HDAC6 results in apoptosis.  Furthermore, HDAC6 is required for the activation of heat-shock factor 1 (HSF1), an activator of heat-shock protein encoding genes (HSPs) and CYLD, a cylindromatosis tumor suppressor gene.  HDAC6 contributes to cancer metastasis since its upregulation increases cell motility in breast cancer MCF-7 cells and its interaction with cortactin regulates motility.  HDAC6 also affects transcription and translation by regulating the heat-shock protein 90 (Hsp90) and stress granules (SGs), respectively.  This review will discuss the role of HDAC6 in the pathogenesis and treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIuDxliM3SH5QHPYJuLg8TfW6udTcc2eaCZE_F2RO-i7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D&md5=8be7e0edb941ebf8b761778c99ad4c57</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1155%2F2011%2F875824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F875824%26sid%3Dliteratum%253Aachs%26aulast%3DAldana-Masangkay%26aufirst%3DG.%2BI.%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26atitle%3DThe%2520role%2520of%2520HDAC6%2520in%2520cancer%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D875824%26doi%3D10.1155%2F2011%2F875824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Kalin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, J. A.</span><span> </span><span class="NLM_article-title">Development and therapeutic implications of selective histone deacetylase 6 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6297</span><span class="NLM_x">–</span> <span class="NLM_lpage">6313</span><span class="refDoi"> DOI: 10.1021/jm4001659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6297-6313&author=J.+H.+Kalinauthor=J.+A.+Bergman&title=Development+and+therapeutic+implications+of+selective+histone+deacetylase+6+inhibitors&doi=10.1021%2Fjm4001659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Kalin, Jay H.; Bergman, Joel A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6297-6313</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated.  The physiol. pathways, protein-protein interactions, and non-histone substrates relating to different pathol. conditions are discussed with regard to HDAC6.  Furthermore, the compds. and methods used to modulate HDAC6 activity are profiled.  The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the mol. tools available.  Potential obstacles and future directions of HDAC6 research are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvFD0xh4CLiLVg90H21EOLACvtfcHk0lgXb_ZWRqJPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslSntrc%253D&md5=e54e7e8b172aba337581341360c0685c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm4001659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001659%26sid%3Dliteratum%253Aachs%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26atitle%3DDevelopment%2520and%2520therapeutic%2520implications%2520of%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6297%26epage%3D6313%26doi%3D10.1021%2Fjm4001659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Haakenson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">HDAC6 and Ovarian Cancer</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">9514</span><span class="NLM_x">–</span> <span class="NLM_lpage">9535</span><span class="refDoi"> DOI: 10.3390/ijms14059514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.3390%2Fijms14059514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23644884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSktLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=9514-9535&author=J.+Haakensonauthor=X.+Zhang&title=HDAC6+and+Ovarian+Cancer&doi=10.3390%2Fijms14059514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 and ovarian cancer</span></div><div class="casAuthors">Haakenson, Joshua; Zhang, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">9514-9535, 22 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways.  Many of the lessons learned from other cancers can be applied to ovarian cancer as well.  HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions.  Not all pro-cancer interactions of HDAC6 involve deacetylation.  The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMibgXjPsdVrVg90H21EOLACvtfcHk0lgXb_ZWRqJPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSktLrJ&md5=35acd64f7b1face6216230f75002624a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3390%2Fijms14059514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms14059514%26sid%3Dliteratum%253Aachs%26aulast%3DHaakenson%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DHDAC6%2520and%2520Ovarian%2520Cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D9514%26epage%3D9535%26doi%3D10.3390%2Fijms14059514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Dallavalle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">Development and therapeutic impact of HDAC6-selective inhibitors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.bcp.2012.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22728920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWgtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=756-765&author=S.+Dallavalleauthor=C.+Pisanoauthor=F.+Zunino&title=Development+and+therapeutic+impact+of+HDAC6-selective+inhibitors&doi=10.1016%2Fj.bcp.2012.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Development and therapeutic impact of HDAC6-selective inhibitors</span></div><div class="casAuthors">Dallavalle, Sabrina; Pisano, Claudio; Zunino, Franco</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">756-765</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDAC) play a key role in regulating gene expression by deacetylating histones.  Some HDAC isoforms can also modulate the function of nonhistone proteins implicated in regulatory processes, and therefore HDACs are recognized as useful targets for therapeutic purposes.  HDAC inhibitors have generated substantial interest as antitumor agents, because they induce various cellular effects, including apoptosis, cell cycle arrest and inhibition of angiogenesis.  The nature of cellular response likely depends on the biol. context and on the pattern of HDAC isoform inhibition.  Various HDAC inhibitors belonging to different structural classes have been developed.  Many inhibitors are characterized by a pan-HDAC inhibitory profile.  The potential advantages of isoform-selective inhibitors over pan-HDAC inhibitors in terms of efficacy or toxicity remain to be defined.  The emerging interest for HDAC6-selective inhibitors is related to the modulation of acetylation of nonhistone regulatory proteins implicated in cancer-relevant processes, including cell migration, metastasis, angiogenesis and stress-response pathways.  This review is focused on the recent development of HDAC inhibitors, with particular ref. to HDAC6-selective inhibitors, and the efforts and perspectives in optimization of their therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAmrF_uWkK6LVg90H21EOLACvtfcHk0lgXb_ZWRqJPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWgtbrJ&md5=b3764e4070e45327493bb3c128f42d96</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DDallavalle%26aufirst%3DS.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DDevelopment%2520and%2520therapeutic%2520impact%2520of%2520HDAC6-selective%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D756%26epage%3D765%26doi%3D10.1016%2Fj.bcp.2012.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irondelle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waharte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizarraga, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavrier, P.</span><span> </span><span class="NLM_article-title">HDAC6 is required for invadopodia activity and invasion by breast tumor cells</span> <span class="citation_source-journal">Eur. J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">135</span><span class="refDoi"> DOI: 10.1016/j.ejcb.2010.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.ejcb.2010.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=20970878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlahs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2011&pages=128-135&author=M.+Reyauthor=M.+Irondelleauthor=F.+Waharteauthor=F.+Lizarragaauthor=P.+Chavrier&title=HDAC6+is+required+for+invadopodia+activity+and+invasion+by+breast+tumor+cells&doi=10.1016%2Fj.ejcb.2010.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is required for invadopodia activity and invasion by breast tumor cells</span></div><div class="casAuthors">Rey, Mercedes; Irondelle, Marie; Waharte, Francois; Lizarraga, Floria; Chavrier, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">128-135</span>CODEN:
                <span class="NLM_cas:coden">EJCBDN</span>;
        ISSN:<span class="NLM_cas:issn">0171-9335</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Invasion across tissue boundaries by metastatic tumor cells depends on the proteolytic degrdn. of the extracellular matrix, initiated by the formation of invadopodia, actin-driven membrane protrusions with matrix-degradative activity.  Yet, mechanisms underlying invadopodia formation remain largely unknown.  In this report, we examd. the role of the histone deacetylase HDAC6 in invadopodia formation and invasion by breast cancer cells.  Using small interfering RNA silencing of protein expression in highly invasive MDA-MB-231 breast adenocarcinoma cells, we show that HDAC6 is required for two-dimensional matrix proteolysis.  In addn., we demonstrate that HDAC6 acts as a tubulin and cortactin deacetylase.  We also report that the inhibition of HDAC6 by siRNA or treatment with HDAC inhibitor TSA results in a decreased invasion capacity of a three-dimensional type I collagen matrix by MDA-MB-231 cells.  These data identify HDAC6 as a crit. component of the invasive app. of tumor cells, in both two- and three-dimensional matrixes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofj2HbNkcN-7Vg90H21EOLACvtfcHk0lgXb_ZWRqJPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlahs7g%253D&md5=294f600a1eeadb541c5f1f61ee7e5a88</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejcb.2010.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejcb.2010.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DRey%26aufirst%3DM.%26aulast%3DIrondelle%26aufirst%3DM.%26aulast%3DWaharte%26aufirst%3DF.%26aulast%3DLizarraga%26aufirst%3DF.%26aulast%3DChavrier%26aufirst%3DP.%26atitle%3DHDAC6%2520is%2520required%2520for%2520invadopodia%2520activity%2520and%2520invasion%2520by%2520breast%2520tumor%2520cells%26jtitle%3DEur.%2520J.%2520Cell%2520Biol.%26date%3D2011%26volume%3D90%26spage%3D128%26epage%3D135%26doi%3D10.1016%2Fj.ejcb.2010.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Castro-Castro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnac, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul-Gilloteaux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavrier, P.</span><span> </span><span class="NLM_article-title">ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion</span> <span class="citation_source-journal">Eur. J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">950</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span><span class="refDoi"> DOI: 10.1016/j.ejcb.2012.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.ejcb.2012.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22902175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aktbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=950-960&author=A.+Castro-Castroauthor=C.+Jankeauthor=G.+Montagnacauthor=P.+Paul-Gilloteauxauthor=P.+Chavrier&title=ATAT1%2FMEC-17+acetyltransferase+and+HDAC6+deacetylase+control+a+balance+of+acetylation+of+alpha-tubulin+and+cortactin+and+regulate+MT1-MMP+trafficking+and+breast+tumor+cell+invasion&doi=10.1016%2Fj.ejcb.2012.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion</span></div><div class="casAuthors">Castro-Castro, Antonio; Janke, Carsten; Montagnac, Guillaume; Paul-Gilloteaux, Perrine; Chavrier, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">950-960</span>CODEN:
                <span class="NLM_cas:coden">EJCBDN</span>;
        ISSN:<span class="NLM_cas:issn">0171-9335</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Invasive tumor cells use proteases to degrade and migrate through the stromal environment consisting of a 3D network of extracellular matrix macromols.  In particular, MT1-MMP, a membrane-anchored metalloproteinase, is crit. during cancer cell invasion.  MT1-MMP is stored in endosomal compartments and then delivered to invadopodia, the specialized plasma membrane domains of invasive cancer cells endowed with extracellular matrix-degrdn. capacity.  In macrophages, traffic of MT1-MMP vesicles to invadopodia-related podosomes requires microtubules.  We previously found that in breast tumor MDA-MB-231 cells an increase of microtubule and cortactin acetylation upon inhibition of HDAC6 correlates with a decrease of matrix degrdn. and invasion in three-dimensional collagen I gel.  Here, we investigated the role of the recently identified α-tubulin N-acetyltransferase 1 ATAT1 in invasive MDA-MB-231 cells.  We found that the dynamics and distribution of MT1-MMP-pos. endosomes require regulation of acetylation levels.  We obsd. that ATAT1 tubulin acetyltransferase binds and regulates cortactin acetylation levels.  In addn., ATAT1 colocalizes with cortactin at the adherent surface of the cells and it is required for 2D migration and invasive migration of MDA-MB-231 cells in collagen matrix.  All together, our data indicate that a balance of acetylation and deacetylation by ATAT1/HDAC6 enzymes with opposite activities regulates the migratory and invasive capacities of breast tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNkeddBjlAjbVg90H21EOLACvtfcHk0lgAMQTx9arzsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aktbjK&md5=8937aa840a2561c51a034f2752ea4fc7</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejcb.2012.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejcb.2012.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DCastro-Castro%26aufirst%3DA.%26aulast%3DJanke%26aufirst%3DC.%26aulast%3DMontagnac%26aufirst%3DG.%26aulast%3DPaul-Gilloteaux%26aufirst%3DP.%26aulast%3DChavrier%26aufirst%3DP.%26atitle%3DATAT1%252FMEC-17%2520acetyltransferase%2520and%2520HDAC6%2520deacetylase%2520control%2520a%2520balance%2520of%2520acetylation%2520of%2520alpha-tubulin%2520and%2520cortactin%2520and%2520regulate%2520MT1-MMP%2520trafficking%2520and%2520breast%2520tumor%2520cell%2520invasion%26jtitle%3DEur.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D91%26spage%3D950%26epage%3D960%26doi%3D10.1016%2Fj.ejcb.2012.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicosia, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khochbin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bepler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e44265</span><span class="refDoi"> DOI: 10.1371/journal.pone.0044265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1371%2Fjournal.pone.0044265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e44265&author=L.+Wangauthor=S.+Xiangauthor=K.+A.+Williamsauthor=H.+Dongauthor=W.+Baiauthor=S.+V.+Nicosiaauthor=S.+Khochbinauthor=G.+Beplerauthor=X.+Zhang&title=Depletion+of+HDAC6+enhances+cisplatin-induced+DNA+damage+and+apoptosis+in+non-small+cell+lung+cancer+cells&doi=10.1371%2Fjournal.pone.0044265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0044265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0044265%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DK.%2BA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DW.%26aulast%3DNicosia%26aufirst%3DS.%2BV.%26aulast%3DKhochbin%26aufirst%3DS.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DDepletion%2520of%2520HDAC6%2520enhances%2520cisplatin-induced%2520DNA%2520damage%2520and%2520apoptosis%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De44265%26doi%3D10.1371%2Fjournal.pone.0044265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Bergman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Villarroel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villagra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotomayor, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9891</span><span class="NLM_x">–</span> <span class="NLM_lpage">9899</span><span class="refDoi"> DOI: 10.1021/jm301098e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301098e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9891-9899&author=J.+A.+Bergmanauthor=K.+Woanauthor=P.+Perez-Villarroelauthor=A.+Villagraauthor=E.+M.+Sotomayorauthor=A.+P.+Kozikowski&title=Selective+histone+deacetylase+6+inhibitors+bearing+substituted+urea+linkers+inhibit+melanoma+cell+growth&doi=10.1021%2Fjm301098e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth</span></div><div class="casAuthors">Bergman, Joel A.; Woan, Karrune; Perez-Villarroel, Patricio; Villagra, Alejandro; Sotomayor, Eduardo M.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9891-9899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies.  In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor.  Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compds. bearing a branched linker group results in increased potency and selectivity for HDAC6.  Compd. 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ∼600-fold relative to the inhibition of HDAC1.  These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth.  To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkTtPLqvwsrVg90H21EOLACvtfcHk0lgV6YXNZ9Xn8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ&md5=d6be4c0efb3922fc35d814ba00ae9ed1</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm301098e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301098e%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DWoan%26aufirst%3DK.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%2520histone%2520deacetylase%25206%2520inhibitors%2520bearing%2520substituted%2520urea%2520linkers%2520inhibit%2520melanoma%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9891%26epage%3D9899%26doi%3D10.1021%2Fjm301098e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Wickstrom, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoumi, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khochbin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fassler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massoumi, R.</span><span> </span><span class="NLM_article-title">CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1038/emboj.2009.317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Femboj.2009.317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=131-144&author=S.+A.+Wickstromauthor=K.+C.+Masoumiauthor=S.+Khochbinauthor=R.+Fasslerauthor=R.+Massoumi&title=CYLD+negatively+regulates+cell-cycle+progression+by+inactivating+HDAC6+and+increasing+the+levels+of+acetylated+tubulin&doi=10.1038%2Femboj.2009.317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Femboj.2009.317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2009.317%26sid%3Dliteratum%253Aachs%26aulast%3DWickstrom%26aufirst%3DS.%2BA.%26aulast%3DMasoumi%26aufirst%3DK.%2BC.%26aulast%3DKhochbin%26aufirst%3DS.%26aulast%3DFassler%26aufirst%3DR.%26aulast%3DMassoumi%26aufirst%3DR.%26atitle%3DCYLD%2520negatively%2520regulates%2520cell-cycle%2520progression%2520by%2520inactivating%2520HDAC6%2520and%2520increasing%2520the%2520levels%2520of%2520acetylated%2520tubulin%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D131%26epage%3D144%26doi%3D10.1038%2Femboj.2009.317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Kijima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horinouchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beppu, T.</span><span> </span><span class="NLM_article-title">Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">22429</span><span class="NLM_x">–</span> <span class="NLM_lpage">22435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=8226751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK3sXlsleks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=22429-22435&author=M.+Kijimaauthor=M.+Yoshidaauthor=K.+Sugitaauthor=S.+Horinouchiauthor=T.+Beppu&title=Trapoxin%2C+an+antitumor+cyclic+tetrapeptide%2C+is+an+irreversible+inhibitor+of+mammalian+histone+deacetylase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase</span></div><div class="casAuthors">Kijima, Masako; Yoshida, Minoru; Sugita, Kenji; Horinouchi, Sueharu; Beppu, Teruhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">22429-35</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Trapoxin A (I), is a fungal product that induces morphol. reversion from transformed to normal in sis-transformed NIH3T3 fibroblasts.  I was found to cause accumulation of highly acetylated core histones in a variety of mammalian cell lines.  In vitro expts. using partially purified mouse histone deacetylase showed that a low concn. of I irreversibly inhibited deacetylation of acetylated histone mols.  Chem. redn. of an epoxide group in I completely abolished the inhibitory activity, suggesting that I binds covalently to the histone deacetylase via the epoxide.  In contrast, inhibition by trichostatin A, a known potent inhibitor of histone deacetylase, was reversible.  Despite the different mode of inhibition, I and trichostatin A induced almost the same biol. effects on the cell cycle and differentiation.  These results strongly suggest that the in vivo effects commonly induced by these agents can be attributed to histone hyperacetylation resulting from the inhibition of histone deacetylase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscgc_V7MoWrVg90H21EOLACvtfcHk0lgV6YXNZ9Xn8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsleks7Y%253D&md5=5252b79bf5604918fea6ecfdb64bc015</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKijima%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DSugita%26aufirst%3DK.%26aulast%3DHorinouchi%26aufirst%3DS.%26aulast%3DBeppu%26aufirst%3DT.%26atitle%3DTrapoxin%252C%2520an%2520antitumor%2520cyclic%2520tetrapeptide%252C%2520is%2520an%2520irreversible%2520inhibitor%2520of%2520mammalian%2520histone%2520deacetylase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D22429%26epage%3D22435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapadar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchini, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billadeau, D. D.</span><span> </span><span class="NLM_article-title">Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4370</span><span class="NLM_x">–</span> <span class="NLM_lpage">4373</span><span class="refDoi"> DOI: 10.1021/jm8002894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4370-4373&author=A.+P.+Kozikowskiauthor=S.+Tapadarauthor=D.+N.+Luchiniauthor=K.+H.+Kimauthor=D.+D.+Billadeau&title=Use+of+the+nitrile+oxide+cycloaddition+%28NOC%29+reaction+for+molecular+probe+generation%3A+a+new+class+of+enzyme+selective+histone+deacetylase+inhibitors+%28HDACIs%29+showing+picomolar+activity+at+HDAC6&doi=10.1021%2Fjm8002894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span></div><div class="casAuthors">Kozikowski, Alan P.; Tapadar, Subhasish; Luchini, Doris N.; Kim, Ki Hwan; Billadeau, Daniel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4370-4373</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of hydroxamate based HDAC inhibitors contg. a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddn. chem.  An HDAC6 selective inhibitor having a potency of ∼2 picomolar was identified.  Some of the compds. were examd. for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA (suberoylanilidehydroxamic acid).  This research provides valuable, new mol. probes for use in exploring HDAC biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7Ca9tXdBvbVg90H21EOLACvtfcHk0lgV6YXNZ9Xn8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D&md5=006c71fe6f2bb09c2c65196e134a695e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm8002894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002894%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DUse%2520of%2520the%2520nitrile%2520oxide%2520cycloaddition%2520%2528NOC%2529%2520reaction%2520for%2520molecular%2520probe%2520generation%253A%2520a%2520new%2520class%2520of%2520enzyme%2520selective%2520histone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%2520showing%2520picomolar%2520activity%2520at%2520HDAC6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4370%26epage%3D4373%26doi%3D10.1021%2Fjm8002894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Guerini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dellacasa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carobbio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Introna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, A.</span><span> </span><span class="NLM_article-title">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1038/sj.leu.2405049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fsj.leu.2405049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18079739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=740-747&author=V.+Gueriniauthor=V.+Barbuiauthor=O.+Spinelliauthor=A.+Salviauthor=C.+Dellacasaauthor=A.+Carobbioauthor=M.+Intronaauthor=T.+Barbuiauthor=J.+Golayauthor=A.+Rambaldi&title=The+histone+deacetylase+inhibitor+ITF2357+selectively+targets+cells+bearing+mutated+JAK2%28V617F%29&doi=10.1038%2Fsj.leu.2405049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F</span></div><div class="casAuthors">Guerini, V.; Barbui, V.; Spinelli, O.; Salvi, A.; Dellacasa, C.; Carobbio, A.; Introna, M.; Barbui, T.; Golay, J.; Rambaldi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line.  The clonogenic activity of JAK2V617F mutated cells was inhibited by low concns. of ITF2357 (IC50 0.001-0.01 μ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation.  Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies.  By western blotting the authors showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line.  By real-time PCR, the authors showed that, upon exposure to ITF2357, JAK2V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated.  Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2V617F mutation through a specific down-modulation of the JAK2V617F protein and inhibition of its downstream signaling.  Leukemia (2008) 22, 740-747; doi:10.1038/sj.leu.2405049; published online 13 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJVQmHmDb8RLVg90H21EOLACvtfcHk0lhjULE6RQ1JNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D&md5=de59fdaf20ec85e733052c09733b9193</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2405049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2405049%26sid%3Dliteratum%253Aachs%26aulast%3DGuerini%26aufirst%3DV.%26aulast%3DBarbui%26aufirst%3DV.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DSalvi%26aufirst%3DA.%26aulast%3DDellacasa%26aufirst%3DC.%26aulast%3DCarobbio%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DGolay%26aufirst%3DJ.%26aulast%3DRambaldi%26aufirst%3DA.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520ITF2357%2520selectively%2520targets%2520cells%2520bearing%2520mutated%2520JAK2%2528V617F%2529%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D740%26epage%3D747%26doi%3D10.1038%2Fsj.leu.2405049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Amaru Calzada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todoerti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donadoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicioli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuana, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finazzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Introna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golay, J.</span><span> </span><span class="NLM_article-title">The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span><span class="refDoi"> DOI: 10.1016/j.exphem.2012.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.exphem.2012.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22579713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVKhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=634-645&author=A.+Amaru+Calzadaauthor=K.+Todoertiauthor=L.+Donadoniauthor=A.+Pellicioliauthor=G.+Tuanaauthor=R.+Gattaauthor=A.+Neriauthor=G.+Finazziauthor=R.+Mantovaniauthor=A.+Rambaldiauthor=M.+Intronaauthor=L.+Lombardiauthor=J.+Golay&title=The+HDAC+inhibitor+Givinostat+modulates+the+hematopoietic+transcription+factors+NFE2+and+C-MYB+in+JAK2%28V617F%29+myeloproliferative+neoplasm+cells&doi=10.1016%2Fj.exphem.2012.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells</span></div><div class="casAuthors">Amaru Calzada, Ariel; Todoerti, Katia; Donadoni, Luca; Pellicioli, Anna; Tuana, Giacomo; Gatta, Raffaella; Neri, Antonino; Finazzi, Guido; Mantovani, Roberto; Rambaldi, Alessandro; Introna, Martino; Lombardi, Luigia; Golay, Josee</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">634-645.e10</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We investigated the mechanism of action of the histone deacetylase inhibitor Givinostat (GVS) in Janus kinase 2 (JAK2)V617F myeloproliferative neoplasm (MPN) cells.  GVS inhibited colony formation and proliferation and induced apoptosis at doses two- to threefold lower in a panel of JAK2V617F MPN compared to JAK2 wild-type myeloid leukemia cell lines.  By global gene expression anal., we obsd. that at 6 h, GVS modulated 293 common genes in the JAK2V617F cell lines HEL and UKE1, of which 19 are implicated in cell cycle regulation and 33 in hematopoiesis.  In particular, the hematopoietic transcription factors NFE2 and C-MYB were downmodulated by the drug specifically in JAK2V617F cells at both the RNA and protein level.  GVS also inhibited JAK2-signal transducer and activator of transcription 5-extracellular signal-regulated kinase 1/2 phosphorylation, but modulation of NFE2 and C-MYB was JAK2-independent, as shown using the JAK2 inhibitor TG101209.  GVS had a direct effect on the NFE2 promoters, as demonstrated by specific enrichment of assocd. histone H3 acetylated at lysine 9.  Modulation by GVS of NFE2 was also obsd. in freshly isolated CD34+ cells from MPN patients, and was accompanied by inhibition of their proliferation and differentiation toward the erythroid lineage.  We conclude that GVS acts on MPN cells through dual JAK2-signal transducer and activator of transcription 5-extracellular signal-regulated kinase 1/2 inhibition and downmodulation of NFE2 and C-MYB transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQdjteEkk71bVg90H21EOLACvtfcHk0lhjULE6RQ1JNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVKhtbs%253D&md5=c930e6fad23d7edf077e1d8abfa8f3dd</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2012.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2012.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DAmaru%2BCalzada%26aufirst%3DA.%26aulast%3DTodoerti%26aufirst%3DK.%26aulast%3DDonadoni%26aufirst%3DL.%26aulast%3DPellicioli%26aufirst%3DA.%26aulast%3DTuana%26aufirst%3DG.%26aulast%3DGatta%26aufirst%3DR.%26aulast%3DNeri%26aufirst%3DA.%26aulast%3DFinazzi%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DR.%26aulast%3DRambaldi%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DLombardi%26aufirst%3DL.%26aulast%3DGolay%26aufirst%3DJ.%26atitle%3DThe%2520HDAC%2520inhibitor%2520Givinostat%2520modulates%2520the%2520hematopoietic%2520transcription%2520factors%2520NFE2%2520and%2520C-MYB%2520in%2520JAK2%2528V617F%2529%2520myeloproliferative%2520neoplasm%2520cells%26jtitle%3DExp.%2520Hematol.%26date%3D2012%26volume%3D40%26spage%3D634%26epage%3D645%26doi%3D10.1016%2Fj.exphem.2012.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Xiong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J. Y.</span><span> </span><span class="NLM_article-title">Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells</span> <span class="citation_source-journal">Mol. Carcinog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1002/mc.20777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fmc.20777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21520296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=174-184&author=H.+Xiongauthor=W.+Duauthor=Y.+J.+Zhangauthor=J.+Hongauthor=W.+Y.+Suauthor=J.+T.+Tangauthor=Y.+C.+Wangauthor=R.+Luauthor=J.+Y.+Fang&title=Trichostatin+A%2C+a+histone+deacetylase+inhibitor%2C+suppresses+JAK2%2FSTAT3+signaling+via+inducing+the+promoter-associated+histone+acetylation+of+SOCS1+and+SOCS3+in+human+colorectal+cancer+cells&doi=10.1002%2Fmc.20777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells</span></div><div class="casAuthors">Xiong, Hua; Du, Wan; Zhang, Yan-Jie; Hong, Jie; Su, Wen-Yu; Tang, Jie-Ting; Wang, Ying-Chao; Lu, Rong; Fang, Jing-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-184</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Aberrant janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling is involved in the oncogenesis of several cancers.  Suppressors of cytokine signaling (SOCS) genes and SH2-contg. protein tyrosine phosphatase 1 (SHP1) proteins, which are neg. regulators of JAK/STAT signaling, have been reported to have tumor suppressor functions.  However, in colorectal cancer (CRC) cells, the mechanisms that regulate SOCS and SHP1 genes, and the cause of abnormalities in the JAK/STAT signaling pathway, remain largely unknown.  The present study shows that trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, leads to the hyperacetylation of histones assocd. with the SOCS1 and SOCS3 promoters, but not the SHP1 promoter in CRC cells.  This indicates that histone modifications are involved in the regulation of SOCS1 and SOCS3.  Moreover, upregulation of SOCS1 and SOCS3 expression was achieved using TSA, which also significantly downregulated JAK2/STAT3 signaling in CRC cells.  We also demonstrate that TSA suppresses the growth of CRC cells, and induces G1 cell cycle arrest and apoptosis through the regulation of downstream targets of JAK2/STAT3 signaling, including Bcl-2, survivin and p16ink4a.  Therefore, our data demonstrate that TSA may induce SOCS1 and SOCS3 expression by inducing histone modifications and consequently inhibits JAK2/STAT3 signaling in CRC cells.  These results also establish a mechanistic link between the inhibition of JAK2/STAT3 signaling and the anticancer action of TSA in CRC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1vZSwy1EJlrVg90H21EOLACvtfcHk0lhjULE6RQ1JNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKk&md5=038e783e9dd7172aa0576f76f2ad8342</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fmc.20777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20777%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DW.%2BY.%26aulast%3DTang%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DFang%26aufirst%3DJ.%2BY.%26atitle%3DTrichostatin%2520A%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520suppresses%2520JAK2%252FSTAT3%2520signaling%2520via%2520inducing%2520the%2520promoter-associated%2520histone%2520acetylation%2520of%2520SOCS1%2520and%2520SOCS3%2520in%2520human%2520colorectal%2520cancer%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2012%26volume%3D51%26spage%3D174%26epage%3D184%26doi%3D10.1002%2Fmc.20777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balusu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savoie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ustun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillella, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">5024</span><span class="NLM_x">–</span> <span class="NLM_lpage">5033</span><span class="refDoi"> DOI: 10.1182/blood-2009-05-222133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1182%2Fblood-2009-05-222133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=19828702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=5024-5033&author=Y.+Wangauthor=W.+Fiskusauthor=D.+G.+Chongauthor=K.+M.+Buckleyauthor=K.+Natarajanauthor=R.+Raoauthor=A.+Joshiauthor=R.+Balusuauthor=S.+Koulauthor=J.+Chenauthor=A.+Savoieauthor=C.+Ustunauthor=A.+P.+Jillellaauthor=P.+Atadjaauthor=R.+L.+Levineauthor=K.+N.+Bhalla&title=Cotreatment+with+panobinostat+and+JAK2+inhibitor+TG101209+attenuates+JAK2V617F+levels+and+signaling+and+exerts+synergistic+cytotoxic+effects+against+human+myeloproliferative+neoplastic+cells&doi=10.1182%2Fblood-2009-05-222133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells</span></div><div class="casAuthors">Wang, Yongchao; Fiskus, Warren; Chong, Daniel G.; Buckley, Kathleen M.; Natarajan, Kavita; Rao, Rekha; Joshi, Atul; Balusu, Ramesh; Koul, Sanjay; Chen, Jianguang; Savoie, Andrew; Ustun, Celalettin; Jillella, Anand P.; Atadja, Peter; Levine, Ross L.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5024-5033</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-neg. myeloproliferative neoplasms (MPNs).  JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs).  Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs.  Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F.  Treatment with PS also disrupted the chaperone assocn. of JAK2V617F with hsp90, promoting proteasomal degrdn. of JAK2V617F.  PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells.  Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34+ HPCs.  These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-pos. MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodK5zBrODMYbVg90H21EOLACvtfcHk0lju_yYALrnQ6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI&md5=061242179d1d48acd664acc8f484f003</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222133%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DChong%26aufirst%3DD.%2BG.%26aulast%3DBuckley%26aufirst%3DK.%2BM.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DBalusu%26aufirst%3DR.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSavoie%26aufirst%3DA.%26aulast%3DUstun%26aufirst%3DC.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DCotreatment%2520with%2520panobinostat%2520and%2520JAK2%2520inhibitor%2520TG101209%2520attenuates%2520JAK2V617F%2520levels%2520and%2520signaling%2520and%2520exerts%2520synergistic%2520cytotoxic%2520effects%2520against%2520human%2520myeloproliferative%2520neoplastic%2520cells%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D5024%26epage%3D5033%26doi%3D10.1182%2Fblood-2009-05-222133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML</span> <span class="citation_source-journal">Blood Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e69</span><span class="refDoi"> DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22829971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=e69&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.+C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+oral+HDAC+inhibitor+pracinostat+%28SB939%29+is+efficacious+and+synergistic+with+the+JAK2+inhibitor+pacritinib+%28SB1518%29+in+preclinical+models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520oral%2520HDAC%2520inhibitor%2520pracinostat%2520%2528SB939%2529%2520is%2520efficacious%2520and%2520synergistic%2520with%2520the%2520JAK2%2520inhibitor%2520pacritinib%2520%2528SB1518%2529%2520in%2520preclinical%2520models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26spage%3De69%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Evrot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andraos, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dammassa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span> </span><span class="NLM_article-title">JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6230</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-13-0905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24081976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6230-6241&author=E.+Evrotauthor=N.+Ebelauthor=V.+Romanetauthor=C.+Roelliauthor=R.+Andraosauthor=Z.+Qianauthor=A.+Dolemeyerauthor=E.+Dammassaauthor=D.+Sterkerauthor=R.+Cozensauthor=F.+Hofmannauthor=M.+Murakamiauthor=F.+Baffertauthor=T.+Radimerski&title=JAK1%2F2+and+Pan-deacetylase+inhibitor+combination+therapy+yields+improved+efficacy+in+preclinical+mouse+models+of+JAK2V617F-driven+disease&doi=10.1158%2F1078-0432.CCR-13-0905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease</span></div><div class="casAuthors">Evrot, Emeline; Ebel, Nicolas; Romanet, Vincent; Roelli, Claudia; Andraos, Rita; Qian, Zhiyan; Doelemeyer, Arno; Dammassa, Ernesta; Sterker, Dario; Cozens, Robert; Hofmann, Francesco; Murakami, Masato; Baffert, Fabienne; Radimerski, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6230-6241</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The myeloproliferative neoplasm myelofibrosis is characterized by frequent deregulation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, and JAK inhibitors were shown to reduce splenomegaly and ameliorate disease-related symptoms.  However, the mutant clone and bone marrow fibrosis persist in the majority of patients.  Using preclin. models, we explored whether JAK and pan-deacetylase inhibitor combination yielded addnl. benefits.  Exptl. Design: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2V617F-driven disease.  A Ba/F3 JAK2V617F cell-driven leukemic disease model was used to identify tolerated and efficacious doses.  The drugs were then evaluated alone and in combination in a mouse model of myeloproliferative neoplasm-like disease based on transplantation of bone marrow transduced with a retrovirus expressing JAK2V617F.  Exposures were detd. in blood and tissues, and phosphorylated STAT5 and acetylated histone H3 pharmacodynamic readouts were assessed in spleen and bone marrow.  Histol. anal. was conducted on spleen and bone marrow, including staining of reticulin fibers in the latter organ.  Results: The combination of ruxolitinib and panobinostat was found to have a more profound effect on splenomegaly, as well as on bone marrow and spleen histol., compared with either agent alone, and the anal. of pharmacodynamic readouts showed that ruxolitinib and panobinostat have nonoverlapping and complementary effects.  Conclusion: Combining JAK1/2 and pan-deacetylase inhibitors was fairly well tolerated and resulted in improved efficacy in mouse models of JAK2V617F-driven disease compared with the single agents.  Thus, the combination of ruxolitinib and panobinostat may represent a promising novel therapeutic modality for myeloproliferative neoplasms.  Clin Cancer Res; 19(22); 6230-41. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEzgbAtJVQ27Vg90H21EOLACvtfcHk0lju_yYALrnQ6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM&md5=ff3662f4ba7be74aa3395046e9516e04</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0905%26sid%3Dliteratum%253Aachs%26aulast%3DEvrot%26aufirst%3DE.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DRoelli%26aufirst%3DC.%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DDolemeyer%26aufirst%3DA.%26aulast%3DDammassa%26aufirst%3DE.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26atitle%3DJAK1%252F2%2520and%2520Pan-deacetylase%2520inhibitor%2520combination%2520therapy%2520yields%2520improved%2520efficacy%2520in%2520preclinical%2520mouse%2520models%2520of%2520JAK2V617F-driven%2520disease%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6230%26epage%3D6241%26doi%3D10.1158%2F1078-0432.CCR-13-0905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Ohlson, S.</span><span> </span><span class="NLM_article-title">Designing transient binding drugs: a new concept for drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.drudis.2008.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.drudis.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18468561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=433-439&author=S.+Ohlson&title=Designing+transient+binding+drugs%3A+a+new+concept+for+drug+discovery&doi=10.1016%2Fj.drudis.2008.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Designing transient binding drugs: A new concept for drug discovery</span></div><div class="casAuthors">Ohlson, Sten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9/10</span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A multitude of weak, or transient, biol. interactions (dissocn. const.: K d > μM), either working alone or in concert, occur frequently throughout biol. systems.  We are starting to appreciate their importance in complex biol. networks.  This realization has important implications to drug discovery as we can question the current paradigm of drug design to find the highest possible binders (drugs) to a given target (receptor).  Development of transient drugs, defined by their binding to target, can be based on high-off-rates, multivalent approaches or multiple targets.  Now, techniques are available to discover such drug candidates.  The greatest problem yet to overcome is probably the mind-set of the individual researcher that weak binders are undesired and therefore of no benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-vxnnjidYrLVg90H21EOLACvtfcHk0lhLuJZRAmg9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWntLk%253D&md5=5aab032fbff1ef8836296ce36aa803a1</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DOhlson%26aufirst%3DS.%26atitle%3DDesigning%2520transient%2520binding%2520drugs%253A%2520a%2520new%2520concept%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D433%26epage%3D439%26doi%3D10.1016%2Fj.drudis.2008.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Ganesan, A.</span><span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of Zinc-Dependent Histone Deacetylases (HDACs)</span>. In  <span class="citation_source-book">Macrocycles in Drug Discovery</span>; <span class="NLM_contrib-group">Levin, J.</span>, Ed.; <span class="NLM_publisher-name">The Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=109-140&author=A.+Ganesanauthor=J.+Levin&title=Macrocycles+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520Zinc-Dependent%2520Histone%2520Deacetylases%2520%2528HDACs%2529%26btitle%3DMacrocycles%2520in%2520Drug%2520Discovery%26aulast%3DLevin%26aufirst%3DJ.%26pub%3DThe%2520Royal%2520Society%2520of%2520Chemistry%26date%3D2015%26spage%3D109%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeller, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grozinger, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S. L.</span><span> </span><span class="NLM_article-title">Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4394</span><span class="refDoi"> DOI: 10.1073/pnas.0430973100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1073%2Fpnas.0430973100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=12677000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=4389-4394&author=S.+J.+Haggartyauthor=K.+M.+Koellerauthor=J.+C.+Wongauthor=C.+M.+Grozingerauthor=S.+L.+Schreiber&title=Domain-selective+small-molecule+inhibitor+of+histone+deacetylase+6+%28HDAC6%29-mediated+tubulin+deacetylation&doi=10.1073%2Fpnas.0430973100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation</span></div><div class="casAuthors">Haggarty, Stephen J.; Koeller, Kathryn M.; Wong, Jason C.; Grozinger, Christina M.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4389-4394</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein acetylation, esp. histone acetylation, is the subject of both research and clin. investigation.  At least four small-mol. histone deacetylase inhibitors are currently in clin. trials for the treatment of cancer.  These and other inhibitors also affect microtubule acetylation.  A multidimensional, chem. genetic screen of 7392 small mols. was used to discover "tubacin," which inhibits α-tubulin deacetylation in mammalian cells.  Tubacin does not affect the level of histone acetylation, gene-expression patterns, or cell-cycle progression.  We provide evidence that class II histone deacetylase 6 (HDAC6) is the intracellular target of tubacin.  Only one of the two catalytic domains of HDAC6 possesses tubulin deacetylase activity, and only this domain is bound by tubacin.  Tubacin treatment did not affect the stability of microtubules but did decrease cell motility.  HDAC6 overexpression disrupted the localization of p58, a protein that mediates binding of Golgi elements to microtubules.  Our results highlight the role of α-tubulin acetylation in mediating the localization of microtubule-assocd. proteins.  They also suggest that small mols. that selectively inhibit HDAC6-mediated α-tubulin deacetylation, a first example of which is tubacin, might have therapeutic applications as antimetastatic and antiangiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbQBWjEZr47rVg90H21EOLACvtfcHk0lhLuJZRAmg9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D&md5=260da1ede64782ddbddda31b740b9782</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0430973100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0430973100%26sid%3Dliteratum%253Aachs%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DKoeller%26aufirst%3DK.%2BM.%26aulast%3DWong%26aufirst%3DJ.%2BC.%26aulast%3DGrozinger%26aufirst%3DC.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DDomain-selective%2520small-molecule%2520inhibitor%2520of%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529-mediated%2520tubulin%2520deacetylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D4389%26epage%3D4394%26doi%3D10.1073%2Fpnas.0430973100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Wagner, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiwer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aidoud, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davoine, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemercier, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holson, E. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1772</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span><span class="refDoi"> DOI: 10.1021/jm301355j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301355j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1772-1776&author=F.+F.+Wagnerauthor=D.+E.+Olsonauthor=J.+P.+Galeauthor=T.+Kayaauthor=M.+Weiwerauthor=N.+Aidoudauthor=M.+Thomasauthor=E.+L.+Davoineauthor=B.+C.+Lemercierauthor=Y.+L.+Zhangauthor=E.+B.+Holson&title=Potent+and+selective+inhibition+of+histone+deacetylase+6+%28HDAC6%29+does+not+require+a+surface-binding+motif&doi=10.1021%2Fjm301355j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif</span></div><div class="casAuthors">Wagner, Florence F.; Olson, David E.; Gale, Jennifer P.; Kaya, Taner; Weiwer, Michel; Aidoud, Nadia; Thomas, Meryl; Davoine, Emeline L.; Lemercier, Berenice C.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1772-1776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6).  Several inhibitors, including compd. 14 (BRD9757), exhibited excellent potency and selectivity despite the absence of a surface-binding motif.  The binding of these highly efficient ligands for HDAC6 is rationalized via structure-activity relationships.  These results demonstrate that high selectivity and potent inhibition of HDAC6 can be achieved through careful choice of linker element only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp84k2hCSqrAbVg90H21EOLACvtfcHk0lhLuJZRAmg9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D&md5=eee6262f17350f3f7c411ab37840e3fe</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm301355j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301355j%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DOlson%26aufirst%3DD.%2BE.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DWeiwer%26aufirst%3DM.%26aulast%3DAidoud%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDavoine%26aufirst%3DE.%2BL.%26aulast%3DLemercier%26aufirst%3DB.%2BC.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520does%2520not%2520require%2520a%2520surface-binding%2520motif%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1772%26epage%3D1776%26doi%3D10.1021%2Fjm301355j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Auzzas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes-Simard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabri, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciacci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanessian, S.</span><span> </span><span class="NLM_article-title">Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8399</span><span class="refDoi"> DOI: 10.1021/jm101092u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101092u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8387-8399&author=L.+Auzzasauthor=A.+Larssonauthor=R.+Materaauthor=A.+Baraldiauthor=B.+Deschenes-Simardauthor=G.+Gianniniauthor=W.+Cabriauthor=G.+Battistuzziauthor=G.+Galloauthor=A.+Ciacciauthor=L.+Vesciauthor=C.+Pisanoauthor=S.+Hanessian&title=Non-natural+macrocyclic+inhibitors+of+histone+deacetylases%3A+design%2C+synthesis%2C+and+activity&doi=10.1021%2Fjm101092u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity</span></div><div class="casAuthors">Auzzas, Luciana; Larsson, Andreas; Matera, Riccardo; Baraldi, Annamaria; Deschenes-Simard, Benoit; Giannini, Giuseppe; Cabri, Walter; Battistuzzi, Gianfranco; Gallo, Grazia; Ciacci, Andrea; Vesci, Loredana; Pisano, Claudio; Hanessian, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8387-8399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonpeptidic chiral macrocycles, e.g. I [X = (CH2)n, n = 1-3], were designed on the basis of an analog of suberoylanilide hydroxamic acid II (SAHA, vorinostat) and evaluated against 11 histone deacetylase (HDAC) isoforms.  The identification of crit. amino acid residues highly conserved in the cap region of HDACs guided the design of the suberoyl-based macrocycles, which were expected to bear a max. common substructure required to target the whole HDAC panel.  A nanomolar HDAC inhibitory profile was obsd. for several compds., which was comparable, if not superior, to that of II.  A promising cytotoxic activity was found for selected macrocycles against lung and colon cancer cell lines.  Further elaboration of selected candidates led to compds. with an improved selectivity against HDAC6 over the other isoenzymes.  Pair-fitting anal. was used to compare one of the best candidates with the natural tetrapeptide apicidin, in an effort to define a general pharmacophore that might be useful in the design of surrogates of peptidic macrocycles as potent and isoform-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJOcBz2w8SRLVg90H21EOLACvtfcHk0lhtrIL4Fk2qlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtb%252FI&md5=061fb93af453824141ca9c0fdb09a701</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm101092u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101092u%26sid%3Dliteratum%253Aachs%26aulast%3DAuzzas%26aufirst%3DL.%26aulast%3DLarsson%26aufirst%3DA.%26aulast%3DMatera%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DA.%26aulast%3DDeschenes-Simard%26aufirst%3DB.%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DBattistuzzi%26aufirst%3DG.%26aulast%3DGallo%26aufirst%3DG.%26aulast%3DCiacci%26aufirst%3DA.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DHanessian%26aufirst%3DS.%26atitle%3DNon-natural%2520macrocyclic%2520inhibitors%2520of%2520histone%2520deacetylases%253A%2520design%252C%2520synthesis%252C%2520and%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8387%26epage%3D8399%26doi%3D10.1021%2Fjm101092u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Darkin-Rattray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurnett, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumley, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allocco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannova, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombrowski, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polishook, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmatz, D. M.</span><span> </span><span class="NLM_article-title">Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">13143</span><span class="NLM_x">–</span> <span class="NLM_lpage">13147</span><span class="refDoi"> DOI: 10.1073/pnas.93.23.13143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1073%2Fpnas.93.23.13143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=8917558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK28XmvV2qtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=13143-13147&author=S.+J.+Darkin-Rattrayauthor=A.+M.+Gurnettauthor=R.+W.+Myersauthor=P.+M.+Dulskiauthor=T.+M.+Crumleyauthor=J.+J.+Alloccoauthor=C.+Cannovaauthor=P.+T.+Meinkeauthor=S.+L.+Collettiauthor=M.+A.+Bednarekauthor=S.+B.+Singhauthor=M.+A.+Goetzauthor=A.+W.+Dombrowskiauthor=J.+D.+Polishookauthor=D.+M.+Schmatz&title=Apicidin%3A+a+novel+antiprotozoal+agent+that+inhibits+parasite+histone+deacetylase&doi=10.1073%2Fpnas.93.23.13143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase</span></div><div class="casAuthors">Darkin-Rattray, Sandra J.; Gurnett, Anne M.; Myers, Robert W.; Dulski, Paula M.; Crumley, Tami M.; Allocco, John J.; Cannova, Christine; Meinke, Peter T.; Colletti, Steven L.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13143-13147</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A novel fungal metabolite, apicidin [cyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)], that exhibits potent, broad spectrum antiprotozoal activity in vitro against Apicomplexan parasites has been identified.  It is also orally and parenterally active in vivo against Plasmodium berghei malaria in mice.  Many Apicomplexan parasites cause serious, life-threatening human and animal diseases, such as malaria, cryptosporidiosis, toxoplasmosis, and coccidiosis, and new therapeutic agents are urgently needed.  Apicidin's antiparasitic activity appears to be due to low nanomolar inhibition of Apicomplexan histone deacetylase (HDA), which induces hyperacetylation of histones in treated parasites.  The acetylation-deacetylation of histones is thought to play a central role in transcriptional control in eukaryotic cells.  Other known HDA inhibitors were also evaluated and found to possess antiparasitic activity, suggesting that HDA is an attractive target for the development of novel antiparasitic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqub6fPyIvFQrVg90H21EOLACvtfcHk0lhtrIL4Fk2qlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvV2qtrk%253D&md5=3738f88674b6e5856d55bab7a0701e22</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.23.13143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.23.13143%26sid%3Dliteratum%253Aachs%26aulast%3DDarkin-Rattray%26aufirst%3DS.%2BJ.%26aulast%3DGurnett%26aufirst%3DA.%2BM.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DDulski%26aufirst%3DP.%2BM.%26aulast%3DCrumley%26aufirst%3DT.%2BM.%26aulast%3DAllocco%26aufirst%3DJ.%2BJ.%26aulast%3DCannova%26aufirst%3DC.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DBednarek%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DGoetz%26aufirst%3DM.%2BA.%26aulast%3DDombrowski%26aufirst%3DA.%2BW.%26aulast%3DPolishook%26aufirst%3DJ.%2BD.%26aulast%3DSchmatz%26aufirst%3DD.%2BM.%26atitle%3DApicidin%253A%2520a%2520novel%2520antiprotozoal%2520agent%2520that%2520inhibits%2520parasite%2520histone%2520deacetylase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D13143%26epage%3D13147%26doi%3D10.1073%2Fpnas.93.23.13143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darkin-Rattray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurnett, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galuska, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allocco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumley, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannova, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmatz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span> </span><span class="NLM_article-title">Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00604-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0960-894X%2800%2900604-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=107-111&author=S.+L.+Collettiauthor=R.+W.+Myersauthor=S.+J.+Darkin-Rattrayauthor=A.+M.+Gurnettauthor=P.+M.+Dulskiauthor=S.+Galuskaauthor=J.+J.+Alloccoauthor=M.+B.+Ayerauthor=C.+Liauthor=J.+Limauthor=T.+M.+Crumleyauthor=C.+Cannovaauthor=D.+M.+Schmatzauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=P.+T.+Meinke&title=Broad+spectrum+antiprotozoal+agents+that+inhibit+histone+deacetylase%3A+structure-activity+relationships+of+apicidin.+Part+1&doi=10.1016%2FS0960-894X%2800%2900604-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900604-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900604-1%26sid%3Dliteratum%253Aachs%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DDarkin-Rattray%26aufirst%3DS.%2BJ.%26aulast%3DGurnett%26aufirst%3DA.%2BM.%26aulast%3DDulski%26aufirst%3DP.%2BM.%26aulast%3DGaluska%26aufirst%3DS.%26aulast%3DAllocco%26aufirst%3DJ.%2BJ.%26aulast%3DAyer%26aufirst%3DM.%2BB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DCrumley%26aufirst%3DT.%2BM.%26aulast%3DCannova%26aufirst%3DC.%26aulast%3DSchmatz%26aufirst%3DD.%2BM.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26atitle%3DBroad%2520spectrum%2520antiprotozoal%2520agents%2520that%2520inhibit%2520histone%2520deacetylase%253A%2520structure-activity%2520relationships%2520of%2520apicidin.%2520Part%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D107%26epage%3D111%26doi%3D10.1016%2FS0960-894X%2800%2900604-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darkin-Rattray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurnett, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galuska, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allocco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumley, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannova, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmatz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span> </span><span class="NLM_article-title">Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00605-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0960-894X%2800%2900605-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=113-117&author=S.+L.+Collettiauthor=R.+W.+Myersauthor=S.+J.+Darkin-Rattrayauthor=A.+M.+Gurnettauthor=P.+M.+Dulskiauthor=S.+Galuskaauthor=J.+J.+Alloccoauthor=M.+B.+Ayerauthor=C.+Liauthor=J.+Limauthor=T.+M.+Crumleyauthor=C.+Cannovaauthor=D.+M.+Schmatzauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=P.+T.+Meinke&title=Broad+spectrum+antiprotozoal+agents+that+inhibit+histone+deacetylase%3A+structure-activity+relationships+of+apicidin.+Part+2&doi=10.1016%2FS0960-894X%2800%2900605-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900605-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900605-3%26sid%3Dliteratum%253Aachs%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DDarkin-Rattray%26aufirst%3DS.%2BJ.%26aulast%3DGurnett%26aufirst%3DA.%2BM.%26aulast%3DDulski%26aufirst%3DP.%2BM.%26aulast%3DGaluska%26aufirst%3DS.%26aulast%3DAllocco%26aufirst%3DJ.%2BJ.%26aulast%3DAyer%26aufirst%3DM.%2BB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DCrumley%26aufirst%3DT.%2BM.%26aulast%3DCannova%26aufirst%3DC.%26aulast%3DSchmatz%26aufirst%3DD.%2BM.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26atitle%3DBroad%2520spectrum%2520antiprotozoal%2520agents%2520that%2520inhibit%2520histone%2520deacetylase%253A%2520structure-activity%2520relationships%2520of%2520apicidin.%2520Part%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D113%26epage%3D117%26doi%3D10.1016%2FS0960-894X%2800%2900605-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenical, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, R. B.</span><span> </span><span class="NLM_article-title">Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">6535</span><span class="NLM_x">–</span> <span class="NLM_lpage">6541</span><span class="refDoi"> DOI: 10.1016/j.tet.2007.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.tet.2007.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVanu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=6535-6541&author=W.+Guauthor=M.+Cuetoauthor=P.+R.+Jensenauthor=W.+Fenicalauthor=R.+B.+Silverman&title=Microsporins+A+and+B%3A+new+histone+deacetylase+inhibitors+from+the+marine-derived+fungus+Microsporum+cf.+gypseum+and+the+solid-phase+synthesis+of+microsporin+A&doi=10.1016%2Fj.tet.2007.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A</span></div><div class="casAuthors">Gu, Wenxin; Cueto, Mercedes; Jensen, Paul R.; Fenical, William; Silverman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">6535-6541</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Two new cyclic peptides, microsporins A (I) and B, were isolated from culture exts. of the marine-derived fungus Microsporum cf. gypseum obtained from a sample of the bryozoan Bugula sp. collected in the U.S. Virgin Islands.  The structures of the new compds. were detd. by extensive interpretation of 2D NMR data and by chem. methods.  Microsporins A and B are potent inhibitors of histone deacetylase and demonstrate cytotoxic activity against human colon adenocarcinoma (HCT-116), as well as against the National Cancer Institute 60 cancer cell panel.  The total synthesis of microsporin A on solid-phase is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoom2iPklesGrVg90H21EOLACvtfcHk0licdNYCGDfwOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVanu74%253D&md5=ac43010ba13b93aacb4a8b5a6e6ce6a6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2007.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2007.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DW.%26aulast%3DCueto%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DP.%2BR.%26aulast%3DFenical%26aufirst%3DW.%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26atitle%3DMicrosporins%2520A%2520and%2520B%253A%2520new%2520histone%2520deacetylase%2520inhibitors%2520from%2520the%2520marine-derived%2520fungus%2520Microsporum%2520cf.%2520gypseum%2520and%2520the%2520solid-phase%2520synthesis%2520of%2520microsporin%2520A%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D6535%26epage%3D6541%26doi%3D10.1016%2Fj.tet.2007.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horinouchi, S.</span><span> </span><span class="NLM_article-title">FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">241</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1006/excr.1998.4027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1006%2Fexcr.1998.4027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=9633520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVGjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1998&pages=126-133&author=H.+Nakajimaauthor=Y.+B.+Kimauthor=H.+Teranoauthor=M.+Yoshidaauthor=S.+Horinouchi&title=FR901228%2C+a+potent+antitumor+antibiotic%2C+is+a+novel+histone+deacetylase+inhibitor&doi=10.1006%2Fexcr.1998.4027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor</span></div><div class="casAuthors">Nakajima, Hidenori; Kim, Young Bae; Terano, Hiroshi; Yoshida, Minoru; Horinouchi, Sueharu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">126-133</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Screening for microbial metabolites that induce transcriptional activation of the SV40 promoter resulted in the identification of two known compds., FR901228 and trichostatin A (TSA).  FR901228 is a potent antitumor drug that is currently under clin. investigation.  TSA is a specific inhibitor of histone deacetylase.  Despite structural differences, both FR901228 and TSA greatly enhanced the transcriptional activity of the SV40 promoter in an enhancer-dependent manner.  The effects of FR901228 on the cell cycle, chromatin structure, and histone acetylation were examd. and compared to the effects of TSA.  Both compds. arrested the cell cycle at both G1 and G2/M phases and induced internucleosomal breakdown of chromatin.  FR901228, like TSA, inhibited the intracellular histone deacetylase activity, as a result of which marked amts. of acetylated histone species accumulated.  Thus, FR901228 is a new type of histone deacetylase inhibitor whose chem. structure is unrelated to known inhibitors such as trichostatins and trapoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDyUNz818nbVg90H21EOLACvtfcHk0licdNYCGDfwOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVGjtLY%253D&md5=f0e72c561596900036c9062bf2db2990</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1006%2Fexcr.1998.4027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.1998.4027%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%2BB.%26aulast%3DTerano%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DHorinouchi%26aufirst%3DS.%26atitle%3DFR901228%252C%2520a%2520potent%2520antitumor%2520antibiotic%252C%2520is%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D1998%26volume%3D241%26spage%3D126%26epage%3D133%26doi%3D10.1006%2Fexcr.1998.4027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Masuoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin-ya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furihata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, H.</span><span> </span><span class="NLM_article-title">Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1016/S0040-4039(00)01874-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0040-4039%2800%2901874-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFGltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=41-44&author=K.+Masuokaauthor=A.+Nagaiauthor=K.+Shin-yaauthor=K.+Furihataauthor=K.+Nagaiauthor=K.-I.+Suzukiauthor=Y.+Hayakawaauthor=H.+Seto&title=Spiruchostatins+A+and+B%2C+novel+gene+expression-enhancing+substances+produced+by+Pseudomonas+sp&doi=10.1016%2FS0040-4039%2800%2901874-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp.</span></div><div class="casAuthors">Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.-i.; Hayakawa, Y.; Seto, H.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-44</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The fermn., isolation, structure detn., and bioactivity of spiruchostatins A and B (I and II, resp.) from Pseudomonas sp. are reported.  I and II possess novel bicyclic depsipeptides involving 4-amino-3-hydroxy-5-methylhexanoic acid and 4-amino-3-hydroxy-5-methylheptanoic acid residues, resp.  I and II, which show TGF-β-activity, induced reporter gene expression under the control of the plasminogen activator inhibitor-1 promoter and were cytostatic in MvlLu cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokWgn-44JpcrVg90H21EOLACvtfcHk0lhP80131D9bGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFGltrs%253D&md5=ecfb97120c1915541855d148aa492bdb</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2901874-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252901874-8%26sid%3Dliteratum%253Aachs%26aulast%3DMasuoka%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DA.%26aulast%3DShin-ya%26aufirst%3DK.%26aulast%3DFurihata%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DK.-I.%26aulast%3DHayakawa%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DH.%26atitle%3DSpiruchostatins%2520A%2520and%2520B%252C%2520novel%2520gene%2520expression-enhancing%2520substances%2520produced%2520by%2520Pseudomonas%2520sp%26jtitle%3DTetrahedron%2520Lett.%26date%3D2001%26volume%3D42%26spage%3D41%26epage%3D44%26doi%3D10.1016%2FS0040-4039%2800%2901874-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Taori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luesch, H.</span><span> </span><span class="NLM_article-title">Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1806</span><span class="NLM_x">–</span> <span class="NLM_lpage">1807</span><span class="refDoi"> DOI: 10.1021/ja7110064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja7110064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFGhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=1806-1807&author=K.+Taoriauthor=V.+J.+Paulauthor=H.+Luesch&title=Structure+and+activity+of+largazole%2C+a+potent+antiproliferative+agent+from+the+Floridian+marine+cyanobacterium+Symploca+sp&doi=10.1021%2Fja7110064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium Symploca sp.</span></div><div class="casAuthors">Taori, Kanchan; Paul, Valerie J.; Luesch, Hendrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1806-1807</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel cytotoxic cyclodepsipeptide, termed largazole, has been isolated from the marine cyanobacterium Symploca sp. collected in the Florida Keys.  Its planar structure was elucidated by 1D and 2D NMR spectroscopy in conjunction with mass spectrometry.  The abs. configuration of largazole was detd. by chem. degrdn. followed by chiral HPLC anal.  Largazole possesses densely assembled unusual structural features, including a rare 4-methylthiazoline linearly fused to a thiazole in its cyclic core and a hitherto undescribed 3-hydroxy-7-mercaptohept-4-enoic acid unit incorporated in an ester, thioester, and amide framework.  Largazole exhibits potent antiproliferative activity and preferentially targets cancer cells over nontransformed cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0JtehDfpXXLVg90H21EOLACvtfcHk0lhP80131D9bGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFGhtw%253D%253D&md5=bcd18bbee431e273c1b646f3c9c1388b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fja7110064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja7110064%26sid%3Dliteratum%253Aachs%26aulast%3DTaori%26aufirst%3DK.%26aulast%3DPaul%26aufirst%3DV.%2BJ.%26aulast%3DLuesch%26aufirst%3DH.%26atitle%3DStructure%2520and%2520activity%2520of%2520largazole%252C%2520a%2520potent%2520antiproliferative%2520agent%2520from%2520the%2520Floridian%2520marine%2520cyanobacterium%2520Symploca%2520sp%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D1806%26epage%3D1807%26doi%3D10.1021%2Fja7110064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Nakao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindoh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Soest, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusetani, N.</span><span> </span><span class="NLM_article-title">Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">7553</span><span class="NLM_x">–</span> <span class="NLM_lpage">7557</span><span class="refDoi"> DOI: 10.1002/anie.200602047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fanie.200602047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=7553-7557&author=Y.+Nakaoauthor=S.+Yoshidaauthor=S.+Matsunagaauthor=N.+Shindohauthor=Y.+Teradaauthor=K.+Nagaiauthor=J.+K.+Yamashitaauthor=A.+Ganesanauthor=R.+W.+van+Soestauthor=N.+Fusetani&title=Azumamides+A-E%3A+histone+deacetylase+inhibitory+cyclic+tetrapeptides+from+the+marine+sponge+Mycale+izuensis&doi=10.1002%2Fanie.200602047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2Fanie.200602047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200602047%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DShindoh%26aufirst%3DN.%26aulast%3DTerada%26aufirst%3DY.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DJ.%2BK.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3Dvan%2BSoest%26aufirst%3DR.%2BW.%26aulast%3DFusetani%26aufirst%3DN.%26atitle%3DAzumamides%2520A-E%253A%2520histone%2520deacetylase%2520inhibitory%2520cyclic%2520tetrapeptides%2520from%2520the%2520marine%2520sponge%2520Mycale%2520izuensis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D7553%26epage%3D7557%26doi%3D10.1002%2Fanie.200602047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, F. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of a potent histone deacetylase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2006</span><span class="refDoi"> DOI: 10.1021/jm061082q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061082q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2003-2006&author=T.+Liuauthor=G.+Kapustinauthor=F.+A.+Etzkorn&title=Design+and+synthesis+of+a+potent+histone+deacetylase+inhibitor&doi=10.1021%2Fjm061082q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm061082q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061082q%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DKapustin%26aufirst%3DG.%26aulast%3DEtzkorn%26aufirst%3DF.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520potent%2520histone%2520deacetylase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2003%26epage%3D2006%26doi%3D10.1021%2Fjm061082q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mossetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grolla, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Micco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tron, G. C.</span><span> </span><span class="NLM_article-title">Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3 + 2] cycloaddition</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1007/s11030-009-9153-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs11030-009-9153-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=109-121&author=T.+Piraliauthor=V.+Faccioauthor=R.+Mossettiauthor=A.+A.+Grollaauthor=S.+Di+Miccoauthor=G.+Bifulcoauthor=A.+A.+Genazzaniauthor=G.+C.+Tron&title=Synthesis%2C+molecular+docking+and+biological+evaluation+as+HDAC+inhibitors+of+cyclopeptide+mimetics+by+a+tandem+three-component+reaction+and+intramolecular+%5B3+%2B+2%5D+cycloaddition&doi=10.1007%2Fs11030-009-9153-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs11030-009-9153-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-009-9153-9%26sid%3Dliteratum%253Aachs%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFaccio%26aufirst%3DV.%26aulast%3DMossetti%26aufirst%3DR.%26aulast%3DGrolla%26aufirst%3DA.%2BA.%26aulast%3DDi%2BMicco%26aufirst%3DS.%26aulast%3DBifulco%26aufirst%3DG.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26aulast%3DTron%26aufirst%3DG.%2BC.%26atitle%3DSynthesis%252C%2520molecular%2520docking%2520and%2520biological%2520evaluation%2520as%2520HDAC%2520inhibitors%2520of%2520cyclopeptide%2520mimetics%2520by%2520a%2520tandem%2520three-component%2520reaction%2520and%2520intramolecular%2520%255B3%2520%252B%25202%255D%2520cycloaddition%26jtitle%3DMol.%2520Diversity%26date%3D2010%26volume%3D14%26spage%3D109%26epage%3D121%26doi%3D10.1007%2Fs11030-009-9153-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Ning, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N. F.</span><span> </span><span class="NLM_article-title">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.ejmech.2015.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25800646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=104-115&author=C.+Q.+Ningauthor=C.+Luauthor=L.+Huauthor=Y.+J.+Biauthor=L.+Yaoauthor=Y.+J.+Heauthor=L.+F.+Liuauthor=X.+Y.+Liuauthor=N.+F.+Yu&title=Macrocyclic+compounds+as+anti-cancer+agents%3A+Design+and+synthesis+of+multi-acting+inhibitors+against+HDAC%2C+FLT3+and+JAK2&doi=10.1016%2Fj.ejmech.2015.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span></div><div class="casAuthors">Ning, Cheng-Qing; Lu, Cheng; Hu, Liang; Bi, Yan-Jing; Yao, Lei; He, Yu-Jun; Liu, Li-Fei; Liu, Xiao-Yu; Yu, Nie-Fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of macrocyclic compds. I [X = O, CH2O; Y = CH2, CO; n = 1, 2; m = 1-5] were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2.  Some of these compds. exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions.  In vitro antiproliferative assay indicated that these compds. were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2V617F mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvwiDjzqtazLVg90H21EOLACvtfcHk0ljptRNiS8eYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D&md5=fc2b93fcbce2998ecd2d6de46a01811d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DY.%2BJ.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DYu%26aufirst%3DN.%2BF.%26atitle%3DMacrocyclic%2520compounds%2520as%2520anti-cancer%2520agents%253A%2520Design%2520and%2520synthesis%2520of%2520multi-acting%2520inhibitors%2520against%2520HDAC%252C%2520FLT3%2520and%2520JAK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2015.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span> </span><span class="NLM_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1007/s10822-012-9572-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs10822-012-9572-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+oxygen-linked+macrocyclic+kinase+inhibitors%3A+discovery+of+SB1518+and+SB1578%2C+potent+inhibitors+of+Janus+kinase+2+%28JAK2%29+and+Fms-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1007%2Fs10822-012-9572-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520oxygen-linked%2520macrocyclic%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520potent%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D437%26epage%3D450%26doi%3D10.1007%2Fs10822-012-9572-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Nolan, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clavier, H.</span><span> </span><span class="NLM_article-title">Chemoselective olefin metathesis transformations mediated by ruthenium complexes</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3305</span><span class="NLM_x">–</span> <span class="NLM_lpage">3316</span><span class="refDoi"> DOI: 10.1039/b912410c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1039%2Fb912410c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=20593074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFyhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=3305-3316&author=S.+P.+Nolanauthor=H.+Clavier&title=Chemoselective+olefin+metathesis+transformations+mediated+by+ruthenium+complexes&doi=10.1039%2Fb912410c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoselective olefin metathesis transformations mediated by ruthenium complexes</span></div><div class="casAuthors">Nolan, Steven P.; Clavier, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3305-3316</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Over the past decade, ruthenium-mediated metathesis transformations, including polymn. reactions, cross-metathesis, ring-closing metathesis, enyne metathesis, ring-rearrangement metathesis, and also tandem processes, represent one of the most studied families of org. reactions.  This has translated into the development of a large no. of structurally diverse catalysts.  Whereas most of these investigations are focused on detg. catalytic performance, only rare examples of studies dealing with chemoselectivity have been reported to date.  Usually, variations are obsd. in product conversions but rarely in product distributions.  In this crit. review, we provide an overview of the stereochem. of newly formed C=C bonds either in ring-closing or cross-metathesis as a function of the catalyst structure.  A discussion of disparities encountered in macrocyclization reactions leading (or not) to the formation of dimeric products is also presented.  Since distinctive metathesis products could be isolated as a function of the ligand borne by the ruthenium center-phosphine or N-heterocyclic carbene in the dissymmetrization of trienes, enyne metathesis and ring rearrangements, these topics are also discussed (72 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN9nKFf5G4lrVg90H21EOLACvtfcHk0ljptRNiS8eYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFyhu7Y%253D&md5=43408b8fc8900396bfdd4a497e60818c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1039%2Fb912410c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb912410c%26sid%3Dliteratum%253Aachs%26aulast%3DNolan%26aufirst%3DS.%2BP.%26aulast%3DClavier%26aufirst%3DH.%26atitle%3DChemoselective%2520olefin%2520metathesis%2520transformations%2520mediated%2520by%2520ruthenium%2520complexes%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2010%26volume%3D39%26spage%3D3305%26epage%3D3316%26doi%3D10.1039%2Fb912410c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Bermudez-Lugo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Gonzalez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosales-Hernandez, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilizaliturri-Flores, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo-Ferrara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa-Basurto, J.</span><span> </span><span class="NLM_article-title">Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2301</span><span class="NLM_x">–</span> <span class="NLM_lpage">2310</span><span class="refDoi"> DOI: 10.1007/s00894-011-1240-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs00894-011-1240-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21968575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2301-2310&author=J.+A.+Bermudez-Lugoauthor=O.+Perez-Gonzalezauthor=M.+C.+Rosales-Hernandezauthor=I.+Ilizaliturri-Floresauthor=J.+Trujillo-Ferraraauthor=J.+Correa-Basurto&title=Exploration+of+the+valproic+acid+binding+site+on+histone+deacetylase+8+using+docking+and+molecular+dynamic+simulations&doi=10.1007%2Fs00894-011-1240-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations</span></div><div class="casAuthors">Bermudez-Lugo, Jorge Antonio; Perez-Gonzalez, Oscar; Rosales-Hernandez, Martha Cecilia; Ilizaliturri-Flores, Ian; Trujillo-Ferrara, Jose; Correa-Basurto, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2301-2310</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epigenetic therapy is an important focus of research for drug development in the treatment of cancer.  Valproic acid (VPA) is a histone deacetylase (HDAC) inhibitor that has been evaluated in clin. studies.  Despite its success in treating cancer, the mechanism of inhibition of VPA in HDAC is unknown.  Here, to this end, the authors used mol. docking and mol. dynamics (MD) simulations to investigate VPA binding to HDAC, employing both native and rebuilt 3-dimensional (3D) structures.  The results showed that VPA, via its carboxyl group, coordinates the Zn atom and other local residues (His-141/His-142 and Tyr-360) located at the catalytic site (CS) of HDAC.  This caused electrostatic and H-bonding interactions while having little interaction with the hydrophobic side-chains, resulting in a low affinity.  However, after several docking studies on different native HDAC 3D structures and after using several snapshots from MD simulations, it became apparent that VPA bound with highest affinity at a site located at the acetyl-releasing channel, termed the hydrophobic active site channel (HASC).  The affinity of VPA for HASC was due to its highly hydrophobic properties that allowed VPA to take part in van der Waals interactions with Tyr-18, Ile-19, Tyr-20, Val-25, Arg-37, Ala-38, Val-41, His-42, Ile-135, and Trp-137, while VPA's carboxylate group had several H-bonding interactions with the backbones of Ser-138, Ile-19, Asn-136, and Trp-137.  MD simulations showed that the HASC door continuously opened and closed, which affected the affinity of VPA to the HASC, but the affinity toward the HASC was consistently higher than that obtained for the CS, suggesting that the HASC could be involved in the mechanism of inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-e-M0_PDozLVg90H21EOLACvtfcHk0lhXsPSdTS2HAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOhtbs%253D&md5=39470c3338c39377a8ba05e4ad5a11e4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs00894-011-1240-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-011-1240-z%26sid%3Dliteratum%253Aachs%26aulast%3DBermudez-Lugo%26aufirst%3DJ.%2BA.%26aulast%3DPerez-Gonzalez%26aufirst%3DO.%26aulast%3DRosales-Hernandez%26aufirst%3DM.%2BC.%26aulast%3DIlizaliturri-Flores%26aufirst%3DI.%26aulast%3DTrujillo-Ferrara%26aufirst%3DJ.%26aulast%3DCorrea-Basurto%26aufirst%3DJ.%26atitle%3DExploration%2520of%2520the%2520valproic%2520acid%2520binding%2520site%2520on%2520histone%2520deacetylase%25208%2520using%2520docking%2520and%2520molecular%2520dynamic%2520simulations%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2012%26volume%3D18%26spage%3D2301%26epage%3D2310%26doi%3D10.1007%2Fs00894-011-1240-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Bieliauskas, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflum, M. K.</span><span> </span><span class="NLM_article-title">Isoform-selective histone deacetylase inhibitors</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1413</span><span class="refDoi"> DOI: 10.1039/b703830p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1039%2Fb703830p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18568166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=1402-1413&author=A.+V.+Bieliauskasauthor=M.+K.+Pflum&title=Isoform-selective+histone+deacetylase+inhibitors&doi=10.1039%2Fb703830p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective histone deacetylase inhibitors</span></div><div class="casAuthors">Bieliauskas, Anton V.; Pflum, Mary Kay H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1402-1413</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer.  As a result, multiple small mol. HDAC inhibitors are in various phases of clin. trials as anti-cancer drugs.  The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.  This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors.  The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXOB_YFWaeZrVg90H21EOLACvtfcHk0lhXsPSdTS2HAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D&md5=326e20da0623a00114f43e5c459c9920</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1039%2Fb703830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703830p%26sid%3Dliteratum%253Aachs%26aulast%3DBieliauskas%26aufirst%3DA.%2BV.%26aulast%3DPflum%26aufirst%3DM.%2BK.%26atitle%3DIsoform-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D1402%26epage%3D1413%26doi%3D10.1039%2Fb703830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lhXsPSdTS2HAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Vishwakarma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shastry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulathingal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijaykanth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajesh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathinasamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kachhadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilambi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajgopal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, S.</span><span> </span><span class="NLM_article-title">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1016/j.intimp.2013.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.intimp.2013.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23541634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=72-78&author=S.+Vishwakarmaauthor=L.+R.+Iyerauthor=M.+Muleyauthor=P.+K.+Singhauthor=A.+Shastryauthor=A.+Saxenaauthor=J.+Kulathingalauthor=G.+Vijaykanthauthor=J.+Raghulauthor=N.+Rajeshauthor=S.+Rathinasamyauthor=V.+Kachhadiaauthor=N.+Kilambiauthor=S.+Rajgopalauthor=G.+Balasubramanianauthor=S.+Narayanan&title=Tubastatin%2C+a+selective+histone+deacetylase+6+inhibitor+shows+anti-inflammatory+and+anti-rheumatic+effects&doi=10.1016%2Fj.intimp.2013.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span></div><div class="casAuthors">Vishwakarma, Santosh; Iyer, Lakshmi R.; Muley, Milind; Singh, Pankaj Kumar; Shastry, Arun; Saxena, Ambrish; Kulathingal, Jayanarayan; Vijaykanth, G.; Raghul, J.; Rajesh, Navin; Rathinasamy, Suresh; Kachhadia, Virendra; Kilambi, Narasimhan; Rajgopal, Sridharan; Balasubramanian, Gopalan; Narayanan, Shridhar</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-78</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epigenetic modifications represent a promising new approach to modulate cell functions as obsd. in autoimmune diseases.  Emerging evidence suggests the utility of HDAC inhibitors in the treatment of chronic immune and inflammatory disorders.  However, class and isoform selective inhibition of HDAC is currently favored as it limits the toxicity that was obsd. with pan-HDAC inhibitors.  HDAC6, a member of the HDAC family, whose major substrate is α-tubulin, is being increasingly implicated in the pathogenesis of inflammatory disorders.  The present study was carried out to study the potential anti-inflammatory and anti-rheumatic effects of HDAC6 selective inhibitor Tubastatin.  Tubastatin, a potent human HDAC6 inhibitor with an IC50 of 11 nM showed significant inhibition of TNF-α and IL-6 in LPS stimulated human THP-1 macrophages with an IC50 of 272 nM and 712 nM, resp.  Addnl., Tubastatin inhibited NO secretion in murine Raw 264.7 macrophages dose dependently with an IC50 of 4.2 μM and induced α-tubulin hyperacetylation corresponding to HDAC6 inhibition in THP-1 cells without affecting the cell viability.  Tubastatin showed significant inhibition of paw vol. at 30 mg/kg i.p. in a Freund's complete adjuvant (FCA) induced animal model of inflammation.  The disease modifying activity of Tubastatin was also evident in collagen induced arthritis DBA1 mouse model at 30 mg/kg i.p.  The significant attenuation of clin. scores (∼ 70%) by Tubastatin was confirmed histopathol. and was found comparable to dexamethasone (∼ 90% inhibition of clin. scores).  Tubastatin showed significant inhibition of IL-6 in paw tissues of arthritic mice.  The present work has demonstrated anti-inflammatory and antirheumatic effects of a selective HDAC6 inhibitor Tubastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVjF7tHATlYbVg90H21EOLACvtfcHk0lgdeROvuRT9YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D&md5=1810b101113330405d3923cbadb628b7</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2013.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2013.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DL.%2BR.%26aulast%3DMuley%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DShastry%26aufirst%3DA.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DKulathingal%26aufirst%3DJ.%26aulast%3DVijaykanth%26aufirst%3DG.%26aulast%3DRaghul%26aufirst%3DJ.%26aulast%3DRajesh%26aufirst%3DN.%26aulast%3DRathinasamy%26aufirst%3DS.%26aulast%3DKachhadia%26aufirst%3DV.%26aulast%3DKilambi%26aufirst%3DN.%26aulast%3DRajgopal%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DG.%26aulast%3DNarayanan%26aufirst%3DS.%26atitle%3DTubastatin%252C%2520a%2520selective%2520histone%2520deacetylase%25206%2520inhibitor%2520shows%2520anti-inflammatory%2520and%2520anti-rheumatic%2520effects%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2013%26volume%3D16%26spage%3D72%26epage%3D78%26doi%3D10.1016%2Fj.intimp.2013.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Estiu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwiatkowski, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span> </span><span class="NLM_article-title">Structural origin of selectivity in class II-selective histone deacetylase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2898</span><span class="NLM_x">–</span> <span class="NLM_lpage">2906</span><span class="refDoi"> DOI: 10.1021/jm7015254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7015254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1OgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2898-2906&author=G.+Estiuauthor=E.+Greenbergauthor=C.+B.+Harrisonauthor=N.+P.+Kwiatkowskiauthor=R.+Mazitschekauthor=J.+E.+Bradnerauthor=O.+Wiest&title=Structural+origin+of+selectivity+in+class+II-selective+histone+deacetylase+inhibitors&doi=10.1021%2Fjm7015254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors</span></div><div class="casAuthors">Estiu, Guillermina; Greenberg, Edward; Harrison, Christopher B.; Kwiatkowski, Nicholas P.; Mazitschek, Ralph; Bradner, James E.; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2898-2906</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of class- and isoform-selective histone deacetylase (HDAC) inhibitors is highly desirable for the study of the complex interactions of these proteins central to transcription regulation as well as for the development of selective HDAC inhibitors as drugs in epigenetics.  To provide a structural basis for the rational design of such inhibitors, a combined computational and exptl. study of inhibition of three different histone deacetylase isoforms, HDAC1, -6, and -8, with three different hydroxamate inhibitors is reported.  While SAHA was found to be unselective for the inhibition of class I and class II HDACs, the other inhibitors were found to be selective toward class II HDACs.  Mol. dynamics simulations indicate that this selectivity is caused by both the overall shape of the protein surface leading to the active site and specific interactions of an aspartate residue in a polar loop and two phenylalanines and a methionine in a nonpolar loop.  Monitoring the specific interactions as a function of the simulation time identifies a key sulfur-π interaction.  The implications of the structural motifs for the design of class II-selective HDAC inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo72HMKgUIVlbVg90H21EOLACvtfcHk0lgdeROvuRT9YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1OgurY%253D&md5=1d40feba51520076866d6bf60555a952</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm7015254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7015254%26sid%3Dliteratum%253Aachs%26aulast%3DEstiu%26aufirst%3DG.%26aulast%3DGreenberg%26aufirst%3DE.%26aulast%3DHarrison%26aufirst%3DC.%2BB.%26aulast%3DKwiatkowski%26aufirst%3DN.%2BP.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DStructural%2520origin%2520of%2520selectivity%2520in%2520class%2520II-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2898%26epage%3D2906%26doi%3D10.1021%2Fjm7015254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule–kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%80%93kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgdeROvuRT9YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2580%2593kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piñeiro, R.</span><span> </span><span class="NLM_article-title">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span> <span class="citation_source-journal">J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1007/s00109-015-1352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs00109-015-1352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=26658520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=5-11&author=B.+Vanhaesebroeckauthor=M.+A.+Whiteheadauthor=R.+Pi%C3%B1eiro&title=Molecules+in+medicine+mini-review%3A+isoforms+of+PI3K+in+biology+and+disease&doi=10.1007%2Fs00109-015-1352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Whitehead, Maria A.; Pineiro, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiol. and disease.  In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease.  Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the etiol. and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders.  The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development.  In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies.  The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5USj-Hs5rVg90H21EOLACvtfcHk0lgFlvxbGcu9BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE&md5=7b78f2b78ddeed390ab133c562ec6725</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2Fs00109-015-1352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-015-1352-5%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DM.%2BA.%26aulast%3DPi%25C3%25B1eiro%26aufirst%3DR.%26atitle%3DMolecules%2520in%2520medicine%2520mini-review%253A%2520isoforms%2520of%2520PI3K%2520in%2520biology%2520and%2520disease%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2016%26volume%3D94%26spage%3D5%26epage%3D11%26doi%3D10.1007%2Fs00109-015-1352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgFlvxbGcu9BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Hurwitz, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uppal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendell, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pipas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainberg, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manges, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R. S.</span><span> </span><span class="NLM_article-title">Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">4039</span><span class="NLM_x">–</span> <span class="NLM_lpage">4047</span><span class="refDoi"> DOI: 10.1200/JCO.2015.61.4578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1200%2FJCO.2015.61.4578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=26351344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SqtbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=4039-4047&author=H.+I.+Hurwitzauthor=N.+Uppalauthor=S.+A.+Wagnerauthor=J.+C.+Bendellauthor=J.+T.+Beckauthor=S.+M.+Wadeauthor=J.+J.+Nemunaitisauthor=P.+J.+Stellaauthor=J.+M.+Pipasauthor=Z.+A.+Wainbergauthor=R.+Mangesauthor=W.+M.+Garrettauthor=D.+S.+Hunterauthor=J.+Clarkauthor=L.+Leopoldauthor=V.+Sandorauthor=R.+S.+Levy&title=Randomized%2C+double-blind%2C+phase+II+study+of+ruxolitinib+or+placebo+in+combination+with+capecitabine+in+patients+with+metastatic+pancreatic+cancer+for+whom+therapy+with+gemcitabine+has+failed&doi=10.1200%2FJCO.2015.61.4578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed</span></div><div class="casAuthors">Hurwitz, Herbert I.; Uppal, Nikhil; Wagner, Stephanie A.; Bendell, Johanna C.; Beck, J. Thaddeus; Wade, Seaborn M., III; Nemunaitis, John J.; Stella, Philip J.; Pipas, J. Marc; Wainberg, Zev A.; Manges, Robert; Garrett, William M.; Hunter, Deborah S.; Clark, Jason; Leopold, Lance; Sandor, Victor; Levy, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4039-4047</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options.  Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clin. course of pancreatic cancer.  Patients and Methods: In this double-blind, phase II study, patients with metastatic pancreatic cancer who had experienced treatment failure with gemcitabine were randomly assigned 1:1 to the JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m2 twice daily) or placebo plus capecitabine.  The primary end point was overall survival (OS); secondary end points included progression-free survival, clin. benefit response, objective response rate, and safety.  Prespecified subgroup analyses evaluated treatment heterogeneity and efficacy in patients with evidence of inflammation.  Results: In the intent-to-treat population (ruxolitinib, n = 64; placebo, n = 63), the hazard ratio was 0.79 (95% CI, 0.53 to 1.18; P = .25) for OS and was 0.75 (95% CI, 0.52 to 1.10; P = .14) for progression-free survival.  In a prespecified subgroup anal. of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011).  Prolonged survival in this subgroup was supported by post hoc analyses of OS that categorized patients by the modified Glasgow Prognostic Score, a systemic inflammation-based prognostic system.  Grade 3 or greater adverse events were obsd. with similar frequency in the ruxolitinib (74.6%) and placebo (81.7%) groups.  Grade 3 or greater anemia was more frequent with ruxolitinib (15.3%; placebo, 1.7%).  Conclusion: Ruxolitinib plus capecitabine was generally well tolerated and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEiprZROUgWbVg90H21EOLACvtfcHk0lgFlvxbGcu9BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SqtbrL&md5=511197949263e459564efdcde24074a8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.61.4578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.61.4578%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%2BI.%26aulast%3DUppal%26aufirst%3DN.%26aulast%3DWagner%26aufirst%3DS.%2BA.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DWade%26aufirst%3DS.%2BM.%26aulast%3DNemunaitis%26aufirst%3DJ.%2BJ.%26aulast%3DStella%26aufirst%3DP.%2BJ.%26aulast%3DPipas%26aufirst%3DJ.%2BM.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DManges%26aufirst%3DR.%26aulast%3DGarrett%26aufirst%3DW.%2BM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DSandor%26aufirst%3DV.%26aulast%3DLevy%26aufirst%3DR.%2BS.%26atitle%3DRandomized%252C%2520double-blind%252C%2520phase%2520II%2520study%2520of%2520ruxolitinib%2520or%2520placebo%2520in%2520combination%2520with%2520capecitabine%2520in%2520patients%2520with%2520metastatic%2520pancreatic%2520cancer%2520for%2520whom%2520therapy%2520with%2520gemcitabine%2520has%2520failed%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D4039%26epage%3D4047%26doi%3D10.1200%2FJCO.2015.61.4578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span> </span><span class="NLM_article-title">Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis</span>. ClinicalTrials.gov; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://clinicaltrials.gov/ct2/show/NCT01433445" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01433445</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Panobinostat+and+Ruxolitinib+in+Primary+Myelofibrosis%2C+Post-polycythemia+Vera-myelofibrosis+or+Post-essential+Thrombocythemia-myelofibrosis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2011%3B+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01433445+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DPanobinostat%2520and%2520Ruxolitinib%2520in%2520Primary%2520Myelofibrosis%252C%2520Post-polycythemia%2520Vera-myelofibrosis%2520or%2520Post-essential%2520Thrombocythemia-myelofibrosis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Yi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.-D.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1705</span><span class="refDoi"> DOI: 10.1016/j.bcp.2007.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.bcp.2007.10.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2008&pages=1697-1705&author=X.+Yiauthor=W.+Weiauthor=S.-Y.+Wangauthor=Z.-Y.+Duauthor=Y.-J.+Xuauthor=X.-D.+Yu&title=Histone+deacetylase+inhibitor+SAHA+induces+ER%CE%B1+degradation+in+breast+cancer+MCF-7+cells+by+CHIP-mediated+ubiquitin+pathway+and+inhibits+survival+signaling&doi=10.1016%2Fj.bcp.2007.10.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2007.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2007.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DDu%26aufirst%3DZ.-Y.%26aulast%3DXu%26aufirst%3DY.-J.%26aulast%3DYu%26aufirst%3DX.-D.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520SAHA%2520induces%2520ER%25CE%25B1%2520degradation%2520in%2520breast%2520cancer%2520MCF-7%2520cells%2520by%2520CHIP-mediated%2520ubiquitin%2520pathway%2520and%2520inhibits%2520survival%2520signaling%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D75%26spage%3D1697%26epage%3D1705%26doi%3D10.1016%2Fj.bcp.2007.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Carlisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauricella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anneo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttitta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fiore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vento, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesoriere, G.</span><span> </span><span class="NLM_article-title">The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">230</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">–</span> <span class="NLM_lpage">1289</span><span class="refDoi"> DOI: 10.1002/jcp.24863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fjcp.24863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25370819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlSktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=2015&pages=1276-1289&author=D.+Carlisiauthor=M.+Lauricellaauthor=A.+D%E2%80%99Anneoauthor=G.+Buttittaauthor=S.+Emanueleauthor=R.+Di+Fioreauthor=R.+Martinezauthor=C.+Rolfoauthor=R.+Ventoauthor=G.+Tesoriere&title=The+synergistic+effect+of+SAHA+and+parthenolide+in+MDA-MB231+breast+cancer+cells&doi=10.1002%2Fjcp.24863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells</span></div><div class="casAuthors">Carlisi, Daniela; Lauricella, Marianna; D'Anneo, Antonella; Buttitta, Giuseppina; Emanuele, Sonia; di Fiore, Riccardo; Martinez, Roberta; Rolfo, Christian; Vento, Renza; Tesoriere, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1276-1289</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The sesquiterpene lactone Parthenolide (PN) exerted a cytotoxic effect on MDA-MB231 cells, a triple-neg. breast cancer (TNBC) cell line, but its effectiveness was scarce when employed at low doses.  This represents an obstacle for a therapeutic utilization of PN.  In order to overcome this difficulty we assocd. to PN the suberoylanilide hydroxamic acid (SAHA), an histone deacetylase inhibitor.  Our results show that SAHA synergistically sensitized MDA-MB231 cells to the cytotoxic effect of PN.  It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity.  However, when the cells were treated with SAHA/PN combination, SAHA suppressed PN effect on Akt/mTOR/Nrf2 pathway, while PN reduced the prosurvival autophagic activity of SAHA.  In addn. SAHA/PN combination induced GSH depletion, fall in Δψm, release of cytochrome c, activation of caspase 3 and apoptosis.  Finally we demonstrated that combined treatment maintained both hyperacetylation of histones H3 and H4 induced by SAHA and down-regulation of DNMT1 expression induced by PN.  Inhibition of the DNA-binding activity of NF-kB, which is detd. by PN, was also obsd. after combined treatment.  In conclusion, combination of PN to SAHA inhibits the cytoprotective responses induced by the single compds., but does not alter the mechanisms leading to the cytotoxic effects.  Taken together our results suggest that this combination could be a candidate for TNBC therapy.  J. Cell. Physiol. 230: 1276-1289, 2015. cpr 2014 Wiley Periodicals, Inc., A Wiley Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18XJZ3XcvvLVg90H21EOLACvtfcHk0ljgE6HQPNiJhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlSktrs%253D&md5=75b3687a0fb68b712e2459aa4f853338</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fjcp.24863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.24863%26sid%3Dliteratum%253Aachs%26aulast%3DCarlisi%26aufirst%3DD.%26aulast%3DLauricella%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Anneo%26aufirst%3DA.%26aulast%3DButtitta%26aufirst%3DG.%26aulast%3DEmanuele%26aufirst%3DS.%26aulast%3DDi%2BFiore%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DVento%26aufirst%3DR.%26aulast%3DTesoriere%26aufirst%3DG.%26atitle%3DThe%2520synergistic%2520effect%2520of%2520SAHA%2520and%2520parthenolide%2520in%2520MDA-MB231%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2015%26volume%3D230%26spage%3D1276%26epage%3D1289%26doi%3D10.1002%2Fjcp.24863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lye, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span> </span><span class="NLM_article-title">Discovery of (2 E)-3-{2-butyl-1-[2-(diethylamino) ethyl]-1 H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4694</span><span class="NLM_x">–</span> <span class="NLM_lpage">4720</span><span class="refDoi"> DOI: 10.1021/jm2003552</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003552" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4694-4720&author=H.+Wangauthor=N.+Yuauthor=D.+Chenauthor=K.+C.+L.+Leeauthor=P.+L.+Lyeauthor=J.+W.+W.+Changauthor=W.+Dengauthor=M.+C.+Y.+Ngauthor=T.+Luauthor=M.+L.+Khooauthor=A.+Poulsenauthor=K.+Sangthongpitagauthor=X.+Wuauthor=C.+Huauthor=K.+C.+Gohauthor=X.+Wangauthor=L.+Fangauthor=K.+L.+Gohauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=P.+Yeoauthor=X.+Liuauthor=Z.+Bondayauthor=J.+M.+Woodauthor=B.+W.+Dymockauthor=E.+Kantharajauthor=E.+T.+Sun&title=Discovery+of+%282+E%29-3-%7B2-butyl-1-%5B2-%28diethylamino%29+ethyl%5D-1+H-benzimidazol-5-yl%7D-N-hydroxyacrylamide+%28SB939%29%2C+an+orally+active+histone+deacetylase+inhibitor+with+a+superior+preclinical+profile&doi=10.1021%2Fjm2003552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm2003552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003552%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BL.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DM.%2BC.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DKhoo%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DK.%2BL.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DKantharaj%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DDiscovery%2520of%2520%25282%2520E%2529-3-%257B2-butyl-1-%255B2-%2528diethylamino%2529%2520ethyl%255D-1%2520H-benzimidazol-5-yl%257D-N-hydroxyacrylamide%2520%2528SB939%2529%252C%2520an%2520orally%2520active%2520histone%2520deacetylase%2520inhibitor%2520with%2520a%2520superior%2520preclinical%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4694%26epage%3D4720%26doi%3D10.1021%2Fjm2003552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Ehrentraut, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherr, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geffers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prochorec-Sobieszek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketterling, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, R. A. F.</span><span> </span><span class="NLM_article-title">t (8; 9)(p22; p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e53767</span><span class="refDoi"> DOI: 10.1371/journal.pone.0053767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1371%2Fjournal.pone.0053767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e53767&author=S.+Ehrentrautauthor=S.+Nagelauthor=M.+E.+Scherrauthor=B.+Schneiderauthor=H.+Quentmeierauthor=R.+Geffersauthor=M.+Kaufmannauthor=C.+Meyerauthor=M.+Prochorec-Sobieszekauthor=R.+P.+Ketterlingauthor=R.+A.+Knudsonauthor=A.+L.+Feldmanauthor=M.+E.+Kadinauthor=H.+G.+Drexlerauthor=R.+A.+F.+MacLeod&title=t+%288%3B+9%29%28p22%3B+p24%29%2FPCM1-JAK2+Activates+SOCS2+and+SOCS3+via+STAT5&doi=10.1371%2Fjournal.pone.0053767"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0053767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0053767%26sid%3Dliteratum%253Aachs%26aulast%3DEhrentraut%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DS.%26aulast%3DScherr%26aufirst%3DM.%2BE.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DGeffers%26aufirst%3DR.%26aulast%3DKaufmann%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DProchorec-Sobieszek%26aufirst%3DM.%26aulast%3DKetterling%26aufirst%3DR.%2BP.%26aulast%3DKnudson%26aufirst%3DR.%2BA.%26aulast%3DFeldman%26aufirst%3DA.%2BL.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26aulast%3DMacLeod%26aufirst%3DR.%2BA.%2BF.%26atitle%3Dt%2520%25288%253B%25209%2529%2528p22%253B%2520p24%2529%252FPCM1-JAK2%2520Activates%2520SOCS2%2520and%2520SOCS3%2520via%2520STAT5%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De53767%26doi%3D10.1371%2Fjournal.pone.0053767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Katagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonezawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuyama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, T.</span><span> </span><span class="NLM_article-title">Two distinct human myeloma cell lines originating from one patient with myeloma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1002/ijc.2910360217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fijc.2910360217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=3926660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADyaL2M3mtVWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1985&pages=241-246&author=S.+Katagiriauthor=T.+Yonezawaauthor=J.+Kuyamaauthor=Y.+Kanayamaauthor=T.+Tamakiauthor=M.+Ohnishiauthor=S.+Taruiauthor=K.+Nishidaauthor=T.+Abe&title=Two+distinct+human+myeloma+cell+lines+originating+from+one+patient+with+myeloma&doi=10.1002%2Fijc.2910360217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Two distinct human myeloma cell lines originating from one patient with myeloma</span></div><div class="casAuthors">Katagiri S; Yonezawa T; Kuyama J; Kanayama Y; Nishida K; Abe T; Tamaki T; Ohnishi M; Tarui S</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-6</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Two distinct cell lines (OPM-1 and OPM-2) were established from the peripheral blood of a 56-year-old female myeloma patient at the stage of terminal leukemic evolution associated with loss of cytoplasmic immunoglobulin heavy chain (G lambda----lambda).  The lines grew in suspension with a doubling time of 36-42 hr and 30-36 hr, respectively.  EBNA was absent from both lines.  The lines synthesized cytoplasmic lambda-chain, but had no detectable surface immunoglobulins.  Fc receptors and complement receptors could not be detected in either line.  The lines had very complex chromosomal abnormalities, but the patterns of chromosomes differed greatly between the two lines.  The two lines, together with the RPMI 8226 line established by Matsuoka et al. (1967), were analyzed for phenotypic expression as defined by a panel of monoclonal antibodies to B cells (B1, BA-1, BA-2, BA-3, OKIa-1 and OKT10/BMA0100).  Neither OPM-1 nor OPM-2 reacted with any of the antibodies tested except OKT10.  OPM-1 cells reacted weakly (less than 30%) with OKT10/BMA0100, while OPM-2 cells showed a fluctuating reactivity, ranging from 40 to 80%, with OKT10/BMA0100.  In contrast, RPMI 8226 reacted strongly with OKT10 and BA-2.  These results demonstrate the presence of phenotypic heterogeneity in all 3 myeloma cell lines, suggesting that the lines might represent different stages of terminal B-cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_-dVNKy-ESisZ1x6zOs0vfW6udTcc2ebJFdBraNb0ALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3mtVWnsw%253D%253D&md5=bf38cf9b35f120a08ab881db395c8f30</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910360217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910360217%26sid%3Dliteratum%253Aachs%26aulast%3DKatagiri%26aufirst%3DS.%26aulast%3DYonezawa%26aufirst%3DT.%26aulast%3DKuyama%26aufirst%3DJ.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DTamaki%26aufirst%3DT.%26aulast%3DOhnishi%26aufirst%3DM.%26aulast%3DTarui%26aufirst%3DS.%26aulast%3DNishida%26aufirst%3DK.%26aulast%3DAbe%26aufirst%3DT.%26atitle%3DTwo%2520distinct%2520human%2520myeloma%2520cell%2520lines%2520originating%2520from%2520one%2520patient%2520with%2520myeloma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1985%26volume%3D36%26spage%3D241%26epage%3D246%26doi%3D10.1002%2Fijc.2910360217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Otsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yawata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, O.</span><span> </span><span class="NLM_article-title">Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=11039672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADC%252BD3cvovVOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2000&pages=216-222&author=T.+Otsukiauthor=H.+Hataauthor=N.+Haradaauthor=H.+Matsuzakiauthor=K.+Yataauthor=H.+Wadaauthor=Y.+Yawataauthor=A.+Uekiauthor=O.+Yamada&title=Cellular+biological+differences+between+human+myeloma+cell+lines+KMS-12-PE+and+KMS-12-BM+established+from+a+single+patient"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient</span></div><div class="casAuthors">Otsuki T; Hata H; Harada N; Matsuzaki H; Yata K; Wada H; Yawata Y; Ueki A; Yamada O</div><div class="citationInfo"><span class="NLM_cas:title">International journal of hematology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-22</span>
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    </div><div class="casAbstract">To clarify cellular biological varieties of myeloma cells, biological differences were analyzed between 2 human myeloma cell lines, KMS-12-PE and KMS-12-BM, derived from pleural effusion and bone marrow, respectively, of a single patient.  Although both lines were considered to be derived from the same clone because both had the same chromosomal marker and immunoglobulin H rearrangement, several biological differences were noted.  CD11a and CD20 were highly expressed in the KMS-12-BM line, whereas the KMS-12-PE line showed a higher expression of CD7 and CD95/Fas.  Although growth was stimulated in KMS-12-BM by interleukin-6 and interferon-alpha, it was inhibited in KMS-12-PE.  In addition, apoptosis inhibitors Bcl-2 and Bcl-X(L) were highly expressed in KMS-12-BM cells.  Because KMS-12-PE was cultivated 2 months before KMS-12-BM, these differences might be related to their origin (pleural effusion and bone marrow) or the phases of disease progression.  However, these biological differences may help clarify myeloma cell biology and lead to improvement in treatment for myeloma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQogaV4rmgZP77NkxioyDXTfW6udTcc2ebJFdBraNb0ALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvovVOhsQ%253D%253D&md5=8514330f8dc5be81ede8dd777ba4bbe8</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuki%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DH.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DMatsuzaki%26aufirst%3DH.%26aulast%3DYata%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DYawata%26aufirst%3DY.%26aulast%3DUeki%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DO.%26atitle%3DCellular%2520biological%2520differences%2520between%2520human%2520myeloma%2520cell%2520lines%2520KMS-12-PE%2520and%2520KMS-12-BM%2520established%2520from%2520a%2520single%2520patient%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2000%26volume%3D72%26spage%3D216%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Matsuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uphoff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishizaki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omoto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, K.</span><span> </span><span class="NLM_article-title">Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins (11; 9)(q23; p22p23)</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1477</span><span class="refDoi"> DOI: 10.1038/sj.leu.2400768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fsj.leu.2400768" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=1469-1477&author=Y.+Matsuoauthor=R.+MacLeodauthor=C.+Uphoffauthor=H.+Drexlerauthor=C.+Nishizakiauthor=Y.+Katayamaauthor=G.+Kimuraauthor=N.+Fujiiauthor=E.+Omotoauthor=M.+Haradaauthor=K.+Orita&title=Two+acute+monocytic+leukemia+%28AML-M5a%29+cell+lines+%28MOLM-13+and+MOLM-14%29+with+interclonal+phenotypic+heterogeneity+showing+MLL-AF9+fusion+resulting+from+an+occult+chromosome+insertion%2C+ins+%2811%3B+9%29%28q23%3B+p22p23%29&doi=10.1038%2Fsj.leu.2400768"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2400768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2400768%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DY.%26aulast%3DMacLeod%26aufirst%3DR.%26aulast%3DUphoff%26aufirst%3DC.%26aulast%3DDrexler%26aufirst%3DH.%26aulast%3DNishizaki%26aufirst%3DC.%26aulast%3DKatayama%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DG.%26aulast%3DFujii%26aufirst%3DN.%26aulast%3DOmoto%26aufirst%3DE.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DOrita%26aufirst%3DK.%26atitle%3DTwo%2520acute%2520monocytic%2520leukemia%2520%2528AML-M5a%2529%2520cell%2520lines%2520%2528MOLM-13%2520and%2520MOLM-14%2529%2520with%2520interclonal%2520phenotypic%2520heterogeneity%2520showing%2520MLL-AF9%2520fusion%2520resulting%2520from%2520an%2520occult%2520chromosome%2520insertion%252C%2520ins%2520%252811%253B%25209%2529%2528q23%253B%2520p22p23%2529%26jtitle%3DLeukemia%26date%3D1997%26volume%3D11%26spage%3D1469%26epage%3D1477%26doi%3D10.1038%2Fsj.leu.2400768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Koeffler, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golde, D. W.</span><span> </span><span class="NLM_article-title">Human myeloid leukemia cell lines: a review</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1980&pages=344-350&author=H.+P.+Koefflerauthor=D.+W.+Golde&title=Human+myeloid+leukemia+cell+lines%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DGolde%26aufirst%3DD.%2BW.%26atitle%3DHuman%2520myeloid%2520leukemia%2520cell%2520lines%253A%2520a%2520review%26jtitle%3DBlood%26date%3D1980%26volume%3D56%26spage%3D344%26epage%3D350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Iqbal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deLeeuw, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinkebiel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybkaer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, I. F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span> </span><span class="NLM_article-title">Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1139</span><span class="NLM_x">–</span> <span class="NLM_lpage">1151</span><span class="refDoi"> DOI: 10.1038/leu.2009.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fleu.2009.3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1139-1151&author=J.+Iqbalauthor=C.+Kucukauthor=R.+J.+deLeeuwauthor=G.+Srivastavaauthor=W.+Tamauthor=H.+Gengauthor=D.+Klinkebielauthor=J.+Christmanauthor=K.+Patelauthor=K.+Caoauthor=L.+Shenauthor=K.+Dybkaerauthor=I.+F.+L.+Tsuiauthor=H.+Aliauthor=N.+Shimizuauthor=W.+Y.+Auauthor=W.+L.+Lamauthor=W.+C.+Chan&title=Genomic+analyses+reveal+global+functional+alterations+that+promote+tumor+growth+and+novel+tumor+suppressor+genes+in+natural+killer-cell+malignancies&doi=10.1038%2Fleu.2009.3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fleu.2009.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2009.3%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DKucuk%26aufirst%3DC.%26aulast%3DdeLeeuw%26aufirst%3DR.%2BJ.%26aulast%3DSrivastava%26aufirst%3DG.%26aulast%3DTam%26aufirst%3DW.%26aulast%3DGeng%26aufirst%3DH.%26aulast%3DKlinkebiel%26aufirst%3DD.%26aulast%3DChristman%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DDybkaer%26aufirst%3DK.%26aulast%3DTsui%26aufirst%3DI.%2BF.%2BL.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DAu%26aufirst%3DW.%2BY.%26aulast%3DLam%26aufirst%3DW.%2BL.%26aulast%3DChan%26aufirst%3DW.%2BC.%26atitle%3DGenomic%2520analyses%2520reveal%2520global%2520functional%2520alterations%2520that%2520promote%2520tumor%2520growth%2520and%2520novel%2520tumor%2520suppressor%2520genes%2520in%2520natural%2520killer-cell%2520malignancies%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1139%26epage%3D1151%26doi%3D10.1038%2Fleu.2009.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Chiang, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, F. C.</span><span> </span><span class="NLM_article-title">Nasal T/natural killer(NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.1002/(SICI)1097-0215(19971104)73:3<332::AID-IJC5>3.0.CO;2-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=9359478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADyaK1c%252Fit1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1997&pages=332-338&author=A.+K.+Chiangauthor=A.+C.+Chanauthor=G.+Srivastavaauthor=F.+C.+Ho&title=Nasal+T%2Fnatural+killer%28NK%29-cell+lymphomas+are+derived+from+Epstein-Barr+virus-infected+cytotoxic+lymphocytes+of+both+NK-+and+T-cell+lineage&doi=10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage</span></div><div class="casAuthors">Chiang A K; Chan A C; Srivastava G; Ho F C</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-8</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">The cellular nature of nasal T/natural killer (NK)-cell lymphomas (NLs) remains controversial.  It is still debatable whether these represent T-cell lymphomas with extensive loss of surface antigens or are, in fact, true NK-cell lymphomas.  They are associated closely with Epstein-Barr virus (EBV), to the extent that EBV-encoded small non-polyadenylated RNAs (EBER) expression can be used as a marker for the neoplastic cells.  The cell lineage of this group of lymphomas was examined further by correlating immunophenotype, genotype and EBV status with the expression of cytotoxic granule-associated proteins, perforin and T-cell intracellular antigen-1 (TIA-1) in 13 cases of NL.  Combined immunophenotypic and gene rearrangement analyses demonstrated that NLs can be identified clearly as either NK-cell or T-cell tumours.  Nasal NK-cell lymphomas lacked clonal rearrangement of both T-cell receptor (TCR) gamma and immunogloulin heavy chain (IgH) genes and were either CD3(Leu4)-CD56+ (8 cases) or CD3(Leu4)+CD56+ (2 cases), whereas nasal T-cell lymphomas had rearranged TCRgamma and germ-line IgH genes and were either CD3(Leu4)+CD56+ (2 cases) or CD3(Leu4)+CD56- (1 case).  Immunohistochemical (IH) studies showed that both perforin and TIA-1 were expressed universally in NL, irrespective of NK- or T-cell lineage.  Dual labelling of TIA-1 by IH and EBER by in situ hybridisation demonstrated that the granule proteins were expressed predominantly by the EBER+ tumour cells.  Our results indicate that NLs are derived from EBV-infected cytotoxic lymphocytes of both NK- and T-cell lineage.  We postulate that cytotoxic lymphocytes generated during the cellular immune response to EBV infection or re-activation at the nasal region themselves may become targets for EBV infection and subsequent transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS18risIAukEZVVjGoY74BafW6udTcc2eZd7LcFwG2P5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252Fit1CgtA%253D%253D&md5=f403d44b3a14894f9b93d389c60bc52c</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819971104%252973%253A3%253C332%253A%253AAID-IJC5%253E3.0.CO%253B2-0%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DA.%2BK.%26aulast%3DChan%26aufirst%3DA.%2BC.%26aulast%3DSrivastava%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DF.%2BC.%26atitle%3DNasal%2520T%252Fnatural%2520killer%2528NK%2529-cell%2520lymphomas%2520are%2520derived%2520from%2520Epstein-Barr%2520virus-infected%2520cytotoxic%2520lymphocytes%2520of%2520both%2520NK-%2520and%2520T-cell%2520lineage%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1997%26volume%3D73%26spage%3D332%26epage%3D338%26doi%3D10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Karube, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span> </span><span class="NLM_article-title">Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1016/j.canlet.2012.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.canlet.2012.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23348693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2013&pages=47-55&author=K.+Karubeauthor=S.+Tsuzukiauthor=N.+Yoshidaauthor=K.+Aritaauthor=H.+Katoauthor=M.+Katayamaauthor=Y.-H.+Koauthor=K.+Ohshimaauthor=S.+Nakamuraauthor=T.+Kinoshitaauthor=M.+Seto&title=Comprehensive+gene+expression+profiles+of+NK+cell+neoplasms+identify+vorinostat+as+an+effective+drug+candidate&doi=10.1016%2Fj.canlet.2012.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate</span></div><div class="casAuthors">Karube, Kennosuke; Tsuzuki, Shinobu; Yoshida, Noriaki; Arita, Kotaro; Kato, Harumi; Katayama, Miyuki; Ko, Young-Hyeh; Ohshima, Koichi; Nakamura, Shigeo; Kinoshita, Tomohiro; Seto, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-55</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NK cell neoplasms are lymphoid malignancies with an aggressive clin. course.  In the present study, we analyzed gene expression profiling of NK cell neoplasms and attempted to identify important mol. pathways and new effective drugs.  Pathway anal. of gene expression profiles suggested the important roles of the JAK-STAT pathway, NF-κB pathway or Wnt pathways in NK cell neoplasms.  Notably, western blot anal. revealed that STAT3 was expressed and phosphorylated at a higher level in NK cell lines than in normal NK cells or other cell lines.  These findings indicate the occurrence of JAK-STAT activation in NK cell neoplasms.  Connectivity Map (CMAP) anal. of gene expression profiles identified candidate drugs against NK cell neoplasms.  Among the drugs suggested by CMAP anal., we focused on puromycin, phenoxybenzamine, LY294002, wortmannin, vorinostat and trichostatin A because they exhibited high enrichment scores.  We added these drugs to NK cell lines and other cell lines.  Among the drugs, vorinostat suppressed NK cell line proliferation at a significantly lower concn. compared to other cell lines.  Suppression of the JAK-STAT pathway appeared to contribute to this effect.  Vorinostat may be a good candidate for use in the therapy against NK cell neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ_s6uHdODnrVg90H21EOLACvtfcHk0lj8hLaCO5JCjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFChsr8%253D&md5=ea546451e7b17cd81b43bf8a14bd1466</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DKarube%26aufirst%3DK.%26aulast%3DTsuzuki%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DN.%26aulast%3DArita%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DKatayama%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.-H.%26aulast%3DOhshima%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26atitle%3DComprehensive%2520gene%2520expression%2520profiles%2520of%2520NK%2520cell%2520neoplasms%2520identify%2520vorinostat%2520as%2520an%2520effective%2520drug%2520candidate%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D333%26spage%3D47%26epage%3D55%26doi%3D10.1016%2Fj.canlet.2012.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">West, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">New and emerging HDAC inhibitors for cancer treatment</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+HDAC+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0lgcEZrC5ec31A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520HDAC%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Hubbert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardiola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T.-P.</span><span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span><span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.-F.+Wangauthor=T.-P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0lgcEZrC5ec31A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Kerr, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyllie, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, A. R.</span><span> </span><span class="NLM_article-title">Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1038/bjc.1972.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fbjc.1972.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=4561027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADyaE3s%252FgsFSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1972&pages=239-257&author=J.+F.+Kerrauthor=A.+H.+Wyllieauthor=A.+R.+Currie&title=Apoptosis%3A+a+basic+biological+phenomenon+with+wide-ranging+implications+in+tissue+kinetics&doi=10.1038%2Fbjc.1972.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics</span></div><div class="casAuthors">Kerr J F; Wyllie A H; Currie A R</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-57</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">The term apoptosis is proposed for a hitherto little recognized mechanism of controlled cell deletion, which appears to play a complementary but opposite role to mitosis in the regulation of animal cell populations.  Its morphological features suggest that it is an active, inherently programmed phenomenon, and it has been shown that it can be initiated or inhibited by a variety of environmental stimuli, both physiological and pathological.The structural changes take place in two discrete stages.  The first comprises nuclear and cytoplasmic condensation and breaking up of the cell into a number of membrane-bound, ultrastructurally well-preserved fragments.  In the second stage these apoptotic bodies are shed from epithelial-lined surfaces or are taken up by other cells, where they undergo a series of changes resembling in vitro autolysis within phagosomes, and are rapidly degraded by lysosomal enzymes derived from the ingesting cells.Apoptosis seems to be involved in cell turnover in many healthy adult tissues and is responsible for focal elimination of cells during normal embryonic development.  It occurs spontaneously in untreated malignant neoplasms, and participates in at least some types of therapeutically induced tumour regression.  It is implicated in both physiological involution and atrophy of various tissues and organs.  It can also be triggered by noxious agents, both in the embryo and adult animal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNWEBcjRkVZzW1zwg2yUK5fW6udTcc2eZv9fQkP_PPebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3s%252FgsFSksw%253D%253D&md5=60211d4b22f18156fa64206b2cad983d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1972.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1972.33%26sid%3Dliteratum%253Aachs%26aulast%3DKerr%26aufirst%3DJ.%2BF.%26aulast%3DWyllie%26aufirst%3DA.%2BH.%26aulast%3DCurrie%26aufirst%3DA.%2BR.%26atitle%3DApoptosis%253A%2520a%2520basic%2520biological%2520phenomenon%2520with%2520wide-ranging%2520implications%2520in%2520tissue%2520kinetics%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1972%26volume%3D26%26spage%3D239%26epage%3D257%26doi%3D10.1038%2Fbjc.1972.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Vermes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffens-Nakken, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reutellingsperger, C.</span><span> </span><span class="NLM_article-title">A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V</span> <span class="citation_source-journal">J. Immunol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/0022-1759(95)00072-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2F0022-1759%2895%2900072-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=7622868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Ojsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1995&pages=39-51&author=I.+Vermesauthor=C.+Haanenauthor=H.+Steffens-Nakkenauthor=C.+Reutellingsperger&title=A+novel+assay+for+apoptosis.+Flow+cytometric+detection+of+phosphatidylserine+expression+on+early+apoptotic+cells+using+fluorescein+labelled+Annexin+V&doi=10.1016%2F0022-1759%2895%2900072-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V</span></div><div class="casAuthors">Vermes, Istvan; Haanen, Clemens; Steffens-Nakken, Helga; Reutelingsperger, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunological Methods</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">JIMMBG</span>;
        ISSN:<span class="NLM_cas:issn">0022-1759</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In the early stages of apoptosis changes occur at the cell surface, which until now have remained difficult to recognize.  One of these plasma membrane alterations is the translocation of phosphatidylserine (PS) from the inner side of the plasma membrane to the outer layer, by which PS becomes exposed at the external surface of the cell.  Annexin V is a Ca2+ dependent phospholipid-binding protein with high affinity for PS.  Hence this protein can be used as a sensitive probe for PS exposure upon the cell membrane.  Translocation of PS to the external cell surface is not unique to apoptosis, but occurs also during cell necrosis.  The difference between these two forms of cell death is that during the initial stages of apoptosis the cell membrane remains intact, while at the very moment that necrosis occurs the cell membrane looses its integrity and becomes leaky.  Therefore the measurement of Annexin V binding to the cell surface as indicative for apoptosis has to be performed in conjunction with a dye exclusion test to establish integrity of the cell membrane.  This paper describes the results of such an assay, as obtained in cultured HSB-2 cells, rendered apoptotic by irradn. and in human lymphocytes, following dexamethasone treatment.  Untreated and treated cells were evaluated for apoptosis by light microscopy, by measuring the amt. of hypo-diploid cells using of DNA flow cytometry (FCM) and by DNA electrophoresis to establish whether or not DNA fragmentation had occurred.  Annexin V binding was assessed using bivariate FCM, and cell staining was evaluated with fluorescein isothiocyanate (FITC)-labeled Annexin V (green fluorescence), simultaneously with dye exclusion of propidium iodide (PI) (neg. for red fluorescence).  The test described, discriminates intact cells (FITC-/PI-), apoptotic cells (FITC+/PI-) and necrotic cells (FITC+/PI+).  In comparison with existing traditional tests the Annexin V assay is sensitive and easy to perform.  The Annexin V assay offers the possibility of detecting early phases of apoptosis before the loss of cell membrane integrity and permits measurements of the kinetics of apoptotic death in relation to the cell cycle.  More extensive FCM will allow discrimination between different cell subpopulations, that may or may not be involved in the apoptotic process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEhoGurJoWT7Vg90H21EOLACvtfcHk0lh7ZML3LNAVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Ojsbo%253D&md5=7931d2e5a8dcf54dafb73e3aa5dc22d9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2F0022-1759%2895%2900072-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-1759%252895%252900072-I%26sid%3Dliteratum%253Aachs%26aulast%3DVermes%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DC.%26aulast%3DSteffens-Nakken%26aufirst%3DH.%26aulast%3DReutellingsperger%26aufirst%3DC.%26atitle%3DA%2520novel%2520assay%2520for%2520apoptosis.%2520Flow%2520cytometric%2520detection%2520of%2520phosphatidylserine%2520expression%2520on%2520early%2520apoptotic%2520cells%2520using%2520fluorescein%2520labelled%2520Annexin%2520V%26jtitle%3DJ.%2520Immunol.%2520Methods%26date%3D1995%26volume%3D184%26spage%3D39%26epage%3D51%26doi%3D10.1016%2F0022-1759%2895%2900072-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">D’Amours, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallmann, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3771</span><span class="NLM_x">–</span> <span class="NLM_lpage">3778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=11707529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=3771-3778&author=D.+D%E2%80%99Amoursauthor=F.+R.+Sallmannauthor=V.+M.+Dixitauthor=G.+G.+Poirier&title=Gain-of-function+of+poly%28ADP-ribose%29+polymerase-1+upon+cleavage+by+apoptotic+proteases%3A+implications+for+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span></div><div class="casAuthors">D'Amours, Damien; Sallmann, Frederic R.; Dixit, Vishva M.; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3771-3778</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribosyl)ation is an important mechanism for the maintenance of genomic integrity in response to DNA damage.  The enzyme responsible for poly(ADP-ribose) synthesis, poly(ADP-ribose) polymerase 1 (PARP-1), has been implicated in two distinct modes of cell death induced by DNA damage, namely apoptosis and necrosis.  During the execution phase of apoptosis, PARP-1 is specifically proteolyzed by caspases to produce an N-terminal DNA-binding domain (DBD) and a C-terminal catalytic fragment.  The functional consequence of this proteolytic event is not known.  However, it has recently been shown that overactivation of full-length PARP-1 can result in energy depletion and necrosis in dying cells.  Here, the authors investigate the mol. basis for the differential involvement of PARP-1 in these two types of cellular demise.  The authors show that the C-terminal apoptotic fragment of PARP-1 loses its DNA-dependent catalytic activity upon cleavage with caspase 3.  However, the N-terminal apoptotic fragment, retains a strong DNA-binding activity and totally inhibits the catalytic activity of uncleaved PARP-1.  This dominant-neg. behavior was confirmed and extended in cellular exts. where DNA repair was completely inhibited by nanomolar concns. of the N-terminal fragment.  Furthermore, overexpression of the apoptotic DBD in mouse fibroblast inhibits endogenous PARP-1 activity very efficiently in vivo, thereby confirming the authors' biochem. observations.  Taken together, these expts. indicate that the apoptotic DBD of PARP-1 acts cooperatively with the proteolytic inactivation of the enzyme to trans-inhibit NAD hydrolysis and to maintain the energy levels of the cell.  These results are consistent with a model in which cleavage of PARP-1 promotes apoptosis by preventing DNA repair-induced survival and by blocking energy depletion-induced necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouW9f4pYihjrVg90H21EOLACvtfcHk0lh7ZML3LNAVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D&md5=18622ce2e1abc4ca30c3d3e92d471b6f</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DD.%26aulast%3DSallmann%26aufirst%3DF.%2BR.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DGain-of-function%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520upon%2520cleavage%2520by%2520apoptotic%2520proteases%253A%2520implications%2520for%2520apoptosis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D3771%26epage%3D3778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Danial, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsmeyer, S. J.</span><span> </span><span class="NLM_article-title">Cell death: critical control points</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00046-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0092-8674%2804%2900046-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=14744432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=205-219&author=N.+N.+Danialauthor=S.+J.+Korsmeyer&title=Cell+death%3A+critical+control+points&doi=10.1016%2FS0092-8674%2804%2900046-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death: Critical control points</span></div><div class="casAuthors">Danial, Nika N.; Korsmeyer, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-219</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review and discussion.  Programmed cell death (apoptosis) is a distinct genetic and biochem. pathway essential to metazoans.  An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis.  Apoptosis has proven to be tightly interwoven with other essential cell pathways.  The identification of crit. control points in the cell death pathway has yielded fundamental insights for basic biol., as well as provided rational targets for new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfuRt2EjV6WLVg90H21EOLACvtfcHk0lh7ZML3LNAVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D&md5=de853177ac091305b7f237e58108f579</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900046-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900046-7%26sid%3Dliteratum%253Aachs%26aulast%3DDanial%26aufirst%3DN.%2BN.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26atitle%3DCell%2520death%253A%2520critical%2520control%2520points%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D205%26epage%3D219%26doi%3D10.1016%2FS0092-8674%2804%2900046-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span>Glide, <span class="NLM_edition">version 6.5</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+6.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2014%3B+http%3A%2F%2Fwww.schrodinger.com+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Polak, E.; Ribiere, G.</span><span> </span><span class="NLM_article-title">Note sur la convergence de méthodes de directions conjuguées</span>. In  <span class="citation_source-journal">ESAIM: Mathematical Modelling and Numerical Analysis—Modélisation Mathématique et Analyse Numérique</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">; </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1969&pages=35-43&author=E.+Polak&author=G.+Ribiere&title=Note+sur+la+convergence+de+m%C3%A9thodes+de+directions+conjugu%C3%A9es"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolak%26aufirst%3DE.%26atitle%3DNote%2520sur%2520la%2520convergence%2520de%2520m%25C3%25A9thodes%2520de%2520directions%2520conjugu%25C3%25A9es%26jtitle%3DESAIM%253A%2520Mathematical%2520Modelling%2520and%2520Numerical%2520Analysis%25E2%2580%2594Mod%25C3%25A9lisation%2520Math%25C3%25A9matique%2520et%2520Analyse%2520Num%25C3%25A9rique%26date%3D1969%26volume%3D3%26spage%3D35%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Methodol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/0898-5529(88)90015-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms&doi=10.1016%2F0898-5529%2888%2990015-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0lgzoSEz_9m2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Methodol.%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116%26doi%3D10.1016%2F0898-5529%2888%2990015-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Lobera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlhaus, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, Q. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trocha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trump, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, G. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmann&title=Selective+class+IIa+histone+deacetylase+inhibition+via+a+nonchelating+zinc-binding+group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0lgzoSEz_9m2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26atitle%3DSelective%2520class%2520IIa%2520histone%2520deacetylase%2520inhibition%2520via%2520a%2520nonchelating%2520zinc-binding%2520group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+assay+of+kinase+catalytic+activity+reveals+features+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lgzoSEz_9m2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520assay%2520of%2520kinase%2520catalytic%2520activity%2520reveals%2520features%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Chen, P.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, F.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, I.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang-Yen, H.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, J.</span><span> </span><span class="NLM_article-title">Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3611</span><span class="NLM_x">–</span> <span class="NLM_lpage">3626</span><span class="refDoi"> DOI: 10.4161/cc.21920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.4161%2Fcc.21920" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=3611-3626&author=P.-H.+Chenauthor=F.-C.+Chienauthor=S.-P.+Leeauthor=W.-E.+Chanauthor=I.-H.+Linauthor=C.-S.+Liuauthor=F.-J.+Leeauthor=J.-S.+Laiauthor=P.+Chenauthor=H.-F.+Yang-Yenauthor=J.+Yen&title=Identification+of+a+novel+function+of+the+clathrin-coated+structure+at+the+plasma+membrane+in+facilitating+GM-CSF+receptor-mediated+activation+of+JAK2&doi=10.4161%2Fcc.21920"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.4161%2Fcc.21920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.21920%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.-H.%26aulast%3DChien%26aufirst%3DF.-C.%26aulast%3DLee%26aufirst%3DS.-P.%26aulast%3DChan%26aufirst%3DW.-E.%26aulast%3DLin%26aufirst%3DI.-H.%26aulast%3DLiu%26aufirst%3DC.-S.%26aulast%3DLee%26aufirst%3DF.-J.%26aulast%3DLai%26aufirst%3DJ.-S.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYang-Yen%26aufirst%3DH.-F.%26aulast%3DYen%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520novel%2520function%2520of%2520the%2520clathrin-coated%2520structure%2520at%2520the%2520plasma%2520membrane%2520in%2520facilitating%2520GM-CSF%2520receptor-mediated%2520activation%2520of%2520JAK2%26jtitle%3DCell%2520Cycle%26date%3D2012%26volume%3D11%26spage%3D3611%26epage%3D3626%26doi%3D10.4161%2Fcc.21920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Kaminski, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span> </span><span class="NLM_article-title">Evaluation and reparametrization of the OPLS-AA force field for protein via comparison with accurate quantum chemical calculations on peptides</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">6474</span><span class="NLM_x">–</span> <span class="NLM_lpage">6487</span><span class="refDoi"> DOI: 10.1021/jp003919d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp003919d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2001&pages=6474-6487&author=G.+A.+Kaminskiauthor=R.+A.+Friesnerauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Evaluation+and+reparametrization+of+the+OPLS-AA+force+field+for+protein+via+comparison+with+accurate+quantum+chemical+calculations+on+peptides&doi=10.1021%2Fjp003919d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjp003919d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp003919d%26sid%3Dliteratum%253Aachs%26aulast%3DKaminski%26aufirst%3DG.%2BA.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DEvaluation%2520and%2520reparametrization%2520of%2520the%2520OPLS-AA%2520force%2520field%2520for%2520protein%2520via%2520comparison%2520with%2520accurate%2520quantum%2520chemical%2520calculations%2520on%2520peptides%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2001%26volume%3D105%26spage%3D6474%26epage%3D6487%26doi%3D10.1021%2Fjp003919d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 52 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yuhao Ren, Shanshan Li, Ren Zhu, Chengying Wan, Dongmei Song, Jiawen Zhu, Guiping Cai, Sihui Long, Lingyi Kong, <span class="NLM_string-name hlFld-ContribAuthor">Wenying Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7468-7482. <a href="https://doi.org/10.1021/acs.jmedchem.1c00136" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00136%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSTAT3%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual-Pathway%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BCancer%26aulast%3DRen%26aufirst%3DYuhao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D24012021%26date%3D27052021%26volume%3D64%26issue%3D11%26spage%3D7468%26epage%3D7482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, Alessandra Lo Bianco, Markus Schweipert, Antonio Laghezza, Fulvio Loiodice, Franz-Josef Meyer-Almes, Renato J. Aguilera, Antonio Lavecchia, <span class="NLM_string-name hlFld-ContribAuthor">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6949-6971. <a href="https://doi.org/10.1021/acs.jmedchem.1c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThiazolidinedione%252B%2525E2%252580%25259CMagic%252BBullets%2525E2%252580%25259D%252BSimultaneously%252BTargeting%252BPPAR%2525CE%2525B3%252Band%252BHDACs%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BInvestigations%252Bof%252Btheir%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntitumor%252BEffects%26aulast%3DTilekar%26aufirst%3DKalpana%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6949%26epage%3D6971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuewu Liang, Shuai Tang, Xuyi Liu, Yingluo Liu, Qifu Xu, Xiaomin Wang, Abdusaid Saidahmatov, Chunpu Li, Jiang Wang, Yu Zhou, Yingjie Zhang, Meiyu Geng, Min Huang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02111%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrrolo%25255B2%25252C3-d%25255Dpyrimidine-based%252BDerivatives%252Bas%252BPotent%252BJAK%25252FHDAC%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRefractory%252BSolid%252BTumors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2021%26date%3D2020%26date%3D07122020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, Mussa Yussuf Khamis, Yi-Han Li, Li-Ying Ma, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Min Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1362-1391. <a href="https://doi.org/10.1021/acs.jmedchem.0c01782" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01782%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BReview%252Bof%252BProgress%252Bin%252BHistone%252BDeacetylase%252B6%252BInhibitors%252BResearch%25253A%252BStructural%252BSpecificity%252Band%252BFunctional%252BDiversity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D01022021%26volume%3D64%26issue%3D3%26spage%3D1362%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Liang, Yi Zhou, Reham M. Elhassan, Xuben Hou, Xinying Yang, <span class="NLM_string-name hlFld-ContribAuthor">Hao Fang</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12083-12099. <a href="https://doi.org/10.1021/acs.jmedchem.0c01454" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01454%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHDAC%2525E2%252580%252593Bax%252BMultiple%252BLigands%252BEnhance%252BBax-Dependent%252BApoptosis%252Bin%252BHeLa%252BCells%26aulast%3DLiang%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21082020%26date%3D06102020%26volume%3D63%26issue%3D20%26spage%3D12083%26epage%3D12099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tingting Liu, Yichao Wan, Yuliang Xiao, Chengcai Xia, <span class="NLM_string-name hlFld-ContribAuthor">Guiyun Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8977-9002. <a href="https://doi.org/10.1021/acs.jmedchem.0c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-Target%252BInhibitors%252BBased%252Bon%252BHDACs%25253A%252BNovel%252BAntitumor%252BAgents%252Bfor%252BCancer%252BTherapy%26aulast%3DLiu%26aufirst%3DTingting%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D23032020%26date%3D30042020%26date%3D22042020%26volume%3D63%26issue%3D17%26spage%3D8977%26epage%3D9002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhou, Xiaoting Liu, Junxin Xue, Lulu Liu, Tao Liang, Wen Li, Xinying Yang, Xuben Hou, <span class="NLM_string-name hlFld-ContribAuthor">Hao Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4701-4715. <a href="https://doi.org/10.1021/acs.jmedchem.9b02161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02161%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPeptide%252BBoronate%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252Band%252BProteasome%252BDual%252BInhibitors%252Bfor%252BOvercoming%252BBortezomib%252BResistance%252Bof%252BMultiple%252BMyeloma%26aulast%3DZhou%26aufirst%3DYi%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24122019%26date%3D23042020%26date%3D08042020%26volume%3D63%26issue%3D9%26spage%3D4701%26epage%3D4715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yepeng Luan, Jerry Li, Jean A. Bernatchez, <span class="NLM_string-name hlFld-ContribAuthor">Rongshi Li</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3171-3183. <a href="https://doi.org/10.1021/acs.jmedchem.8b00189" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00189</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00189%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252Band%252BHistone%252BDeacetylase%252BHybrid%252BInhibitors%252Bfor%252BCancer%252BTherapy%26aulast%3DLuan%26aufirst%3DYepeng%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D16112018%26date%3D12112018%26volume%3D62%26issue%3D7%26spage%3D3171%26epage%3D3183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela De Simone, Valeria La Pietra, Nibal Betari, Nicola Petragnani, Mariarosaria Conte, Simona Daniele, Deborah Pietrobono, Claudia Martini, Sabrina Petralla, Raffaella Casadei, Lara Davani, Flavia Frabetti, Pasquale Russomanno, Ettore Novellino, Serena Montanari, Vincenzo Tumiatti, Patrizia Ballerini, Federica Sarno, Angela Nebbioso, Lucia Altucci, Barbara Monti, Vincenza Andrisano, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Milelli</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 469-474. <a href="https://doi.org/10.1021/acsmedchemlett.8b00507" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00507%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bthe%252BFirst-in-Class%252BGSK-3%2525CE%2525B2%25252FHDAC%252BDual%252BInhibitor%252Bas%252BDisease-Modifying%252BAgent%252BTo%252BCombat%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DDe%2BSimone%26aufirst%3DAngela%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D26102018%26date%3D04022019%26date%3D07022019%26date%3D04022019%26volume%3D10%26issue%3D4%26spage%3D469%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C. James Chou, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5304-5322. <a href="https://doi.org/10.1021/acs.jmedchem.8b00384" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPazopanib-Based%252BHDAC%252Band%252BVEGFR%252BDual%252BInhibitors%252BTargeting%252BCancer%252BEpigenetics%252Band%252BAngiogenesis%252BSimultaneously%26aulast%3DZang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D07062018%26date%3D22052018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongtao Li, Xiaohe Luo, Qingxiang Guo, Yongwei Nie, Tianqi Wang, Chao Zhang, Zhi Huang, Xin Wang, Yanhua Liu, Yanan Chen, Jianyu Zheng, Shengyong Yang, Yan Fan, <span class="NLM_string-name hlFld-ContribAuthor">Rong Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 3166-3192. <a href="https://doi.org/10.1021/acs.jmedchem.8b00209" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00209%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN1-%2525284-%252528%2525287-Cyclopentyl-6-%252528dimethylcarbamoyl%252529-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-2-yl%252529amino%252529phenyl%252529-N8-hydroxyoctanediamide%252Bas%252Ba%252BNovel%252BInhibitor%252BTargeting%252BCyclin-dependent%252BKinase%252B4%25252F9%252B%252528CDK4%25252F9%252529%252Band%252BHistone%252BDeacetlyase1%252B%252528HDAC1%252529%252Bagainst%252BMalignant%252BCancer%26aulast%3DLi%26aufirst%3DYongtao%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D07022018%26date%3D23032018%26date%3D08032018%26volume%3D61%26issue%3D7%26spage%3D3166%26epage%3D3192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Prachi  Singh</span>, <span class="hlFld-ContribAuthor ">Minh-Dao  Duong-Thi</span>, <span class="hlFld-ContribAuthor ">Jeannie X. T.  Lee</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8336-8357. <a href="https://doi.org/10.1021/acs.jmedchem.7b00678" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BLigand%252BEfficient%252BDual%252BInhibitors%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BBased%252Bon%252BRuxolitinib%252Band%252BVorinostat%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11052017%26date%3D10102017%26date%3D26102017%26date%3D27092017%26volume%3D60%26issue%3D20%26spage%3D8336%26epage%3D8357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Juan  Yan</span>, <span class="hlFld-ContribAuthor ">Lang  Wang</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Limin  Zeng</span>, <span class="hlFld-ContribAuthor ">Minmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenwen  Duan</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Jingchen  Cao</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Aijun  Shen</span>, and <span class="hlFld-ContribAuthor ">Youhong  Hu</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (8)
                                     , 830-834. <a href="https://doi.org/10.1021/acsmedchemlett.7b00172" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00172</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00172%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Bthe%252BFirst%252Bc-Met%25252FHDAC%252BInhibitors%252BBased%252Bon%252BPyridazinone%252BDerivatives%26aulast%3DLu%26aufirst%3DDong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22042017%26date%3D18072017%26date%3D19072017%26date%3D10082017%26date%3D18072017%26volume%3D8%26issue%3D8%26spage%3D830%26epage%3D834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Hai  Wang</span>, <span class="hlFld-ContribAuthor ">Lian  Qin</span>, <span class="hlFld-ContribAuthor ">Jie  Ren</span>, <span class="hlFld-ContribAuthor ">Qiushuang  Sun</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Yi  Zhong</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhixia  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113394. <a href="https://doi.org/10.1016/j.ejmech.2021.113394" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113394%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bimidazopyrrolopyridines%252Bderivatives%252Bas%252Bnovel%252Band%252Bselective%252Binhibitors%252Bof%252BJAK2%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2021%26volume%3D218%26spage%3D113394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eclair Venturini  Filho</span>, <span class="hlFld-ContribAuthor ">Erick M.C.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sergio  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sandro J.  Greco</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidines: Recent synthetic procedures and anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>209 </em>, 132256. <a href="https://doi.org/10.1016/j.tet.2021.132256" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132256%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAminopyrimidines%25253A%252BRecent%252Bsynthetic%252Bprocedures%252Band%252Banticancer%252Bactivities%26aulast%3DFilho%26aufirst%3DEclair%2BVenturini%26date%3D2021%26volume%3D209%26spage%3D132256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduardo  Hernández-Vázquez</span>, <span class="hlFld-ContribAuthor ">Yoarhy A.  Amador-Sánchez</span>, <span class="hlFld-ContribAuthor ">Marco A.  Cruz-Mendoza</span>, <span class="hlFld-ContribAuthor ">María T.  Ramírez-Apán</span>, <span class="hlFld-ContribAuthor ">Luis D.  Miranda</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent synthesis and anti-proliferative screening of biaryl triazole-containing cyclophanes. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127899. <a href="https://doi.org/10.1016/j.bmcl.2021.127899" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127899%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMulticomponent%252Bsynthesis%252Band%252Banti-proliferative%252Bscreening%252Bof%252Bbiaryl%252Btriazole-containing%252Bcyclophanes%26aulast%3DHern%25C3%25A1ndez-V%25C3%25A1zquez%26aufirst%3DEduardo%26date%3D2021%26volume%3D40%26spage%3D127899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David G.  Covell</span>, . </span><span class="cited-content_cbyCitation_article-title">Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , e0243336. <a href="https://doi.org/10.1371/journal.pone.0243336" title="DOI URL">https://doi.org/10.1371/journal.pone.0243336</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0243336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0243336%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DBioinformatic%252Banalysis%252Blinking%252Bgenomic%252Bdefects%252Bto%252Bchemosensitivity%252Band%252Bmechanism%252Bof%252Baction%26aulast%3DCovell%26aufirst%3DDavid%2BG.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D4%26spage%3De0243336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandria M.  Chan</span>, <span class="hlFld-ContribAuthor ">Steven  Fletcher</span>. </span><span class="cited-content_cbyCitation_article-title">Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (2)
                                     , 178-196. <a href="https://doi.org/10.1039/D0MD00286K" title="DOI URL">https://doi.org/10.1039/D0MD00286K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00286K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00286K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DShifting%252Bthe%252Bparadigm%252Bin%252Btreating%252Bmulti-factorial%252Bdiseases%25253A%252Bpolypharmacological%252Bco-inhibitors%252Bof%252BHDAC6%26aulast%3DChan%26aufirst%3DAlexandria%2BM.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D2%26spage%3D178%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaopeng  Peng</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Sun</span>, <span class="hlFld-ContribAuthor ">Peihua  Kuang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112831. <a href="https://doi.org/10.1016/j.ejmech.2020.112831" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bon%252BHDAC%252Binhibitors%252Bwith%252Bdual%252Btargeting%252Bcapabilities%252Bfor%252Bcancer%252Btreatment%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2020%26volume%3D208%26spage%3D112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Biersack</span>, <span class="hlFld-ContribAuthor ">Sibel  Polat</span>, <span class="hlFld-ContribAuthor ">Michael  Höpfner</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer properties of chimeric HDAC and kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2020,</strong> <em>184 </em><a href="https://doi.org/10.1016/j.semcancer.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAnticancer%252Bproperties%252Bof%252Bchimeric%252BHDAC%252Band%252Bkinase%252Binhibitors%26aulast%3DBiersack%26aufirst%3DBernhard%26date%3D2020%26volume%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yufeng  Xiao</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in small molecular modulators targeting histone deacetylase 6. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (4)
                                     , FDD53. <a href="https://doi.org/10.4155/fdd-2020-0023" title="DOI URL">https://doi.org/10.4155/fdd-2020-0023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0023%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DRecent%252Badvances%252Bin%252Bsmall%252Bmolecular%252Bmodulators%252Btargeting%252Bhistone%252Bdeacetylase%252B6%26aulast%3DXiao%26aufirst%3DYufeng%26date%3D2020%26volume%3D2%26issue%3D4%26spage%3DFDD53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerhard  Rogler</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of JAK inhibitors in Crohn’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2020,</strong> <em>14 </em>
                                    (Supplement_2)
                                     , S746-S754. <a href="https://doi.org/10.1093/ecco-jcc/jjz186" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjz186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjz186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjz186%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DEfficacy%252Bof%252BJAK%252Binhibitors%252Bin%252BCrohn%2525E2%252580%252599s%252BDisease%26aulast%3DRogler%26aufirst%3DGerhard%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3DSupplement_2%26spage%3DS746%26epage%3DS754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaviarasan  Lakshmanan</span>, <span class="hlFld-ContribAuthor ">Gowramma  Byran</span>, <span class="hlFld-ContribAuthor ">Manal  Mohammed</span>. </span><span class="cited-content_cbyCitation_article-title">A Brief Review on Dual Target of PARP1 and STAT3 for Cancer Therapy: A Novel Perception. </span><span class="cited-content_cbyCitation_journal-name">Current Enzyme Inhibition</span><span> <strong>2020,</strong> <em>16 </em>
                                    (2)
                                     , 115-134. <a href="https://doi.org/10.2174/1573408016666200316114209" title="DOI URL">https://doi.org/10.2174/1573408016666200316114209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573408016666200316114209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573408016666200316114209%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Enzyme%2520Inhibition%26atitle%3DA%252BBrief%252BReview%252Bon%252BDual%252BTarget%252Bof%252BPARP1%252Band%252BSTAT3%252Bfor%252BCancer%252BTherapy%25253A%252BA%252BNovel%252BPerception%26aulast%3DLakshmanan%26aufirst%3DKaviarasan%26date%3D2020%26volume%3D16%26issue%3D2%26spage%3D115%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaorui  Xie</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunfei  Wei</span>, <span class="hlFld-ContribAuthor ">Heliang  Du</span>, <span class="hlFld-ContribAuthor ">Yuanbo  Xu</span>, <span class="hlFld-ContribAuthor ">Qihao  Xu</span>, <span class="hlFld-ContribAuthor ">Yongkui  Jing</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111991. <a href="https://doi.org/10.1016/j.ejmech.2019.111991" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111991%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252B18%2525CE%2525B2-glycyrrhetinic%252Bacid%252Bconjugate%252Bwith%252BVorinostat%252Bdegrades%252BHDAC3%252Band%252BHDAC6%252Bwith%252Bimproved%252Bantitumor%252Beffects%26aulast%3DHuang%26aufirst%3DMin%26date%3D2020%26volume%3D188%26spage%3D111991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Yuqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Shouyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Lan  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-target kinase drug design: Current strategies and future directions in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 112025. <a href="https://doi.org/10.1016/j.ejmech.2019.112025" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112025%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-target%252Bkinase%252Bdrug%252Bdesign%25253A%252BCurrent%252Bstrategies%252Band%252Bfuture%252Bdirections%252Bin%252Bcancer%252Btherapy%26aulast%3DSun%26aufirst%3DDejuan%26date%3D2020%26volume%3D188%26spage%3D112025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faria  Sultana</span>, <span class="hlFld-ContribAuthor ">Kesari Lakshmi  Manasa</span>, <span class="hlFld-ContribAuthor ">Siddiq Pasha  Shaik</span>, <span class="hlFld-ContribAuthor ">Srinivasa Reddy  Bonam</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (40)
                                     , 7212-7280. <a href="https://doi.org/10.2174/0929867325666180530094120" title="DOI URL">https://doi.org/10.2174/0929867325666180530094120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180530094120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180530094120%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DZinc%252BDependent%252BHistone%252BDeacetylase%252BInhibitors%252Bin%252BCancer%252BTherapeutics%25253A%252BRecent%252BUpdate%26aulast%3DSultana%26aufirst%3DFaria%26date%3D2020%26volume%3D26%26issue%3D40%26spage%3D7212%26epage%3D7280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samir  Mehndiratta</span>, <span class="hlFld-ContribAuthor ">Mei-Hsiang  Lin</span>, <span class="hlFld-ContribAuthor ">Yi-Wen  Wu</span>, <span class="hlFld-ContribAuthor ">Chun-Han  Chen</span>, <span class="hlFld-ContribAuthor ">Tung-Yun  Wu</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiang  Chuang</span>, <span class="hlFld-ContribAuthor ">Min-Wu  Chao</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Shiow-Lin  Pan</span>, <span class="hlFld-ContribAuthor ">Mei-Chuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111725. <a href="https://doi.org/10.1016/j.ejmech.2019.111725" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111725%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-alkyl-hydroxybenzoyl%252Banilide%252Bhydroxamates%252Bas%252Bdual%252Binhibitors%252Bof%252BHDAC%252Band%252BHSP90%25252C%252Bdownregulating%252BIFN-%2525CE%2525B3%252Binduced%252BPD-L1%252Bexpression%26aulast%3DMehndiratta%26aufirst%3DSamir%26date%3D2020%26volume%3D185%26spage%3D111725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uttara  Soumyanarayanan</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Shozeb  Haider</span>, <span class="hlFld-ContribAuthor ">Adina Huey  Fang Nee</span>, <span class="hlFld-ContribAuthor ">Jie Xin  Tong</span>, <span class="hlFld-ContribAuthor ">Kevin S.W.  Tan</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>184 </em>, 111755. <a href="https://doi.org/10.1016/j.ejmech.2019.111755" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111755%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bpotent%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252B3%25252F6%252Bselective%252Bdual%252Binhibitor%26aulast%3DSoumyanarayanan%26aufirst%3DUttara%26date%3D2019%26volume%3D184%26spage%3D111755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dai</span>, <span class="hlFld-ContribAuthor ">Tian</span>, <span class="hlFld-ContribAuthor ">Li</span>, <span class="hlFld-ContribAuthor ">Shang</span>, <span class="hlFld-ContribAuthor ">Luo</span>, <span class="hlFld-ContribAuthor ">Wang</span>, <span class="hlFld-ContribAuthor ">Li</span>, <span class="hlFld-ContribAuthor ">Zhang</span>, <span class="hlFld-ContribAuthor ">Li</span>, <span class="hlFld-ContribAuthor ">Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Michael Addition Reaction Catalyzed by Imidazolium Chloride to Protect Amino Groups and Construct Medium Ring Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (23)
                                     , 4224. <a href="https://doi.org/10.3390/molecules24234224" title="DOI URL">https://doi.org/10.3390/molecules24234224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24234224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24234224%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMichael%252BAddition%252BReaction%252BCatalyzed%252Bby%252BImidazolium%252BChloride%252Bto%252BProtect%252BAmino%252BGroups%252Band%252BConstruct%252BMedium%252BRing%252BHeterocycles%26aulast%3DDai%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D23%26spage%3D4224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuewu  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (15)
                                     , 1849-1852. <a href="https://doi.org/10.4155/fmc-2019-0168" title="DOI URL">https://doi.org/10.4155/fmc-2019-0168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0168%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DNovel-targeted%252Btherapy%252Bfor%252Bhematological%252Bmalignancies%252Bwith%252BJAK%252Band%252BHDAC%252Bdual%252Binhibitors%26aulast%3DLiang%26aufirst%3DXuewu%26date%3D2019%26volume%3D11%26issue%3D15%26spage%3D1849%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 842-874. <a href="https://doi.org/10.2174/1871520619666190118120708" title="DOI URL">https://doi.org/10.2174/1871520619666190118120708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DMulti-Targeting%252BAnticancer%252BAgents%25253A%252BRational%252BApproaches%25252C%252BSynthetic%252BRoutes%252Band%252BStructure%252BActivity%252BRelationship%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D842%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feifei  Yang</span>, <span class="hlFld-ContribAuthor ">Na  Zhao</span>, <span class="hlFld-ContribAuthor ">Di  Ge</span>, <span class="hlFld-ContribAuthor ">Yihua  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Next-generation of selective histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (34)
                                     , 19571-19583. <a href="https://doi.org/10.1039/C9RA02985K" title="DOI URL">https://doi.org/10.1039/C9RA02985K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA02985K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA02985K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DNext-generation%252Bof%252Bselective%252Bhistone%252Bdeacetylase%252Binhibitors%26aulast%3DYang%26aufirst%3DFeifei%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D34%26spage%3D19571%26epage%3D19583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Stazi</span>, <span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Andrea  Mattevi</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 89-100. <a href="https://doi.org/10.1016/j.cbpa.2019.03.002" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DHistone%252Bdeacetylases%252Bas%252Ban%252Bepigenetic%252Bpillar%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhybrid%252Binhibitors%252Bin%252Bcancer%26aulast%3DStazi%26aufirst%3DGiulia%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie  Guerra</span>, <span class="hlFld-ContribAuthor ">Karen  Cichowski</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Cancer at the Intersection of Signaling and Epigenetics. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Cancer Biology</span><span> <strong>2019,</strong> <em>3 </em>
                                    (1)
                                     , 365-384. <a href="https://doi.org/10.1146/annurev-cancerbio-030617-050400" title="DOI URL">https://doi.org/10.1146/annurev-cancerbio-030617-050400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-cancerbio-030617-050400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-cancerbio-030617-050400%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Cancer%2520Biology%26atitle%3DTargeting%252BCancer%252Bat%252Bthe%252BIntersection%252Bof%252BSignaling%252Band%252BEpigenetics%26aulast%3DGuerra%26aufirst%3DStephanie%26date%3D2019%26volume%3D3%26issue%3D1%26spage%3D365%26epage%3D384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-yi  Chu-Farseeva</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 593-619. <a href="https://doi.org/10.1016/j.ejmech.2018.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpotent%252Bdual%252Binhibitors%252Bof%252BJAK2%252Band%252BHDAC%252Bbased%252Bon%252Bfusing%252Bthe%252Bpharmacophores%252Bof%252BXL019%252Band%252Bvorinostat%26aulast%3DChu-Farseeva%26aufirst%3DYu-yi%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba M.  Hesham</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (6)
                                     , 2058-2109. <a href="https://doi.org/10.1002/med.21505" title="DOI URL">https://doi.org/10.1002/med.21505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21505%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DChimeric%252BHDAC%252Binhibitors%25253A%252BComprehensive%252Breview%252Bon%252Bthe%252BHDAC-based%252Bstrategies%252Bdeveloped%252Bto%252Bcombat%252Bcancer%26aulast%3DHesham%26aufirst%3DHeba%2BM.%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D6%26spage%3D2058%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yicheng  Mei</span>, <span class="hlFld-ContribAuthor ">Baowei  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational application of drug promiscuity in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (15)
                                     , 1835-1851. <a href="https://doi.org/10.4155/fmc-2018-0018" title="DOI URL">https://doi.org/10.4155/fmc-2018-0018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0018%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bapplication%252Bof%252Bdrug%252Bpromiscuity%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DMei%26aufirst%3DYicheng%26date%3D2018%26volume%3D10%26issue%3D15%26spage%3D1835%26epage%3D1851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (15)
                                     , 2636-2640. <a href="https://doi.org/10.1016/j.bmcl.2018.06.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.06.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMerging%252Bof%252Bruxolitinib%252Band%252Bvorinostat%252Bleads%252Bto%252Bhighly%252Bpotent%252Binhibitors%252Bof%252BJAK2%252Band%252Bhistone%252Bdeacetylase%252B6%252B%252528HDAC6%252529%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2018%26volume%3D28%26issue%3D15%26spage%3D2636%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (8)
                                     , 1357-1362. <a href="https://doi.org/10.1016/j.bmcl.2018.03.009" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Btriple%252Binhibitors%252Bof%252Bjanus%252Bkinase%252B%252528JAK%252529%25252C%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Band%252BHeat%252BShock%252BProtein%252B90%252B%252528HSP90%252529%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2018%26volume%3D28%26issue%3D8%26spage%3D1357%26epage%3D1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 449-463. <a href="https://doi.org/10.1016/j.ejmech.2017.11.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploiting%252Bpolypharmacology%252Bfor%252Bimproving%252Btherapeutic%252Boutcome%252Bof%252Bkinase%252Binhibitors%252B%252528KIs%252529%25253A%252BAn%252Bupdate%252Bof%252Brecent%252Bmedicinal%252Bchemistry%252Befforts%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2018%26volume%3D143%26spage%3D449%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishani I.  Sahay</span>, <span class="hlFld-ContribAuthor ">Prasanna S.  Ghalsasi</span>, <span class="hlFld-ContribAuthor ">Mala  Singh</span>, <span class="hlFld-ContribAuthor ">Rasheedunnisa  Begum</span>. </span><span class="cited-content_cbyCitation_article-title">Revisiting aryl amidine synthesis using metal amide and/or ammonia gas: Novel molecules and their biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2017,</strong> <em>47 </em>
                                    (15)
                                     , 1400-1408. <a href="https://doi.org/10.1080/00397911.2017.1330959" title="DOI URL">https://doi.org/10.1080/00397911.2017.1330959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2017.1330959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2017.1330959%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DRevisiting%252Baryl%252Bamidine%252Bsynthesis%252Busing%252Bmetal%252Bamide%252Band%25252For%252Bammonia%252Bgas%25253A%252BNovel%252Bmolecules%252Band%252Btheir%252Bbiological%252Bevaluation%26aulast%3DSahay%26aufirst%3DIshani%2BI.%26date%3D2017%26date%3D2017%26volume%3D47%26issue%3D15%26spage%3D1400%26epage%3D1408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong-geng  Fu</span>, <span class="hlFld-ContribAuthor ">Yuan  Sun</span>, <span class="hlFld-ContribAuthor ">Wen-bing  Sheng</span>, <span class="hlFld-ContribAuthor ">Duan-fang  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 195-211. <a href="https://doi.org/10.1016/j.ejmech.2017.05.016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252Bmulti-targeted%252Bagents%25253A%252BAn%252Bemerging%252Banticancer%252Bdrug%252Bdiscovery%252Bparadigm%26aulast%3DFu%26aufirst%3DRong-geng%26date%3D2017%26volume%3D136%26spage%3D195%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of dual inhibitors, HDAC inhibitor <b>1</b> and JAK2/FLT3 inhibitor <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic showing plans for merged JAK–HDAC pharmacophore taking advantage of the solvent binding channel in JAK2 and the probable interactions to be gained by a merged inhibitor at the entrance to the HDAC substrate binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates <b>4</b>–<b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>4a</b>–<b>7a</b>, Cs<sub>2</sub>CO<sub>3</sub>, TBAI, DMF, 120 °C, 18 h, 45–82% yield; (b) <b>8a</b>, TBAI, MeCN, reflux, 72 h, 62% yield.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Intermediates <b>10</b>–<b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O (2:1), reflux, 3 h; (b) <b>10a</b>–<b>12a</b>, NMM, ClCO<sub>2</sub>Et, DCM, O °C to RT, 18 h, 59–79% (over 2 steps).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Intermediates <b>26</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, RT, 2 h; (b) SOCl<sub>2</sub>, DCM, RT, 18 h; (c) allyl alcohol, reflux, 3 h, 35% (3 steps); (d) MOMCl, NaBH<sub>4</sub>, MeOH, RT, 2 h; (e) <i>c</i>·NaOH, NEt<sub>3</sub>BnCl, allyl bromide, RT, 72 h; (f) 4 M HCl, THF, reflux, 3 h, 72% yield (3 steps); (g) NaBH<sub>4</sub>, MeOH, RT, 2 h; (h) PPh<sub>3</sub>, CCl<sub>3</sub>CN, DCM, RT, 16 h; (i) allyl alcohol, reflux, 4 h, 35% (3 steps); (j) K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux, 18 h, 84–100%; (k) <b>20</b>, Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O (2:1), reflux, 3 h; (l) TsOH.H<sub>2</sub>O, dioxane, 95 °C, 18 h, 28–62% (2 steps); (m) Grubbs II, DCM, 4 M HCl, reflux, 3 h, 62–83% yield.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Test Compounds <b>31</b>–<b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) KOTMS, THF, RT, 2 h; (b) <i>c.</i>HCl, RT, 18 h, 44 to 83% yield (2 steps); (c) HATU, NH<sub>2</sub>OTHP, NEt<sub>3</sub>, DMSO, RT, 3 d; (d) 4 M HCl in dioxane, RT, 18 h, 12–62% yield.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking of <b>51</b> into HDAC6. (A) Electrostatic surface of HDAC6 shown with blue indicating positively charged areas and red indicating negatively charged areas. The hydroxamate is bound deep in the Zn pocket, while the large macrocyclic cap forms very good surface complementarity. A pocket unique to HDAC6 is formed by Pro748 and Leu749 into which the hydrophobic linker of the macrocyle is bound. (B) Detailed interactions between <b>51</b> and HDAC6 residues Tyr782, His610, and His611 of HDAC6 form hydrogen bonds with the hydroxamate that also coordinates the catalytic Zn in a bidentate manner. Tyr782 together with Pro501 also forms part of the surface for macrocycle binding. A possible hydrogen bond between the kinase hinge-binding pyrimidine NH can be seen with the backbone carbonyl of Ser498.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docking of <b>51</b> into HDAC1. (A) Electrostatic surface of HDAC1 shown with blue indicating positively charged areas and red indicating negatively charged areas. The hydroxamate is bound in the Zn pocket, while the large macrocyclic cap is positioned on the highly solvent exposed surface. (B) Detailed interactions between <b>51</b> and HDAC1 residues Tyr303, His140, and His141 of HDAC1 form hydrogen bonds with the hydroxamate that also coordinates the catalytic Zn in a bidentate manner. There also appears to be a hydrogen bond formed between the pyrimidine NH and the backbone carbonyl of Gly27, possibly explaining the midnanomolar potency of <b>51</b> against HDAC1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking of <b>51</b> into JAK2. (A) Electrostatic surface of JAK2 shown with blue indicating positively charged areas and red indicating negatively charged areas. The macrocycle is binding in the ATP cavity with very good surface complementarity, very similar to the reported orientation of <b>2</b>.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> (B) Detailed interactions with the protein residues. The aminopyrimidine binds to the backbone of the hinge residue Leu932 with a donor–acceptor hydrogen bond arrangement. The oxygen of the macrocyclic linker of <b>51</b> makes close contacts, possibly hydrogen bonds, with both side chain hydroxyl and backbone NH of Ser936.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0025.jpeg" id="rightTab-GRAPHIC-d88e1913-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Kinase panel screening data of compound <b>51</b> against 97 kinases (DiscoveRx) tested at a concentration of 100 nM. The TREE<i>spot</i> map indicates the very high selectivity of compound <b>51</b>. From 90 nonmutated kinases only nine were hit with <35% of control binding remaining (approximately equates to an IC<sub>50</sub> of around 10 μM). “S” scores are all less than 0.1, indicating a high degree of kinase selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>51</b> effectively blocks colony formation in the erythroleukemia cell line HEL92.1.7 expressing endogenous JAK2<sup>V617F</sup>. HEL92.1.7 cells were grown in methylcellulose (ClonaCell-TCS medium) and treated with compound <b>51</b> at the respective concentrations. After 14–16 days, colonies were counted. (A) Bar graph indicating dose response based on total cell populations. Data is presented as mean ± SEM. (B) Photographs of selected colonies indicating controls (a1, a2), treatment with <b>51</b> at 0.2 μM (b1, b2), 1.0 μM (c1, c2), and 2.0 μM (d1, d2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>51</b> effectively blocks dual signaling pathways in MM and AML cell lines. (A) KMS-12-BM and (B) MOLM-14 were treated with <b>51</b> at the respective concentrations and time points. Tubastatin was used as a positive control for HDAC6 inhibition (48 h treatment). After lysis, acetylated tubulin (Ac-Tubulin) and acetylated histone 3 (Ac-H3) were detected by immunoblotting. Subsequently, as a loading control, the same membranes were reprobed with tubulin and H3, respectively. (C) KMS-12-BM and (D) MOLM-14 were pretreated with <b>51</b> for 3 h and then were treated with 10 ng/mL of IL-6 for 15 min. Compound <b>2</b> was used as a positive control for the inhibition of the JAK2 pathway in each cell line at approximately its IC<sub>50</sub> concentration (2 μM for KMS-12-BM and 0.1 μM for MOLM-14). After lysis, p-STAT3(TY705) was detected by immunoblotting. The same membranes were reprobed with STAT3 to detect total protein levels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>51</b> effectively blocks dual signaling pathways in the erythroleukemia cell line HEL92.1.7 expressing endogenous JAK2<sup>V617F</sup>. (A) HEL92.1.7 cells were treated with <b>1</b> and <b>51</b> at the respective concentrations for 1 h. After lysis, acetylated tubulin (Ac-tubulin) and acetylated histone 3 (Ac-H3) were detected by immunoblotting. Subsequently, as a loading control, the same membranes were reprobed with tubulin and H3, respectively. (B) Quantification of HDAC inhibitory responses by densitometry. (C) HEL92.1.7 cells were treated with <b>51</b> at the respective concentrations for 1 h. After lysis, p-JAK2 and p-STAT5 were detected by immunoblotting. The same membranes were reprobed with JAK2 and STAT5 to detect total protein levels. (D) Quantification of JAK inhibitory responses by densitometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound <b>51</b> triggers apoptosis in AML cell line, MOLM-14. (A) MOLM-14 cells were treated with compound <b>51</b> for 4, 24, and 48 h at the concentrations indicated and subsequently stained by annexin-V FITC and propidium iodide (PI). Fluorescence was measured via flow cytometry (LSRII), and at least 10000 events were analyzed. (B) Annexin V FITC vs propidium iodide plots from the gated cells show the populations corresponding to viable and nonapoptotic (annexin V–PI−), early (annexin V+PI−), and late (annexin V+PI+) apoptotic cells following 48 h treatment of compound <b>51</b> (for 4 and 24 h time points, see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf" class="ext-link">Supporting Information</a>) (C) MOLM-14 cells were treated with <b>51</b> at the respective concentrations and time points and then lysed. Doxorubicin (1 μM) was utilized as a positive control for induction of PARP cleavage. Cleaved PARP was detected by immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/medium/jm-2016-00157f_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Rat microsomal stability data for <b>51</b> and <b>52</b>. (A) Plot of parent remaining against time for male and female mirosomes. (B) The parameters of <i>T</i><sub>1/2</sub> and Cl<sub>int,app</sub> values (mean ± SD) for <b>51</b> and <b>52</b> (3 μM) upon incubation at 37 °C for 45 min in male (MRLM) and female (FRLM) rat liver microsomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00157/20160916/images/large/jm-2016-00157f_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00157&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02106" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02106" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 123 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Stewart, B. W.; Wild, C. P.</span> <span class="citation_source-book">World Cancer Report 2014</span>; <span class="NLM_publisher-name">World Health Organization: International Agency for Research on Cancer</span>: <span class="NLM_publisher-loc">Geneva</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+W.+Stewart&author=C.+P.+Wild&title=World+Cancer+Report+2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DB.%2BW.%26btitle%3DWorld%2520Cancer%2520Report%25202014%26pub%3DWorld%2520Health%2520Organization%253A%2520International%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerji, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Combinatorial drug therapy for cancer in the post-genomic era</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">692</span><span class="refDoi"> DOI: 10.1038/nbt.2284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt.2284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22781697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=679-692&author=B.+Al-Lazikaniauthor=U.+Banerjiauthor=P.+Workman&title=Combinatorial+drug+therapy+for+cancer+in+the+post-genomic+era&doi=10.1038%2Fnbt.2284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug therapy for cancer in the post-genomic era</span></div><div class="casAuthors">Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted.  Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups.  This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach.  However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility.  One soln. to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5IOOPfsgR7Vg90H21EOLACvtfcHk0lg-Wfo9c8DzYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFGmtLg%253D&md5=a61b1b222a7146a92366f57cb0e708ca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2284%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DCombinatorial%2520drug%2520therapy%2520for%2520cancer%2520in%2520the%2520post-genomic%2520era%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnbt.2284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">From magic bullets to designed multiple ligands</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+magic+bullets+to+designed+multiple+ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lg-Wfo9c8DzYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520magic%2520bullets%2520to%2520designed%2520multiple%2520ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C. T.</span><span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leharauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eY85H6P8gh01Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Schwartz, G. K.</span> <span class="citation_source-book">Combination Cancer Therapy: Modulators and Potentiators</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1385%2F1592598641" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=G.+K.+Schwartz&title=Combination+Cancer+Therapy%3A+Modulators+and+Potentiators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1385%2F1592598641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1385%252F1592598641%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26btitle%3DCombination%2520Cancer%2520Therapy%253A%2520Modulators%2520and%2520Potentiators%26pub%3DHumana%2520Press%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span><span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lj98IoZMownHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">O’Boyle, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meegan, M. J.</span><span> </span><span class="NLM_article-title">Designed multiple ligands for cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4722</span><span class="NLM_x">–</span> <span class="NLM_lpage">4737</span><span class="refDoi"> DOI: 10.2174/092986711797535344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.2174%2F092986711797535344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21919848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyhsLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4722-4737&author=N.+M.+O%E2%80%99Boyleauthor=M.+J.+Meegan&title=Designed+multiple+ligands+for+cancer+therapy&doi=10.2174%2F092986711797535344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands for cancer therapy</span></div><div class="casAuthors">O'Boyle, N. M.; Meegan, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">4722-4737</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of a single chem. entity with desirable activity at more than one biol. target is an attractive one.  Increasingly, multiple complex biochem. pathways are implicated in a variety of diseases including cancer.  Successful treatment of these conditions often depends on pharmaceutical intervention at multiple pathways, with a combination of different drugs.  Designed multiple ligands (DMLs) are drugs which act at multiple biomol. targets.  Numerous terms have been used to describe such ligands, including multiple-target directed ligands, heterodimers, promiscuous drugs and pan-agonists.  However, although there are many reported examples of multiple-targeting anti-cancer agents, no review of these has been presented to date.  A huge variety of biol. signalling-pathways, proteins and enzymes are currently targeted and implicated in the pathogenesis of cancer.  This review will provide an overview of reported designed multiple ligands for cancer and an exploration of the advantages and drawbacks of such compds.  The review also provides brief commentaries on the biol. processes and proteins that are currently targeted in cancer therapy and the potential for dual or triple targeting of these with designed multiple ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS2P_3Ows00bVg90H21EOLACvtfcHk0li4I3J_xub-pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyhsLnF&md5=6d9f613ed668a18663fc2369a1041341</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986711797535344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797535344%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3DDesigned%2520multiple%2520ligands%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4722%26epage%3D4737%26doi%3D10.2174%2F092986711797535344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0li4I3J_xub-pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Rodrigues, D. A.</span> <span class="citation_source-book">Drug-Drug Interactions</span>, <span class="NLM_edition">2nd</span> ed.; <span class="NLM_publisher-name">CRC Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+A.+Rodrigues&title=Drug-Drug+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26btitle%3DDrug-Drug%2520Interactions%26pub%3DCRC%2520Press%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Costantino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlocco, D.</span><span> </span><span class="NLM_article-title">Designed multiple ligands: basic research vs clinical outcomes</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3353</span><span class="NLM_x">–</span> <span class="NLM_lpage">3387</span><span class="refDoi"> DOI: 10.2174/092986712801215883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.2174%2F092986712801215883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22680630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3353-3387&author=L.+Costantinoauthor=D.+Barlocco&title=Designed+multiple+ligands%3A+basic+research+vs+clinical+outcomes&doi=10.2174%2F092986712801215883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Designed multiple ligands: basic research vs clinical outcomes</span></div><div class="casAuthors">Costantino, L.; Barlocco, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3353-3387</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. treatment of multifactorial pathologies (e.g. cancer, Alzheimer's disease, psychiatric disorders), is still a major challenge.  Many researches have been published dealing with the design of multiple ligands, able to act at the same time towards several targets relevant for a given pathol.  In the present review, the clin. results about these compds. have been reported, together with the design strategy adopted, in order to allow a crit. evaluation of the outcomes of these efforts.  What is emerging is that several effective design strategies of multitarget compds. are available, and the choice among these appears to be dependent on the therapeutic area considered.  However, at present, besides multitarget drugs discovered during optimization efforts by means of phenotypic assays, drug coadministrations or fixed dose formulations appear to be more useful therapeutic options than designed multiple ligands; this scenario will change when systems biol. will be able to select crit. targets, i.e. nodal proteins that should be inhibited in order to obtain a therapeutic action; at this point, the design of multiple ligands will allow a renaissance of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobv_P2UM6L_7Vg90H21EOLACvtfcHk0lh7VOjGhM5wHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOhtrrN&md5=82123bbafc10a19c65a0bc0c5be72546</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F092986712801215883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801215883%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DL.%26aulast%3DBarlocco%26aufirst%3DD.%26atitle%3DDesigned%2520multiple%2520ligands%253A%2520basic%2520research%2520vs%2520clinical%2520outcomes%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3353%26epage%3D3387%26doi%3D10.2174%2F092986712801215883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Peters, J.-U.</span> <span class="citation_source-book">Polypharmacology in Drug Discovery</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2F9781118098141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.-U.+Peters&title=Polypharmacology+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F9781118098141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118098141%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.-U.%26btitle%3DPolypharmacology%2520in%2520Drug%2520Discovery%26pub%3DWiley%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Peters, J. U.</span><span> </span><span class="NLM_article-title">Polypharmacology - foe or friend?</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8955</span><span class="NLM_x">–</span> <span class="NLM_lpage">8971</span><span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+foe+or+friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lh7VOjGhM5wHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520foe%2520or%2520friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0lgXB9-LM_9Hew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasco, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5032</span><span class="NLM_x">–</span> <span class="NLM_lpage">5040</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-0570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-14-0570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25107918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5032-5040&author=T.+Shimizuauthor=P.+M.+LoRussoauthor=K.+P.+Papadopoulosauthor=A.+Patnaikauthor=M.+Beeramauthor=L.+S.+Smithauthor=D.+W.+Rascoauthor=T.+A.+Maysauthor=G.+Chambersauthor=A.+Maauthor=J.+Wangauthor=R.+Laliberteauthor=M.+Voiauthor=A.+W.+Tolcher&title=Phase+I+first-in-human+study+of+CUDC-101%2C+a+multitargeted+inhibitor+of+HDACs%2C+EGFR%2C+and+HER2+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-14-0570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Shimizu, Toshio; LoRusso, Patricia M.; Papadopoulos, Kyri P.; Patnaik, Amita; Beeram, Muralidhar; Smith, Lon S.; Rasco, Drew W.; Mays, Theresa A.; Chambers, Glenda; Ma, Anna; Wang, Jing; Laliberte, Robert; Voi, Maurizio; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5032-5040</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-h i.v. (i.v.) infusion for 5 consecutive days every 2 wk.  Exptl. Design: Twenty-five patients with advanced solid tumors received escalating doses of CUDC-101 (range, 75-300 mg/m2/day) following a std. 3 + 3 dose escalation design.  Results: The MTD was detd. to be 275 mg/m2.  Common grade 1/2 adverse events included nausea, fatigue, vomiting, dyspnea, pyrexia, and dry skin.  DLTs occurred in 1 patient in the 275-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 1) and 3 patients in the 300-mg/m2 dose cohort (grade 2 serum creatinine elevation, n = 2; pericarditis, n = 1), all of which were transient and reversible.  CUDC-101 exposure increased linearly with the mean max. concn. (Cmax), clearance (CL), vol. of distribution at steady-state (Vdss), area under curve (AUC), and terminal elimination half-life (t1/2) at the MTD dose of 9.3 mg/L, 51.2 L/h, 39.6 L, 9.95 h·ng/mL and 4.4 h, resp.  Acetylated histone H3 induction was obsd. in posttreatment skin samples from 3 patients in the 275-mg/m2 dose cohort, suggesting adequate systemic exposure and target inhibition.  One patient with gastric cancer had a partial response and 6 patients had stable disease.  Conclusion: CUDC-101 administered by 1-h i.v. infusion for 5 consecutive days every 2 wk was generally well tolerated with preliminary evidence of antitumor activity.  A dose of 275 mg/m2 is recommended for further clin. testing.  Clin Cancer Res; 20(19); 5032-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUrKXLHOzT6LVg90H21EOLACvtfcHk0lgXB9-LM_9Hew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtbzP&md5=62860afa08733980f47047880e11a5ba</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-0570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-0570%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DL.%2BS.%26aulast%3DRasco%26aufirst%3DD.%2BW.%26aulast%3DMays%26aufirst%3DT.%2BA.%26aulast%3DChambers%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DPhase%2520I%2520first-in-human%2520study%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5032%26epage%3D5040%26doi%3D10.1158%2F1078-0432.CCR-14-0570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pursell, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selmi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savagner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span> </span><span class="NLM_article-title">Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1535-7163.MCT-12-1045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23536719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=925-936&author=J.+Wangauthor=N.+W.+Pursellauthor=M.+E.+Samsonauthor=R.+Atoyanauthor=A.+W.+Maauthor=A.+Selmiauthor=W.+Xuauthor=X.+Caiauthor=M.+Voiauthor=P.+Savagnerauthor=C.+J.+Lai&title=Potential+advantages+of+CUDC-101%2C+a+multitargeted+HDAC%2C+EGFR%2C+and+HER2+inhibitor%2C+in+treating+drug+resistance+and+preventing+cancer+cell+migration+and+invasion&doi=10.1158%2F1535-7163.MCT-12-1045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion</span></div><div class="casAuthors">Wang, Jing; Pursell, Natalie W.; Samson, Maria Elena S.; Atoyan, Ruzanna; Ma, Anna W.; Selmi, Abdelkader; Xu, Wanlu; Cai, Xiong; Voi, Maurizio; Savagner, Pierre; Lai, Cheng-Jung</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">925-936</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a novel, small-mol., anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2.  It is currently in phase I clin. development in patients with solid tumors.  Previously, we reported that CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models.  We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.  CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non-small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells.  Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration.  Mol Cancer Ther; 12(6); 925-36. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgzk8IJVCcT7Vg90H21EOLACvtfcHk0lj-pEmPU5MZag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVOks70%253D&md5=3d2d647e92c06c6f4c5293c6d0e1285d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPursell%26aufirst%3DN.%2BW.%26aulast%3DSamson%26aufirst%3DM.%2BE.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DSelmi%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DSavagner%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26atitle%3DPotential%2520advantages%2520of%2520CUDC-101%252C%2520a%2520multitargeted%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%252C%2520in%2520treating%2520drug%2520resistance%2520and%2520preventing%2520cancer%2520cell%2520migration%2520and%2520invasion%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D925%26epage%3D936%26doi%3D10.1158%2F1535-7163.MCT-12-1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Seo, S. Y.</span><span> </span><span class="NLM_article-title">Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery</span> <span class="citation_source-journal">Arch. Pharmacal Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span><span class="refDoi"> DOI: 10.1007/s12272-012-0221-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs12272-012-0221-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22370774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=197-200&author=S.+Y.+Seo&title=Multi-targeted+hybrids+based+on+HDAC+inhibitors+for+anti-cancer+drug+discovery&doi=10.1007%2Fs12272-012-0221-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery</span></div><div class="casAuthors">Seo, Seung-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-200</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">Multi-targeted hybrids combine two drugs in a single mol. to have greater medicinal effects than its individual components.  Recently, a no. of anti-cancer drug candidates such as CUDC-101 (Curis) have been designed based on linking properly two selected pharmacophores endowed with activity against different therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSulm2ApOOprVg90H21EOLACvtfcHk0lj-pEmPU5MZag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyns7o%253D&md5=3285f75262c7a19e05822ad48624fc05</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs12272-012-0221-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-012-0221-9%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DS.%2BY.%26atitle%3DMulti-targeted%2520hybrids%2520based%2520on%2520HDAC%2520inhibitors%2520for%2520anti-cancer%2520drug%2520discovery%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2012%26volume%3D35%26spage%3D197%26epage%3D200%26doi%3D10.1007%2Fs12272-012-0221-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2000</span><span class="NLM_x">–</span> <span class="NLM_lpage">2009</span><span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.+X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.+J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDC-101%29+as+a+potent+multi-acting+HDAC%2C+EGFR%2C+and+HER2+inhibitor+for+the+treatment+of+cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lj-pEmPU5MZag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDC-101%2529%2520as%2520a%2520potent%2520multi-acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Qian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voi, M.</span><span> </span><span class="NLM_article-title">Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4104</span><span class="NLM_x">–</span> <span class="NLM_lpage">4113</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.+J.+Laiauthor=R.+Baoauthor=D.+G.+Wangauthor=J.+Wangauthor=G.+X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.+X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+network+disruption+by+a+single+molecule+inhibitor+targeting+both+histone+deacetylase+activity+and+phosphatidylinositol+3-kinase+signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lgiyLxxXG2AfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520network%2520disruption%2520by%2520a%2520single%2520molecule%2520inhibitor%2520targeting%2520both%2520histone%2520deacetylase%2520activity%2520and%2520phosphatidylinositol%25203-kinase%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu-Farseeva, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span> </span><span class="NLM_article-title">Selective JAK inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1439</span><span class="NLM_x">–</span> <span class="NLM_lpage">1471</span><span class="refDoi"> DOI: 10.4155/fmc.14.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.4155%2Ffmc.14.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25329199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1439-1471&author=B.+W.+Dymockauthor=E.+G.+Yangauthor=Y.+Chu-Farseevaauthor=L.+Yao&title=Selective+JAK+inhibitors&doi=10.4155%2Ffmc.14.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Selective JAK inhibitors</span></div><div class="casAuthors">Dymock, Brian W.; Yang, Eugene Guorong; Chu-Farseeva, Yuyi; Yao, Lianbin</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1439-1471</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders.  Recent progress in the discovery of selective inhibitors has been significant, with selective compds. now reported for each isoform.  This article summarizes the current state-of-the-art with a discussion of the most recently described selective compds.  X-ray co-crystal structures reveal the mol. reasons for the obsd. biochem. selectivity.  A concluding anal. of JAK inhibitors in the clinic highlights increased clin. trial activity and diversity of indications.  Selective JAK inhibitors, as single agents or in combination regimens, have a very promising future in the treatment of oncol., immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6G9eFT7Ww27Vg90H21EOLACvtfcHk0lgiyLxxXG2AfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOhu7jI&md5=343aa75228918e6e4e063adb1fed96f1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.92%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DChu-Farseeva%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26atitle%3DSelective%2520JAK%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D1439%26epage%3D1471%26doi%3D10.4155%2Ffmc.14.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">See, C. S.</span><span> </span><span class="NLM_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1517/13543776.2013.765862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1517%2F13543776.2013.765862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23367873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=449-501&author=B.+W.+Dymockauthor=C.+S.+See&title=Inhibitors+of+JAK2+and+JAK3%3A+an+update+on+the+patent+literature+2010+-+2012&doi=10.1517%2F13543776.2013.765862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012</span></div><div class="casAuthors">Dymock, Brian W.; See, Cheng Shang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-501</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Janus kinases (JAKs) comprise a family of four enzymes, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), centrally implicated in cell signaling processes important in cancer and immune-inflammatory diseases.  Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.  There are many new JAK family enzyme inhibitors in the clinic now with a range of selectivity profiles.  More selective JAK2 or JAK3 compds. are now coming through in considerable nos. and this review attempts to provide an update of the recent patent literature of those new compds.  An overview is given on the diversity of core structures employed for inhibitor design showing that the vast majority of compds. are based on classic ATP-competitive kinase inhibitor heterocycles.Areas covered: This review updates new patents claiming JAK2 and/or JAK3 inhibitors published from 2010 to 2012.  Pre-2010 patents have been extensively covered in previous reviews.  Comments on the context of each chem. series are given where applicable to orient the readers on the bewildering array of mol. designs now available.  This review does not cover JAK1 or TYK2 inhibitors but mention is made of these where they occur within series of JAK2/3 inhibitors.  Given the overlap between many pharmacophores, it was not possible to completely sep. inhibitors of JAK2 from JAK3, hence the material is organized by JAK2, JAK3 and JAK2/3 and within each section by alphabetical order of the patent assignee, some companies having published five or more patents, such as Ambit (10), Incyte (9), Galapagos (7), Almirall (6) and Biocryst (5).  A total of 98 patents are reviewed herein.Expert opinion: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.  Selectivity against the four individual JAK family enzymes, JAK1, 2, 3 and TYK2, is now a key goal since they each play subtly different roles in cytokine-induced cell signaling.  The future looks bright for patients as many new drugs are being developed and now combinations of JAK inhibitors with other targeted agents are being studied in the clinic.  These advances are expected to lead to further significant progress improving patient outcomes and quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbpx3w37MTHrVg90H21EOLACvtfcHk0lhK1RvknML3pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWmtLg%253D&md5=a958c185f6c6d500ce19c04eb5665247</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DSee%26aufirst%3DC.%2BS.%26atitle%3DInhibitors%2520of%2520JAK2%2520and%2520JAK3%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202010%2520-%25202012%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D449%26epage%3D501%26doi%3D10.1517%2F13543776.2013.765862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Couedic, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raslova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennaceur-Griscelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span><span class="refDoi"> DOI: 10.1038/nature03546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnature03546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15793561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Couedicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Garconauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennaceur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signalling+causes+polycythaemia+vera&doi=10.1038%2Fnature03546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</span></div><div class="casAuthors">James, Chloe; Ugo, Valerie; Le Couedic, Jean-Pierre; Staerk, Judith; Delhommeau, Francois; Lacout, Catherine; Garcon, Loic; Raslova, Hana; Berger, Roland; Bennaceur-Griscelli, Annelise; Villeval, Jean Luc; Constantinescu, Stefan N.; Casadevall, Nicole; Vainchenker, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7037</span>),
    <span class="NLM_cas:pages">1144-1148</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative disorders are clonal hematopoietic stem cell malignancies characterized by independency or hypersensitivity of hematopoietic progenitors to numerous cytokines.  The mol. basis of most myeloproliferative disorders is unknown.  On the basis of the model of chronic myeloid leukemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases.  Polycythemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythemia diversely assocd. with thrombocytosis, leukocytosis and splenomegaly.  Polycythemia vera progenitors are hypersensitive to erythropoietin and other cytokines.  Here, the authors describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythemia vera patients.  The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model.  As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new mol. classification of these disorders and novel therapeutical approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy-6NigTwc97Vg90H21EOLACvtfcHk0lhK1RvknML3pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsF2ltbk%253D&md5=9e9c223dd4e2da2ebf52d14edda85963</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature03546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03546%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCouedic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGarcon%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennaceur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signalling%2520causes%2520polycythaemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148%26doi%3D10.1038%2Fnature03546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kralovics, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passamonti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passweg, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tichelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazzola, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoda, R. C.</span><span> </span><span class="NLM_article-title">A gain-of-function mutation of JAK2 in myeloproliferative disorders</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">1779</span><span class="NLM_x">–</span> <span class="NLM_lpage">1790</span><span class="refDoi"> DOI: 10.1056/NEJMoa051113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1056%2FNEJMoa051113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15858187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1779-1790&author=R.+Kralovicsauthor=F.+Passamontiauthor=A.+S.+Buserauthor=S.+S.+Teoauthor=R.+Tiedtauthor=J.+R.+Passwegauthor=A.+Tichelliauthor=M.+Cazzolaauthor=R.+C.+Skoda&title=A+gain-of-function+mutation+of+JAK2+in+myeloproliferative+disorders&doi=10.1056%2FNEJMoa051113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A gain-of-function mutation of JAK2 in myeloproliferative disorders</span></div><div class="casAuthors">Kralovics, Robert; Passamonti, Francesco; Buser, Andreas S.; Teo, Soon-Siong; Tiedt, Ralph; Passweg, Jakob R.; Tichelli, Andre; Cazzola, Mario; Skoda, Radek C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1779-1790</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal myeloproliferative disorders arising from a multi-potent progenitor.  The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases.  METHODS We performed microsatellite mapping of the 9pLOH region and DNA sequencing in 244 patients with myeloproliferative disorders (128 with polycythemia vera, 93 with essential thrombocythemia, and 23 with idiopathic myelofibrosis).  RESULTS Microsatellite mapping identified a 9pLOH region that included the Janus kinase 2 (JAK2) gene.  In patients with 9pLOH, JAK2 had a homozygous G→T transversion, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F).  All 51 patients with 9pLOH had the V617F mutation.  Of 193 patients without 9pLOH, 66 were heterozygous for V617F and 127 did not have the mutation.  The frequency of V617F was 65 % among patients with polycythemia vera (83 of 128), 57 % among patients with idiopathic myelofibrosis (13 of 23), and 23 % among patients with essential thrombocythemia (21 of 93).  V617F is a somatic mutation present in hematopoietic cells.  Mitotic recombination probably causes both 9pLOH and the transition from heterozygosity to homozygosity for V617F.  Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages.  Patients with the V617F mutation had a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage, and thrombosis) and treatment with cytoreductive therapy than patients with wild-type JAK2.  CONCLUSIONS A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqTe7EsB_527Vg90H21EOLACvtfcHk0lhjtgiHX7QOBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFyhsLw%253D&md5=5dd4bc090ded1c812b61923cad36e77e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051113%26sid%3Dliteratum%253Aachs%26aulast%3DKralovics%26aufirst%3DR.%26aulast%3DPassamonti%26aufirst%3DF.%26aulast%3DBuser%26aufirst%3DA.%2BS.%26aulast%3DTeo%26aufirst%3DS.%2BS.%26aulast%3DTiedt%26aufirst%3DR.%26aulast%3DPassweg%26aufirst%3DJ.%2BR.%26aulast%3DTichelli%26aufirst%3DA.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DA%2520gain-of-function%2520mutation%2520of%2520JAK2%2520in%2520myeloproliferative%2520disorders%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1779%26epage%3D1790%26doi%3D10.1056%2FNEJMoa051113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourouclas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassiliou, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bench, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, A. R.</span><span> </span><span class="NLM_article-title">Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1016/S0140-6736(05)74230-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0140-6736%2805%2974230-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erberauthor=A.+R.+Green&title=Acquired+mutation+of+the+tyrosine+kinase+JAK2+in+human+myeloproliferative+disorders&doi=10.1016%2FS0140-6736%2805%2974230-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974230-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974230-6%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26atitle%3DAcquired%2520mutation%2520of%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520human%2520myeloproliferative%2520disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061%26doi%3D10.1016%2FS0140-6736%2805%2974230-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krantz, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z. J.</span><span> </span><span class="NLM_article-title">Identification of an acquired JAK2 mutation in polycythemia vera</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">22788</span><span class="NLM_x">–</span> <span class="NLM_lpage">22792</span><span class="refDoi"> DOI: 10.1074/jbc.C500138200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1074%2Fjbc.C500138200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=22788-22792&author=R.+Zhaoauthor=S.+Xingauthor=Z.+Liauthor=X.+Fuauthor=Q.+Liauthor=S.+B.+Krantzauthor=Z.+J.+Zhao&title=Identification+of+an+acquired+JAK2+mutation+in+polycythemia+vera&doi=10.1074%2Fjbc.C500138200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C500138200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C500138200%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DXing%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DKrantz%26aufirst%3DS.%2BB.%26aulast%3DZhao%26aufirst%3DZ.%2BJ.%26atitle%3DIdentification%2520of%2520an%2520acquired%2520JAK2%2520mutation%2520in%2520polycythemia%2520vera%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D22788%26epage%3D22792%26doi%3D10.1074%2Fjbc.C500138200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiladjian, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Ali, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisslinger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalbovskaya, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuitty, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoops, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barosi, G.</span><span> </span><span class="NLM_article-title">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1056/NEJMoa1110556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1056%2FNEJMoa1110556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22375970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=787-798&author=C.+Harrisonauthor=J.+J.+Kiladjianauthor=H.+K.+Al-Aliauthor=H.+Gisslingerauthor=R.+Waltzmanauthor=V.+Stalbovskayaauthor=M.+McQuittyauthor=D.+S.+Hunterauthor=R.+Levyauthor=L.+Knoopsauthor=F.+Cervantesauthor=A.+M.+Vannucchiauthor=T.+Barbuiauthor=G.+Barosi&title=JAK+inhibition+with+ruxolitinib+versus+best+available+therapy+for+myelofibrosis&doi=10.1056%2FNEJMoa1110556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis</span></div><div class="casAuthors">Harrison, Claire; Kiladjian, Jean-Jacques; Al-Ali, Haifa Kathrin; Gisslinger, Heinz; Waltzman, Roger; Stalbovskaya, Viktoriya; McQuitty, Mari; Hunter, Deborah S.; Levy, Richard; Knoops, Laurent; Cervantes, Francisco; Vannucchi, Alessandro M.; Barbui, Tiziano; Barosi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Treatment options for myelofibrosis are limited.  We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.  METHODS: We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis to receive oral ruxolitinib or the best available therapy.  The primary end point and key secondary end point of the study were the percentage of patients with at least a 35% redn. in spleen vol. at week 48 and at week 24, resp., as assessed with the use of magnetic resonance imaging or computed tomog.  RESULTS: A total of 28% of the patients in the ruxolitinib group had at least a 35% redn. in spleen vol. at week 48, as compared with 0% in the group receiving the best available therapy (P<0.001); the corresponding percentages at week 24 were 32% and 0% (P<0.001).  At 48 wk, the mean palpable spleen length had decreased by 56% with ruxolitinib but had increased by 4% with the best available therapy.  The median duration of response with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 mo.  Patients in the ruxolitinib group had an improvement in overall quality-of-life measures and a redn. in symptoms assocd. with myelofibrosis.  The most common hematol. abnormalities of grade 3 or higher in either group were thrombocytopenia and anemia, which were managed with a dose redn., interruption of treatment, or transfusion.  One patient in each group discontinued treatment owing to thrombocytopenia, and none discontinued owing to anemia.  Nonhematol. adverse events were rare and mostly grade 1 or 2.  Two cases of acute myeloid leukemia were reported with the best available therapy.  CONCLUSIONS: Continuous ruxolitinib therapy, as compared with the best available therapy, was assocd. with marked and durable redns. in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.  An influence on overall survival has not yet been shown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP7WEm5MUTc7Vg90H21EOLACvtfcHk0lhNsh4G9Rpo-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsV2qurs%253D&md5=80494b8923fa49536383523066b22b19</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1110556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1110556%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKiladjian%26aufirst%3DJ.%2BJ.%26aulast%3DAl-Ali%26aufirst%3DH.%2BK.%26aulast%3DGisslinger%26aufirst%3DH.%26aulast%3DWaltzman%26aufirst%3DR.%26aulast%3DStalbovskaya%26aufirst%3DV.%26aulast%3DMcQuitty%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DKnoops%26aufirst%3DL.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DBarosi%26aufirst%3DG.%26atitle%3DJAK%2520inhibition%2520with%2520ruxolitinib%2520versus%2520best%2520available%2520therapy%2520for%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D787%26epage%3D798%26doi%3D10.1056%2FNEJMoa1110556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Ruxolitinib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1038/nrd3652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnrd3652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22293561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=103-104&author=R.+A.+Mesaauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Ruxolitinib&doi=10.1038%2Fnrd3652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib</span></div><div class="casAuthors">Mesa, Ruben A.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-104</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Nov. 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-mol. inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf2yAGCsbIA7Vg90H21EOLACvtfcHk0lhNsh4G9Rpo-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Crtbs%253D&md5=5bcfbd15f4478268330ffc4c8855762d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd3652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3652%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DRuxolitinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D103%26epage%3D104%26doi%3D10.1038%2Fnrd3652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lgtrkGne1WPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span><span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0lgtrkGne1WPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amalini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. W.</span><span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1751</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span><span class="refDoi"> DOI: 10.1038/leu.2011.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fleu.2011.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21691275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1751-1759&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=C.+Y.+Huauthor=H.+Hentzeauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=Y.+K.+Lohauthor=L.+C.+Ongauthor=A.+D.+Williamauthor=A.+Leeauthor=A.+Poulsenauthor=R.+Jayaramanauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=B.+W.+Dymockauthor=J.+W.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies&doi=10.1038%2Fleu.2011.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span></div><div class="casAuthors">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A. D.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ong, K. H.; Ethirajulu, K.; Dymock, B. W.; Wood, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1751-1759</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 n for JAK2WT and JAK2V617F, resp.) within the JAK family (IC50=1280, 520 and 50 n for JAK1, JK3 and TYK2, resp.) and fms-like tyrosine kinase-3 (FLT3; IC50=22 n).  SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs.  As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.  SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2V617F-driven disease model.  SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a s.c. model generated with SET-2 cells derived from a JAK2V617F patient with megakaryoblastic leukemia.  Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease.  In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models.  These favorable properties are now being confirmed in clin. studies in patients with myelofibrosis and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOG8Fk52CR87Vg90H21EOLACvtfcHk0lgtrkGne1WPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGqu7bL&md5=ae5a5ae0efaaa8f51909e8c82c84610d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.148%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHu%26aufirst%3DC.%2BY.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DWood%26aufirst%3DJ.%2BW.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011%26volume%3D25%26spage%3D1751%26epage%3D1759%26doi%3D10.1038%2Fleu.2011.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Padrnos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis</span> <span class="citation_source-journal">Expert Opin. Orphan Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">733</span><span class="refDoi"> DOI: 10.1517/21678707.2014.927761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1517%2F21678707.2014.927761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKhs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=725-733&author=L.+Padrnosauthor=R.+A.+Mesa&title=A+closer+look+at+pacritinib%3A+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+myelofibrosis&doi=10.1517%2F21678707.2014.927761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A closer look at : a JAK2/FLT3 inhibitor for the treatment of myelofibrosis</span></div><div class="casAuthors">Padrnos, Leslie; Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Orphan Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">725-733</span>CODEN:
                <span class="NLM_cas:coden">EOODAJ</span>;
        ISSN:<span class="NLM_cas:issn">2167-8707</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Myelofibrosis (MF) is a chronic myeloid neoplasm that bears a significant symptom burden, impacts on quality of life and carries a risk of transformation to acute leukemia.  Advances in MF therapy by inhibition of Janus kinase type 2 (JAK2) receptor have shown clin. improvements in spleen size and symptom burden, but are often limited by hematol. side effects.  Areas covered: Treatment for patients with MF who are not suitable candidates for allogeneic stem cell transplant is limited and, historically, palliative in intent.  The approval of ruxolitinib, a JAK2 inhibitor, has enabled clin. improvement in these individuals.  In this paper, treatments for MF are briefly reviewed, including historically palliative therapies and the clin. data leading to ruxolitinib approval.  This JAK2 therapy is limited by cytopenias, either due to the disease process or a medication side effect.  Finally, the preclin. and clin. data of use in MF and other hematol. conditions are evaluated.  Expert opinion: Ruxolitinib use in patients with MF who are deemed to be inappropriate transplant candidates can be limited by cytopenias, particularly thrombocytopenia.  This demonstrates an unmet therapeutic need in patients with MF.  Pacritinib, SB1518, a dual JAK2 and FMS-like tyrosine kinase 3 inhibitor has been suggested to provide clin. benefit to patients with MF without producing adverse hematol. events that restrict ruxolitinib utility.  If ongoing phase 3 trials of pacritinib are pos., based on efficacy to improve splenomegaly and constitutional symptoms with a tolerable adverse event profile, pacritinib may provide a much needed oral therapeutic option for patients with MF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvl1lEpppHo7Vg90H21EOLACvtfcHk0ljgEhcc3tk6Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKhs77N&md5=95456c875deb0a52b36823877e2bcac5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F21678707.2014.927761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F21678707.2014.927761%26sid%3Dliteratum%253Aachs%26aulast%3DPadrnos%26aufirst%3DL.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DA%2520closer%2520look%2520at%2520pacritinib%253A%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2014%26volume%3D2%26spage%3D725%26epage%3D733%26doi%3D10.1517%2F21678707.2014.927761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span> </span><span class="NLM_article-title">Oral pacritinib versus best available therapy to treat myelofibrosis with thrombocytopenia (PAC326)</span>. ClinicalTrials.gov; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="https://www.clinicaltrials.gov/ct2/show/NCT02055781?term=pacritinib&amp;rank=2" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT02055781?term=pacritinib&rank=2</a> (accessed April10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+pacritinib+versus+best+available+therapy+to+treat+myelofibrosis+with+thrombocytopenia+%28PAC326%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2014%3B+https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02055781%3Fterm%3Dpacritinib%26rank%3D2+%28accessed+April10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DOral%2520pacritinib%2520versus%2520best%2520available%2520therapy%2520to%2520treat%2520myelofibrosis%2520with%2520thrombocytopenia%2520%2528PAC326%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><div class="note"><p class="first last">CTI BioPharma initiates rolling submission of U.S. new drug application for pacritinib for the treatment of patients with myelofibrosis.</p></div><a href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&amp;p=RssLanding&amp;cat=news&amp;id=2114525" class="extLink">http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2114525</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CTI+BioPharma+initiates+rolling+submission+of+U.S.+new+drug+application+for+pacritinib+for+the+treatment+of+patients+with+myelofibrosis.http%3A%2F%2Finvestors.ctibiopharma.com%2Fphoenix.zhtml%3Fc%3D92775%26p%3DRssLanding%26cat%3Dnews%26id%3D2114525+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Koppikar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilpivaara, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hricik, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullally, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Wahab, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marubayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">489</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1038/nature11303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnature11303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22820254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=489&publication_year=2012&pages=155-159&author=P.+Koppikarauthor=N.+Bhagwatauthor=O.+Kilpivaaraauthor=T.+Manshouriauthor=M.+Adliauthor=T.+Hricikauthor=F.+Liuauthor=L.+M.+Saundersauthor=A.+Mullallyauthor=O.+Abdel-Wahabauthor=L.+Leungauthor=A.+Weinsteinauthor=S.+Marubayashiauthor=A.+Goelauthor=M.+Gonenauthor=Z.+Estrovauthor=B.+L.+Ebertauthor=G.+Chiosisauthor=S.+D.+Nimerauthor=B.+E.+Bernsteinauthor=S.+Verstovsekauthor=R.+L.+Levine&title=Heterodimeric+JAK-STAT+activation+as+a+mechanism+of+persistence+to+JAK2+inhibitor+therapy&doi=10.1038%2Fnature11303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy</span></div><div class="casAuthors">Koppikar, Priya; Bhagwat, Neha; Kilpivaara, Outi; Manshouri, Taghi; Adli, Mazhar; Hricik, Todd; Liu, Fan; Saunders, Lindsay M.; Mullally, Ann; Abdel-Wahab, Omar; Leung, Laura; Weinstein, Abby; Marubayashi, Sachie; Goel, Aviva; Goenen, Mithat; Estrov, Zeev; Ebert, Benjamin L.; Chiosis, Gabriela; Nimer, Stephen D.; Bernstein, Bradley E.; Verstovsek, Srdan; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">489</span>
        (<span class="NLM_cas:issue">7414</span>),
    <span class="NLM_cas:pages">155-159</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL) in most patients with myeloproliferative neoplasm (MPN) led to the clin. development of JAK2 kinase inhibitors.  JAK2 inhibitor therapy improves MPN-assocd. splenomegaly and systemic symptoms but does not significantly decrease or eliminate the MPN clone in most patients with MPN.  We therefore sought to characterize mechanisms by which MPN cells persist despite chronic inhibition of JAK2.  Here we show that JAK2 inhibitor persistence is assocd. with reactivation of JAK-STAT signalling and with heterodimerization between activated JAK2 and JAK1 or TYK2, consistent with activation of JAK2 intrans by other JAK kinases.  Further, this phenomenon is reversible: JAK2 inhibitor withdrawal is assocd. with resensitization to JAK2 kinase inhibitors and with reversible changes in JAK2 expression.  We saw increased JAK2 heterodimerization and sustained JAK2 activation in cell lines, in murine models and in patients treated with JAK2 inhibitors.  RNA interference and pharmacol. studies show that JAK2-inhibitor-persistent cells remain dependent on JAK2 protein expression.  Consequently, therapies that result in JAK2 degrdn. retain efficacy in persistent cells and may provide addnl. benefit to patients with JAK2-dependent malignancies treated with JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKcCqEPMbLLVg90H21EOLACvtfcHk0ljgEhcc3tk6Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt7fI&md5=3289538048859aa236965d985b2ef79f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnature11303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11303%26sid%3Dliteratum%253Aachs%26aulast%3DKoppikar%26aufirst%3DP.%26aulast%3DBhagwat%26aufirst%3DN.%26aulast%3DKilpivaara%26aufirst%3DO.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DAdli%26aufirst%3DM.%26aulast%3DHricik%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DSaunders%26aufirst%3DL.%2BM.%26aulast%3DMullally%26aufirst%3DA.%26aulast%3DAbdel-Wahab%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DWeinstein%26aufirst%3DA.%26aulast%3DMarubayashi%26aufirst%3DS.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DGonen%26aufirst%3DM.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DBernstein%26aufirst%3DB.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DHeterodimeric%2520JAK-STAT%2520activation%2520as%2520a%2520mechanism%2520of%2520persistence%2520to%2520JAK2%2520inhibitor%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D489%26spage%3D155%26epage%3D159%26doi%3D10.1038%2Fnature11303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">LaFave, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">JAK2 the future: therapeutic strategies for JAK-dependent malignancies</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">582</span><span class="refDoi"> DOI: 10.1016/j.tips.2012.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.tips.2012.08.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=574-582&author=L.+M.+LaFaveauthor=R.+L.+Levine&title=JAK2+the+future%3A+therapeutic+strategies+for+JAK-dependent+malignancies&doi=10.1016%2Fj.tips.2012.08.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DLaFave%26aufirst%3DL.%2BM.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DJAK2%2520the%2520future%253A%2520therapeutic%2520strategies%2520for%2520JAK-dependent%2520malignancies%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D574%26epage%3D582%26doi%3D10.1016%2Fj.tips.2012.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Santos, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1097/MOH.0b013e32835d8e10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1097%2FMOH.0b013e32835d8e10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23385614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=123-129&author=F.+P.+Santosauthor=S.+Verstovsek&title=What+is+next+beyond+janus+kinase+2+inhibitors+for+primary+myelofibrosis%3F&doi=10.1097%2FMOH.0b013e32835d8e10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-129</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymic inhibition is timely.  Recent findings: There are several compds. with different mechanisms of action undergoing preclin. and clin. testing in myelofibrosis.  Heat shock protein inhibitors and histone deacetylase inhibitors induce JAK2 degrdn. and downregulation of intracellular oncogenic signalling, and may overcome resistance to JAK2 inhibitors.  Reversal of bone marrow fibrosis is still a therapeutic challenge in this disease, and mAbs targeting transforming growth factor-β and lysyl oxidase like-2 may prove efficacious.  Promising compds. inhibiting signal transducer and activator of transcription 5 activity and inducing megakaryocyte polyploidization are in preclin. testing.  Summary: Although none of these new drugs have been approved for therapy of myelofibrosis, their activity is being tested in clin. trials, alone or in combination with JAK2 inhibitors.  Patients with myelofibrosis should be encouraged to participate in clin. trials testing novel compds. for this disorder, particularly if they have failed a trial of JAK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gqDFCRlvYrVg90H21EOLACvtfcHk0lhCbgYSvrQiPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1egsbs%253D&md5=49159c335e02a416c0541d8b92069f4e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e32835d8e10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e32835d8e10%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DWhat%2520is%2520next%2520beyond%2520janus%2520kinase%25202%2520inhibitors%2520for%2520primary%2520myelofibrosis%253F%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2013%26volume%3D20%26spage%3D123%26epage%3D129%26doi%3D10.1097%2FMOH.0b013e32835d8e10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Meyer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2059</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-13-0279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24583800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=2051-2059&author=S.+C.+Meyerauthor=R.+L.+Levine&title=Molecular+pathways%3A+molecular+basis+for+sensitivity+and+resistance+to+JAK+kinase+inhibitors&doi=10.1158%2F1078-0432.CCR-13-0279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors</span></div><div class="casAuthors">Meyer, Sara C.; Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2051-2059</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways.  Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK-STAT signaling is assocd. with hematol. malignancies, autoimmune disorders, and immune-deficient conditions.  Genetic alterations of JAK2 occur in the majority of patients with myeloproliferative neoplasms and occur in a subset of patients with acute leukemias.  JAK-mediated signaling critically relies on STAT transcription factors, and on activation of the MAPK and PI3K/Akt signaling axes.  Hyperactive JAK at the apex of these potent oncogenic signaling pathways therefore represents an important target for small-mol. kinase inhibitors in different disease states.  The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, resp., and addnl. ATP-competitive JAK inhibitors are in clin. development.  Although these agents show clin. activity, the ability of these JAK inhibitors to induce clin./mol. remissions in hematol. malignancies seems limited and resistance upon chronic drug exposure is seen.  Alternative modes of targeting JAK2 such as allosteric kinase inhibition or HSP90 inhibition are under evaluation, as is the use of histone deacetylase inhibitors.  Combination therapy approaches integrating inhibition of STAT, PI3K/Akt, and MAPK pathways with JAK kinase inhibitors might be crit. to overcome malignancies characterized by dysregulated JAK signaling.  Clin Cancer Res; 20(8); 2051-9. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgmYqhJDI07Vg90H21EOLACvtfcHk0lhCbgYSvrQiPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtl2ms78%253D&md5=7c7ad00b5c8020fd660d86c057827eb2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0279%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMolecular%2520pathways%253A%2520molecular%2520basis%2520for%2520sensitivity%2520and%2520resistance%2520to%2520JAK%2520kinase%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D2051%26epage%3D2059%26doi%3D10.1158%2F1078-0432.CCR-13-0279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Bartalucci, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotunno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vannucchi, A. M.</span><span> </span><span class="NLM_article-title">Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms</span> <span class="citation_source-journal">J. Cell Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1385</span><span class="NLM_x">–</span> <span class="NLM_lpage">1396</span><span class="refDoi"> DOI: 10.1111/jcmm.12162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1111%2Fjcmm.12162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24237791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFel" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1385-1396&author=N.+Bartalucciauthor=L.+Tozziauthor=C.+Boganiauthor=S.+Martinelliauthor=G.+Rotunnoauthor=J.+L.+Villevalauthor=A.+M.+Vannucchi&title=Co-targeting+the+PI3K%2FmTOR+and+JAK2+signalling+pathways+produces+synergistic+activity+against+myeloproliferative+neoplasms&doi=10.1111%2Fjcmm.12162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms</span></div><div class="casAuthors">Bartalucci, Niccolo; Tozzi, Lorenzo; Bogani, Costanza; Martinelli, Serena; Rotunno, Giada; Villeval, Jean-Luc; Vannucchi, Alessandro M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1385-1396</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aberrant JAK2 signalling plays a central role in myeloproliferative neoplasms (MPN).  JAK2 inhibitors have proven to be clin. efficacious, however, they are not mutation-specific and competent enough to suppress neoplastic clonal hematopoiesis.  We hypothesized that, by simultaneously targeting multiple activated signalling pathways, MPN could be more effectively treated.  To this end we investigated the efficacy of BEZ235, a dual PI3K/mTOR inhibitor, alone and in combination with the JAK1/JAK2 inhibitor ruxolitinib, in different preclin. models of MPN.  Single-agent BEZ235 inhibited the proliferation and induced cell cycle arrest and apoptosis of mouse and human JAK2V617F mutated cell lines at concns. significantly lower than those required to inhibit the wild-type counterpart, and preferentially prevented colony formation from JAK2V617F knock-in mice and patients' progenitor cells compared with normal ones.  Co-treatment of BEZ235 and ruxolitinib produced significant synergism in all these in-vitro models.  Co-treatment was also more effective than single drugs in reducing the extent of disease and prolonging survival of immunodeficient mice injected with JAK2V617F-mutated Ba/F3-EPOR cells and in reducing spleen size, decreasing reticulocyte count and improving spleen histopathol. in conditional JAK2V617F knock-in mice.  In conclusion, combined inhibition of PI3K/mTOR and JAK2 signalling may represent a novel therapeutic strategy in MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMZ0bIwRV_fbVg90H21EOLACvtfcHk0lhCbgYSvrQiPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFel&md5=9c57f8ab9657273f6492bea4d3e82847</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12162%26sid%3Dliteratum%253Aachs%26aulast%3DBartalucci%26aufirst%3DN.%26aulast%3DTozzi%26aufirst%3DL.%26aulast%3DBogani%26aufirst%3DC.%26aulast%3DMartinelli%26aufirst%3DS.%26aulast%3DRotunno%26aufirst%3DG.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DVannucchi%26aufirst%3DA.%2BM.%26atitle%3DCo-targeting%2520the%2520PI3K%252FmTOR%2520and%2520JAK2%2520signalling%2520pathways%2520produces%2520synergistic%2520activity%2520against%2520myeloproliferative%2520neoplasms%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1385%26epage%3D1396%26doi%3D10.1111%2Fjcmm.12162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Choong, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecquet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendharkar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaconu, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defour, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. A.</span><span> </span><span class="NLM_article-title">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span> <span class="citation_source-journal">J. Cell Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1397</span><span class="NLM_x">–</span> <span class="NLM_lpage">1409</span><span class="refDoi"> DOI: 10.1111/jcmm.12156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1111%2Fjcmm.12156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24251790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFan" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1397-1409&author=M.+L.+Choongauthor=C.+Pecquetauthor=V.+Pendharkarauthor=C.+C.+Diaconuauthor=J.+W.+Yongauthor=S.+J.+Taiauthor=S.+F.+Wangauthor=J.+P.+Defourauthor=K.+Sangthongpitagauthor=J.+L.+Villevalauthor=W.+Vainchenkerauthor=S.+N.+Constantinescuauthor=M.+A.+Lee&title=Combination+treatment+for+myeloproliferative+neoplasms+using+JAK+and+pan-class+I+PI3K+inhibitors&doi=10.1111%2Fjcmm.12156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors</span></div><div class="casAuthors">Choong, Meng Ling; Pecquet, Christian; Pendharkar, Vishal; Diaconu, Carmen C.; Yong, Jacklyn Wei Yan; Tai, Shi Jing; Wang, Si Fang; Defour, Jean-Philippe; Sangthongpitag, Kanda; Villeval, Jean-Luc; Vainchenker, William; Constantinescu, Stefan N.; Lee, May Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1397-1409</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiol. JAK2 signalling.  We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clin. trials, synergized in inhibiting growth of haematopoietic cells expressing mutant and wild-type forms of JAK2 (V617F) or thrombopoietin receptor (W515L).  Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol-3'-kinase (PI3K) inhibitor mol. showed strong synergic inhibition by Chou and Talalay anal. with JAK2 and JAK2/JAK1 inhibitors.  Other pan-class I, but not gamma or delta specific PI3K inhibitors, also synergized with JAK2 inhibitors.  Synergy was not obsd. in Bcr-Abl transformed cells.  The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen wt. in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.  It also exerted strong inhibitory effects on erythropoietin-independent erythroid colonies from MPN patients and JAK2 V617F knock-in mice, where at certain doses, a preferential inhibition of JAK2 V617F mutated progenitors was detected.  Our data support the use of a combination of JAK2 and pan-class I PI3K inhibitors in the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwYG9JAajg0rVg90H21EOLACvtfcHk0lhBd0wRMOTNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFan&md5=f2fdba575d0402f6d971b1db53d41981</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12156%26sid%3Dliteratum%253Aachs%26aulast%3DChoong%26aufirst%3DM.%2BL.%26aulast%3DPecquet%26aufirst%3DC.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DDiaconu%26aufirst%3DC.%2BC.%26aulast%3DYong%26aufirst%3DJ.%2BW.%26aulast%3DTai%26aufirst%3DS.%2BJ.%26aulast%3DWang%26aufirst%3DS.%2BF.%26aulast%3DDefour%26aufirst%3DJ.%2BP.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DVainchenker%26aufirst%3DW.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DLee%26aufirst%3DM.%2BA.%26atitle%3DCombination%2520treatment%2520for%2520myeloproliferative%2520neoplasms%2520using%2520JAK%2520and%2520pan-class%2520I%2520PI3K%2520inhibitors%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1397%26epage%3D1409%26doi%3D10.1111%2Fjcmm.12156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Waibel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralli, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidacs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virely, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sia, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bracken, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins-Underwood, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takiguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickins, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghysdael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullighan, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1047</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span><span class="refDoi"> DOI: 10.1016/j.celrep.2013.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.celrep.2013.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24268771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=1047-1059&author=M.+Waibelauthor=V.+S.+Solomonauthor=D.+A.+Knightauthor=R.+A.+Ralliauthor=S.+K.+Kimauthor=K.+M.+Banksauthor=E.+Vidacsauthor=C.+Virelyauthor=K.+C.+Siaauthor=L.+S.+Brackenauthor=R.+Collins-Underwoodauthor=C.+Drenbergauthor=L.+B.+Ramseyauthor=S.+C.+Meyerauthor=M.+Takiguchiauthor=R.+A.+Dickinsauthor=R.+Levineauthor=J.+Ghysdaelauthor=M.+A.+Dawsonauthor=R.+B.+Lockauthor=C.+G.+Mullighanauthor=R.+W.+Johnstone&title=Combined+targeting+of+JAK2+and+Bcl-2%2FBcl-xL+to+cure+mutant+JAK2-driven+malignancies+and+overcome+acquired+resistance+to+JAK2+inhibitors&doi=10.1016%2Fj.celrep.2013.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors</span></div><div class="casAuthors">Waibel, Michaela; Solomon, Vanessa S.; Knight, Deborah A.; Ralli, Rachael A.; Kim, Sang-Kyu; Banks, Kellie-Marie; Vidacs, Eva; Virely, Clemence; Sia, Keith C. S.; Bracken, Lauryn S.; Collins-Underwood, Racquel; Drenberg, Christina; Ramsey, Laura B.; Meyer, Sara C.; Takiguchi, Megumi; Dickins, Ross A.; Levine, Ross; Ghysdael, Jacques; Dawson, Mark A.; Lock, Richard B.; Mullighan, Charles G.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1047-1059</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To design rational therapies for JAK2-driven hematol. malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2.  In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathways were constitutively active, and gene expression profiling of TEL-JAK2 T-ALL cells revealed the upregulation of prosurvival Bcl-2 family genes.  Combining the Bcl-2/Bcl-xL inhibitor ABT-737 with JAK2 inhibitors mediated prolonged disease regressions and cures in mice bearing primary human and mouse JAK2 mutant tumors.  Moreover, combined targeting of JAK2 and Bcl-2/Bcl-xL was able to circumvent and overcome acquired resistance to single-agent JAK2 inhibitor treatment.  Thus, inhibiting the oncogenic JAK2 signaling network at two nodal points, at the initiating stage (JAK2) and the effector stage (Bcl-2/Bcl-xL), is highly effective and provides a clearly superior therapeutic benefit than targeting just one node.  Therefore, we have defined a potentially curative treatment for hematol. malignancies expressing constitutively active JAK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMiJQ8J0GL_7Vg90H21EOLACvtfcHk0lhBd0wRMOTNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKit7jN&md5=cd6ec40bd071fa0f811dee36bb882588</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2013.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2013.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DWaibel%26aufirst%3DM.%26aulast%3DSolomon%26aufirst%3DV.%2BS.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DRalli%26aufirst%3DR.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DBanks%26aufirst%3DK.%2BM.%26aulast%3DVidacs%26aufirst%3DE.%26aulast%3DVirely%26aufirst%3DC.%26aulast%3DSia%26aufirst%3DK.%2BC.%26aulast%3DBracken%26aufirst%3DL.%2BS.%26aulast%3DCollins-Underwood%26aufirst%3DR.%26aulast%3DDrenberg%26aufirst%3DC.%26aulast%3DRamsey%26aufirst%3DL.%2BB.%26aulast%3DMeyer%26aufirst%3DS.%2BC.%26aulast%3DTakiguchi%26aufirst%3DM.%26aulast%3DDickins%26aufirst%3DR.%2BA.%26aulast%3DLevine%26aufirst%3DR.%26aulast%3DGhysdael%26aufirst%3DJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DMullighan%26aufirst%3DC.%2BG.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DCombined%2520targeting%2520of%2520JAK2%2520and%2520Bcl-2%252FBcl-xL%2520to%2520cure%2520mutant%2520JAK2-driven%2520malignancies%2520and%2520overcome%2520acquired%2520resistance%2520to%2520JAK2%2520inhibitors%26jtitle%3DCell%2520Rep.%26date%3D2013%26volume%3D5%26spage%3D1047%26epage%3D1059%26doi%3D10.1016%2Fj.celrep.2013.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Grunstein, M.</span><span> </span><span class="NLM_article-title">Histone acetylation in chromatin structure and transcription</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">389</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1038/38664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2F38664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=9311776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=349-352&author=M.+Grunstein&title=Histone+acetylation+in+chromatin+structure+and+transcription&doi=10.1038%2F38664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Histone acetylation in chromatin structure and transcription</span></div><div class="casAuthors">Grunstein, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6649</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review with 75 refs.  The amino termini of histones extend from the nucleosomal core and are modified by acetyltransferase and deacetylases during the cell cycle.  These acetylation patterns may direct histone assembly and help regulate the unfolding and activity of genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodv2Ds8rzh-rVg90H21EOLACvtfcHk0lgGsfD3kHVIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D&md5=cdd287ff2d87e9c89944366b71aaf6d9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2F38664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F38664%26sid%3Dliteratum%253Aachs%26aulast%3DGrunstein%26aufirst%3DM.%26atitle%3DHistone%2520acetylation%2520in%2520chromatin%2520structure%2520and%2520transcription%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D349%26epage%3D352%26doi%3D10.1038%2F38664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">de Ruijter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gennip, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, H. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kuilenburg, A. B.</span><span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">749</span><span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=12429021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+de+Ruijterauthor=A.+H.+van+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+van+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases (HDACs): characterization of the classical HDAC family</span></div><div class="casAuthors">de Ruijter, Annemieke J. M.; van Gennip, Albert H.; Caron, Huib N.; Kemp, Stephan; van Kuilenburg, Andre B. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-749</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review, with refs.  Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation.  Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect.  Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones.  The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity.  SAGE (serial anal. of gene expression) data show that HDACs are generally expressed in almost all tissues investigated.  Surprisingly, no major differences were obsd. between the expression pattern in normal and malignant tissues.  However, significant variation in HDAC expression was obsd. within tissue types.  HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis.  This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN1-6ct5EQtrVg90H21EOLACvtfcHk0lgGsfD3kHVIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKiu7o%253D&md5=8a521cd3ddcf046b4b806ebf9f1476b4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRuijter%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGennip%26aufirst%3DA.%2BH.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3Dvan%2BKuilenburg%26aufirst%3DA.%2BB.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Witt, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deubzer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehme, I.</span><span> </span><span class="NLM_article-title">HDAC family: What are the cancer relevant targets?</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=HDAC+family%3A+What+are+the+cancer+relevant+targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0lgGsfD3kHVIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520family%253A%2520What%2520are%2520the%2520cancer%2520relevant%2520targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wagner, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackanson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span> </span><span class="NLM_article-title">Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</span> <span class="citation_source-journal">Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span><span class="refDoi"> DOI: 10.1007/s13148-010-0012-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs13148-010-0012-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21258646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=117-136&author=J.+M.+Wagnerauthor=B.+Hackansonauthor=M.+Lubbertauthor=M.+Jung&title=Histone+deacetylase+%28HDAC%29+inhibitors+in+recent+clinical+trials+for+cancer+therapy&doi=10.1007%2Fs13148-010-0012-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy</span></div><div class="casAuthors">Wagner, Julia M.; Hackanson, Bjoern; Luebbert, Michael; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">117-136</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7075</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heritable changes in gene expression that are not based upon alterations in the DNA sequence are defined as epigenetics.  The most common mechanisms of epigenetic regulation are the methylation of CpG islands within the DNA and the modification of amino acids in the N-terminal histone tails.  In the last years, it became evident that the onset of cancer and its progression may not occur only due to genetic mutations but also because of changes in the patterns of epigenetic modifications.  In contrast to genetic mutations, which are almost impossible to reverse, epigenetic changes are potentially reversible.  This implies that they are amenable to pharmacol. interventions.  Therefore, a lot of work in recent years has focussed on the development of small mol. enzyme inhibitors like DNA-methyltransferase inhibitors or inhibitors of histone-modifying enzymes.  These may reverse misregulated epigenetic states and be implemented in the treatment of cancer or other diseases, e.g., neurol. disorders.  Today, several epigenetic drugs are already approved by the FDA and the EMEA for cancer treatment and around ten histone deacetylase (HDAC) inhibitors are in clin. development.  This review will give an update on recent clin. trials of the HDAC inhibitors used systemically that were reported in 2009 and 2010 and will present an overview of different biomarkers to monitor the biol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62EyFQbmSEbVg90H21EOLACvtfcHk0lgGsfD3kHVIDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeqsrrF&md5=c2b02cc37f94c85c4496822b9bf13af9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs13148-010-0012-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13148-010-0012-4%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BM.%26aulast%3DHackanson%26aufirst%3DB.%26aulast%3DLubbert%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHistone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%2520in%2520recent%2520clinical%2520trials%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Epigenet.%26date%3D2010%26volume%3D1%26spage%3D117%26epage%3D136%26doi%3D10.1007%2Fs13148-010-0012-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lgb7xQSL09cjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Pazdur, R.</span> <span class="citation_source-book">FDA Approval for Romidepsin</span>; <span class="NLM_publisher-name">National Cancer Institute</span>: <span class="NLM_publisher-name">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.cancer.gov/about-cancer/treatment/drugs/fda-romidepsin" class="extLink">http://www.cancer.gov/about-cancer/treatment/drugs/fda-romidepsin</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Pazdur&title=FDA+Approval+for+Romidepsin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPazdur%26aufirst%3DR.%26btitle%3DFDA%2520Approval%2520for%2520Romidepsin%26pub%3DNational%2520Cancer%2520Institute%26pub%3DBethesda%252C%2520MD%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span>Belinostat; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm" class="extLink">http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Belinostat%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm403960.htm+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DBelinostat%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Panobinostat: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span><span class="refDoi"> DOI: 10.1007/s40265-015-0388-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs40265-015-0388-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=695-704&author=K.+P.+Garnock-Jones&title=Panobinostat%3A+first+global+approval&doi=10.1007%2Fs40265-015-0388-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0388-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0388-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DPanobinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D695%26epage%3D704%26doi%3D10.1007%2Fs40265-015-0388-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">HDAC inhibitors still need a home run, despite recent approval</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1038/nrd4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnrd4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25829268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=225-226&author=M.+Guha&title=HDAC+inhibitors+still+need+a+home+run%2C+despite+recent+approval&doi=10.1038%2Fnrd4583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors still need a home run, despite recent approval</span></div><div class="casAuthors">Guha, Malini</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-226</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A beleaguered class of epigenetic modulators continues to struggle for oncol. success, but new insights into their mechanisms in cancer may yet offer hope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdd1X74wEP7Vg90H21EOLACvtfcHk0lgb7xQSL09cjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1artLs%253D&md5=011db36451b31bc7d19e8ffab8281af8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4583%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHDAC%2520inhibitors%2520still%2520need%2520a%2520home%2520run%252C%2520despite%2520recent%2520approval%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D225%26epage%3D226%26doi%3D10.1038%2Fnrd4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Yao, T. P.; Seto, E.</span> <span class="citation_source-book">Histone Deacetylases: The Biology and Clinical Implications</span>; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2F978-3-642-21631-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+P.+Yao&author=E.+Seto&title=Histone+Deacetylases%3A+The+Biology+and+Clinical+Implications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-21631-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-642-21631-2%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DT.%2BP.%26btitle%3DHistone%2520Deacetylases%253A%2520The%2520Biology%2520and%2520Clinical%2520Implications%26pub%3DSpringer-Verlag%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Malvaez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuown, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogge, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astarabadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreiro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusche, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. A.</span><span> </span><span class="NLM_article-title">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2647</span><span class="NLM_x">–</span> <span class="NLM_lpage">2652</span><span class="refDoi"> DOI: 10.1073/pnas.1213364110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1073%2Fpnas.1213364110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23297220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2647-2652&author=M.+Malvaezauthor=S.+C.+McQuownauthor=G.+A.+Roggeauthor=M.+Astarabadiauthor=V.+Jacquesauthor=S.+Carreiroauthor=J.+R.+Ruscheauthor=M.+A.+Wood&title=HDAC3-selective+inhibitor+enhances+extinction+of+cocaine-seeking+behavior+in+a+persistent+manner&doi=10.1073%2Fpnas.1213364110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span></div><div class="casAuthors">Malvaez, Melissa; McQuown, Susan C.; Rogge, George A.; Astarabadi, Mariam; Jacques, Vincent; Carreiro, Samantha; Rusche, James R.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2647-2652, S2647/1-S2647/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement.  A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior.  Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement.  We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to neg. effects on performance or reconsolidation.  These are key distinctions with regard to any compd. being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction.  Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects.  During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens.  Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance.  These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzdD0_EQYfrVg90H21EOLACvtfcHk0li0_iYaWt71Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D&md5=37fd432cbf96bd2c30b7d5ac9eefcf45</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213364110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213364110%26sid%3Dliteratum%253Aachs%26aulast%3DMalvaez%26aufirst%3DM.%26aulast%3DMcQuown%26aufirst%3DS.%2BC.%26aulast%3DRogge%26aufirst%3DG.%2BA.%26aulast%3DAstarabadi%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DCarreiro%26aufirst%3DS.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHDAC3-selective%2520inhibitor%2520enhances%2520extinction%2520of%2520cocaine-seeking%2520behavior%2520in%2520a%2520persistent%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D2647%26epage%3D2652%26doi%3D10.1073%2Fpnas.1213364110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Decroos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christianson, D. W.</span><span> </span><span class="NLM_article-title">Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2135</span><span class="refDoi"> DOI: 10.1021/acs.biochem.5b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFWhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=2126-2135&author=C.+Decroosauthor=D.+J.+Clausenauthor=B.+E.+Hainesauthor=O.+Wiestauthor=R.+M.+Williamsauthor=D.+W.+Christianson&title=Variable+active+site+loop+conformations+accommodate+the+binding+of+macrocyclic+largazole+analogues+to+HDAC8&doi=10.1021%2Facs.biochem.5b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Variable Active Site Loop Conformations Accommodate the Binding of Macrocyclic Largazole Analogues to HDAC8</span></div><div class="casAuthors">Decroos, Christophe; Clausen, Dane J.; Haines, Brandon E.; Wiest, Olaf; Williams, Robert M.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2126-2135</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The macrocyclic depsipeptide Largazole is a potent inhibitor of metal-dependent histone deacetylases (HDACs), some of which are drug targets for cancer chemotherapy.  Indeed, Largazole partially resembles Romidepsin (FK228), a macrocyclic depsipeptide already approved for clin. use.  Each inhibitor contains a pendant side chain thiol that coordinates to the active site Zn2+ ion, as obsd. in the x-ray crystal structure of the HDAC8-Largazole complex [Cole, K. E., Dowling, D. P., Boone, M. A., Phillips, A. J., and Christianson, D. W. (2011) J. Am. Chem. Soc.133, 12474].  Here, the authors report the x-ray crystal structures of HDAC8 complexed with three synthetic analogs of Largazole in which the depsipeptide ester is replaced with a rigid amide linkage.  In two of these analogs, a six-membered pyridine ring is also substituted (with two different orientations) for the five-membered thiazole ring in the macrocycle skeleton.  The side chain thiol group of each analog coordinates to the active site Zn2+ ion with nearly ideal geometry, thereby preserving the hallmark structural feature of inhibition by Largazole.  Surprisingly, in comparison with the binding of Largazole, these analogs trigger alternative conformational changes in loops L1 and L2 flanking the active site.  However, despite these structural differences, inhibitory potency is generally comparable to, or just moderately less than, the inhibitory potency of Largazole.  Thus, this study reveals important new structure-affinity relationships for the binding of macrocyclic inhibitors to HDAC8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVqkyTC6gxrVg90H21EOLACvtfcHk0li0_iYaWt71Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFWhsrw%253D&md5=10dc284a6e017f9881be14de4bff2c03</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00010%26sid%3Dliteratum%253Aachs%26aulast%3DDecroos%26aufirst%3DC.%26aulast%3DClausen%26aufirst%3DD.%2BJ.%26aulast%3DHaines%26aufirst%3DB.%2BE.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DWilliams%26aufirst%3DR.%2BM.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DVariable%2520active%2520site%2520loop%2520conformations%2520accommodate%2520the%2520binding%2520of%2520macrocyclic%2520largazole%2520analogues%2520to%2520HDAC8%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D2126%26epage%3D2135%26doi%3D10.1021%2Facs.biochem.5b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Huang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. I.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1815</span><span class="NLM_x">–</span> <span class="NLM_lpage">1824</span><span class="refDoi"> DOI: 10.1002/cmdc.201200300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fcmdc.201200300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22907916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1815-1824&author=W.+J.+Huangauthor=Y.+C.+Wangauthor=S.+W.+Chaoauthor=C.+Y.+Yangauthor=L.+C.+Chenauthor=M.+H.+Linauthor=W.+C.+Houauthor=M.+Y.+Chenauthor=T.+L.+Leeauthor=P.+Yangauthor=C.+I.+Chang&title=Synthesis+and+biological+evaluation+of+ortho-aryl+N-hydroxycinnamides+as+potent+histone+deacetylase+%28HDAC%29+8+isoform-selective+inhibitors&doi=10.1002%2Fcmdc.201200300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of ortho-Aryl N-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors</span></div><div class="casAuthors">Huang, Wei-Jan; Wang, Yi-Ching; Chao, Shi-Wei; Yang, Chen-Yui; Chen, Liang-Chieh; Lin, Mei-Hsiang; Hou, Wen-Chi; Chen, Mei-Yu; Lee, Tai-Lin; Yang, Ping; Chang, Chung-I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1815-1824, S1815/1-S1815/41</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes that play a crucial role in biol. process and diseases.  In contrast to other isoenzymes, HDAC8 is uniquely incapable of histone acetylation.  To delineate its physiol. function, we developed HDAC8-selective inhibitors using knowledge-based design combined with structural modeling techniques.  Enzyme inhibitory anal. demonstrated that some of the resulting compds. exhibited anti-HDAC8 activity superior to PCI34051, a known HDAC8-specific inhibitor, with IC50 values in the range of 5-50 nM.  Among them, compd. (I) showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5); it exhibited cytotoxicity against human lung CL1-5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR-90 cells.  Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1-5 is higher than that in H1299 and CL1-1 cells, a result consistent with the differential cytotoxicity of compd. I.  These results suggest the effectiveness of our design concept, which may lead to a tool compd. for studying the specific role of HDAC8 in cellular biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop4xm7qu7wc7Vg90H21EOLACvtfcHk0lhwuc3TY2rAAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL&md5=05279fdc5e9bc353f12fa3b1b0f3e365</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200300%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DChao%26aufirst%3DS.%2BW.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DHou%26aufirst%3DW.%2BC.%26aulast%3DChen%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%2BI.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520ortho-aryl%2520N-hydroxycinnamides%2520as%2520potent%2520histone%2520deacetylase%2520%2528HDAC%2529%25208%2520isoform-selective%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1815%26epage%3D1824%26doi%3D10.1002%2Fcmdc.201200300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahige, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, N.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1002/cmdc.201300414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fcmdc.201300414" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=657-664&author=T.+Suzukiauthor=N.+Mutoauthor=M.+Bandoauthor=Y.+Itohauthor=A.+Masakiauthor=M.+Riauthor=Y.+Otaauthor=H.+Nakagawaauthor=S.+Iidaauthor=K.+Shirahigeauthor=N.+Miyata&title=Design%2C+synthesis%2C+and+biological+activity+of+NCC149+derivatives+as+histone+deacetylase+8-selective+inhibitors&doi=10.1002%2Fcmdc.201300414"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300414%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMuto%26aufirst%3DN.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DMasaki%26aufirst%3DA.%26aulast%3DRi%26aufirst%3DM.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DIida%26aufirst%3DS.%26aulast%3DShirahige%26aufirst%3DK.%26aulast%3DMiyata%26aufirst%3DN.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activity%2520of%2520NCC149%2520derivatives%2520as%2520histone%2520deacetylase%25208-selective%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D657%26epage%3D664%26doi%3D10.1002%2Fcmdc.201300414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="NLM_x">–</span> <span class="NLM_lpage">10846</span><span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lhwuc3TY2rAAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Aldana-Masangkay, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, K. M.</span><span> </span><span class="NLM_article-title">The role of HDAC6 in cancer</span> <span class="citation_source-journal">J. Biomed. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">875824</span><span class="refDoi"> DOI: 10.1155/2011/875824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1155%2F2011%2F875824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21076528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=875824&author=G.+I.+Aldana-Masangkayauthor=K.+M.+Sakamoto&title=The+role+of+HDAC6+in+cancer&doi=10.1155%2F2011%2F875824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The role of HDAC6 in cancer</span></div><div class="casAuthors">Aldana-Masangkay Grace I; Sakamoto Kathleen M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">875824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a member of the HDAC family whose major substrate is α-tubulin, has become a target for drug development to treat cancer due to its major contribution in oncogenic cell transformation.  Overexpression of HDAC6 correlates with tumorigenesis and improved survival; therefore, HDAC6 may be used as a marker for prognosis.  Previous work demonstrated that in multiple myeloma cells, inhibition of HDAC6 results in apoptosis.  Furthermore, HDAC6 is required for the activation of heat-shock factor 1 (HSF1), an activator of heat-shock protein encoding genes (HSPs) and CYLD, a cylindromatosis tumor suppressor gene.  HDAC6 contributes to cancer metastasis since its upregulation increases cell motility in breast cancer MCF-7 cells and its interaction with cortactin regulates motility.  HDAC6 also affects transcription and translation by regulating the heat-shock protein 90 (Hsp90) and stress granules (SGs), respectively.  This review will discuss the role of HDAC6 in the pathogenesis and treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIuDxliM3SH5QHPYJuLg8TfW6udTcc2eYsB8qPqrjLzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D&md5=8be7e0edb941ebf8b761778c99ad4c57</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1155%2F2011%2F875824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F875824%26sid%3Dliteratum%253Aachs%26aulast%3DAldana-Masangkay%26aufirst%3DG.%2BI.%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26atitle%3DThe%2520role%2520of%2520HDAC6%2520in%2520cancer%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D875824%26doi%3D10.1155%2F2011%2F875824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Kalin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, J. A.</span><span> </span><span class="NLM_article-title">Development and therapeutic implications of selective histone deacetylase 6 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6297</span><span class="NLM_x">–</span> <span class="NLM_lpage">6313</span><span class="refDoi"> DOI: 10.1021/jm4001659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6297-6313&author=J.+H.+Kalinauthor=J.+A.+Bergman&title=Development+and+therapeutic+implications+of+selective+histone+deacetylase+6+inhibitors&doi=10.1021%2Fjm4001659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Kalin, Jay H.; Bergman, Joel A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6297-6313</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides an in depth look at the numerous disease states in which histone deacetylase 6 (HDAC6) has been implicated.  The physiol. pathways, protein-protein interactions, and non-histone substrates relating to different pathol. conditions are discussed with regard to HDAC6.  Furthermore, the compds. and methods used to modulate HDAC6 activity are profiled.  The latter half of this Perspective analyzes reported HDAC6 selective inhibitors in terms of structure, potency, and selectivity over the other HDAC isoforms with the intent of providing a comprehensive overview of the mol. tools available.  Potential obstacles and future directions of HDAC6 research are also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvFD0xh4CLiLVg90H21EOLACvtfcHk0lgPw-2ZzaMntQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslSntrc%253D&md5=e54e7e8b172aba337581341360c0685c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm4001659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001659%26sid%3Dliteratum%253Aachs%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26atitle%3DDevelopment%2520and%2520therapeutic%2520implications%2520of%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6297%26epage%3D6313%26doi%3D10.1021%2Fjm4001659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Haakenson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">HDAC6 and Ovarian Cancer</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">9514</span><span class="NLM_x">–</span> <span class="NLM_lpage">9535</span><span class="refDoi"> DOI: 10.3390/ijms14059514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.3390%2Fijms14059514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23644884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSktLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=9514-9535&author=J.+Haakensonauthor=X.+Zhang&title=HDAC6+and+Ovarian+Cancer&doi=10.3390%2Fijms14059514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 and ovarian cancer</span></div><div class="casAuthors">Haakenson, Joshua; Zhang, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">9514-9535, 22 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways.  Many of the lessons learned from other cancers can be applied to ovarian cancer as well.  HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions.  Not all pro-cancer interactions of HDAC6 involve deacetylation.  The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMibgXjPsdVrVg90H21EOLACvtfcHk0lgPw-2ZzaMntQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSktLrJ&md5=35acd64f7b1face6216230f75002624a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3390%2Fijms14059514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms14059514%26sid%3Dliteratum%253Aachs%26aulast%3DHaakenson%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DHDAC6%2520and%2520Ovarian%2520Cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D9514%26epage%3D9535%26doi%3D10.3390%2Fijms14059514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Dallavalle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">Development and therapeutic impact of HDAC6-selective inhibitors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.bcp.2012.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22728920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWgtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=756-765&author=S.+Dallavalleauthor=C.+Pisanoauthor=F.+Zunino&title=Development+and+therapeutic+impact+of+HDAC6-selective+inhibitors&doi=10.1016%2Fj.bcp.2012.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Development and therapeutic impact of HDAC6-selective inhibitors</span></div><div class="casAuthors">Dallavalle, Sabrina; Pisano, Claudio; Zunino, Franco</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">756-765</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDAC) play a key role in regulating gene expression by deacetylating histones.  Some HDAC isoforms can also modulate the function of nonhistone proteins implicated in regulatory processes, and therefore HDACs are recognized as useful targets for therapeutic purposes.  HDAC inhibitors have generated substantial interest as antitumor agents, because they induce various cellular effects, including apoptosis, cell cycle arrest and inhibition of angiogenesis.  The nature of cellular response likely depends on the biol. context and on the pattern of HDAC isoform inhibition.  Various HDAC inhibitors belonging to different structural classes have been developed.  Many inhibitors are characterized by a pan-HDAC inhibitory profile.  The potential advantages of isoform-selective inhibitors over pan-HDAC inhibitors in terms of efficacy or toxicity remain to be defined.  The emerging interest for HDAC6-selective inhibitors is related to the modulation of acetylation of nonhistone regulatory proteins implicated in cancer-relevant processes, including cell migration, metastasis, angiogenesis and stress-response pathways.  This review is focused on the recent development of HDAC inhibitors, with particular ref. to HDAC6-selective inhibitors, and the efforts and perspectives in optimization of their therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAmrF_uWkK6LVg90H21EOLACvtfcHk0lgKtSjmHLTTUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWgtbrJ&md5=b3764e4070e45327493bb3c128f42d96</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DDallavalle%26aufirst%3DS.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DDevelopment%2520and%2520therapeutic%2520impact%2520of%2520HDAC6-selective%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D756%26epage%3D765%26doi%3D10.1016%2Fj.bcp.2012.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irondelle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waharte, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizarraga, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavrier, P.</span><span> </span><span class="NLM_article-title">HDAC6 is required for invadopodia activity and invasion by breast tumor cells</span> <span class="citation_source-journal">Eur. J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">135</span><span class="refDoi"> DOI: 10.1016/j.ejcb.2010.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.ejcb.2010.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=20970878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlahs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2011&pages=128-135&author=M.+Reyauthor=M.+Irondelleauthor=F.+Waharteauthor=F.+Lizarragaauthor=P.+Chavrier&title=HDAC6+is+required+for+invadopodia+activity+and+invasion+by+breast+tumor+cells&doi=10.1016%2Fj.ejcb.2010.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is required for invadopodia activity and invasion by breast tumor cells</span></div><div class="casAuthors">Rey, Mercedes; Irondelle, Marie; Waharte, Francois; Lizarraga, Floria; Chavrier, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">128-135</span>CODEN:
                <span class="NLM_cas:coden">EJCBDN</span>;
        ISSN:<span class="NLM_cas:issn">0171-9335</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Invasion across tissue boundaries by metastatic tumor cells depends on the proteolytic degrdn. of the extracellular matrix, initiated by the formation of invadopodia, actin-driven membrane protrusions with matrix-degradative activity.  Yet, mechanisms underlying invadopodia formation remain largely unknown.  In this report, we examd. the role of the histone deacetylase HDAC6 in invadopodia formation and invasion by breast cancer cells.  Using small interfering RNA silencing of protein expression in highly invasive MDA-MB-231 breast adenocarcinoma cells, we show that HDAC6 is required for two-dimensional matrix proteolysis.  In addn., we demonstrate that HDAC6 acts as a tubulin and cortactin deacetylase.  We also report that the inhibition of HDAC6 by siRNA or treatment with HDAC inhibitor TSA results in a decreased invasion capacity of a three-dimensional type I collagen matrix by MDA-MB-231 cells.  These data identify HDAC6 as a crit. component of the invasive app. of tumor cells, in both two- and three-dimensional matrixes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofj2HbNkcN-7Vg90H21EOLACvtfcHk0lgKtSjmHLTTUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlahs7g%253D&md5=294f600a1eeadb541c5f1f61ee7e5a88</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejcb.2010.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejcb.2010.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DRey%26aufirst%3DM.%26aulast%3DIrondelle%26aufirst%3DM.%26aulast%3DWaharte%26aufirst%3DF.%26aulast%3DLizarraga%26aufirst%3DF.%26aulast%3DChavrier%26aufirst%3DP.%26atitle%3DHDAC6%2520is%2520required%2520for%2520invadopodia%2520activity%2520and%2520invasion%2520by%2520breast%2520tumor%2520cells%26jtitle%3DEur.%2520J.%2520Cell%2520Biol.%26date%3D2011%26volume%3D90%26spage%3D128%26epage%3D135%26doi%3D10.1016%2Fj.ejcb.2010.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Castro-Castro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnac, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul-Gilloteaux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavrier, P.</span><span> </span><span class="NLM_article-title">ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion</span> <span class="citation_source-journal">Eur. J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">950</span><span class="NLM_x">–</span> <span class="NLM_lpage">960</span><span class="refDoi"> DOI: 10.1016/j.ejcb.2012.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.ejcb.2012.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22902175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aktbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=950-960&author=A.+Castro-Castroauthor=C.+Jankeauthor=G.+Montagnacauthor=P.+Paul-Gilloteauxauthor=P.+Chavrier&title=ATAT1%2FMEC-17+acetyltransferase+and+HDAC6+deacetylase+control+a+balance+of+acetylation+of+alpha-tubulin+and+cortactin+and+regulate+MT1-MMP+trafficking+and+breast+tumor+cell+invasion&doi=10.1016%2Fj.ejcb.2012.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion</span></div><div class="casAuthors">Castro-Castro, Antonio; Janke, Carsten; Montagnac, Guillaume; Paul-Gilloteaux, Perrine; Chavrier, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">950-960</span>CODEN:
                <span class="NLM_cas:coden">EJCBDN</span>;
        ISSN:<span class="NLM_cas:issn">0171-9335</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Invasive tumor cells use proteases to degrade and migrate through the stromal environment consisting of a 3D network of extracellular matrix macromols.  In particular, MT1-MMP, a membrane-anchored metalloproteinase, is crit. during cancer cell invasion.  MT1-MMP is stored in endosomal compartments and then delivered to invadopodia, the specialized plasma membrane domains of invasive cancer cells endowed with extracellular matrix-degrdn. capacity.  In macrophages, traffic of MT1-MMP vesicles to invadopodia-related podosomes requires microtubules.  We previously found that in breast tumor MDA-MB-231 cells an increase of microtubule and cortactin acetylation upon inhibition of HDAC6 correlates with a decrease of matrix degrdn. and invasion in three-dimensional collagen I gel.  Here, we investigated the role of the recently identified α-tubulin N-acetyltransferase 1 ATAT1 in invasive MDA-MB-231 cells.  We found that the dynamics and distribution of MT1-MMP-pos. endosomes require regulation of acetylation levels.  We obsd. that ATAT1 tubulin acetyltransferase binds and regulates cortactin acetylation levels.  In addn., ATAT1 colocalizes with cortactin at the adherent surface of the cells and it is required for 2D migration and invasive migration of MDA-MB-231 cells in collagen matrix.  All together, our data indicate that a balance of acetylation and deacetylation by ATAT1/HDAC6 enzymes with opposite activities regulates the migratory and invasive capacities of breast tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNkeddBjlAjbVg90H21EOLACvtfcHk0li9821Fv1ZLjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aktbjK&md5=8937aa840a2561c51a034f2752ea4fc7</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejcb.2012.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejcb.2012.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DCastro-Castro%26aufirst%3DA.%26aulast%3DJanke%26aufirst%3DC.%26aulast%3DMontagnac%26aufirst%3DG.%26aulast%3DPaul-Gilloteaux%26aufirst%3DP.%26aulast%3DChavrier%26aufirst%3DP.%26atitle%3DATAT1%252FMEC-17%2520acetyltransferase%2520and%2520HDAC6%2520deacetylase%2520control%2520a%2520balance%2520of%2520acetylation%2520of%2520alpha-tubulin%2520and%2520cortactin%2520and%2520regulate%2520MT1-MMP%2520trafficking%2520and%2520breast%2520tumor%2520cell%2520invasion%26jtitle%3DEur.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D91%26spage%3D950%26epage%3D960%26doi%3D10.1016%2Fj.ejcb.2012.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicosia, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khochbin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bepler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e44265</span><span class="refDoi"> DOI: 10.1371/journal.pone.0044265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1371%2Fjournal.pone.0044265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e44265&author=L.+Wangauthor=S.+Xiangauthor=K.+A.+Williamsauthor=H.+Dongauthor=W.+Baiauthor=S.+V.+Nicosiaauthor=S.+Khochbinauthor=G.+Beplerauthor=X.+Zhang&title=Depletion+of+HDAC6+enhances+cisplatin-induced+DNA+damage+and+apoptosis+in+non-small+cell+lung+cancer+cells&doi=10.1371%2Fjournal.pone.0044265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0044265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0044265%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DK.%2BA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DW.%26aulast%3DNicosia%26aufirst%3DS.%2BV.%26aulast%3DKhochbin%26aufirst%3DS.%26aulast%3DBepler%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DDepletion%2520of%2520HDAC6%2520enhances%2520cisplatin-induced%2520DNA%2520damage%2520and%2520apoptosis%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De44265%26doi%3D10.1371%2Fjournal.pone.0044265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Bergman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Villarroel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villagra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotomayor, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9891</span><span class="NLM_x">–</span> <span class="NLM_lpage">9899</span><span class="refDoi"> DOI: 10.1021/jm301098e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301098e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9891-9899&author=J.+A.+Bergmanauthor=K.+Woanauthor=P.+Perez-Villarroelauthor=A.+Villagraauthor=E.+M.+Sotomayorauthor=A.+P.+Kozikowski&title=Selective+histone+deacetylase+6+inhibitors+bearing+substituted+urea+linkers+inhibit+melanoma+cell+growth&doi=10.1021%2Fjm301098e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth</span></div><div class="casAuthors">Bergman, Joel A.; Woan, Karrune; Perez-Villarroel, Patricio; Villagra, Alejandro; Sotomayor, Eduardo M.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9891-9899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies.  In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor.  Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compds. bearing a branched linker group results in increased potency and selectivity for HDAC6.  Compd. 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ∼600-fold relative to the inhibition of HDAC1.  These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth.  To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkTtPLqvwsrVg90H21EOLACvtfcHk0li9821Fv1ZLjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ&md5=d6be4c0efb3922fc35d814ba00ae9ed1</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm301098e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301098e%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DWoan%26aufirst%3DK.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%2520histone%2520deacetylase%25206%2520inhibitors%2520bearing%2520substituted%2520urea%2520linkers%2520inhibit%2520melanoma%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9891%26epage%3D9899%26doi%3D10.1021%2Fjm301098e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Wickstrom, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoumi, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khochbin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fassler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massoumi, R.</span><span> </span><span class="NLM_article-title">CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1038/emboj.2009.317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Femboj.2009.317" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=131-144&author=S.+A.+Wickstromauthor=K.+C.+Masoumiauthor=S.+Khochbinauthor=R.+Fasslerauthor=R.+Massoumi&title=CYLD+negatively+regulates+cell-cycle+progression+by+inactivating+HDAC6+and+increasing+the+levels+of+acetylated+tubulin&doi=10.1038%2Femboj.2009.317"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Femboj.2009.317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2009.317%26sid%3Dliteratum%253Aachs%26aulast%3DWickstrom%26aufirst%3DS.%2BA.%26aulast%3DMasoumi%26aufirst%3DK.%2BC.%26aulast%3DKhochbin%26aufirst%3DS.%26aulast%3DFassler%26aufirst%3DR.%26aulast%3DMassoumi%26aufirst%3DR.%26atitle%3DCYLD%2520negatively%2520regulates%2520cell-cycle%2520progression%2520by%2520inactivating%2520HDAC6%2520and%2520increasing%2520the%2520levels%2520of%2520acetylated%2520tubulin%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D131%26epage%3D144%26doi%3D10.1038%2Femboj.2009.317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Kijima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horinouchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beppu, T.</span><span> </span><span class="NLM_article-title">Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">22429</span><span class="NLM_x">–</span> <span class="NLM_lpage">22435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=8226751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK3sXlsleks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=22429-22435&author=M.+Kijimaauthor=M.+Yoshidaauthor=K.+Sugitaauthor=S.+Horinouchiauthor=T.+Beppu&title=Trapoxin%2C+an+antitumor+cyclic+tetrapeptide%2C+is+an+irreversible+inhibitor+of+mammalian+histone+deacetylase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase</span></div><div class="casAuthors">Kijima, Masako; Yoshida, Minoru; Sugita, Kenji; Horinouchi, Sueharu; Beppu, Teruhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">22429-35</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Trapoxin A (I), is a fungal product that induces morphol. reversion from transformed to normal in sis-transformed NIH3T3 fibroblasts.  I was found to cause accumulation of highly acetylated core histones in a variety of mammalian cell lines.  In vitro expts. using partially purified mouse histone deacetylase showed that a low concn. of I irreversibly inhibited deacetylation of acetylated histone mols.  Chem. redn. of an epoxide group in I completely abolished the inhibitory activity, suggesting that I binds covalently to the histone deacetylase via the epoxide.  In contrast, inhibition by trichostatin A, a known potent inhibitor of histone deacetylase, was reversible.  Despite the different mode of inhibition, I and trichostatin A induced almost the same biol. effects on the cell cycle and differentiation.  These results strongly suggest that the in vivo effects commonly induced by these agents can be attributed to histone hyperacetylation resulting from the inhibition of histone deacetylase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqscgc_V7MoWrVg90H21EOLACvtfcHk0ljJrGMZdBbHyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsleks7Y%253D&md5=5252b79bf5604918fea6ecfdb64bc015</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKijima%26aufirst%3DM.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DSugita%26aufirst%3DK.%26aulast%3DHorinouchi%26aufirst%3DS.%26aulast%3DBeppu%26aufirst%3DT.%26atitle%3DTrapoxin%252C%2520an%2520antitumor%2520cyclic%2520tetrapeptide%252C%2520is%2520an%2520irreversible%2520inhibitor%2520of%2520mammalian%2520histone%2520deacetylase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D22429%26epage%3D22435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapadar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchini, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billadeau, D. D.</span><span> </span><span class="NLM_article-title">Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4370</span><span class="NLM_x">–</span> <span class="NLM_lpage">4373</span><span class="refDoi"> DOI: 10.1021/jm8002894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4370-4373&author=A.+P.+Kozikowskiauthor=S.+Tapadarauthor=D.+N.+Luchiniauthor=K.+H.+Kimauthor=D.+D.+Billadeau&title=Use+of+the+nitrile+oxide+cycloaddition+%28NOC%29+reaction+for+molecular+probe+generation%3A+a+new+class+of+enzyme+selective+histone+deacetylase+inhibitors+%28HDACIs%29+showing+picomolar+activity+at+HDAC6&doi=10.1021%2Fjm8002894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span></div><div class="casAuthors">Kozikowski, Alan P.; Tapadar, Subhasish; Luchini, Doris N.; Kim, Ki Hwan; Billadeau, Daniel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4370-4373</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of hydroxamate based HDAC inhibitors contg. a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddn. chem.  An HDAC6 selective inhibitor having a potency of ∼2 picomolar was identified.  Some of the compds. were examd. for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA (suberoylanilidehydroxamic acid).  This research provides valuable, new mol. probes for use in exploring HDAC biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7Ca9tXdBvbVg90H21EOLACvtfcHk0lggI0VsWqxOlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D&md5=006c71fe6f2bb09c2c65196e134a695e</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm8002894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002894%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DUse%2520of%2520the%2520nitrile%2520oxide%2520cycloaddition%2520%2528NOC%2529%2520reaction%2520for%2520molecular%2520probe%2520generation%253A%2520a%2520new%2520class%2520of%2520enzyme%2520selective%2520histone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%2520showing%2520picomolar%2520activity%2520at%2520HDAC6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4370%26epage%3D4373%26doi%3D10.1021%2Fjm8002894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Guerini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinelli, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dellacasa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carobbio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Introna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, A.</span><span> </span><span class="NLM_article-title">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1038/sj.leu.2405049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fsj.leu.2405049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18079739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=740-747&author=V.+Gueriniauthor=V.+Barbuiauthor=O.+Spinelliauthor=A.+Salviauthor=C.+Dellacasaauthor=A.+Carobbioauthor=M.+Intronaauthor=T.+Barbuiauthor=J.+Golayauthor=A.+Rambaldi&title=The+histone+deacetylase+inhibitor+ITF2357+selectively+targets+cells+bearing+mutated+JAK2%28V617F%29&doi=10.1038%2Fsj.leu.2405049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F</span></div><div class="casAuthors">Guerini, V.; Barbui, V.; Spinelli, O.; Salvi, A.; Dellacasa, C.; Carobbio, A.; Introna, M.; Barbui, T.; Golay, J.; Rambaldi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors investigated the activity of ITF2357, a novel histone deacetylase inhibitor (HDACi) with antitumor activity, on cells carrying the JAK2V617F mutation obtained from polycythemia vera (PV) and essential thrombocythemia (ET) patients as well as the HEL cell line.  The clonogenic activity of JAK2V617F mutated cells was inhibited by low concns. of ITF2357 (IC50 0.001-0.01 μ), 100- to 250-fold lower than required to inhibit growth of normal or tumor cells lacking this mutation.  Under these conditions, ITF2357 allowed a seven fold increase in the outgrowth of unmutated over mutated colonies.  By western blotting the authors showed that in HEL cells, ITF2357 led to the disappearance of total and phosphorylated JAK2V617F as well as pSTAT5 and pSTAT3, but it did not affect the wild-type JAK2 or STAT proteins in the control K562 cell line.  By real-time PCR, the authors showed that, upon exposure to ITF2357, JAK2V617F mRNA was not modified in granulocytes from PV patients while the expression of the PRV-1 gene, a known target of JAK2, was rapidly downmodulated.  Altogether, the data presented suggest that ITF2357 inhibits proliferation of cells bearing the JAK2V617F mutation through a specific down-modulation of the JAK2V617F protein and inhibition of its downstream signaling.  Leukemia (2008) 22, 740-747; doi:10.1038/sj.leu.2405049; published online 13 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJVQmHmDb8RLVg90H21EOLACvtfcHk0lggI0VsWqxOlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks12rt7g%253D&md5=de59fdaf20ec85e733052c09733b9193</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2405049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2405049%26sid%3Dliteratum%253Aachs%26aulast%3DGuerini%26aufirst%3DV.%26aulast%3DBarbui%26aufirst%3DV.%26aulast%3DSpinelli%26aufirst%3DO.%26aulast%3DSalvi%26aufirst%3DA.%26aulast%3DDellacasa%26aufirst%3DC.%26aulast%3DCarobbio%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DBarbui%26aufirst%3DT.%26aulast%3DGolay%26aufirst%3DJ.%26aulast%3DRambaldi%26aufirst%3DA.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520ITF2357%2520selectively%2520targets%2520cells%2520bearing%2520mutated%2520JAK2%2528V617F%2529%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D740%26epage%3D747%26doi%3D10.1038%2Fsj.leu.2405049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Amaru Calzada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todoerti, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donadoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicioli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuana, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finazzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantovani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Introna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golay, J.</span><span> </span><span class="NLM_article-title">The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span><span class="refDoi"> DOI: 10.1016/j.exphem.2012.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.exphem.2012.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22579713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVKhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=634-645&author=A.+Amaru+Calzadaauthor=K.+Todoertiauthor=L.+Donadoniauthor=A.+Pellicioliauthor=G.+Tuanaauthor=R.+Gattaauthor=A.+Neriauthor=G.+Finazziauthor=R.+Mantovaniauthor=A.+Rambaldiauthor=M.+Intronaauthor=L.+Lombardiauthor=J.+Golay&title=The+HDAC+inhibitor+Givinostat+modulates+the+hematopoietic+transcription+factors+NFE2+and+C-MYB+in+JAK2%28V617F%29+myeloproliferative+neoplasm+cells&doi=10.1016%2Fj.exphem.2012.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells</span></div><div class="casAuthors">Amaru Calzada, Ariel; Todoerti, Katia; Donadoni, Luca; Pellicioli, Anna; Tuana, Giacomo; Gatta, Raffaella; Neri, Antonino; Finazzi, Guido; Mantovani, Roberto; Rambaldi, Alessandro; Introna, Martino; Lombardi, Luigia; Golay, Josee</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">634-645.e10</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We investigated the mechanism of action of the histone deacetylase inhibitor Givinostat (GVS) in Janus kinase 2 (JAK2)V617F myeloproliferative neoplasm (MPN) cells.  GVS inhibited colony formation and proliferation and induced apoptosis at doses two- to threefold lower in a panel of JAK2V617F MPN compared to JAK2 wild-type myeloid leukemia cell lines.  By global gene expression anal., we obsd. that at 6 h, GVS modulated 293 common genes in the JAK2V617F cell lines HEL and UKE1, of which 19 are implicated in cell cycle regulation and 33 in hematopoiesis.  In particular, the hematopoietic transcription factors NFE2 and C-MYB were downmodulated by the drug specifically in JAK2V617F cells at both the RNA and protein level.  GVS also inhibited JAK2-signal transducer and activator of transcription 5-extracellular signal-regulated kinase 1/2 phosphorylation, but modulation of NFE2 and C-MYB was JAK2-independent, as shown using the JAK2 inhibitor TG101209.  GVS had a direct effect on the NFE2 promoters, as demonstrated by specific enrichment of assocd. histone H3 acetylated at lysine 9.  Modulation by GVS of NFE2 was also obsd. in freshly isolated CD34+ cells from MPN patients, and was accompanied by inhibition of their proliferation and differentiation toward the erythroid lineage.  We conclude that GVS acts on MPN cells through dual JAK2-signal transducer and activator of transcription 5-extracellular signal-regulated kinase 1/2 inhibition and downmodulation of NFE2 and C-MYB transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQdjteEkk71bVg90H21EOLACvtfcHk0liIVzeR5qn0rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVKhtbs%253D&md5=c930e6fad23d7edf077e1d8abfa8f3dd</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2012.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2012.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DAmaru%2BCalzada%26aufirst%3DA.%26aulast%3DTodoerti%26aufirst%3DK.%26aulast%3DDonadoni%26aufirst%3DL.%26aulast%3DPellicioli%26aufirst%3DA.%26aulast%3DTuana%26aufirst%3DG.%26aulast%3DGatta%26aufirst%3DR.%26aulast%3DNeri%26aufirst%3DA.%26aulast%3DFinazzi%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DR.%26aulast%3DRambaldi%26aufirst%3DA.%26aulast%3DIntrona%26aufirst%3DM.%26aulast%3DLombardi%26aufirst%3DL.%26aulast%3DGolay%26aufirst%3DJ.%26atitle%3DThe%2520HDAC%2520inhibitor%2520Givinostat%2520modulates%2520the%2520hematopoietic%2520transcription%2520factors%2520NFE2%2520and%2520C-MYB%2520in%2520JAK2%2528V617F%2529%2520myeloproliferative%2520neoplasm%2520cells%26jtitle%3DExp.%2520Hematol.%26date%3D2012%26volume%3D40%26spage%3D634%26epage%3D645%26doi%3D10.1016%2Fj.exphem.2012.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Xiong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, J. Y.</span><span> </span><span class="NLM_article-title">Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells</span> <span class="citation_source-journal">Mol. Carcinog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">174</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1002/mc.20777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fmc.20777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21520296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=174-184&author=H.+Xiongauthor=W.+Duauthor=Y.+J.+Zhangauthor=J.+Hongauthor=W.+Y.+Suauthor=J.+T.+Tangauthor=Y.+C.+Wangauthor=R.+Luauthor=J.+Y.+Fang&title=Trichostatin+A%2C+a+histone+deacetylase+inhibitor%2C+suppresses+JAK2%2FSTAT3+signaling+via+inducing+the+promoter-associated+histone+acetylation+of+SOCS1+and+SOCS3+in+human+colorectal+cancer+cells&doi=10.1002%2Fmc.20777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells</span></div><div class="casAuthors">Xiong, Hua; Du, Wan; Zhang, Yan-Jie; Hong, Jie; Su, Wen-Yu; Tang, Jie-Ting; Wang, Ying-Chao; Lu, Rong; Fang, Jing-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-184</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Aberrant janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling is involved in the oncogenesis of several cancers.  Suppressors of cytokine signaling (SOCS) genes and SH2-contg. protein tyrosine phosphatase 1 (SHP1) proteins, which are neg. regulators of JAK/STAT signaling, have been reported to have tumor suppressor functions.  However, in colorectal cancer (CRC) cells, the mechanisms that regulate SOCS and SHP1 genes, and the cause of abnormalities in the JAK/STAT signaling pathway, remain largely unknown.  The present study shows that trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, leads to the hyperacetylation of histones assocd. with the SOCS1 and SOCS3 promoters, but not the SHP1 promoter in CRC cells.  This indicates that histone modifications are involved in the regulation of SOCS1 and SOCS3.  Moreover, upregulation of SOCS1 and SOCS3 expression was achieved using TSA, which also significantly downregulated JAK2/STAT3 signaling in CRC cells.  We also demonstrate that TSA suppresses the growth of CRC cells, and induces G1 cell cycle arrest and apoptosis through the regulation of downstream targets of JAK2/STAT3 signaling, including Bcl-2, survivin and p16ink4a.  Therefore, our data demonstrate that TSA may induce SOCS1 and SOCS3 expression by inducing histone modifications and consequently inhibits JAK2/STAT3 signaling in CRC cells.  These results also establish a mechanistic link between the inhibition of JAK2/STAT3 signaling and the anticancer action of TSA in CRC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1vZSwy1EJlrVg90H21EOLACvtfcHk0liIVzeR5qn0rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKk&md5=038e783e9dd7172aa0576f76f2ad8342</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fmc.20777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20777%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DW.%2BY.%26aulast%3DTang%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DFang%26aufirst%3DJ.%2BY.%26atitle%3DTrichostatin%2520A%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520suppresses%2520JAK2%252FSTAT3%2520signaling%2520via%2520inducing%2520the%2520promoter-associated%2520histone%2520acetylation%2520of%2520SOCS1%2520and%2520SOCS3%2520in%2520human%2520colorectal%2520cancer%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2012%26volume%3D51%26spage%3D174%26epage%3D184%26doi%3D10.1002%2Fmc.20777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiskus, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balusu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savoie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ustun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillella, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atadja, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhalla, K. N.</span><span> </span><span class="NLM_article-title">Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">5024</span><span class="NLM_x">–</span> <span class="NLM_lpage">5033</span><span class="refDoi"> DOI: 10.1182/blood-2009-05-222133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1182%2Fblood-2009-05-222133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=19828702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=5024-5033&author=Y.+Wangauthor=W.+Fiskusauthor=D.+G.+Chongauthor=K.+M.+Buckleyauthor=K.+Natarajanauthor=R.+Raoauthor=A.+Joshiauthor=R.+Balusuauthor=S.+Koulauthor=J.+Chenauthor=A.+Savoieauthor=C.+Ustunauthor=A.+P.+Jillellaauthor=P.+Atadjaauthor=R.+L.+Levineauthor=K.+N.+Bhalla&title=Cotreatment+with+panobinostat+and+JAK2+inhibitor+TG101209+attenuates+JAK2V617F+levels+and+signaling+and+exerts+synergistic+cytotoxic+effects+against+human+myeloproliferative+neoplastic+cells&doi=10.1182%2Fblood-2009-05-222133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells</span></div><div class="casAuthors">Wang, Yongchao; Fiskus, Warren; Chong, Daniel G.; Buckley, Kathleen M.; Natarajan, Kavita; Rao, Rekha; Joshi, Atul; Balusu, Ramesh; Koul, Sanjay; Chen, Jianguang; Savoie, Andrew; Ustun, Celalettin; Jillella, Anand P.; Atadja, Peter; Levine, Ross L.; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5024-5033</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL-neg. myeloproliferative neoplasms (MPNs).  JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 (PI3)/AKT pathways, conferring proliferative and survival advantages in the MPN hematopoietic progenitor cells (HPCs).  Treatment with the pan-histone deacetylase (HDAC) inhibitor panobinostat (PS) is known to inhibit the chaperone function of heat shock protein 90, as well as induce growth arrest and apoptosis of transformed HPCs.  Here, we demonstrate that PS treatment depletes the autophosphorylation, expression, and downstream signaling of JAK2V617F.  Treatment with PS also disrupted the chaperone assocn. of JAK2V617F with hsp90, promoting proteasomal degrdn. of JAK2V617F.  PS also induced apoptosis of the cultured JAK2V617F-expressing human erythroleukemia HEL92.1.7 and Ba/F3-JAK2V617F cells.  Treatment with the JAK2 TK inhibitor TG101209 attenuated JAK2V617F autophosphorylation and induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with PS and TG101209 further depleted JAK/STAT signaling and synergistically induced apoptosis of HEL92.1.7 and Ba/F3-JAK2V617F cells.  Cotreatment with TG101209 and PS exerted greater cytotoxicity against primary CD34+ MPN cells than normal CD34+ HPCs.  These in vitro findings suggest combination therapy with HDAC and JAK2V617F inhibitors is of potential value for the treatment of JAK2V617F-pos. MPN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodK5zBrODMYbVg90H21EOLACvtfcHk0ljKKyxhXxO_iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2gsb%252FI&md5=061242179d1d48acd664acc8f484f003</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-05-222133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-05-222133%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DChong%26aufirst%3DD.%2BG.%26aulast%3DBuckley%26aufirst%3DK.%2BM.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DBalusu%26aufirst%3DR.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSavoie%26aufirst%3DA.%26aulast%3DUstun%26aufirst%3DC.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DAtadja%26aufirst%3DP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DCotreatment%2520with%2520panobinostat%2520and%2520JAK2%2520inhibitor%2520TG101209%2520attenuates%2520JAK2V617F%2520levels%2520and%2520signaling%2520and%2520exerts%2520synergistic%2520cytotoxic%2520effects%2520against%2520human%2520myeloproliferative%2520neoplastic%2520cells%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D5024%26epage%3D5033%26doi%3D10.1182%2Fblood-2009-05-222133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Novotny-Diermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentze, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span> </span><span class="NLM_article-title">The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML</span> <span class="citation_source-journal">Blood Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e69</span><span class="refDoi"> DOI: 10.1038/bcj.2012.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fbcj.2012.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22829971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=e69&author=V.+Novotny-Diermayrauthor=S.+Hartauthor=K.+C.+Gohauthor=A.+Cheongauthor=L.+C.+Ongauthor=H.+Hentzeauthor=M.+K.+Pashaauthor=R.+Jayaramanauthor=K.+Ethirajuluauthor=J.+M.+Wood&title=The+oral+HDAC+inhibitor+pracinostat+%28SB939%29+is+efficacious+and+synergistic+with+the+JAK2+inhibitor+pacritinib+%28SB1518%29+in+preclinical+models+of+AML&doi=10.1038%2Fbcj.2012.14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.14%26sid%3Dliteratum%253Aachs%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DHentze%26aufirst%3DH.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520oral%2520HDAC%2520inhibitor%2520pracinostat%2520%2528SB939%2529%2520is%2520efficacious%2520and%2520synergistic%2520with%2520the%2520JAK2%2520inhibitor%2520pacritinib%2520%2528SB1518%2529%2520in%2520preclinical%2520models%2520of%2520AML%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26spage%3De69%26doi%3D10.1038%2Fbcj.2012.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Evrot, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andraos, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dammassa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baffert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radimerski, T.</span><span> </span><span class="NLM_article-title">JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6230</span><span class="NLM_x">–</span> <span class="NLM_lpage">6241</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1158%2F1078-0432.CCR-13-0905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24081976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6230-6241&author=E.+Evrotauthor=N.+Ebelauthor=V.+Romanetauthor=C.+Roelliauthor=R.+Andraosauthor=Z.+Qianauthor=A.+Dolemeyerauthor=E.+Dammassaauthor=D.+Sterkerauthor=R.+Cozensauthor=F.+Hofmannauthor=M.+Murakamiauthor=F.+Baffertauthor=T.+Radimerski&title=JAK1%2F2+and+Pan-deacetylase+inhibitor+combination+therapy+yields+improved+efficacy+in+preclinical+mouse+models+of+JAK2V617F-driven+disease&doi=10.1158%2F1078-0432.CCR-13-0905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease</span></div><div class="casAuthors">Evrot, Emeline; Ebel, Nicolas; Romanet, Vincent; Roelli, Claudia; Andraos, Rita; Qian, Zhiyan; Doelemeyer, Arno; Dammassa, Ernesta; Sterker, Dario; Cozens, Robert; Hofmann, Francesco; Murakami, Masato; Baffert, Fabienne; Radimerski, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6230-6241</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The myeloproliferative neoplasm myelofibrosis is characterized by frequent deregulation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, and JAK inhibitors were shown to reduce splenomegaly and ameliorate disease-related symptoms.  However, the mutant clone and bone marrow fibrosis persist in the majority of patients.  Using preclin. models, we explored whether JAK and pan-deacetylase inhibitor combination yielded addnl. benefits.  Exptl. Design: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2V617F-driven disease.  A Ba/F3 JAK2V617F cell-driven leukemic disease model was used to identify tolerated and efficacious doses.  The drugs were then evaluated alone and in combination in a mouse model of myeloproliferative neoplasm-like disease based on transplantation of bone marrow transduced with a retrovirus expressing JAK2V617F.  Exposures were detd. in blood and tissues, and phosphorylated STAT5 and acetylated histone H3 pharmacodynamic readouts were assessed in spleen and bone marrow.  Histol. anal. was conducted on spleen and bone marrow, including staining of reticulin fibers in the latter organ.  Results: The combination of ruxolitinib and panobinostat was found to have a more profound effect on splenomegaly, as well as on bone marrow and spleen histol., compared with either agent alone, and the anal. of pharmacodynamic readouts showed that ruxolitinib and panobinostat have nonoverlapping and complementary effects.  Conclusion: Combining JAK1/2 and pan-deacetylase inhibitors was fairly well tolerated and resulted in improved efficacy in mouse models of JAK2V617F-driven disease compared with the single agents.  Thus, the combination of ruxolitinib and panobinostat may represent a promising novel therapeutic modality for myeloproliferative neoplasms.  Clin Cancer Res; 19(22); 6230-41. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEzgbAtJVQ27Vg90H21EOLACvtfcHk0lh1xAH3nT1HUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyku7jM&md5=ff3662f4ba7be74aa3395046e9516e04</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0905%26sid%3Dliteratum%253Aachs%26aulast%3DEvrot%26aufirst%3DE.%26aulast%3DEbel%26aufirst%3DN.%26aulast%3DRomanet%26aufirst%3DV.%26aulast%3DRoelli%26aufirst%3DC.%26aulast%3DAndraos%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DDolemeyer%26aufirst%3DA.%26aulast%3DDammassa%26aufirst%3DE.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DBaffert%26aufirst%3DF.%26aulast%3DRadimerski%26aufirst%3DT.%26atitle%3DJAK1%252F2%2520and%2520Pan-deacetylase%2520inhibitor%2520combination%2520therapy%2520yields%2520improved%2520efficacy%2520in%2520preclinical%2520mouse%2520models%2520of%2520JAK2V617F-driven%2520disease%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6230%26epage%3D6241%26doi%3D10.1158%2F1078-0432.CCR-13-0905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Ohlson, S.</span><span> </span><span class="NLM_article-title">Designing transient binding drugs: a new concept for drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.drudis.2008.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.drudis.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18468561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=433-439&author=S.+Ohlson&title=Designing+transient+binding+drugs%3A+a+new+concept+for+drug+discovery&doi=10.1016%2Fj.drudis.2008.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Designing transient binding drugs: A new concept for drug discovery</span></div><div class="casAuthors">Ohlson, Sten</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9/10</span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  A multitude of weak, or transient, biol. interactions (dissocn. const.: K d > μM), either working alone or in concert, occur frequently throughout biol. systems.  We are starting to appreciate their importance in complex biol. networks.  This realization has important implications to drug discovery as we can question the current paradigm of drug design to find the highest possible binders (drugs) to a given target (receptor).  Development of transient drugs, defined by their binding to target, can be based on high-off-rates, multivalent approaches or multiple targets.  Now, techniques are available to discover such drug candidates.  The greatest problem yet to overcome is probably the mind-set of the individual researcher that weak binders are undesired and therefore of no benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-vxnnjidYrLVg90H21EOLACvtfcHk0lh1xAH3nT1HUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWntLk%253D&md5=5aab032fbff1ef8836296ce36aa803a1</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DOhlson%26aufirst%3DS.%26atitle%3DDesigning%2520transient%2520binding%2520drugs%253A%2520a%2520new%2520concept%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2008%26volume%3D13%26spage%3D433%26epage%3D439%26doi%3D10.1016%2Fj.drudis.2008.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Ganesan, A.</span><span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of Zinc-Dependent Histone Deacetylases (HDACs)</span>. In  <span class="citation_source-book">Macrocycles in Drug Discovery</span>; <span class="NLM_contrib-group">Levin, J.</span>, Ed.; <span class="NLM_publisher-name">The Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=109-140&author=A.+Ganesanauthor=J.+Levin&title=Macrocycles+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520Zinc-Dependent%2520Histone%2520Deacetylases%2520%2528HDACs%2529%26btitle%3DMacrocycles%2520in%2520Drug%2520Discovery%26aulast%3DLevin%26aufirst%3DJ.%26pub%3DThe%2520Royal%2520Society%2520of%2520Chemistry%26date%3D2015%26spage%3D109%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeller, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grozinger, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S. L.</span><span> </span><span class="NLM_article-title">Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">4389</span><span class="NLM_x">–</span> <span class="NLM_lpage">4394</span><span class="refDoi"> DOI: 10.1073/pnas.0430973100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1073%2Fpnas.0430973100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=12677000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=4389-4394&author=S.+J.+Haggartyauthor=K.+M.+Koellerauthor=J.+C.+Wongauthor=C.+M.+Grozingerauthor=S.+L.+Schreiber&title=Domain-selective+small-molecule+inhibitor+of+histone+deacetylase+6+%28HDAC6%29-mediated+tubulin+deacetylation&doi=10.1073%2Fpnas.0430973100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation</span></div><div class="casAuthors">Haggarty, Stephen J.; Koeller, Kathryn M.; Wong, Jason C.; Grozinger, Christina M.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4389-4394</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein acetylation, esp. histone acetylation, is the subject of both research and clin. investigation.  At least four small-mol. histone deacetylase inhibitors are currently in clin. trials for the treatment of cancer.  These and other inhibitors also affect microtubule acetylation.  A multidimensional, chem. genetic screen of 7392 small mols. was used to discover "tubacin," which inhibits α-tubulin deacetylation in mammalian cells.  Tubacin does not affect the level of histone acetylation, gene-expression patterns, or cell-cycle progression.  We provide evidence that class II histone deacetylase 6 (HDAC6) is the intracellular target of tubacin.  Only one of the two catalytic domains of HDAC6 possesses tubulin deacetylase activity, and only this domain is bound by tubacin.  Tubacin treatment did not affect the stability of microtubules but did decrease cell motility.  HDAC6 overexpression disrupted the localization of p58, a protein that mediates binding of Golgi elements to microtubules.  Our results highlight the role of α-tubulin acetylation in mediating the localization of microtubule-assocd. proteins.  They also suggest that small mols. that selectively inhibit HDAC6-mediated α-tubulin deacetylation, a first example of which is tubacin, might have therapeutic applications as antimetastatic and antiangiogenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbQBWjEZr47rVg90H21EOLACvtfcHk0lhygAkhEUtRZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjt12gtL0%253D&md5=260da1ede64782ddbddda31b740b9782</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0430973100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0430973100%26sid%3Dliteratum%253Aachs%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DKoeller%26aufirst%3DK.%2BM.%26aulast%3DWong%26aufirst%3DJ.%2BC.%26aulast%3DGrozinger%26aufirst%3DC.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DDomain-selective%2520small-molecule%2520inhibitor%2520of%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529-mediated%2520tubulin%2520deacetylation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D4389%26epage%3D4394%26doi%3D10.1073%2Fpnas.0430973100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Wagner, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiwer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aidoud, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davoine, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemercier, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holson, E. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1772</span><span class="NLM_x">–</span> <span class="NLM_lpage">1776</span><span class="refDoi"> DOI: 10.1021/jm301355j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301355j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1772-1776&author=F.+F.+Wagnerauthor=D.+E.+Olsonauthor=J.+P.+Galeauthor=T.+Kayaauthor=M.+Weiwerauthor=N.+Aidoudauthor=M.+Thomasauthor=E.+L.+Davoineauthor=B.+C.+Lemercierauthor=Y.+L.+Zhangauthor=E.+B.+Holson&title=Potent+and+selective+inhibition+of+histone+deacetylase+6+%28HDAC6%29+does+not+require+a+surface-binding+motif&doi=10.1021%2Fjm301355j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif</span></div><div class="casAuthors">Wagner, Florence F.; Olson, David E.; Gale, Jennifer P.; Kaya, Taner; Weiwer, Michel; Aidoud, Nadia; Thomas, Meryl; Davoine, Emeline L.; Lemercier, Berenice C.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1772-1776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6).  Several inhibitors, including compd. 14 (BRD9757), exhibited excellent potency and selectivity despite the absence of a surface-binding motif.  The binding of these highly efficient ligands for HDAC6 is rationalized via structure-activity relationships.  These results demonstrate that high selectivity and potent inhibition of HDAC6 can be achieved through careful choice of linker element only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp84k2hCSqrAbVg90H21EOLACvtfcHk0lhygAkhEUtRZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D&md5=eee6262f17350f3f7c411ab37840e3fe</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm301355j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301355j%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DOlson%26aufirst%3DD.%2BE.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DWeiwer%26aufirst%3DM.%26aulast%3DAidoud%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDavoine%26aufirst%3DE.%2BL.%26aulast%3DLemercier%26aufirst%3DB.%2BC.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520does%2520not%2520require%2520a%2520surface-binding%2520motif%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1772%26epage%3D1776%26doi%3D10.1021%2Fjm301355j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Auzzas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes-Simard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabri, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battistuzzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciacci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanessian, S.</span><span> </span><span class="NLM_article-title">Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8399</span><span class="refDoi"> DOI: 10.1021/jm101092u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101092u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8387-8399&author=L.+Auzzasauthor=A.+Larssonauthor=R.+Materaauthor=A.+Baraldiauthor=B.+Deschenes-Simardauthor=G.+Gianniniauthor=W.+Cabriauthor=G.+Battistuzziauthor=G.+Galloauthor=A.+Ciacciauthor=L.+Vesciauthor=C.+Pisanoauthor=S.+Hanessian&title=Non-natural+macrocyclic+inhibitors+of+histone+deacetylases%3A+design%2C+synthesis%2C+and+activity&doi=10.1021%2Fjm101092u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity</span></div><div class="casAuthors">Auzzas, Luciana; Larsson, Andreas; Matera, Riccardo; Baraldi, Annamaria; Deschenes-Simard, Benoit; Giannini, Giuseppe; Cabri, Walter; Battistuzzi, Gianfranco; Gallo, Grazia; Ciacci, Andrea; Vesci, Loredana; Pisano, Claudio; Hanessian, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8387-8399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonpeptidic chiral macrocycles, e.g. I [X = (CH2)n, n = 1-3], were designed on the basis of an analog of suberoylanilide hydroxamic acid II (SAHA, vorinostat) and evaluated against 11 histone deacetylase (HDAC) isoforms.  The identification of crit. amino acid residues highly conserved in the cap region of HDACs guided the design of the suberoyl-based macrocycles, which were expected to bear a max. common substructure required to target the whole HDAC panel.  A nanomolar HDAC inhibitory profile was obsd. for several compds., which was comparable, if not superior, to that of II.  A promising cytotoxic activity was found for selected macrocycles against lung and colon cancer cell lines.  Further elaboration of selected candidates led to compds. with an improved selectivity against HDAC6 over the other isoenzymes.  Pair-fitting anal. was used to compare one of the best candidates with the natural tetrapeptide apicidin, in an effort to define a general pharmacophore that might be useful in the design of surrogates of peptidic macrocycles as potent and isoform-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJOcBz2w8SRLVg90H21EOLACvtfcHk0liBhoOIsrtbKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWrtb%252FI&md5=061fb93af453824141ca9c0fdb09a701</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm101092u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101092u%26sid%3Dliteratum%253Aachs%26aulast%3DAuzzas%26aufirst%3DL.%26aulast%3DLarsson%26aufirst%3DA.%26aulast%3DMatera%26aufirst%3DR.%26aulast%3DBaraldi%26aufirst%3DA.%26aulast%3DDeschenes-Simard%26aufirst%3DB.%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DBattistuzzi%26aufirst%3DG.%26aulast%3DGallo%26aufirst%3DG.%26aulast%3DCiacci%26aufirst%3DA.%26aulast%3DVesci%26aufirst%3DL.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DHanessian%26aufirst%3DS.%26atitle%3DNon-natural%2520macrocyclic%2520inhibitors%2520of%2520histone%2520deacetylases%253A%2520design%252C%2520synthesis%252C%2520and%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8387%26epage%3D8399%26doi%3D10.1021%2Fjm101092u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Darkin-Rattray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurnett, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumley, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allocco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannova, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombrowski, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polishook, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmatz, D. M.</span><span> </span><span class="NLM_article-title">Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">13143</span><span class="NLM_x">–</span> <span class="NLM_lpage">13147</span><span class="refDoi"> DOI: 10.1073/pnas.93.23.13143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1073%2Fpnas.93.23.13143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=8917558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK28XmvV2qtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=13143-13147&author=S.+J.+Darkin-Rattrayauthor=A.+M.+Gurnettauthor=R.+W.+Myersauthor=P.+M.+Dulskiauthor=T.+M.+Crumleyauthor=J.+J.+Alloccoauthor=C.+Cannovaauthor=P.+T.+Meinkeauthor=S.+L.+Collettiauthor=M.+A.+Bednarekauthor=S.+B.+Singhauthor=M.+A.+Goetzauthor=A.+W.+Dombrowskiauthor=J.+D.+Polishookauthor=D.+M.+Schmatz&title=Apicidin%3A+a+novel+antiprotozoal+agent+that+inhibits+parasite+histone+deacetylase&doi=10.1073%2Fpnas.93.23.13143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase</span></div><div class="casAuthors">Darkin-Rattray, Sandra J.; Gurnett, Anne M.; Myers, Robert W.; Dulski, Paula M.; Crumley, Tami M.; Allocco, John J.; Cannova, Christine; Meinke, Peter T.; Colletti, Steven L.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">13143-13147</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A novel fungal metabolite, apicidin [cyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)], that exhibits potent, broad spectrum antiprotozoal activity in vitro against Apicomplexan parasites has been identified.  It is also orally and parenterally active in vivo against Plasmodium berghei malaria in mice.  Many Apicomplexan parasites cause serious, life-threatening human and animal diseases, such as malaria, cryptosporidiosis, toxoplasmosis, and coccidiosis, and new therapeutic agents are urgently needed.  Apicidin's antiparasitic activity appears to be due to low nanomolar inhibition of Apicomplexan histone deacetylase (HDA), which induces hyperacetylation of histones in treated parasites.  The acetylation-deacetylation of histones is thought to play a central role in transcriptional control in eukaryotic cells.  Other known HDA inhibitors were also evaluated and found to possess antiparasitic activity, suggesting that HDA is an attractive target for the development of novel antiparasitic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqub6fPyIvFQrVg90H21EOLACvtfcHk0liBhoOIsrtbKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvV2qtrk%253D&md5=3738f88674b6e5856d55bab7a0701e22</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.23.13143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.23.13143%26sid%3Dliteratum%253Aachs%26aulast%3DDarkin-Rattray%26aufirst%3DS.%2BJ.%26aulast%3DGurnett%26aufirst%3DA.%2BM.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DDulski%26aufirst%3DP.%2BM.%26aulast%3DCrumley%26aufirst%3DT.%2BM.%26aulast%3DAllocco%26aufirst%3DJ.%2BJ.%26aulast%3DCannova%26aufirst%3DC.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DBednarek%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26aulast%3DGoetz%26aufirst%3DM.%2BA.%26aulast%3DDombrowski%26aufirst%3DA.%2BW.%26aulast%3DPolishook%26aufirst%3DJ.%2BD.%26aulast%3DSchmatz%26aufirst%3DD.%2BM.%26atitle%3DApicidin%253A%2520a%2520novel%2520antiprotozoal%2520agent%2520that%2520inhibits%2520parasite%2520histone%2520deacetylase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D13143%26epage%3D13147%26doi%3D10.1073%2Fpnas.93.23.13143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darkin-Rattray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurnett, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galuska, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allocco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumley, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannova, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmatz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span> </span><span class="NLM_article-title">Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00604-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0960-894X%2800%2900604-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=107-111&author=S.+L.+Collettiauthor=R.+W.+Myersauthor=S.+J.+Darkin-Rattrayauthor=A.+M.+Gurnettauthor=P.+M.+Dulskiauthor=S.+Galuskaauthor=J.+J.+Alloccoauthor=M.+B.+Ayerauthor=C.+Liauthor=J.+Limauthor=T.+M.+Crumleyauthor=C.+Cannovaauthor=D.+M.+Schmatzauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=P.+T.+Meinke&title=Broad+spectrum+antiprotozoal+agents+that+inhibit+histone+deacetylase%3A+structure-activity+relationships+of+apicidin.+Part+1&doi=10.1016%2FS0960-894X%2800%2900604-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900604-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900604-1%26sid%3Dliteratum%253Aachs%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DDarkin-Rattray%26aufirst%3DS.%2BJ.%26aulast%3DGurnett%26aufirst%3DA.%2BM.%26aulast%3DDulski%26aufirst%3DP.%2BM.%26aulast%3DGaluska%26aufirst%3DS.%26aulast%3DAllocco%26aufirst%3DJ.%2BJ.%26aulast%3DAyer%26aufirst%3DM.%2BB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DCrumley%26aufirst%3DT.%2BM.%26aulast%3DCannova%26aufirst%3DC.%26aulast%3DSchmatz%26aufirst%3DD.%2BM.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26atitle%3DBroad%2520spectrum%2520antiprotozoal%2520agents%2520that%2520inhibit%2520histone%2520deacetylase%253A%2520structure-activity%2520relationships%2520of%2520apicidin.%2520Part%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D107%26epage%3D111%26doi%3D10.1016%2FS0960-894X%2800%2900604-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Colletti, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darkin-Rattray, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurnett, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galuska, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allocco, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumley, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannova, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmatz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P. T.</span><span> </span><span class="NLM_article-title">Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00605-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0960-894X%2800%2900605-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=113-117&author=S.+L.+Collettiauthor=R.+W.+Myersauthor=S.+J.+Darkin-Rattrayauthor=A.+M.+Gurnettauthor=P.+M.+Dulskiauthor=S.+Galuskaauthor=J.+J.+Alloccoauthor=M.+B.+Ayerauthor=C.+Liauthor=J.+Limauthor=T.+M.+Crumleyauthor=C.+Cannovaauthor=D.+M.+Schmatzauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=P.+T.+Meinke&title=Broad+spectrum+antiprotozoal+agents+that+inhibit+histone+deacetylase%3A+structure-activity+relationships+of+apicidin.+Part+2&doi=10.1016%2FS0960-894X%2800%2900605-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900605-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900605-3%26sid%3Dliteratum%253Aachs%26aulast%3DColletti%26aufirst%3DS.%2BL.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DDarkin-Rattray%26aufirst%3DS.%2BJ.%26aulast%3DGurnett%26aufirst%3DA.%2BM.%26aulast%3DDulski%26aufirst%3DP.%2BM.%26aulast%3DGaluska%26aufirst%3DS.%26aulast%3DAllocco%26aufirst%3DJ.%2BJ.%26aulast%3DAyer%26aufirst%3DM.%2BB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DCrumley%26aufirst%3DT.%2BM.%26aulast%3DCannova%26aufirst%3DC.%26aulast%3DSchmatz%26aufirst%3DD.%2BM.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26atitle%3DBroad%2520spectrum%2520antiprotozoal%2520agents%2520that%2520inhibit%2520histone%2520deacetylase%253A%2520structure-activity%2520relationships%2520of%2520apicidin.%2520Part%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D113%26epage%3D117%26doi%3D10.1016%2FS0960-894X%2800%2900605-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenical, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, R. B.</span><span> </span><span class="NLM_article-title">Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">6535</span><span class="NLM_x">–</span> <span class="NLM_lpage">6541</span><span class="refDoi"> DOI: 10.1016/j.tet.2007.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.tet.2007.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVanu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=6535-6541&author=W.+Guauthor=M.+Cuetoauthor=P.+R.+Jensenauthor=W.+Fenicalauthor=R.+B.+Silverman&title=Microsporins+A+and+B%3A+new+histone+deacetylase+inhibitors+from+the+marine-derived+fungus+Microsporum+cf.+gypseum+and+the+solid-phase+synthesis+of+microsporin+A&doi=10.1016%2Fj.tet.2007.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A</span></div><div class="casAuthors">Gu, Wenxin; Cueto, Mercedes; Jensen, Paul R.; Fenical, William; Silverman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">6535-6541</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Two new cyclic peptides, microsporins A (I) and B, were isolated from culture exts. of the marine-derived fungus Microsporum cf. gypseum obtained from a sample of the bryozoan Bugula sp. collected in the U.S. Virgin Islands.  The structures of the new compds. were detd. by extensive interpretation of 2D NMR data and by chem. methods.  Microsporins A and B are potent inhibitors of histone deacetylase and demonstrate cytotoxic activity against human colon adenocarcinoma (HCT-116), as well as against the National Cancer Institute 60 cancer cell panel.  The total synthesis of microsporin A on solid-phase is also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoom2iPklesGrVg90H21EOLACvtfcHk0lgWVIkUnb9DSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVanu74%253D&md5=ac43010ba13b93aacb4a8b5a6e6ce6a6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2007.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2007.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DW.%26aulast%3DCueto%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DP.%2BR.%26aulast%3DFenical%26aufirst%3DW.%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26atitle%3DMicrosporins%2520A%2520and%2520B%253A%2520new%2520histone%2520deacetylase%2520inhibitors%2520from%2520the%2520marine-derived%2520fungus%2520Microsporum%2520cf.%2520gypseum%2520and%2520the%2520solid-phase%2520synthesis%2520of%2520microsporin%2520A%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D6535%26epage%3D6541%26doi%3D10.1016%2Fj.tet.2007.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horinouchi, S.</span><span> </span><span class="NLM_article-title">FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">241</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1006/excr.1998.4027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1006%2Fexcr.1998.4027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=9633520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVGjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=1998&pages=126-133&author=H.+Nakajimaauthor=Y.+B.+Kimauthor=H.+Teranoauthor=M.+Yoshidaauthor=S.+Horinouchi&title=FR901228%2C+a+potent+antitumor+antibiotic%2C+is+a+novel+histone+deacetylase+inhibitor&doi=10.1006%2Fexcr.1998.4027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor</span></div><div class="casAuthors">Nakajima, Hidenori; Kim, Young Bae; Terano, Hiroshi; Yoshida, Minoru; Horinouchi, Sueharu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">126-133</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Screening for microbial metabolites that induce transcriptional activation of the SV40 promoter resulted in the identification of two known compds., FR901228 and trichostatin A (TSA).  FR901228 is a potent antitumor drug that is currently under clin. investigation.  TSA is a specific inhibitor of histone deacetylase.  Despite structural differences, both FR901228 and TSA greatly enhanced the transcriptional activity of the SV40 promoter in an enhancer-dependent manner.  The effects of FR901228 on the cell cycle, chromatin structure, and histone acetylation were examd. and compared to the effects of TSA.  Both compds. arrested the cell cycle at both G1 and G2/M phases and induced internucleosomal breakdown of chromatin.  FR901228, like TSA, inhibited the intracellular histone deacetylase activity, as a result of which marked amts. of acetylated histone species accumulated.  Thus, FR901228 is a new type of histone deacetylase inhibitor whose chem. structure is unrelated to known inhibitors such as trichostatins and trapoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDyUNz818nbVg90H21EOLACvtfcHk0lgQlwN2mprzkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVGjtLY%253D&md5=f0e72c561596900036c9062bf2db2990</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1006%2Fexcr.1998.4027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.1998.4027%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DY.%2BB.%26aulast%3DTerano%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DHorinouchi%26aufirst%3DS.%26atitle%3DFR901228%252C%2520a%2520potent%2520antitumor%2520antibiotic%252C%2520is%2520a%2520novel%2520histone%2520deacetylase%2520inhibitor%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D1998%26volume%3D241%26spage%3D126%26epage%3D133%26doi%3D10.1006%2Fexcr.1998.4027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Masuoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin-ya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furihata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, H.</span><span> </span><span class="NLM_article-title">Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1016/S0040-4039(00)01874-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0040-4039%2800%2901874-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFGltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=41-44&author=K.+Masuokaauthor=A.+Nagaiauthor=K.+Shin-yaauthor=K.+Furihataauthor=K.+Nagaiauthor=K.-I.+Suzukiauthor=Y.+Hayakawaauthor=H.+Seto&title=Spiruchostatins+A+and+B%2C+novel+gene+expression-enhancing+substances+produced+by+Pseudomonas+sp&doi=10.1016%2FS0040-4039%2800%2901874-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp.</span></div><div class="casAuthors">Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.-i.; Hayakawa, Y.; Seto, H.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-44</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The fermn., isolation, structure detn., and bioactivity of spiruchostatins A and B (I and II, resp.) from Pseudomonas sp. are reported.  I and II possess novel bicyclic depsipeptides involving 4-amino-3-hydroxy-5-methylhexanoic acid and 4-amino-3-hydroxy-5-methylheptanoic acid residues, resp.  I and II, which show TGF-β-activity, induced reporter gene expression under the control of the plasminogen activator inhibitor-1 promoter and were cytostatic in MvlLu cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokWgn-44JpcrVg90H21EOLACvtfcHk0lgQlwN2mprzkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFGltrs%253D&md5=ecfb97120c1915541855d148aa492bdb</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2901874-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252901874-8%26sid%3Dliteratum%253Aachs%26aulast%3DMasuoka%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DA.%26aulast%3DShin-ya%26aufirst%3DK.%26aulast%3DFurihata%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DK.-I.%26aulast%3DHayakawa%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DH.%26atitle%3DSpiruchostatins%2520A%2520and%2520B%252C%2520novel%2520gene%2520expression-enhancing%2520substances%2520produced%2520by%2520Pseudomonas%2520sp%26jtitle%3DTetrahedron%2520Lett.%26date%3D2001%26volume%3D42%26spage%3D41%26epage%3D44%26doi%3D10.1016%2FS0040-4039%2800%2901874-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Taori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luesch, H.</span><span> </span><span class="NLM_article-title">Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1806</span><span class="NLM_x">–</span> <span class="NLM_lpage">1807</span><span class="refDoi"> DOI: 10.1021/ja7110064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja7110064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotFGhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=1806-1807&author=K.+Taoriauthor=V.+J.+Paulauthor=H.+Luesch&title=Structure+and+activity+of+largazole%2C+a+potent+antiproliferative+agent+from+the+Floridian+marine+cyanobacterium+Symploca+sp&doi=10.1021%2Fja7110064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium Symploca sp.</span></div><div class="casAuthors">Taori, Kanchan; Paul, Valerie J.; Luesch, Hendrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1806-1807</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel cytotoxic cyclodepsipeptide, termed largazole, has been isolated from the marine cyanobacterium Symploca sp. collected in the Florida Keys.  Its planar structure was elucidated by 1D and 2D NMR spectroscopy in conjunction with mass spectrometry.  The abs. configuration of largazole was detd. by chem. degrdn. followed by chiral HPLC anal.  Largazole possesses densely assembled unusual structural features, including a rare 4-methylthiazoline linearly fused to a thiazole in its cyclic core and a hitherto undescribed 3-hydroxy-7-mercaptohept-4-enoic acid unit incorporated in an ester, thioester, and amide framework.  Largazole exhibits potent antiproliferative activity and preferentially targets cancer cells over nontransformed cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0JtehDfpXXLVg90H21EOLACvtfcHk0lhcdaE1e0BJhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotFGhtw%253D%253D&md5=bcd18bbee431e273c1b646f3c9c1388b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fja7110064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja7110064%26sid%3Dliteratum%253Aachs%26aulast%3DTaori%26aufirst%3DK.%26aulast%3DPaul%26aufirst%3DV.%2BJ.%26aulast%3DLuesch%26aufirst%3DH.%26atitle%3DStructure%2520and%2520activity%2520of%2520largazole%252C%2520a%2520potent%2520antiproliferative%2520agent%2520from%2520the%2520Floridian%2520marine%2520cyanobacterium%2520Symploca%2520sp%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D1806%26epage%3D1807%26doi%3D10.1021%2Fja7110064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Nakao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindoh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganesan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Soest, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusetani, N.</span><span> </span><span class="NLM_article-title">Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">7553</span><span class="NLM_x">–</span> <span class="NLM_lpage">7557</span><span class="refDoi"> DOI: 10.1002/anie.200602047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fanie.200602047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=7553-7557&author=Y.+Nakaoauthor=S.+Yoshidaauthor=S.+Matsunagaauthor=N.+Shindohauthor=Y.+Teradaauthor=K.+Nagaiauthor=J.+K.+Yamashitaauthor=A.+Ganesanauthor=R.+W.+van+Soestauthor=N.+Fusetani&title=Azumamides+A-E%3A+histone+deacetylase+inhibitory+cyclic+tetrapeptides+from+the+marine+sponge+Mycale+izuensis&doi=10.1002%2Fanie.200602047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2Fanie.200602047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200602047%26sid%3Dliteratum%253Aachs%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DShindoh%26aufirst%3DN.%26aulast%3DTerada%26aufirst%3DY.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DJ.%2BK.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3Dvan%2BSoest%26aufirst%3DR.%2BW.%26aulast%3DFusetani%26aufirst%3DN.%26atitle%3DAzumamides%2520A-E%253A%2520histone%2520deacetylase%2520inhibitory%2520cyclic%2520tetrapeptides%2520from%2520the%2520marine%2520sponge%2520Mycale%2520izuensis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D7553%26epage%3D7557%26doi%3D10.1002%2Fanie.200602047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapustin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, F. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of a potent histone deacetylase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2006</span><span class="refDoi"> DOI: 10.1021/jm061082q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061082q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2003-2006&author=T.+Liuauthor=G.+Kapustinauthor=F.+A.+Etzkorn&title=Design+and+synthesis+of+a+potent+histone+deacetylase+inhibitor&doi=10.1021%2Fjm061082q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm061082q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061082q%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DKapustin%26aufirst%3DG.%26aulast%3DEtzkorn%26aufirst%3DF.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520potent%2520histone%2520deacetylase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2003%26epage%3D2006%26doi%3D10.1021%2Fjm061082q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Pirali, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faccio, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mossetti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grolla, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Micco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifulco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tron, G. C.</span><span> </span><span class="NLM_article-title">Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3 + 2] cycloaddition</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1007/s11030-009-9153-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs11030-009-9153-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=109-121&author=T.+Piraliauthor=V.+Faccioauthor=R.+Mossettiauthor=A.+A.+Grollaauthor=S.+Di+Miccoauthor=G.+Bifulcoauthor=A.+A.+Genazzaniauthor=G.+C.+Tron&title=Synthesis%2C+molecular+docking+and+biological+evaluation+as+HDAC+inhibitors+of+cyclopeptide+mimetics+by+a+tandem+three-component+reaction+and+intramolecular+%5B3+%2B+2%5D+cycloaddition&doi=10.1007%2Fs11030-009-9153-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs11030-009-9153-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-009-9153-9%26sid%3Dliteratum%253Aachs%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFaccio%26aufirst%3DV.%26aulast%3DMossetti%26aufirst%3DR.%26aulast%3DGrolla%26aufirst%3DA.%2BA.%26aulast%3DDi%2BMicco%26aufirst%3DS.%26aulast%3DBifulco%26aufirst%3DG.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26aulast%3DTron%26aufirst%3DG.%2BC.%26atitle%3DSynthesis%252C%2520molecular%2520docking%2520and%2520biological%2520evaluation%2520as%2520HDAC%2520inhibitors%2520of%2520cyclopeptide%2520mimetics%2520by%2520a%2520tandem%2520three-component%2520reaction%2520and%2520intramolecular%2520%255B3%2520%252B%25202%255D%2520cycloaddition%26jtitle%3DMol.%2520Diversity%26date%3D2010%26volume%3D14%26spage%3D109%26epage%3D121%26doi%3D10.1007%2Fs11030-009-9153-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Ning, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N. F.</span><span> </span><span class="NLM_article-title">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.ejmech.2015.03.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25800646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=104-115&author=C.+Q.+Ningauthor=C.+Luauthor=L.+Huauthor=Y.+J.+Biauthor=L.+Yaoauthor=Y.+J.+Heauthor=L.+F.+Liuauthor=X.+Y.+Liuauthor=N.+F.+Yu&title=Macrocyclic+compounds+as+anti-cancer+agents%3A+Design+and+synthesis+of+multi-acting+inhibitors+against+HDAC%2C+FLT3+and+JAK2&doi=10.1016%2Fj.ejmech.2015.03.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2</span></div><div class="casAuthors">Ning, Cheng-Qing; Lu, Cheng; Hu, Liang; Bi, Yan-Jing; Yao, Lei; He, Yu-Jun; Liu, Li-Fei; Liu, Xiao-Yu; Yu, Nie-Fang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-115</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of macrocyclic compds. I [X = O, CH2O; Y = CH2, CO; n = 1, 2; m = 1-5] were designed and synthesized as multi-target inhibitors targeting HDAC, FLT3 and JAK2.  Some of these compds. exhibited potent HDAC inhibition as well as FLT3 and JAK2 inhibition under both cell-free and cellular conditions.  In vitro antiproliferative assay indicated that these compds. were interestingly more cytotoxic to MV4-11 cells bearing FLT3-ITD mutation and HEL cells bearing JAK2V617F mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvwiDjzqtazLVg90H21EOLACvtfcHk0li0uN0rRRVDfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWitbY%253D&md5=fc2b93fcbce2998ecd2d6de46a01811d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DC.%2BQ.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBi%26aufirst%3DY.%2BJ.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DY.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DYu%26aufirst%3DN.%2BF.%26atitle%3DMacrocyclic%2520compounds%2520as%2520anti-cancer%2520agents%253A%2520Design%2520and%2520synthesis%2520of%2520multi-acting%2520inhibitors%2520against%2520HDAC%252C%2520FLT3%2520and%2520JAK2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115%26doi%3D10.1016%2Fj.ejmech.2015.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B.</span><span> </span><span class="NLM_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1007/s10822-012-9572-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs10822-012-9572-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=437-450&author=A.+Poulsenauthor=A.+Williamauthor=S.+Blanchardauthor=A.+Leeauthor=H.+Nagarajauthor=H.+Wangauthor=E.+Teoauthor=E.+Tanauthor=K.+C.+Gohauthor=B.+Dymock&title=Structure-based+design+of+oxygen-linked+macrocyclic+kinase+inhibitors%3A+discovery+of+SB1518+and+SB1578%2C+potent+inhibitors+of+Janus+kinase+2+%28JAK2%29+and+Fms-like+tyrosine+kinase-3+%28FLT3%29&doi=10.1007%2Fs10822-012-9572-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTeo%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DDymock%26aufirst%3DB.%26atitle%3DStructure-based%2520design%2520of%2520oxygen-linked%2520macrocyclic%2520kinase%2520inhibitors%253A%2520discovery%2520of%2520SB1518%2520and%2520SB1578%252C%2520potent%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520and%2520Fms-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2012%26volume%3D26%26spage%3D437%26epage%3D450%26doi%3D10.1007%2Fs10822-012-9572-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Nolan, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clavier, H.</span><span> </span><span class="NLM_article-title">Chemoselective olefin metathesis transformations mediated by ruthenium complexes</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3305</span><span class="NLM_x">–</span> <span class="NLM_lpage">3316</span><span class="refDoi"> DOI: 10.1039/b912410c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1039%2Fb912410c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=20593074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFyhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=3305-3316&author=S.+P.+Nolanauthor=H.+Clavier&title=Chemoselective+olefin+metathesis+transformations+mediated+by+ruthenium+complexes&doi=10.1039%2Fb912410c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoselective olefin metathesis transformations mediated by ruthenium complexes</span></div><div class="casAuthors">Nolan, Steven P.; Clavier, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3305-3316</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Over the past decade, ruthenium-mediated metathesis transformations, including polymn. reactions, cross-metathesis, ring-closing metathesis, enyne metathesis, ring-rearrangement metathesis, and also tandem processes, represent one of the most studied families of org. reactions.  This has translated into the development of a large no. of structurally diverse catalysts.  Whereas most of these investigations are focused on detg. catalytic performance, only rare examples of studies dealing with chemoselectivity have been reported to date.  Usually, variations are obsd. in product conversions but rarely in product distributions.  In this crit. review, we provide an overview of the stereochem. of newly formed C=C bonds either in ring-closing or cross-metathesis as a function of the catalyst structure.  A discussion of disparities encountered in macrocyclization reactions leading (or not) to the formation of dimeric products is also presented.  Since distinctive metathesis products could be isolated as a function of the ligand borne by the ruthenium center-phosphine or N-heterocyclic carbene in the dissymmetrization of trienes, enyne metathesis and ring rearrangements, these topics are also discussed (72 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN9nKFf5G4lrVg90H21EOLACvtfcHk0lgJPqTS5pMbGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFyhu7Y%253D&md5=43408b8fc8900396bfdd4a497e60818c</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1039%2Fb912410c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb912410c%26sid%3Dliteratum%253Aachs%26aulast%3DNolan%26aufirst%3DS.%2BP.%26aulast%3DClavier%26aufirst%3DH.%26atitle%3DChemoselective%2520olefin%2520metathesis%2520transformations%2520mediated%2520by%2520ruthenium%2520complexes%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2010%26volume%3D39%26spage%3D3305%26epage%3D3316%26doi%3D10.1039%2Fb912410c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Bermudez-Lugo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Gonzalez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosales-Hernandez, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilizaliturri-Flores, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo-Ferrara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correa-Basurto, J.</span><span> </span><span class="NLM_article-title">Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2301</span><span class="NLM_x">–</span> <span class="NLM_lpage">2310</span><span class="refDoi"> DOI: 10.1007/s00894-011-1240-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs00894-011-1240-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=21968575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2301-2310&author=J.+A.+Bermudez-Lugoauthor=O.+Perez-Gonzalezauthor=M.+C.+Rosales-Hernandezauthor=I.+Ilizaliturri-Floresauthor=J.+Trujillo-Ferraraauthor=J.+Correa-Basurto&title=Exploration+of+the+valproic+acid+binding+site+on+histone+deacetylase+8+using+docking+and+molecular+dynamic+simulations&doi=10.1007%2Fs00894-011-1240-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations</span></div><div class="casAuthors">Bermudez-Lugo, Jorge Antonio; Perez-Gonzalez, Oscar; Rosales-Hernandez, Martha Cecilia; Ilizaliturri-Flores, Ian; Trujillo-Ferrara, Jose; Correa-Basurto, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2301-2310</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epigenetic therapy is an important focus of research for drug development in the treatment of cancer.  Valproic acid (VPA) is a histone deacetylase (HDAC) inhibitor that has been evaluated in clin. studies.  Despite its success in treating cancer, the mechanism of inhibition of VPA in HDAC is unknown.  Here, to this end, the authors used mol. docking and mol. dynamics (MD) simulations to investigate VPA binding to HDAC, employing both native and rebuilt 3-dimensional (3D) structures.  The results showed that VPA, via its carboxyl group, coordinates the Zn atom and other local residues (His-141/His-142 and Tyr-360) located at the catalytic site (CS) of HDAC.  This caused electrostatic and H-bonding interactions while having little interaction with the hydrophobic side-chains, resulting in a low affinity.  However, after several docking studies on different native HDAC 3D structures and after using several snapshots from MD simulations, it became apparent that VPA bound with highest affinity at a site located at the acetyl-releasing channel, termed the hydrophobic active site channel (HASC).  The affinity of VPA for HASC was due to its highly hydrophobic properties that allowed VPA to take part in van der Waals interactions with Tyr-18, Ile-19, Tyr-20, Val-25, Arg-37, Ala-38, Val-41, His-42, Ile-135, and Trp-137, while VPA's carboxylate group had several H-bonding interactions with the backbones of Ser-138, Ile-19, Asn-136, and Trp-137.  MD simulations showed that the HASC door continuously opened and closed, which affected the affinity of VPA to the HASC, but the affinity toward the HASC was consistently higher than that obtained for the CS, suggesting that the HASC could be involved in the mechanism of inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-e-M0_PDozLVg90H21EOLACvtfcHk0lgJPqTS5pMbGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFOhtbs%253D&md5=39470c3338c39377a8ba05e4ad5a11e4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs00894-011-1240-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-011-1240-z%26sid%3Dliteratum%253Aachs%26aulast%3DBermudez-Lugo%26aufirst%3DJ.%2BA.%26aulast%3DPerez-Gonzalez%26aufirst%3DO.%26aulast%3DRosales-Hernandez%26aufirst%3DM.%2BC.%26aulast%3DIlizaliturri-Flores%26aufirst%3DI.%26aulast%3DTrujillo-Ferrara%26aufirst%3DJ.%26aulast%3DCorrea-Basurto%26aufirst%3DJ.%26atitle%3DExploration%2520of%2520the%2520valproic%2520acid%2520binding%2520site%2520on%2520histone%2520deacetylase%25208%2520using%2520docking%2520and%2520molecular%2520dynamic%2520simulations%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2012%26volume%3D18%26spage%3D2301%26epage%3D2310%26doi%3D10.1007%2Fs00894-011-1240-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Bieliauskas, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pflum, M. K.</span><span> </span><span class="NLM_article-title">Isoform-selective histone deacetylase inhibitors</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1402</span><span class="NLM_x">–</span> <span class="NLM_lpage">1413</span><span class="refDoi"> DOI: 10.1039/b703830p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1039%2Fb703830p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18568166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=1402-1413&author=A.+V.+Bieliauskasauthor=M.+K.+Pflum&title=Isoform-selective+histone+deacetylase+inhibitors&doi=10.1039%2Fb703830p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective histone deacetylase inhibitors</span></div><div class="casAuthors">Bieliauskas, Anton V.; Pflum, Mary Kay H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1402-1413</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer.  As a result, multiple small mol. HDAC inhibitors are in various phases of clin. trials as anti-cancer drugs.  The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes.  This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors.  The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXOB_YFWaeZrVg90H21EOLACvtfcHk0ljknEskQTG4sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFejsbs%253D&md5=326e20da0623a00114f43e5c459c9920</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1039%2Fb703830p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb703830p%26sid%3Dliteratum%253Aachs%26aulast%3DBieliauskas%26aufirst%3DA.%2BV.%26aulast%3DPflum%26aufirst%3DM.%2BK.%26atitle%3DIsoform-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26spage%3D1402%26epage%3D1413%26doi%3D10.1039%2Fb703830p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. H.</span><span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljknEskQTG4sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Vishwakarma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shastry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulathingal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vijaykanth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajesh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathinasamy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kachhadia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilambi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajgopal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, S.</span><span> </span><span class="NLM_article-title">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span> <span class="citation_source-journal">Int. Immunopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1016/j.intimp.2013.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.intimp.2013.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23541634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=72-78&author=S.+Vishwakarmaauthor=L.+R.+Iyerauthor=M.+Muleyauthor=P.+K.+Singhauthor=A.+Shastryauthor=A.+Saxenaauthor=J.+Kulathingalauthor=G.+Vijaykanthauthor=J.+Raghulauthor=N.+Rajeshauthor=S.+Rathinasamyauthor=V.+Kachhadiaauthor=N.+Kilambiauthor=S.+Rajgopalauthor=G.+Balasubramanianauthor=S.+Narayanan&title=Tubastatin%2C+a+selective+histone+deacetylase+6+inhibitor+shows+anti-inflammatory+and+anti-rheumatic+effects&doi=10.1016%2Fj.intimp.2013.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects</span></div><div class="casAuthors">Vishwakarma, Santosh; Iyer, Lakshmi R.; Muley, Milind; Singh, Pankaj Kumar; Shastry, Arun; Saxena, Ambrish; Kulathingal, Jayanarayan; Vijaykanth, G.; Raghul, J.; Rajesh, Navin; Rathinasamy, Suresh; Kachhadia, Virendra; Kilambi, Narasimhan; Rajgopal, Sridharan; Balasubramanian, Gopalan; Narayanan, Shridhar</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-78</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Epigenetic modifications represent a promising new approach to modulate cell functions as obsd. in autoimmune diseases.  Emerging evidence suggests the utility of HDAC inhibitors in the treatment of chronic immune and inflammatory disorders.  However, class and isoform selective inhibition of HDAC is currently favored as it limits the toxicity that was obsd. with pan-HDAC inhibitors.  HDAC6, a member of the HDAC family, whose major substrate is α-tubulin, is being increasingly implicated in the pathogenesis of inflammatory disorders.  The present study was carried out to study the potential anti-inflammatory and anti-rheumatic effects of HDAC6 selective inhibitor Tubastatin.  Tubastatin, a potent human HDAC6 inhibitor with an IC50 of 11 nM showed significant inhibition of TNF-α and IL-6 in LPS stimulated human THP-1 macrophages with an IC50 of 272 nM and 712 nM, resp.  Addnl., Tubastatin inhibited NO secretion in murine Raw 264.7 macrophages dose dependently with an IC50 of 4.2 μM and induced α-tubulin hyperacetylation corresponding to HDAC6 inhibition in THP-1 cells without affecting the cell viability.  Tubastatin showed significant inhibition of paw vol. at 30 mg/kg i.p. in a Freund's complete adjuvant (FCA) induced animal model of inflammation.  The disease modifying activity of Tubastatin was also evident in collagen induced arthritis DBA1 mouse model at 30 mg/kg i.p.  The significant attenuation of clin. scores (∼ 70%) by Tubastatin was confirmed histopathol. and was found comparable to dexamethasone (∼ 90% inhibition of clin. scores).  Tubastatin showed significant inhibition of IL-6 in paw tissues of arthritic mice.  The present work has demonstrated anti-inflammatory and antirheumatic effects of a selective HDAC6 inhibitor Tubastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVjF7tHATlYbVg90H21EOLACvtfcHk0ljGg0L4AOkuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlWjsr4%253D&md5=1810b101113330405d3923cbadb628b7</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2013.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2013.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DL.%2BR.%26aulast%3DMuley%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DShastry%26aufirst%3DA.%26aulast%3DSaxena%26aufirst%3DA.%26aulast%3DKulathingal%26aufirst%3DJ.%26aulast%3DVijaykanth%26aufirst%3DG.%26aulast%3DRaghul%26aufirst%3DJ.%26aulast%3DRajesh%26aufirst%3DN.%26aulast%3DRathinasamy%26aufirst%3DS.%26aulast%3DKachhadia%26aufirst%3DV.%26aulast%3DKilambi%26aufirst%3DN.%26aulast%3DRajgopal%26aufirst%3DS.%26aulast%3DBalasubramanian%26aufirst%3DG.%26aulast%3DNarayanan%26aufirst%3DS.%26atitle%3DTubastatin%252C%2520a%2520selective%2520histone%2520deacetylase%25206%2520inhibitor%2520shows%2520anti-inflammatory%2520and%2520anti-rheumatic%2520effects%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2013%26volume%3D16%26spage%3D72%26epage%3D78%26doi%3D10.1016%2Fj.intimp.2013.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Estiu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwiatkowski, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span> </span><span class="NLM_article-title">Structural origin of selectivity in class II-selective histone deacetylase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2898</span><span class="NLM_x">–</span> <span class="NLM_lpage">2906</span><span class="refDoi"> DOI: 10.1021/jm7015254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7015254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1OgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2898-2906&author=G.+Estiuauthor=E.+Greenbergauthor=C.+B.+Harrisonauthor=N.+P.+Kwiatkowskiauthor=R.+Mazitschekauthor=J.+E.+Bradnerauthor=O.+Wiest&title=Structural+origin+of+selectivity+in+class+II-selective+histone+deacetylase+inhibitors&doi=10.1021%2Fjm7015254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Origin of Selectivity in Class II-Selective Histone Deacetylase Inhibitors</span></div><div class="casAuthors">Estiu, Guillermina; Greenberg, Edward; Harrison, Christopher B.; Kwiatkowski, Nicholas P.; Mazitschek, Ralph; Bradner, James E.; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2898-2906</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of class- and isoform-selective histone deacetylase (HDAC) inhibitors is highly desirable for the study of the complex interactions of these proteins central to transcription regulation as well as for the development of selective HDAC inhibitors as drugs in epigenetics.  To provide a structural basis for the rational design of such inhibitors, a combined computational and exptl. study of inhibition of three different histone deacetylase isoforms, HDAC1, -6, and -8, with three different hydroxamate inhibitors is reported.  While SAHA was found to be unselective for the inhibition of class I and class II HDACs, the other inhibitors were found to be selective toward class II HDACs.  Mol. dynamics simulations indicate that this selectivity is caused by both the overall shape of the protein surface leading to the active site and specific interactions of an aspartate residue in a polar loop and two phenylalanines and a methionine in a nonpolar loop.  Monitoring the specific interactions as a function of the simulation time identifies a key sulfur-π interaction.  The implications of the structural motifs for the design of class II-selective HDAC inhibitors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo72HMKgUIVlbVg90H21EOLACvtfcHk0ljGg0L4AOkuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1OgurY%253D&md5=1d40feba51520076866d6bf60555a952</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fjm7015254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7015254%26sid%3Dliteratum%253Aachs%26aulast%3DEstiu%26aufirst%3DG.%26aulast%3DGreenberg%26aufirst%3DE.%26aulast%3DHarrison%26aufirst%3DC.%2BB.%26aulast%3DKwiatkowski%26aufirst%3DN.%2BP.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DStructural%2520origin%2520of%2520selectivity%2520in%2520class%2520II-selective%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2898%26epage%3D2906%26doi%3D10.1021%2Fjm7015254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lélias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule–kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%80%93kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljGg0L4AOkuzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2580%2593kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piñeiro, R.</span><span> </span><span class="NLM_article-title">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span> <span class="citation_source-journal">J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1007/s00109-015-1352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1007%2Fs00109-015-1352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=26658520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=5-11&author=B.+Vanhaesebroeckauthor=M.+A.+Whiteheadauthor=R.+Pi%C3%B1eiro&title=Molecules+in+medicine+mini-review%3A+isoforms+of+PI3K+in+biology+and+disease&doi=10.1007%2Fs00109-015-1352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Whitehead, Maria A.; Pineiro, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiol. and disease.  In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease.  Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the etiol. and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders.  The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development.  In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies.  The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5USj-Hs5rVg90H21EOLACvtfcHk0lgBHHQsBDvUAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE&md5=7b78f2b78ddeed390ab133c562ec6725</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1007%2Fs00109-015-1352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-015-1352-5%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DM.%2BA.%26aulast%3DPi%25C3%25B1eiro%26aufirst%3DR.%26atitle%3DMolecules%2520in%2520medicine%2520mini-review%253A%2520isoforms%2520of%2520PI3K%2520in%2520biology%2520and%2520disease%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2016%26volume%3D94%26spage%3D5%26epage%3D11%26doi%3D10.1007%2Fs00109-015-1352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgBHHQsBDvUAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Hurwitz, H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uppal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendell, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pipas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainberg, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manges, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandor, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R. S.</span><span> </span><span class="NLM_article-title">Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">4039</span><span class="NLM_x">–</span> <span class="NLM_lpage">4047</span><span class="refDoi"> DOI: 10.1200/JCO.2015.61.4578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1200%2FJCO.2015.61.4578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=26351344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SqtbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=4039-4047&author=H.+I.+Hurwitzauthor=N.+Uppalauthor=S.+A.+Wagnerauthor=J.+C.+Bendellauthor=J.+T.+Beckauthor=S.+M.+Wadeauthor=J.+J.+Nemunaitisauthor=P.+J.+Stellaauthor=J.+M.+Pipasauthor=Z.+A.+Wainbergauthor=R.+Mangesauthor=W.+M.+Garrettauthor=D.+S.+Hunterauthor=J.+Clarkauthor=L.+Leopoldauthor=V.+Sandorauthor=R.+S.+Levy&title=Randomized%2C+double-blind%2C+phase+II+study+of+ruxolitinib+or+placebo+in+combination+with+capecitabine+in+patients+with+metastatic+pancreatic+cancer+for+whom+therapy+with+gemcitabine+has+failed&doi=10.1200%2FJCO.2015.61.4578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed</span></div><div class="casAuthors">Hurwitz, Herbert I.; Uppal, Nikhil; Wagner, Stephanie A.; Bendell, Johanna C.; Beck, J. Thaddeus; Wade, Seaborn M., III; Nemunaitis, John J.; Stella, Philip J.; Pipas, J. Marc; Wainberg, Zev A.; Manges, Robert; Garrett, William M.; Hunter, Deborah S.; Clark, Jason; Leopold, Lance; Sandor, Victor; Levy, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4039-4047</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options.  Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clin. course of pancreatic cancer.  Patients and Methods: In this double-blind, phase II study, patients with metastatic pancreatic cancer who had experienced treatment failure with gemcitabine were randomly assigned 1:1 to the JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m2 twice daily) or placebo plus capecitabine.  The primary end point was overall survival (OS); secondary end points included progression-free survival, clin. benefit response, objective response rate, and safety.  Prespecified subgroup analyses evaluated treatment heterogeneity and efficacy in patients with evidence of inflammation.  Results: In the intent-to-treat population (ruxolitinib, n = 64; placebo, n = 63), the hazard ratio was 0.79 (95% CI, 0.53 to 1.18; P = .25) for OS and was 0.75 (95% CI, 0.52 to 1.10; P = .14) for progression-free survival.  In a prespecified subgroup anal. of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011).  Prolonged survival in this subgroup was supported by post hoc analyses of OS that categorized patients by the modified Glasgow Prognostic Score, a systemic inflammation-based prognostic system.  Grade 3 or greater adverse events were obsd. with similar frequency in the ruxolitinib (74.6%) and placebo (81.7%) groups.  Grade 3 or greater anemia was more frequent with ruxolitinib (15.3%; placebo, 1.7%).  Conclusion: Ruxolitinib plus capecitabine was generally well tolerated and may improve survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEiprZROUgWbVg90H21EOLACvtfcHk0lgZSO1M_9h4Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SqtbrL&md5=511197949263e459564efdcde24074a8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.61.4578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.61.4578%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%2BI.%26aulast%3DUppal%26aufirst%3DN.%26aulast%3DWagner%26aufirst%3DS.%2BA.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DWade%26aufirst%3DS.%2BM.%26aulast%3DNemunaitis%26aufirst%3DJ.%2BJ.%26aulast%3DStella%26aufirst%3DP.%2BJ.%26aulast%3DPipas%26aufirst%3DJ.%2BM.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DManges%26aufirst%3DR.%26aulast%3DGarrett%26aufirst%3DW.%2BM.%26aulast%3DHunter%26aufirst%3DD.%2BS.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DL.%26aulast%3DSandor%26aufirst%3DV.%26aulast%3DLevy%26aufirst%3DR.%2BS.%26atitle%3DRandomized%252C%2520double-blind%252C%2520phase%2520II%2520study%2520of%2520ruxolitinib%2520or%2520placebo%2520in%2520combination%2520with%2520capecitabine%2520in%2520patients%2520with%2520metastatic%2520pancreatic%2520cancer%2520for%2520whom%2520therapy%2520with%2520gemcitabine%2520has%2520failed%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D4039%26epage%3D4047%26doi%3D10.1200%2FJCO.2015.61.4578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span> </span><span class="NLM_article-title">Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis</span>. ClinicalTrials.gov; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://clinicaltrials.gov/ct2/show/NCT01433445" class="extLink">http://clinicaltrials.gov/ct2/show/NCT01433445</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Panobinostat+and+Ruxolitinib+in+Primary+Myelofibrosis%2C+Post-polycythemia+Vera-myelofibrosis+or+Post-essential+Thrombocythemia-myelofibrosis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2011%3B+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01433445+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DPanobinostat%2520and%2520Ruxolitinib%2520in%2520Primary%2520Myelofibrosis%252C%2520Post-polycythemia%2520Vera-myelofibrosis%2520or%2520Post-essential%2520Thrombocythemia-myelofibrosis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Yi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Z.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.-D.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1697</span><span class="NLM_x">–</span> <span class="NLM_lpage">1705</span><span class="refDoi"> DOI: 10.1016/j.bcp.2007.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.bcp.2007.10.035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2008&pages=1697-1705&author=X.+Yiauthor=W.+Weiauthor=S.-Y.+Wangauthor=Z.-Y.+Duauthor=Y.-J.+Xuauthor=X.-D.+Yu&title=Histone+deacetylase+inhibitor+SAHA+induces+ER%CE%B1+degradation+in+breast+cancer+MCF-7+cells+by+CHIP-mediated+ubiquitin+pathway+and+inhibits+survival+signaling&doi=10.1016%2Fj.bcp.2007.10.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2007.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2007.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DDu%26aufirst%3DZ.-Y.%26aulast%3DXu%26aufirst%3DY.-J.%26aulast%3DYu%26aufirst%3DX.-D.%26atitle%3DHistone%2520deacetylase%2520inhibitor%2520SAHA%2520induces%2520ER%25CE%25B1%2520degradation%2520in%2520breast%2520cancer%2520MCF-7%2520cells%2520by%2520CHIP-mediated%2520ubiquitin%2520pathway%2520and%2520inhibits%2520survival%2520signaling%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D75%26spage%3D1697%26epage%3D1705%26doi%3D10.1016%2Fj.bcp.2007.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Carlisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauricella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anneo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buttitta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fiore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vento, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesoriere, G.</span><span> </span><span class="NLM_article-title">The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">230</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">–</span> <span class="NLM_lpage">1289</span><span class="refDoi"> DOI: 10.1002/jcp.24863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fjcp.24863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=25370819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlSktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=230&publication_year=2015&pages=1276-1289&author=D.+Carlisiauthor=M.+Lauricellaauthor=A.+D%E2%80%99Anneoauthor=G.+Buttittaauthor=S.+Emanueleauthor=R.+Di+Fioreauthor=R.+Martinezauthor=C.+Rolfoauthor=R.+Ventoauthor=G.+Tesoriere&title=The+synergistic+effect+of+SAHA+and+parthenolide+in+MDA-MB231+breast+cancer+cells&doi=10.1002%2Fjcp.24863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells</span></div><div class="casAuthors">Carlisi, Daniela; Lauricella, Marianna; D'Anneo, Antonella; Buttitta, Giuseppina; Emanuele, Sonia; di Fiore, Riccardo; Martinez, Roberta; Rolfo, Christian; Vento, Renza; Tesoriere, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">230</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1276-1289</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The sesquiterpene lactone Parthenolide (PN) exerted a cytotoxic effect on MDA-MB231 cells, a triple-neg. breast cancer (TNBC) cell line, but its effectiveness was scarce when employed at low doses.  This represents an obstacle for a therapeutic utilization of PN.  In order to overcome this difficulty we assocd. to PN the suberoylanilide hydroxamic acid (SAHA), an histone deacetylase inhibitor.  Our results show that SAHA synergistically sensitized MDA-MB231 cells to the cytotoxic effect of PN.  It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity.  However, when the cells were treated with SAHA/PN combination, SAHA suppressed PN effect on Akt/mTOR/Nrf2 pathway, while PN reduced the prosurvival autophagic activity of SAHA.  In addn. SAHA/PN combination induced GSH depletion, fall in Δψm, release of cytochrome c, activation of caspase 3 and apoptosis.  Finally we demonstrated that combined treatment maintained both hyperacetylation of histones H3 and H4 induced by SAHA and down-regulation of DNMT1 expression induced by PN.  Inhibition of the DNA-binding activity of NF-kB, which is detd. by PN, was also obsd. after combined treatment.  In conclusion, combination of PN to SAHA inhibits the cytoprotective responses induced by the single compds., but does not alter the mechanisms leading to the cytotoxic effects.  Taken together our results suggest that this combination could be a candidate for TNBC therapy.  J. Cell. Physiol. 230: 1276-1289, 2015. cpr 2014 Wiley Periodicals, Inc., A Wiley Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18XJZ3XcvvLVg90H21EOLACvtfcHk0lgZSO1M_9h4Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlSktrs%253D&md5=75b3687a0fb68b712e2459aa4f853338</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fjcp.24863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.24863%26sid%3Dliteratum%253Aachs%26aulast%3DCarlisi%26aufirst%3DD.%26aulast%3DLauricella%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Anneo%26aufirst%3DA.%26aulast%3DButtitta%26aufirst%3DG.%26aulast%3DEmanuele%26aufirst%3DS.%26aulast%3DDi%2BFiore%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DVento%26aufirst%3DR.%26aulast%3DTesoriere%26aufirst%3DG.%26atitle%3DThe%2520synergistic%2520effect%2520of%2520SAHA%2520and%2520parthenolide%2520in%2520MDA-MB231%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2015%26volume%3D230%26spage%3D1276%26epage%3D1289%26doi%3D10.1002%2Fjcp.24863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lye, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, M. C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khoo, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangthongpitag, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khng, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonday, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantharaj, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span> </span><span class="NLM_article-title">Discovery of (2 E)-3-{2-butyl-1-[2-(diethylamino) ethyl]-1 H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4694</span><span class="NLM_x">–</span> <span class="NLM_lpage">4720</span><span class="refDoi"> DOI: 10.1021/jm2003552</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003552" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4694-4720&author=H.+Wangauthor=N.+Yuauthor=D.+Chenauthor=K.+C.+L.+Leeauthor=P.+L.+Lyeauthor=J.+W.+W.+Changauthor=W.+Dengauthor=M.+C.+Y.+Ngauthor=T.+Luauthor=M.+L.+Khooauthor=A.+Poulsenauthor=K.+Sangthongpitagauthor=X.+Wuauthor=C.+Huauthor=K.+C.+Gohauthor=X.+Wangauthor=L.+Fangauthor=K.+L.+Gohauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=P.+Yeoauthor=X.+Liuauthor=Z.+Bondayauthor=J.+M.+Woodauthor=B.+W.+Dymockauthor=E.+Kantharajauthor=E.+T.+Sun&title=Discovery+of+%282+E%29-3-%7B2-butyl-1-%5B2-%28diethylamino%29+ethyl%5D-1+H-benzimidazol-5-yl%7D-N-hydroxyacrylamide+%28SB939%29%2C+an+orally+active+histone+deacetylase+inhibitor+with+a+superior+preclinical+profile&doi=10.1021%2Fjm2003552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm2003552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003552%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BL.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DM.%2BC.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DKhoo%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DK.%2BL.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DKantharaj%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DDiscovery%2520of%2520%25282%2520E%2529-3-%257B2-butyl-1-%255B2-%2528diethylamino%2529%2520ethyl%255D-1%2520H-benzimidazol-5-yl%257D-N-hydroxyacrylamide%2520%2528SB939%2529%252C%2520an%2520orally%2520active%2520histone%2520deacetylase%2520inhibitor%2520with%2520a%2520superior%2520preclinical%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4694%26epage%3D4720%26doi%3D10.1021%2Fjm2003552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Ehrentraut, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherr, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geffers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prochorec-Sobieszek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketterling, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, R. A. F.</span><span> </span><span class="NLM_article-title">t (8; 9)(p22; p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e53767</span><span class="refDoi"> DOI: 10.1371/journal.pone.0053767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1371%2Fjournal.pone.0053767" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e53767&author=S.+Ehrentrautauthor=S.+Nagelauthor=M.+E.+Scherrauthor=B.+Schneiderauthor=H.+Quentmeierauthor=R.+Geffersauthor=M.+Kaufmannauthor=C.+Meyerauthor=M.+Prochorec-Sobieszekauthor=R.+P.+Ketterlingauthor=R.+A.+Knudsonauthor=A.+L.+Feldmanauthor=M.+E.+Kadinauthor=H.+G.+Drexlerauthor=R.+A.+F.+MacLeod&title=t+%288%3B+9%29%28p22%3B+p24%29%2FPCM1-JAK2+Activates+SOCS2+and+SOCS3+via+STAT5&doi=10.1371%2Fjournal.pone.0053767"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0053767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0053767%26sid%3Dliteratum%253Aachs%26aulast%3DEhrentraut%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DS.%26aulast%3DScherr%26aufirst%3DM.%2BE.%26aulast%3DSchneider%26aufirst%3DB.%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DGeffers%26aufirst%3DR.%26aulast%3DKaufmann%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DProchorec-Sobieszek%26aufirst%3DM.%26aulast%3DKetterling%26aufirst%3DR.%2BP.%26aulast%3DKnudson%26aufirst%3DR.%2BA.%26aulast%3DFeldman%26aufirst%3DA.%2BL.%26aulast%3DKadin%26aufirst%3DM.%2BE.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26aulast%3DMacLeod%26aufirst%3DR.%2BA.%2BF.%26atitle%3Dt%2520%25288%253B%25209%2529%2528p22%253B%2520p24%2529%252FPCM1-JAK2%2520Activates%2520SOCS2%2520and%2520SOCS3%2520via%2520STAT5%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De53767%26doi%3D10.1371%2Fjournal.pone.0053767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Katagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonezawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuyama, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohnishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, T.</span><span> </span><span class="NLM_article-title">Two distinct human myeloma cell lines originating from one patient with myeloma</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1002/ijc.2910360217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2Fijc.2910360217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=3926660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADyaL2M3mtVWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1985&pages=241-246&author=S.+Katagiriauthor=T.+Yonezawaauthor=J.+Kuyamaauthor=Y.+Kanayamaauthor=T.+Tamakiauthor=M.+Ohnishiauthor=S.+Taruiauthor=K.+Nishidaauthor=T.+Abe&title=Two+distinct+human+myeloma+cell+lines+originating+from+one+patient+with+myeloma&doi=10.1002%2Fijc.2910360217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Two distinct human myeloma cell lines originating from one patient with myeloma</span></div><div class="casAuthors">Katagiri S; Yonezawa T; Kuyama J; Kanayama Y; Nishida K; Abe T; Tamaki T; Ohnishi M; Tarui S</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-6</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Two distinct cell lines (OPM-1 and OPM-2) were established from the peripheral blood of a 56-year-old female myeloma patient at the stage of terminal leukemic evolution associated with loss of cytoplasmic immunoglobulin heavy chain (G lambda----lambda).  The lines grew in suspension with a doubling time of 36-42 hr and 30-36 hr, respectively.  EBNA was absent from both lines.  The lines synthesized cytoplasmic lambda-chain, but had no detectable surface immunoglobulins.  Fc receptors and complement receptors could not be detected in either line.  The lines had very complex chromosomal abnormalities, but the patterns of chromosomes differed greatly between the two lines.  The two lines, together with the RPMI 8226 line established by Matsuoka et al. (1967), were analyzed for phenotypic expression as defined by a panel of monoclonal antibodies to B cells (B1, BA-1, BA-2, BA-3, OKIa-1 and OKT10/BMA0100).  Neither OPM-1 nor OPM-2 reacted with any of the antibodies tested except OKT10.  OPM-1 cells reacted weakly (less than 30%) with OKT10/BMA0100, while OPM-2 cells showed a fluctuating reactivity, ranging from 40 to 80%, with OKT10/BMA0100.  In contrast, RPMI 8226 reacted strongly with OKT10 and BA-2.  These results demonstrate the presence of phenotypic heterogeneity in all 3 myeloma cell lines, suggesting that the lines might represent different stages of terminal B-cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_-dVNKy-ESisZ1x6zOs0vfW6udTcc2eZmbY-nZXVrJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M3mtVWnsw%253D%253D&md5=bf38cf9b35f120a08ab881db395c8f30</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910360217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910360217%26sid%3Dliteratum%253Aachs%26aulast%3DKatagiri%26aufirst%3DS.%26aulast%3DYonezawa%26aufirst%3DT.%26aulast%3DKuyama%26aufirst%3DJ.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DTamaki%26aufirst%3DT.%26aulast%3DOhnishi%26aufirst%3DM.%26aulast%3DTarui%26aufirst%3DS.%26aulast%3DNishida%26aufirst%3DK.%26aulast%3DAbe%26aufirst%3DT.%26atitle%3DTwo%2520distinct%2520human%2520myeloma%2520cell%2520lines%2520originating%2520from%2520one%2520patient%2520with%2520myeloma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1985%26volume%3D36%26spage%3D241%26epage%3D246%26doi%3D10.1002%2Fijc.2910360217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Otsuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yawata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, O.</span><span> </span><span class="NLM_article-title">Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=11039672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADC%252BD3cvovVOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2000&pages=216-222&author=T.+Otsukiauthor=H.+Hataauthor=N.+Haradaauthor=H.+Matsuzakiauthor=K.+Yataauthor=H.+Wadaauthor=Y.+Yawataauthor=A.+Uekiauthor=O.+Yamada&title=Cellular+biological+differences+between+human+myeloma+cell+lines+KMS-12-PE+and+KMS-12-BM+established+from+a+single+patient"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient</span></div><div class="casAuthors">Otsuki T; Hata H; Harada N; Matsuzaki H; Yata K; Wada H; Yawata Y; Ueki A; Yamada O</div><div class="citationInfo"><span class="NLM_cas:title">International journal of hematology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-22</span>
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    </div><div class="casAbstract">To clarify cellular biological varieties of myeloma cells, biological differences were analyzed between 2 human myeloma cell lines, KMS-12-PE and KMS-12-BM, derived from pleural effusion and bone marrow, respectively, of a single patient.  Although both lines were considered to be derived from the same clone because both had the same chromosomal marker and immunoglobulin H rearrangement, several biological differences were noted.  CD11a and CD20 were highly expressed in the KMS-12-BM line, whereas the KMS-12-PE line showed a higher expression of CD7 and CD95/Fas.  Although growth was stimulated in KMS-12-BM by interleukin-6 and interferon-alpha, it was inhibited in KMS-12-PE.  In addition, apoptosis inhibitors Bcl-2 and Bcl-X(L) were highly expressed in KMS-12-BM cells.  Because KMS-12-PE was cultivated 2 months before KMS-12-BM, these differences might be related to their origin (pleural effusion and bone marrow) or the phases of disease progression.  However, these biological differences may help clarify myeloma cell biology and lead to improvement in treatment for myeloma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQogaV4rmgZP77NkxioyDXTfW6udTcc2eY1vX897BWbeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvovVOhsQ%253D%253D&md5=8514330f8dc5be81ede8dd777ba4bbe8</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOtsuki%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DH.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DMatsuzaki%26aufirst%3DH.%26aulast%3DYata%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DYawata%26aufirst%3DY.%26aulast%3DUeki%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DO.%26atitle%3DCellular%2520biological%2520differences%2520between%2520human%2520myeloma%2520cell%2520lines%2520KMS-12-PE%2520and%2520KMS-12-BM%2520established%2520from%2520a%2520single%2520patient%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2000%26volume%3D72%26spage%3D216%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Matsuo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uphoff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishizaki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omoto, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orita, K.</span><span> </span><span class="NLM_article-title">Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins (11; 9)(q23; p22p23)</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1469</span><span class="NLM_x">–</span> <span class="NLM_lpage">1477</span><span class="refDoi"> DOI: 10.1038/sj.leu.2400768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fsj.leu.2400768" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=1469-1477&author=Y.+Matsuoauthor=R.+MacLeodauthor=C.+Uphoffauthor=H.+Drexlerauthor=C.+Nishizakiauthor=Y.+Katayamaauthor=G.+Kimuraauthor=N.+Fujiiauthor=E.+Omotoauthor=M.+Haradaauthor=K.+Orita&title=Two+acute+monocytic+leukemia+%28AML-M5a%29+cell+lines+%28MOLM-13+and+MOLM-14%29+with+interclonal+phenotypic+heterogeneity+showing+MLL-AF9+fusion+resulting+from+an+occult+chromosome+insertion%2C+ins+%2811%3B+9%29%28q23%3B+p22p23%29&doi=10.1038%2Fsj.leu.2400768"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2400768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2400768%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DY.%26aulast%3DMacLeod%26aufirst%3DR.%26aulast%3DUphoff%26aufirst%3DC.%26aulast%3DDrexler%26aufirst%3DH.%26aulast%3DNishizaki%26aufirst%3DC.%26aulast%3DKatayama%26aufirst%3DY.%26aulast%3DKimura%26aufirst%3DG.%26aulast%3DFujii%26aufirst%3DN.%26aulast%3DOmoto%26aufirst%3DE.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DOrita%26aufirst%3DK.%26atitle%3DTwo%2520acute%2520monocytic%2520leukemia%2520%2528AML-M5a%2529%2520cell%2520lines%2520%2528MOLM-13%2520and%2520MOLM-14%2529%2520with%2520interclonal%2520phenotypic%2520heterogeneity%2520showing%2520MLL-AF9%2520fusion%2520resulting%2520from%2520an%2520occult%2520chromosome%2520insertion%252C%2520ins%2520%252811%253B%25209%2529%2528q23%253B%2520p22p23%2529%26jtitle%3DLeukemia%26date%3D1997%26volume%3D11%26spage%3D1469%26epage%3D1477%26doi%3D10.1038%2Fsj.leu.2400768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Koeffler, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golde, D. W.</span><span> </span><span class="NLM_article-title">Human myeloid leukemia cell lines: a review</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1980&pages=344-350&author=H.+P.+Koefflerauthor=D.+W.+Golde&title=Human+myeloid+leukemia+cell+lines%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DGolde%26aufirst%3DD.%2BW.%26atitle%3DHuman%2520myeloid%2520leukemia%2520cell%2520lines%253A%2520a%2520review%26jtitle%3DBlood%26date%3D1980%26volume%3D56%26spage%3D344%26epage%3D350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Iqbal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deLeeuw, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinkebiel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dybkaer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, I. F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span> </span><span class="NLM_article-title">Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1139</span><span class="NLM_x">–</span> <span class="NLM_lpage">1151</span><span class="refDoi"> DOI: 10.1038/leu.2009.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fleu.2009.3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1139-1151&author=J.+Iqbalauthor=C.+Kucukauthor=R.+J.+deLeeuwauthor=G.+Srivastavaauthor=W.+Tamauthor=H.+Gengauthor=D.+Klinkebielauthor=J.+Christmanauthor=K.+Patelauthor=K.+Caoauthor=L.+Shenauthor=K.+Dybkaerauthor=I.+F.+L.+Tsuiauthor=H.+Aliauthor=N.+Shimizuauthor=W.+Y.+Auauthor=W.+L.+Lamauthor=W.+C.+Chan&title=Genomic+analyses+reveal+global+functional+alterations+that+promote+tumor+growth+and+novel+tumor+suppressor+genes+in+natural+killer-cell+malignancies&doi=10.1038%2Fleu.2009.3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fleu.2009.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2009.3%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DKucuk%26aufirst%3DC.%26aulast%3DdeLeeuw%26aufirst%3DR.%2BJ.%26aulast%3DSrivastava%26aufirst%3DG.%26aulast%3DTam%26aufirst%3DW.%26aulast%3DGeng%26aufirst%3DH.%26aulast%3DKlinkebiel%26aufirst%3DD.%26aulast%3DChristman%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DDybkaer%26aufirst%3DK.%26aulast%3DTsui%26aufirst%3DI.%2BF.%2BL.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DAu%26aufirst%3DW.%2BY.%26aulast%3DLam%26aufirst%3DW.%2BL.%26aulast%3DChan%26aufirst%3DW.%2BC.%26atitle%3DGenomic%2520analyses%2520reveal%2520global%2520functional%2520alterations%2520that%2520promote%2520tumor%2520growth%2520and%2520novel%2520tumor%2520suppressor%2520genes%2520in%2520natural%2520killer-cell%2520malignancies%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1139%26epage%3D1151%26doi%3D10.1038%2Fleu.2009.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Chiang, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srivastava, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, F. C.</span><span> </span><span class="NLM_article-title">Nasal T/natural killer(NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">332</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.1002/(SICI)1097-0215(19971104)73:3<332::AID-IJC5>3.0.CO;2-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=9359478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADyaK1c%252Fit1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1997&pages=332-338&author=A.+K.+Chiangauthor=A.+C.+Chanauthor=G.+Srivastavaauthor=F.+C.+Ho&title=Nasal+T%2Fnatural+killer%28NK%29-cell+lymphomas+are+derived+from+Epstein-Barr+virus-infected+cytotoxic+lymphocytes+of+both+NK-+and+T-cell+lineage&doi=10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage</span></div><div class="casAuthors">Chiang A K; Chan A C; Srivastava G; Ho F C</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-8</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">The cellular nature of nasal T/natural killer (NK)-cell lymphomas (NLs) remains controversial.  It is still debatable whether these represent T-cell lymphomas with extensive loss of surface antigens or are, in fact, true NK-cell lymphomas.  They are associated closely with Epstein-Barr virus (EBV), to the extent that EBV-encoded small non-polyadenylated RNAs (EBER) expression can be used as a marker for the neoplastic cells.  The cell lineage of this group of lymphomas was examined further by correlating immunophenotype, genotype and EBV status with the expression of cytotoxic granule-associated proteins, perforin and T-cell intracellular antigen-1 (TIA-1) in 13 cases of NL.  Combined immunophenotypic and gene rearrangement analyses demonstrated that NLs can be identified clearly as either NK-cell or T-cell tumours.  Nasal NK-cell lymphomas lacked clonal rearrangement of both T-cell receptor (TCR) gamma and immunogloulin heavy chain (IgH) genes and were either CD3(Leu4)-CD56+ (8 cases) or CD3(Leu4)+CD56+ (2 cases), whereas nasal T-cell lymphomas had rearranged TCRgamma and germ-line IgH genes and were either CD3(Leu4)+CD56+ (2 cases) or CD3(Leu4)+CD56- (1 case).  Immunohistochemical (IH) studies showed that both perforin and TIA-1 were expressed universally in NL, irrespective of NK- or T-cell lineage.  Dual labelling of TIA-1 by IH and EBER by in situ hybridisation demonstrated that the granule proteins were expressed predominantly by the EBER+ tumour cells.  Our results indicate that NLs are derived from EBV-infected cytotoxic lymphocytes of both NK- and T-cell lineage.  We postulate that cytotoxic lymphocytes generated during the cellular immune response to EBV infection or re-activation at the nasal region themselves may become targets for EBV infection and subsequent transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS18risIAukEZVVjGoY74BafW6udTcc2eY1vX897BWbeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252Fit1CgtA%253D%253D&md5=f403d44b3a14894f9b93d389c60bc52c</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819971104%252973%253A3%253C332%253A%253AAID-IJC5%253E3.0.CO%253B2-0%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DA.%2BK.%26aulast%3DChan%26aufirst%3DA.%2BC.%26aulast%3DSrivastava%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DF.%2BC.%26atitle%3DNasal%2520T%252Fnatural%2520killer%2528NK%2529-cell%2520lymphomas%2520are%2520derived%2520from%2520Epstein-Barr%2520virus-infected%2520cytotoxic%2520lymphocytes%2520of%2520both%2520NK-%2520and%2520T-cell%2520lineage%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1997%26volume%3D73%26spage%3D332%26epage%3D338%26doi%3D10.1002%2F%28SICI%291097-0215%2819971104%2973%3A3%3C332%3A%3AAID-IJC5%3E3.0.CO%3B2-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Karube, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuzuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, M.</span><span> </span><span class="NLM_article-title">Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">333</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1016/j.canlet.2012.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2Fj.canlet.2012.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23348693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2013&pages=47-55&author=K.+Karubeauthor=S.+Tsuzukiauthor=N.+Yoshidaauthor=K.+Aritaauthor=H.+Katoauthor=M.+Katayamaauthor=Y.-H.+Koauthor=K.+Ohshimaauthor=S.+Nakamuraauthor=T.+Kinoshitaauthor=M.+Seto&title=Comprehensive+gene+expression+profiles+of+NK+cell+neoplasms+identify+vorinostat+as+an+effective+drug+candidate&doi=10.1016%2Fj.canlet.2012.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate</span></div><div class="casAuthors">Karube, Kennosuke; Tsuzuki, Shinobu; Yoshida, Noriaki; Arita, Kotaro; Kato, Harumi; Katayama, Miyuki; Ko, Young-Hyeh; Ohshima, Koichi; Nakamura, Shigeo; Kinoshita, Tomohiro; Seto, Masao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-55</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NK cell neoplasms are lymphoid malignancies with an aggressive clin. course.  In the present study, we analyzed gene expression profiling of NK cell neoplasms and attempted to identify important mol. pathways and new effective drugs.  Pathway anal. of gene expression profiles suggested the important roles of the JAK-STAT pathway, NF-κB pathway or Wnt pathways in NK cell neoplasms.  Notably, western blot anal. revealed that STAT3 was expressed and phosphorylated at a higher level in NK cell lines than in normal NK cells or other cell lines.  These findings indicate the occurrence of JAK-STAT activation in NK cell neoplasms.  Connectivity Map (CMAP) anal. of gene expression profiles identified candidate drugs against NK cell neoplasms.  Among the drugs suggested by CMAP anal., we focused on puromycin, phenoxybenzamine, LY294002, wortmannin, vorinostat and trichostatin A because they exhibited high enrichment scores.  We added these drugs to NK cell lines and other cell lines.  Among the drugs, vorinostat suppressed NK cell line proliferation at a significantly lower concn. compared to other cell lines.  Suppression of the JAK-STAT pathway appeared to contribute to this effect.  Vorinostat may be a good candidate for use in the therapy against NK cell neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ_s6uHdODnrVg90H21EOLACvtfcHk0li5jMnLasuRXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFChsr8%253D&md5=ea546451e7b17cd81b43bf8a14bd1466</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DKarube%26aufirst%3DK.%26aulast%3DTsuzuki%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DN.%26aulast%3DArita%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DKatayama%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.-H.%26aulast%3DOhshima%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26atitle%3DComprehensive%2520gene%2520expression%2520profiles%2520of%2520NK%2520cell%2520neoplasms%2520identify%2520vorinostat%2520as%2520an%2520effective%2520drug%2520candidate%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D333%26spage%3D47%26epage%3D55%26doi%3D10.1016%2Fj.canlet.2012.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">West, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">New and emerging HDAC inhibitors for cancer treatment</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+HDAC+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0li5jMnLasuRXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520HDAC%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Hubbert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guardiola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nixon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, T.-P.</span><span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">458</span><span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.-F.+Wangauthor=T.-P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0li5jMnLasuRXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.-F.%26aulast%3DYao%26aufirst%3DT.-P.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Kerr, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyllie, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, A. R.</span><span> </span><span class="NLM_article-title">Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.1038/bjc.1972.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fbjc.1972.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=4561027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A280%3ADyaE3s%252FgsFSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1972&pages=239-257&author=J.+F.+Kerrauthor=A.+H.+Wyllieauthor=A.+R.+Currie&title=Apoptosis%3A+a+basic+biological+phenomenon+with+wide-ranging+implications+in+tissue+kinetics&doi=10.1038%2Fbjc.1972.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics</span></div><div class="casAuthors">Kerr J F; Wyllie A H; Currie A R</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-57</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">The term apoptosis is proposed for a hitherto little recognized mechanism of controlled cell deletion, which appears to play a complementary but opposite role to mitosis in the regulation of animal cell populations.  Its morphological features suggest that it is an active, inherently programmed phenomenon, and it has been shown that it can be initiated or inhibited by a variety of environmental stimuli, both physiological and pathological.The structural changes take place in two discrete stages.  The first comprises nuclear and cytoplasmic condensation and breaking up of the cell into a number of membrane-bound, ultrastructurally well-preserved fragments.  In the second stage these apoptotic bodies are shed from epithelial-lined surfaces or are taken up by other cells, where they undergo a series of changes resembling in vitro autolysis within phagosomes, and are rapidly degraded by lysosomal enzymes derived from the ingesting cells.Apoptosis seems to be involved in cell turnover in many healthy adult tissues and is responsible for focal elimination of cells during normal embryonic development.  It occurs spontaneously in untreated malignant neoplasms, and participates in at least some types of therapeutically induced tumour regression.  It is implicated in both physiological involution and atrophy of various tissues and organs.  It can also be triggered by noxious agents, both in the embryo and adult animal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNWEBcjRkVZzW1zwg2yUK5fW6udTcc2eYTxKb0mQP8kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3s%252FgsFSksw%253D%253D&md5=60211d4b22f18156fa64206b2cad983d</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1972.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1972.33%26sid%3Dliteratum%253Aachs%26aulast%3DKerr%26aufirst%3DJ.%2BF.%26aulast%3DWyllie%26aufirst%3DA.%2BH.%26aulast%3DCurrie%26aufirst%3DA.%2BR.%26atitle%3DApoptosis%253A%2520a%2520basic%2520biological%2520phenomenon%2520with%2520wide-ranging%2520implications%2520in%2520tissue%2520kinetics%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1972%26volume%3D26%26spage%3D239%26epage%3D257%26doi%3D10.1038%2Fbjc.1972.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Vermes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffens-Nakken, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reutellingsperger, C.</span><span> </span><span class="NLM_article-title">A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V</span> <span class="citation_source-journal">J. Immunol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/0022-1759(95)00072-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2F0022-1759%2895%2900072-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=7622868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Ojsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1995&pages=39-51&author=I.+Vermesauthor=C.+Haanenauthor=H.+Steffens-Nakkenauthor=C.+Reutellingsperger&title=A+novel+assay+for+apoptosis.+Flow+cytometric+detection+of+phosphatidylserine+expression+on+early+apoptotic+cells+using+fluorescein+labelled+Annexin+V&doi=10.1016%2F0022-1759%2895%2900072-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V</span></div><div class="casAuthors">Vermes, Istvan; Haanen, Clemens; Steffens-Nakken, Helga; Reutelingsperger, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunological Methods</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">JIMMBG</span>;
        ISSN:<span class="NLM_cas:issn">0022-1759</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In the early stages of apoptosis changes occur at the cell surface, which until now have remained difficult to recognize.  One of these plasma membrane alterations is the translocation of phosphatidylserine (PS) from the inner side of the plasma membrane to the outer layer, by which PS becomes exposed at the external surface of the cell.  Annexin V is a Ca2+ dependent phospholipid-binding protein with high affinity for PS.  Hence this protein can be used as a sensitive probe for PS exposure upon the cell membrane.  Translocation of PS to the external cell surface is not unique to apoptosis, but occurs also during cell necrosis.  The difference between these two forms of cell death is that during the initial stages of apoptosis the cell membrane remains intact, while at the very moment that necrosis occurs the cell membrane looses its integrity and becomes leaky.  Therefore the measurement of Annexin V binding to the cell surface as indicative for apoptosis has to be performed in conjunction with a dye exclusion test to establish integrity of the cell membrane.  This paper describes the results of such an assay, as obtained in cultured HSB-2 cells, rendered apoptotic by irradn. and in human lymphocytes, following dexamethasone treatment.  Untreated and treated cells were evaluated for apoptosis by light microscopy, by measuring the amt. of hypo-diploid cells using of DNA flow cytometry (FCM) and by DNA electrophoresis to establish whether or not DNA fragmentation had occurred.  Annexin V binding was assessed using bivariate FCM, and cell staining was evaluated with fluorescein isothiocyanate (FITC)-labeled Annexin V (green fluorescence), simultaneously with dye exclusion of propidium iodide (PI) (neg. for red fluorescence).  The test described, discriminates intact cells (FITC-/PI-), apoptotic cells (FITC+/PI-) and necrotic cells (FITC+/PI+).  In comparison with existing traditional tests the Annexin V assay is sensitive and easy to perform.  The Annexin V assay offers the possibility of detecting early phases of apoptosis before the loss of cell membrane integrity and permits measurements of the kinetics of apoptotic death in relation to the cell cycle.  More extensive FCM will allow discrimination between different cell subpopulations, that may or may not be involved in the apoptotic process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEhoGurJoWT7Vg90H21EOLACvtfcHk0lh39mY5CQaf2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Ojsbo%253D&md5=7931d2e5a8dcf54dafb73e3aa5dc22d9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2F0022-1759%2895%2900072-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0022-1759%252895%252900072-I%26sid%3Dliteratum%253Aachs%26aulast%3DVermes%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DC.%26aulast%3DSteffens-Nakken%26aufirst%3DH.%26aulast%3DReutellingsperger%26aufirst%3DC.%26atitle%3DA%2520novel%2520assay%2520for%2520apoptosis.%2520Flow%2520cytometric%2520detection%2520of%2520phosphatidylserine%2520expression%2520on%2520early%2520apoptotic%2520cells%2520using%2520fluorescein%2520labelled%2520Annexin%2520V%26jtitle%3DJ.%2520Immunol.%2520Methods%26date%3D1995%26volume%3D184%26spage%3D39%26epage%3D51%26doi%3D10.1016%2F0022-1759%2895%2900072-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">D’Amours, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallmann, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3771</span><span class="NLM_x">–</span> <span class="NLM_lpage">3778</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=11707529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=3771-3778&author=D.+D%E2%80%99Amoursauthor=F.+R.+Sallmannauthor=V.+M.+Dixitauthor=G.+G.+Poirier&title=Gain-of-function+of+poly%28ADP-ribose%29+polymerase-1+upon+cleavage+by+apoptotic+proteases%3A+implications+for+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis</span></div><div class="casAuthors">D'Amours, Damien; Sallmann, Frederic R.; Dixit, Vishva M.; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3771-3778</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Poly(ADP-ribosyl)ation is an important mechanism for the maintenance of genomic integrity in response to DNA damage.  The enzyme responsible for poly(ADP-ribose) synthesis, poly(ADP-ribose) polymerase 1 (PARP-1), has been implicated in two distinct modes of cell death induced by DNA damage, namely apoptosis and necrosis.  During the execution phase of apoptosis, PARP-1 is specifically proteolyzed by caspases to produce an N-terminal DNA-binding domain (DBD) and a C-terminal catalytic fragment.  The functional consequence of this proteolytic event is not known.  However, it has recently been shown that overactivation of full-length PARP-1 can result in energy depletion and necrosis in dying cells.  Here, the authors investigate the mol. basis for the differential involvement of PARP-1 in these two types of cellular demise.  The authors show that the C-terminal apoptotic fragment of PARP-1 loses its DNA-dependent catalytic activity upon cleavage with caspase 3.  However, the N-terminal apoptotic fragment, retains a strong DNA-binding activity and totally inhibits the catalytic activity of uncleaved PARP-1.  This dominant-neg. behavior was confirmed and extended in cellular exts. where DNA repair was completely inhibited by nanomolar concns. of the N-terminal fragment.  Furthermore, overexpression of the apoptotic DBD in mouse fibroblast inhibits endogenous PARP-1 activity very efficiently in vivo, thereby confirming the authors' biochem. observations.  Taken together, these expts. indicate that the apoptotic DBD of PARP-1 acts cooperatively with the proteolytic inactivation of the enzyme to trans-inhibit NAD hydrolysis and to maintain the energy levels of the cell.  These results are consistent with a model in which cleavage of PARP-1 promotes apoptosis by preventing DNA repair-induced survival and by blocking energy depletion-induced necrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouW9f4pYihjrVg90H21EOLACvtfcHk0lh39mY5CQaf2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot12nsrk%253D&md5=18622ce2e1abc4ca30c3d3e92d471b6f</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amours%26aufirst%3DD.%26aulast%3DSallmann%26aufirst%3DF.%2BR.%26aulast%3DDixit%26aufirst%3DV.%2BM.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DGain-of-function%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520upon%2520cleavage%2520by%2520apoptotic%2520proteases%253A%2520implications%2520for%2520apoptosis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D3771%26epage%3D3778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Danial, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsmeyer, S. J.</span><span> </span><span class="NLM_article-title">Cell death: critical control points</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00046-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2FS0092-8674%2804%2900046-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=14744432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=205-219&author=N.+N.+Danialauthor=S.+J.+Korsmeyer&title=Cell+death%3A+critical+control+points&doi=10.1016%2FS0092-8674%2804%2900046-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death: Critical control points</span></div><div class="casAuthors">Danial, Nika N.; Korsmeyer, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-219</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review and discussion.  Programmed cell death (apoptosis) is a distinct genetic and biochem. pathway essential to metazoans.  An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis.  Apoptosis has proven to be tightly interwoven with other essential cell pathways.  The identification of crit. control points in the cell death pathway has yielded fundamental insights for basic biol., as well as provided rational targets for new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfuRt2EjV6WLVg90H21EOLACvtfcHk0lgpcWxoI3Hvlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D&md5=de853177ac091305b7f237e58108f579</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900046-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900046-7%26sid%3Dliteratum%253Aachs%26aulast%3DDanial%26aufirst%3DN.%2BN.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26atitle%3DCell%2520death%253A%2520critical%2520control%2520points%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D205%26epage%3D219%26doi%3D10.1016%2FS0092-8674%2804%2900046-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span>Glide, <span class="NLM_edition">version 6.5</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a> (accessed April 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+6.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2014%3B+http%3A%2F%2Fwww.schrodinger.com+%28accessed+April+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Polak, E.; Ribiere, G.</span><span> </span><span class="NLM_article-title">Note sur la convergence de méthodes de directions conjuguées</span>. In  <span class="citation_source-journal">ESAIM: Mathematical Modelling and Numerical Analysis—Modélisation Mathématique et Analyse Numérique</span>,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">; </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1969&pages=35-43&author=E.+Polak&author=G.+Ribiere&title=Note+sur+la+convergence+de+m%C3%A9thodes+de+directions+conjugu%C3%A9es"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPolak%26aufirst%3DE.%26atitle%3DNote%2520sur%2520la%2520convergence%2520de%2520m%25C3%25A9thodes%2520de%2520directions%2520conjugu%25C3%25A9es%26jtitle%3DESAIM%253A%2520Mathematical%2520Modelling%2520and%2520Numerical%2520Analysis%25E2%2580%2594Mod%25C3%25A9lisation%2520Math%25C3%25A9matique%2520et%2520Analyse%2520Num%25C3%25A9rique%26date%3D1969%26volume%3D3%26spage%3D35%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Methodol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/0898-5529(88)90015-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms&doi=10.1016%2F0898-5529%2888%2990015-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0lgpcWxoI3Hvlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Methodol.%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116%26doi%3D10.1016%2F0898-5529%2888%2990015-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Lobera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madauss, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pohlhaus, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, Q. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trocha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trump, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, G. A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmann&title=Selective+class+IIa+histone+deacetylase+inhibition+via+a+nonchelating+zinc-binding+group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0lgpcWxoI3Hvlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26atitle%3DSelective%2520class%2520IIa%2520histone%2520deacetylase%2520inhibition%2520via%2520a%2520nonchelating%2520zinc-binding%2520group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+assay+of+kinase+catalytic+activity+reveals+features+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0liuOracQ85Lsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520assay%2520of%2520kinase%2520catalytic%2520activity%2520reveals%2520features%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Chen, P.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, F.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, I.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang-Yen, H.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, J.</span><span> </span><span class="NLM_article-title">Identification of a novel function of the clathrin-coated structure at the plasma membrane in facilitating GM-CSF receptor-mediated activation of JAK2</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3611</span><span class="NLM_x">–</span> <span class="NLM_lpage">3626</span><span class="refDoi"> DOI: 10.4161/cc.21920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;key=10.4161%2Fcc.21920" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=3611-3626&author=P.-H.+Chenauthor=F.-C.+Chienauthor=S.-P.+Leeauthor=W.-E.+Chanauthor=I.-H.+Linauthor=C.-S.+Liuauthor=F.-J.+Leeauthor=J.-S.+Laiauthor=P.+Chenauthor=H.-F.+Yang-Yenauthor=J.+Yen&title=Identification+of+a+novel+function+of+the+clathrin-coated+structure+at+the+plasma+membrane+in+facilitating+GM-CSF+receptor-mediated+activation+of+JAK2&doi=10.4161%2Fcc.21920"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.4161%2Fcc.21920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.21920%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.-H.%26aulast%3DChien%26aufirst%3DF.-C.%26aulast%3DLee%26aufirst%3DS.-P.%26aulast%3DChan%26aufirst%3DW.-E.%26aulast%3DLin%26aufirst%3DI.-H.%26aulast%3DLiu%26aufirst%3DC.-S.%26aulast%3DLee%26aufirst%3DF.-J.%26aulast%3DLai%26aufirst%3DJ.-S.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYang-Yen%26aufirst%3DH.-F.%26aulast%3DYen%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520novel%2520function%2520of%2520the%2520clathrin-coated%2520structure%2520at%2520the%2520plasma%2520membrane%2520in%2520facilitating%2520GM-CSF%2520receptor-mediated%2520activation%2520of%2520JAK2%26jtitle%3DCell%2520Cycle%26date%3D2012%26volume%3D11%26spage%3D3611%26epage%3D3626%26doi%3D10.4161%2Fcc.21920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Kaminski, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span> </span><span class="NLM_article-title">Evaluation and reparametrization of the OPLS-AA force field for protein via comparison with accurate quantum chemical calculations on peptides</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">6474</span><span class="NLM_x">–</span> <span class="NLM_lpage">6487</span><span class="refDoi"> DOI: 10.1021/jp003919d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp003919d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2001&pages=6474-6487&author=G.+A.+Kaminskiauthor=R.+A.+Friesnerauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Evaluation+and+reparametrization+of+the+OPLS-AA+force+field+for+protein+via+comparison+with+accurate+quantum+chemical+calculations+on+peptides&doi=10.1021%2Fjp003919d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjp003919d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp003919d%26sid%3Dliteratum%253Aachs%26aulast%3DKaminski%26aufirst%3DG.%2BA.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DEvaluation%2520and%2520reparametrization%2520of%2520the%2520OPLS-AA%2520force%2520field%2520for%2520protein%2520via%2520comparison%2520with%2520accurate%2520quantum%2520chemical%2520calculations%2520on%2520peptides%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2001%26volume%3D105%26spage%3D6474%26epage%3D6487%26doi%3D10.1021%2Fjp003919d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW','PDB','2VQW'); return false;">PDB: 2VQW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX','PDB','4BKX'); return false;">PDB: 4BKX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ','PDB','4LXZ'); return false;">PDB: 4LXZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i88"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00157">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80638"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00157">10.1021/acs.jmedchem.6b00157</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional synthesis of compounds, NMR and HPLC spectra for all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_001.pdf">jm6b00157_si_001.pdf (21.77 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00157/suppl_file/jm6b00157_si_002.csv">jm6b00157_si_002.csv (3.33 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00157%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-18" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00157" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797a77fdbd32b5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
